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1 SUMMARY
Protection of tissues from the devastating effects of immune responses is essential for the 
integrity of the organism. Tolerance mechanisms, such as T cell depletion or anergy induction 
by natural and adaptive regulatory T cells, tolerogenic dendritic cells and parenchymal cells 
control potentially auto-reactive lymphocytes. In addition, organs that are particularly 
sensitive to damage by inflammation, so called immune privileged sites, are protected by 
tissue barriers and contain an immunosuppressive microenvironment.  
There is increasing evidence that processes establishing immune privilege overlap with those 
associated with tolerance induction. However, there is much yet to learn about the molecules 
with a role in immune regulation. This knowledge could help in the understanding of systemic 
diseases, such as autoimmunity and cancer, and introduce novel principles concerning 
transplantation tolerance.  
Aim of this study was the identification of novel molecules that are potential mediators of 
peripheral tolerance. Starting from a transgenic mouse model for peripheral CD8 T cell 
tolerance, identification of such candidate genes was attempted by wide range gene 
expression analysis. Dickkopf 3 (Dkk3) was 10-fold upregulated in regulatory CD8 T cells. 
Interestingly, Dkk3 mRNA was previously shown to be present in peripheral tissues, such as 
the brain, the eye, the spinal cord, the ovary and the uterus, pointing to a possible role in 
immune priviledge. Moreover, Dkk3 was reported to inhibit the ERK MAPK pathway in 
tumor cells, which is also crucial for T cell receptor signal transduction. Taking all the above 
into consideration, it was hypothesized that Dkk3 might be involved in immune regulation. 
Here, Dkk3 was identified as a novel modulator of immune responses. Dkk3 protein was 
shown to be expressed by the transgenic regulatory CD8 T cells and was indispensable for the 
suppression of naïve T cells. In detail, Dkk3 deficient transgenic mice displayed no CD8 T 
cell tolerance and regulatory CD8 T cells could not exert their suppressive function in the 
presence of anti-Dkk3 blocking antibody.  
The immune regulatory function of Dkk3 was not limited to the transgenic mouse model of 
CD8 T cell tolerance. Polyclonal T cells from Dkk3 deficient mice showed hyperproliferation 
and increased IL-2 production. This effect could be explained by the fact that the ERK MAPK 
is overactivated in the absence of Dkk3.  
Among the tissues that express Dkk3 in high amounts are the immune privileged organs 
(central nervous system (CNS), ovaries, placenta), the liver, which is a crucial site for the 
establishment of T cell tolerance to oral antigens, the heart and the lung. On the other hand, 
Dkk3 expression could not be detected in the lymphoid organs and the serum. Given the 
SUMMARY 
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observed suppressive activity of Dkk3. it might control potentially harmful T cell responses in 
the above mentioned immune privileged organs. 
Indeed, the immune regulatory role of Dkk3 in the CNS could be demonstrated in the context 
of experimental autoimmune encephalitis (EAE). Absence of neuron-derived Dkk3 led to 
severe and persistent EAE, due to lack of suppression of activated CD8 T cells. In addition, 
blocking of the secreted Dkk3 with the respective anti-Dkk3 antibody resulted in increased 
disease chronicity.  
In conclusion, Dkk3 is a universal immune regulator, employed by transgenic tolerant CD8 T 
cells and immune privileged organs in order to control excessive T cell responses. 
ZUSAMENFASSUNG 
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2 ZUSAMENFASSUNG 
Der Schutz von Organstrukturen vor zerstörerischen Effekten durch Immunreaktionen ist 
essentiell für die Integrität des Organismus. Toleranzmechanismen wie T-Zelldepletion, 
Anergieinduktion oder Kontrolle durch regulatorische T-Zellen, tolerogene Dendritische 
Zellen und parenchymale Zellen kontrollieren autoreaktive Lymphozyten. Des Weiteren sind 
besonders empfindliche Organe, mit sehr begrenzter Möglichkeit der Regeneration, so 
genannte immunprivilegierte Organe, durch anatomische Barrieren und ein immun 
suppressives Mikromilieu geschützt. 
Es gibt verstärkte Hinweise, dass die Mechanismen, welche lokale Immunsuppression 
innerhalb von Organen etablieren, mit denen überlappen, die systemische T-Zelltoleranz 
erzeugen. Jedoch herrscht weiterhin Unklarheit über die wesentlichen Moleküle, die für die 
Immunregulation die zentrale Rolle spielen. Dieses Wissen könnte für Therapieoptionen von 
Autoimmun- oder Krebserkrankungen sowie für die Induktion von Transplantationstoleranz 
hilfreich sein. 
Ziel dieser  Arbeit war die Identifikation neuer Moleküle, welche für die periphere Toleranz 
von Bedeutung sind. Das im Labor etablierte transgene Mausmodel der peripheren CD8 T-
Zelltoleranz wurde für die Beschreibung solcher Kandidatengene mittels 
Genexpressionsanalysen genutzt. Dickkopf 3 (Dkk3) wurde als 10-fach hoch-reguliert in 
toleranten CD8 T-Zellen identifiziert. Dkk3 mRNA war bis dahin in peripheren Geweben 
inklusive dem Gehirn, dem Auge, den Eierstöcken und der Gebärmutter gefunden worden. 
Zusätzlich war beschrieben worden, dass Dkk3 überexpremiert in Tumorzelllinien, den ERK 
MAPK Signalweg inhibiert, welcher auch in die T-Zellsignalübertragung involviert ist. Daher 
wurde die Hypothese aufgestellt, dass Dkk3 eine Funktion in der Immunregulation haben 
könnte. 
In dieser Arbeit wird Dkk3 als neuer Modulator von Immunantworten identifiziert. Die 
Induktion von Dkk3 Protein wurde in transgenen regulatorischen CD8 T-Zellen gefunden und 
war notwendig für deren regulatorische Funktion. So waren die Dkk3-defizientnen transgenen 
Mäuse nicht tolerant gegenüber dem Modellantigen und die regulatorische Funktion der CD8 
T-Zellen war aufgehoben in Anwesenheit von Dkk3-blockierendem Antikörpern. 
Die immunregulatorische Funktion von Dkk3 war nicht auf das transgene Mausmodel 
begrenzt. Polyklonale T-Zellen von Dkk3-defizienten Mäusen waren hyper-proliferativ und 
produzierten verstärkt IL-2. Diese Beobachtung konnte durch eine verstärkte Aktivierung der 
ERK MAP-Kinase erkärt werden. 
ZUSAMENFASSUNG 
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Zu den Organen mit hoher Expression von Dkk3 gehören immunpriviligierte Organe (ZNS, 
Plazenta), die Leber, welche eine zentrale Bedeutung für die orale Toleranz inne hat, das Herz 
und die Lunge. Dkk3 konnte hingegen nicht in den lymphoiden Organen und dem Serum 
nachgewiesen werden. Insofern wurde vermutet, dass Dkk3 an der Etablierung eines lokalen 
immunsuppressiven Mikromillieus beteiligt sein könnte. 
In der Tat konnte die immunregulatorische Funktion von Dkk3 im Model der Experimentellen 
Autoimmunen Enzephalitis (EAE) demonstriert werden. Ohne die Produktion von Dkk3 
durch Neuronen in den Dkk3 defizienten Tieren war der Verlauf von EAE durch die fehlende 
Kontrolle aktivierter CD8 T-Zellen stärker und länger anhaltend. So führte auch die 
Applikation des Dkk3-spezifischen Antikörpers eine Woche nach der peripheren Aktivierung 
der T-Zellen zu verstärkter Chronizität von EAE. 
Somit wird hier Dkk3 als universeller Immunregulator identifiziert, welcher von der 
regulatorischen transgenen CD8 T-Zellpopulation und von Zellen immunpriviligierter Organe 
genutzt wird. 
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3 INTRODUCTION 
3.1 Introduction to the immune system 
The immune system employs diverse elaborate mechanisms to protect the organism against 
pathogens. The immunological responses are classified in two main branches, the innate and 
adaptive immunity. The innate immune system responds to a microbial infection in a generic, 
non specific way. On the other hand, the adaptive immune system can successfully 
discriminate between self and foreign antigens and involves antigen-specific responses to 
viruses, bacteria and extracellular parasites. The main effector cells of the adaptive immunity 
are the lymphocytes. The lymphocytes are cells of hematopoietic origin that carry antigen-
specific receptors of great diversity. The B cells are the mediators of humoral adaptive 
responses. Their main role is the antigen recognition and antigen-specific antibody secretion, 
which in turns leads e.g. to the complement-mediated killing of microbes or to the 
neutralization of microbial products that are toxic for the host.  
Apart from the humoral responses, adaptive immunity is achieved by T cell responses. T cells 
originate from the bone marrow and further develop in the thymus (Moore et al. 1965; 
Micklem et al. 1966; Moore et al. 1967). The thymus-derived mature CD4 and CD8 T cells 
display a T cell receptor (TCR) repertoire of at least 2.5x107 diverse specificities. Therefore 
they can recognize a broad spectrum of antigenic peptides, presented on MHC class I 
molecules by the host cells and MHC class II molecules by professional antigen presenting 
cells (APCs). Antigen recognition by the TCR in combination with costimulatory signals, 
delivered by the APCs, lead to T cell activation and proliferation (June et al. 1994).  
CD4 T cells are otherwise called helper T cells and upon activation they proliferate and 
produce proinflammatory cytokines. Thereby they promote the activation and proliferation of 
CD8 T cells and the function of phagocytes and macrophages in response to intracellular 
bacterial infections. Moreover, CD4 helper cells play a central part in the destruction of 
extracellular pathogens by activating B cells. There are three classes of CD4 T cell responses, 
depending on the nature of the antigen and the cytokine-milieu at the site of inflammation. 
Th1 CD4 T cells develop in the presence of IL-12, secrete mainly IFN-γ and respond to 
intracellular microbes (Schmitt et al. 1994). Th2 responses are characterized by IL-4 secretion 
upon encounter of extracellular pathogens in the presence of IL-4 (Street et al. 1991; Cardell 
et al. 1992). The IL-17-producing Th17 CD4 T cells have been recently identified (Harrington 
et al. 2006). They have been reported to differentiate in the presence of TGF-β and IL-6 
(Stockinger et al. 2007) and to respond to extracellular bacteria by inducing strong 
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inflammation (Korn et al. 2007; Ouyang et al. 2008). Independently of what their target 
pathogen is, all CD4 T cells are activated upon antigen presentation on MHC class II 
complexes by professional APCs, most usually dendritic cells (DCs). 
CD8 T cells mediate cytotoxic T cell responses. They recognize antigenic peptides presented 
on MHC class I complexes by host cells or cross-presented by DCs (Zinkernagel et al. 1979; 
Azuma et al. 1992; Albert et al. 1998). Upon activation CD8 T cells kill the infected cells or 
the tumor cells by release of perforin and granzymes. Perforin forms pores to the target’s cell 
membrane through which granzymes can enter the cell and induce apoptosis (Griffiths 1995).  
The potency of the mammalian adaptive immune system lies on the mentioned highly 
sophisticated effector responses but also the long-lasting immunologic memory. Memory 
CD4 and CD8 T cells are developed during the anti-microbial responses, survive for long 
time and effectively prevent disease upon a second encounter with the same pathogen 
(Zinkernagel et al. 1996). 
3.2 Immunological Tolerance 
3.2.1 The role of immunological tolerance 
The mammalian immune system protects the host from a broad spectrum of pathogenic 
microorganisms while avoiding misguided or excessive immune reactions that would be 
deleterious to the individual. Adaptive immune responses are characterized by enormous 
diversity in antigen recognition, high antigen specificity, potent effector activity and long-
lasting immunologic memory. Because of this potency, serious damage to the host may ensue 
if aberrant immune responses are triggered against self, such as in case of autoimmunity or 
allergy. Immunological tolerance assures the unresponsiveness of the adaptive immune 
system to self antigens and the control of the quality and magnitude of the adaptive immune 
responses, so that host is protected and immune homeostasis is preserved.  
The diverse mechanisms by which T cell tolerance is established will be explicitly discussed 
below. First the basic principles of central tolerance will be described. Next, all strategies 
reported to suppress self reactive T cells and T cell hypereactivity in peripheral tissues will be 
addressed. Furthermore, the mechanisms of local protection against the devastating results of 
T cell responses, which are vital for the immune privileged organs, will be reviewed. Since in 
this thesis the role of Dickkopf 3 as a mediator of peripheral T cell tolerance and immune 
privilege will be explored, the last paragraphs of this chapter will focus on the current 
knowledge about the expression, structure and function of this protein. 
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3.2.2 Central T cell Tolerance 
The term central tolerance is used to describe the mechanisms taking place in the thymus 
during T cell development, which result in the elimination and control of auto-reactive T 
cells. The two major branches of central tolerance are the clonal deletion of self-specific T 
cells and the intrathymic induction of natural CD4+CD25+Foxp3+ regulatory T cells (nTregs). 
3.2.2.1 Clonal Deletion 
The proper function of the adaptive immune system is firmly dependent on the diversity of 
the TCR repertoire. The development of a T cell population that carries a wide spectrum of 
antigen specificities and is able to recognize MHC-bound antigenic peptides takes place in the 
thymus. Progenitor T cells described as double negative, i.e. lacking expression of CD4 and 
CD8, the molecules that will ultimately define the functional status of T cells, are generated in 
the bone marrow and migrate to the thymus. There, initially the TCRβ and, after entering the 
double positive (CD4+CD8+, DP) stage, the TCRα genes undergo random recombination by 
the RAG1/RAG2 enzymatic complex (Figure 1).  
 
Figure 3-1. Schematic representation of T cell 
development in the thymus. T cell progenitors, 
described as double negative thymocytes undergo 
random recombination of the TCRβ genes and 
become double positive thymocytes. Followingly the 
TCRα genes are rearranged and the TCR-positive 
thymocytes differentiate to CD4 and CD8 single 
positive T cells. Adapted from Immunity:The 
immune response in infectious and inflammatory 
disease (DeFranco, Locksley and Robertson) 
 
The randomly generated TCRs are next tested for their ability to recognize the host’s MHC 
molecules, in a process called positive selection. Positive selection is conducted in the thymic 
cortex (Anderson et al. 1994). Only the T cells with a TCR able to recognize self-MHC 
molecules get a survival signal and are positively selected (Zinkernagel et al. 1974; Kisielow 
1988; Wagner 2007). An estimated 90-95% of DP T cells that are not able to bind to the 
available MHC complexes undergo death by neglect (Huesmann et al. 1991). 
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The risk of randomly developing a T cell population with an extremely high TCR diversity 
would be high, if a checkpoint for the elimination of auto-reactive specificities was not 
present. The possibility of autoimmunity is minimized by deleting the auto-reactive T cells 
before they escape the thymus. This process is described as negative selection or clonal 
deletion and takes place in the thymic medulla. Clonal deletion occurs upon self antigen 
presentation by the medullary thymic epithelial cells (mTECs) (Burkly et al. 1993; Volkmann 
et al. 1997) and the thymic dendritic cells (Brocker et al. 1997). mTECs promiscuously 
express a variety of tissue restricted antigens (TRAs), under the transcriptional regulation of 
Autoimmune Regulator (AIRE). Self-antigens expressed by mTECs represent virtually all the 
parenchymal organs, thereby mirroring the peripheral self (Derbinski et al. 2001). TRAs have 
been shown to be either presented by mTECs themselves or transferred to and cross-presented 
by thymic dendritic cells (Gallegos et al. 2004). The MHC-self antigen recognition by a TCR 
usually leads to the deletion of the respective T cell.  
Even though this process is highly efficient, since approximately 50-70% of the positively 
selected T cells are thought to be subject to negative selection (van Meerwijk et al. 1997), not 
all auto-reactive T cells are eliminated by clonal deletion. An additional mechanism of central 
tolerance is the thymic development of regulatory T cells (Kappler et al. 1987; Modigliani et 
al. 1996; Itoh et al. 1999). 
3.2.2.2 Naturally arising CD4+CD25+FoxP3+ regulatory T cells (nTregs) 
Naturally arising CD4+CD25+FoxP3+ regulatory T cells are a specialized subset of T cells 
with suppressive and regulatory properties. They have been shown to suppress proliferation of 
naïve T cells, their differentiation into effector T cells and the effector functions of activated 
CD4 and CD8 T cells. Moreover, they have been reported to regulate the function of natural 
killer cells, natural killer T cells, B cells, macrophages and dendritic cells (Sakaguchi et al. 
2008). The suppressive activity of nTreg cells requires their prior activation through their T 
cell receptor. Once activated, nTreg cells can also suppress other T cells in an antigen-
nonspecific way. Their importance in immune regulation is demonstrated by the development 
of autoimmune diseases following their ablation (Shevach et al. 2001; Kim et al. 2007). The 
transcription factor forkhead box protein P3 (Foxp3) is expressed specifically in the natural 
Treg cell lineage and is a master regulator of Treg cell development (Fontenot et al. 2003; 
Hori et al. 2003). 
Like conventional T cells, nTreg cells develop in the thymus, through positive selection (Itoh 
et al. 1999). Data from a variety of systems indicate that the development of functional 
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peripheral Treg from their intrathymic precursors also involves an extrathymic phase, 
dependent on the presence, in the periphery, of the relevant self-antigen (Seddon et al. 2000). 
Until recently it was believed that they express a TCR repertoire enriched in self specificities, 
distinct from that of conventional T cells (Hsieh et al. 2006). The development of Treg cells 
was thought to be driven by high-affinity interactions between TCRs on developing 
thymocytes and self peptide–MHC complexes on thymic epithelial cells (Jordan et al. 2001; 
Kawahata et al. 2002). The affinities of such interactions were proposed to be somewhere 
between the affinities of interactions triggering positive and negative selection of thymocytes 
(Figure 2) (Apostolou et al. 2002; Kawahata et al. 2002). However, this view was challenged 
by a recent study indicating that TCR repertoire of Treg cells was as diverse as in 
conventional T cells and self TCR specificities in the Treg population were rare (Pacholczyk 
et al. 2007). Thus it is possible that one result of commitment to the Treg cell lineage is an 
increased resistance to negative selection in the thymus resulting in a population of Treg cells 
with a TCR repertoire similar to conventional T cells but likely with slightly higher affinity to 
self (Stephens et al. 2007). 
  
Figure 3-2. Development of naturally arising regulatory T cells in the thymus. (a) The promiscuously 
expressed TRAs are presented and cross-presented by mTECs respectively. This leads to the deletion of auto-
reactive T cells but also to the development of CD4CD25Foxp3 regulatory T cells that are self antigen-specific. 
Adapted from: Self representation in the thymus: an extended view. Bruno Kyewski & Jens Derbinski, Nat Rev 
Immunol, 2004. (b) Developing T cells with affinity for self peptide-MHC complexes that is higher than in 
conventional T cells and lower than in negatively selected thymocytes are positively selected to become nTreg 
cells. Adapted from: Regulatory T cells in the control of immune pathology, Kevin J. Maloy & Fiona Powrie, 
Nat Immunol, 2001.   
3.2.3 Peripheral T cell Tolerance 
Central tolerance is very efficient, but it is still incomplete. Self-reactive T cells, especially 
those with a lower affinity for self-antigens, can escape negative selection (Bouneaud et al. 
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2000). Also, certain antigens, for which tolerance is required, may not be expressed in the 
thymus. This is the case for most harmless environmental proteins, to which chronic immune 
reactivity must not develop.  
Furthermore, T cell responses mounted against pathogens need to be controlled in order to 
avoid extended tissue damage. Apart from the naturally occurring regulatory T cells that 
develop in the thymus and regulate the immune responses in the periphery there are additional 
mechanisms for controlling autoreactive T cells in the tissues. Cell intrinsic processes, which 
control excessive T cell activation, include the deletion of or anergy induction in self-specific 
T cells. On the other hand, systemic regulation of cell populations is based on self-antigen 
presentation by immature dendritic cells and parenchymal cells, as well as regulatory T cell 
induction in the tissues. 
3.2.3.1 Deletion by activation induced cell death  
Activation induced cell death (AICD) restrains the for the host tissues devastating 
consequences of T cell hyperactivation. Additionally, the molecular mechanisms of AICD are 
employed by immune regulators (i.e. tolerogenic dendritic cells and Tregs) to extinguish self-
reactive T cells, as it will be later on discussed.  
Following repeated T cell activation by their specific antigen, T cells undergo apoptosis by 
AICD. AICD is brought about by the crosslinking of death receptors on T cells. Death 
receptors are a subclass of the tumor necrosis factor receptor (TNFR) family, which trigger 
apoptosis. The best studied mechanism of AICD is Fas-mediated T cell death (Alderson et al. 
1995; Mogil et al. 1995). Resting naïve T cells carry the Fas molecule (CD95) on their 
surface. TCR stimulation in the presence of IL-2 results in Fas upregulation (Refaeli et al. 
1998) and upon repeated antigen stimulation, the Fas ligand (FasL) is also expressed on 
activated T cells (Lenardo et al. 1999). Additionally, FasL is expressed by immune privileged 
organs. Ligation of Fas to the FasL leads to the formation of the death-inducing signaling 
complex (DISC) with subsequent activation of caspases, resulting in caspase-mediated 
apoptosis (Nagata 1997). Other death ligands and receptors, such as the TRAIL molecule and 
its receptor have also been implied to contribute to AICD. (Jeremias et al. 1998; Mariani et al. 
1998). 
3.2.3.2 T cell anergy 
Anergy has been described as a long lasting cell intrinsic state of T cell unresponsiveness 
(Jenkins et al. 1987; Fathman et al. 2007). It is associated with a nearly complete block of T 
cell proliferation and IL-2 production (Quill et al. 1987). Secretion of other cytokines, such as 
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IFNγ, is reduced during anergy but this can be reversed with strong stimuli (i.e. the presence 
of IL-2 and IL-15). T cell anergy is suggested to be a result of suboptimal TCR activation, 
due to the lack of costimulatory molecules on the antigen presenting cells (Quill et al. 1987; 
Schwartz 2003) or due to T cell stimulation by peptide-MHC complexes with low TCR 
avidity (Sloan-Lancaster et al. 1993). In vivo T cell anergy has been observed after systemic 
delivery of superantigens (Kawabe et al. 1990), adoptive transfer of TCR transgenic T cells 
into hosts that express the cognate antigen as a self antigen (Kearney et al. 1994) and the 
administration of soluble peptide antigen into TCR transgenic mice (Kearney et al. 1994; 
Dubois et al. 1998). 
At the molecular level, T cell anergy is the result of the overactivation of the nuclear factor of 
activated T cells (NFAT), which then becomes disproportionate to the activator protein 1 
(AP-1) levels (Kang et al. 1992; Lyakh et al. 1997; Macian et al. 2002). Defective 
extracellular regulated kinase (ERK) and Jun N-terminal kinase (JNK) MAPK signaling is the 
cause of reduced AP-1 DNA binding and subsequent IL-2 transcription (Li et al. 1996). The 
small GTPase Ras which is upstream of the MAPK pathways is fully activated after 
coactivation with CD28. However, in anergic T cells, Ras GTP-loading is defective (Fields et 
al. 1996). In detail, diacylglycerol kinase α (DGKα) upregulation in anergic T cells prevents 
diacylglycerol analog (DAG) signalling from inducing to the GTP loading of the Ras 
molecules by Ras guanyl-releasing protein 1 (RASGRP1) (Figure 4) (Fathman et al. 2007).
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Figure 3-3.  Schematic representation of the signalling pathways in T cell activation and T cell anergy 
induction. (a) T cell activation involves both TCR and CD28 stimulation, which finally lead to NFAT activation 
and AP1 formation, leading to IL-2 transcription. (b) Absence of T cell costimulation leads to anergy induction. 
This involves NFAT activation as well as defective Ras activation due to the inhibition of DAG signaling by 
DGKα. Αdapted from: Molecular mechanisms of CD4+ T-cell anergy, C. Garrison Fathman and Neil B. 
Lineberry, Nat Rev Immunol, 2007. 
Moreover, the induction of the EGR transcription factor by the upregulated NFAT has also 
been shown to contribute to the anergic state (Harris et al. 2004; Safford et al. 2005). 
Additionally, many reports have implicated an important role for E3 ubiquitin ligases in 
anergy. Protein poly-ubiquitination is a post-translational mechanism of governing cellular 
events by leading to proteasomal protein degradation (Pickart et al. 2004). The E3 ubiquitin 
ligases CBL-B, GRAIL and ITCH have been demonstrated to be crucial for the establishment 
of T cell anergy in vitro and in vivo (Heissmeyer et al. 2004; Loeser et al. 2007; Schartner et 
al. 2007) . 
3.2.3.3 Natural regulatory T cells 
Naturally arising FoxP3+ regulatory T cells, which are developed in the thymus as described 
above, greatly contribute to the maintenance of systemic tolerance. FoxP3 loss-of-function 
mutations result in the lethal X-linked lymphoproliferative disorder of the naturally arising 
scurfy mouse strain, and the homologous human disorder IPEX syndrome (‘immune 
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dysregulation, polyendocrinopathy, enteropathy, X-linked’ syndrome), which are attributed to 
impaired Treg development (Chatila et al. 2000; Bennett et al. 2001). FoxP3 has been shown 
to interact with the transcription factors NFAT (Wu et al. 2006) and AML1/Runx1 (Ono et al. 
2007), that otherwise induce gene-expression related to the differentiation and proliferation of 
effector T cells. Thereby it represses the transcription of proinflammatory cytokines and 
induces immune-suppressive molecules. 
A range of molecular mechanisms for Treg mediated immune regulation have been identified 
by in vitro and in vivo studies of their function. Since natural Tregs constitutively express 
CD25, which is the high-affinity receptor for IL-2, they have been reported to suppress 
effector T cells in vitro and in vivo by IL-2 deprivation-mediated apoptosis (Pandiyan et al. 
2007). Additionally, Tregs have been shown to act by immunosuppressive cytokine secretion, 
cell-contact suppression and functional modification or killing of APCs. Treg-secreted 
cytokines such as IL-10 (Belkaid et al. 2002), TGF-β (Maloy et al. 2003; Li et al. 2007) and 
the newlly identified IL-35 (Collison et al. 2007) have been demonstrated to be mediators of 
suppression either in vivo or in vitro. Moreover, during inflammation Treg cells are able to 
kill the activated T cells or APCs through cell-contact by a granzyme B- (Gondek et al. 2005) 
and perforin- (Grossman et al. 2004) dependent mechanism (Cao et al. 2007). Furthermore 
they have been indicated to inhibit T cell proliferation in vitro by delivering cAMP through 
gap junctions (Bopp et al. 2007), or to suppress activated T cells in vitro and in vivo by 
generating pericellular adenosine with CD39 and CD73 enzymatic activity (Deaglio et al. 
2007). Finally, activated Tregs downmodulate CD80/86 expression on APCs and stimulate 
dendritic cells, in a CTLA-4 dependent manner, to form the enzyme indolamine 2, 3 
dioxygenase (IDO). IDO is a potent immunosuppressive enzyme, which catalyzes the 
catabolism of tryptophan, an aminoacid that is essential for T cell proliferation (Puccetti et al. 
2007).  
All the mechanisms mentioned above, contribute to the regulatory role of nTreg cells during 
the steady state (immune homeostasis) or during an active immune response. These 
mechanisms can act independently of each other or in combination, depending on the local 
microenvironment as well as on the strength and duration of the antigenic stimulus (Figure 3) 
(Tang et al. 2008). 
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Figure 3-4. Schematic representation of the molecular mechanisms reported to contribute to the 
regulatory role of nTregs. The potential contribution of the above mentioned mechanisms in homeostatic 
control (steady state), damage control (inflammation) and infectious tolerance are depicted. Adapted from: The 
FoxP3+ regulatory T cell: a jack of all trades, master of regulation, Qizhi Tang & Jeffrey A Bluestone, Nat 
Immunol, 2008. 
3.2.3.4 Adaptive regulatory T cells  
Apart from the nTreg cells many regulatory T cell populations have been described to develop 
in the periphery. The CD4+CD25+ regulatory T cells that differentiate from naïve T cells in 
the periphery are called adaptive or induced regulatory T cells. They are suggested to be 
triggered by low-affinity antigen or altered TCR signal transduction and, unlike the natural 
Tregs, do not necessarily display biased anti-self TCR repertoire (Bluestone et al. 2003). This 
implicates their regulatory function in the context of anti-pathogen immune response 
suppression and oral- or probiotic-antigen tolerance (Groux 2001). Adaptive regulatory T 
cells mainly suppress immune responses in a cytokine dependent manner (Maloy et al. 2001).  
Naïve T cells have been shown to acquire FoxP3 expression and consequently Treg function 
in the periphery in several experimental models. It has been observed in vitro that antigenic 
stimulation in the presence of TGF-β triggers naïve T cell differentiation to FoxP3+ T cells 
(Chen et al. 2003; Apostolou et al. 2004; Kretschmer et al. 2005). FoxP3 induction by TGF-β 
is due to demathylation of CpG motifs within the foxp3 locus. Strikingly this chromatin 
modification is incomplete, when compared to the methylation state in the foxp3 locus of 
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nTreg cells. Therefore, induced FoxP3+ regulatory T cells can loose FoxP3 expression and 
suppressive function when deprived of TGF-β (Floess et al. 2007). 
 Interestingly, the presence of TGF-β, IL-2 and retinoic acid (which is secreted by a particular 
subset of dendritic cells in the gut-associated lymphoid tissue) facilitate the generation of 
FoxP3+ T cells in vitro. Hence FoxP3 Treg induction upon oral antigen-presentation by 
retinoic acid-producing dendritic cells could be a plausible mechanism of oral tolerance. Yet, 
what remains to be determined is the stability of the peripherally induced FoxP3 Tregs in vivo 
and their contribution to the peripheral pool of the regulatory T cells (Sakaguchi et al. 2008). 
Besides FoxP3+ Tregs, several other types of inducible regulatory T cells have been 
described. For example, repeated antigen stimulation of CD4 T cells in the presence of IL-10 
in vitro leads to the development of so called Tr1 cells (Chen et al. 1994; Groux et al. 1997). 
Tr1 cells secrete IL-10 and TGF-β. They have been shown to control the activation of naïve 
and memory T cells in vivo and in vitro and to suppress Th1 and Th2 responses to pathogens, 
tumors and alloantigens, antibody production by B cells and the APC stimulatory capacity. 
The presence of Tr1 cells in the small intestine has been associated with the protection against 
colitis. 
It is noteworthy to mention that a variety of other T cell subpopulations, including 
CD8+CD122+ (Endharti et al. 2005), CD8+CD28- T cells (Filaci et al. 2004), CD4-CD8- (Chen 
et al. 2004) and γδ T cells (Hayday et al. 2003) have also been reported to exert an 
immunosuppressive activity. 
3.2.3.5 Tolerance induction by dendritic cells 
Dendritic cells are highly specialized antigen presenting cells (APCs), that process and 
present antigenic peptides to T cells (Steinman et al. 1978; Banchereau et al. 1998). During 
inflammation DCs process both microbial and self proteins (e.g. derived from dead cells). 
However, they induce a specific immune response against pathogens but not against self 
antigens. Thus, they contribute to peripheral autoreactive T cell tolerance (Steinman et al. 
2003). The exact mechanism of tolerance induction by dendritic cells is still unclear, so only 
an overview of the most accepted notions will be given below. 
Initially, it has been proposed that in the steady state immature DCs in peripheral tissues take 
up soluble proteins or apoptotic bodies arising from cell turnover. Upon migration to the 
secondary lymphoid organs, they present or cross-present (Heath et al. 1998; Kurts et al. 
1998) these self antigens, inducing either deletion or anergy of the autoreactive CD4 and CD8 
T cells respectively (Steinman et al. 2002; Morelli et al. 2003). Alternatively, short-lived 
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migratory DCs may function as antigen-transporting cells that transfer self antigens to longer-
lived spleen- and lymphnode-resident DCs with inherent tolerogenic function.  
Later it has been shown that DC migration, as well as self antigen processing and presentation 
for tolerance induction, require partial DC maturation (Lutz et al. 2002). Semi-mature DCs, or 
otherwise named quiescent mature DCs, exhibit upregulated levels of surface MHC and T 
cell-costimulatory molecules and produce low amounts of IL-10 and no IL-12. The 
tolerogenic quiescent mature DCs have been demonstrated to promote FoxP3+ Treg and Tr1 
differentiation and expansion and release the suppressive mediators  IL-10 and IDO (Morelli 
et al. 2003). 
The tolerogenic features of DCs are lost after full maturation, which occurs in the presence of 
TLR-ligands (e.g. dsRNA, LPS, CpG oligunucleotides), proinflammatory cytokines (i.e.GM-
CSF, IL-1β, TNF-α, IFN-α, prostaglandin E2) and interaction of the TNFR family molecules 
on the DC surface (i.e. CD40, TNFR, RANK) with their ligands. Activated DCs upregulate 
MHC class II, costimulatory molecules (such as CD80 (B7.1), CD86 (B7.2), CD40) and 
CCR7 on their surface and secrete proinflammatory cytokines like IL-1α, IL-1β, IL-6, IL-12 
and IFNα. This in turn allows the initiation of an effective immune response in the draining 
lymphnodes. Although activated DCs still present self antigens, the prior establishment of self 
tolerance prevents detrimental autoimmune responses. 
3.2.3.6 Tolerance induction by parenchymal cells 
3.2.3.6.1 Tolerance induction in the liver 
The liver is continuously exposed to both potential pathogens and commensal bacterial- or 
food-derived antigens through the portal vein. Tolerance to oral antigens is assured not only 
by the generation of adaptive CD4 regulatory T cells in the gut associated lymphoid tissue 
(GALT) (Sun et al. 2007), but importantly by the induction of suppressive T cells in the liver. 
Intraportal antigen application results in systemic antigen-specific tolerance, suggesting that 
the liver is particularly capable of actively inducing peripheral tolerance. In addition, it has 
been shown that concomitant liver transplantation from the same donor prolongs allograft 
survival (Calne et al. 1969; Praseedom et al. 2001). Many mechanisms are proposed to 
underlie tolerance induction in the liver. For instance, liver dendritic cells have been 
demonstrated to produce high amounts of suppressive IL-10. Importantly, liver parenchymal 
cells are also crucial for the establishment of CD8 T cell peripheral tolerance in the liver 
(Crispe et al. 2006). 
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When leukocytes pass with the blood flow through the liver sinusoids, they come in contact 
with the liver sinusoidal endothelial cells (LSEC) that line the sinusoids. Since LSEC 
constitutively express various surface molecules associated with professional APCs, such as 
MHC class I and II, CD54 (ICAM-I), CD106 (VCAM-I), the costimulatory molecules CD80, 
CD86 (Lohse et al. 1996) and CD40 (Leifeld et al. 1999), they are able to present soluble 
antigen to CD4 T cells and cross-present antigen to CD8 T cells.  Following priming by 
LSEC in vitro, CD4 T cells do not differentiate into Th1 cells (Knolle et al. 1999). In vivo, 
intravenously applicated ovalbumin is cross-presented by LSEC to CD8 T cells, which then 
become non-cytotoxic (Limmer et al. 2000).  
LSEC do not constitute the only liver cell type capable of inducing T cell tolerance. 
Hepatocytes are also thought to be involved in T cell peripheral tolerance induction. This was 
shown in transgenic mice, expressing the MHC class I Kb molecule only on hepatocytes, 
under the control of the C-reactive protein (CRP) promoter, and carrying Kb specific Des-
TCR CD8 T cells (Des-TCRxCRP-Kb mice). The Des-TCR CD8 T cells recognize only an 
intact Kb antigen presented by the hepatocytes and are thus rendered tolerant. As a result Kb 
positive skin grafts are accepted by the DesTCRxCRP-Kb mice (Ferber et al. 1994). 
3.2.3.6.2 Tolerance induction in the skin 
During adult life naïve T cells do not access peripheral tissues, such as the skin and the lung, 
but traffic only in the secondary lymphoid organs (Kimpton et al. 1995; Alferink et al. 1998). 
However, it has been shown that CD8 T cells are tolerized against antigens expressed by skin 
parenchymal cells. More specifically, transgenic mice expressing the Kb antigen under the 
KeratinIV promoter on hair follicle keratinocytes and carrying the Kb-specific Des-TCR T 
cells are tolerant to Kb. Notably, they have been demonstrated to accept Kb positive skin and 
tumor grafts (Alferink et al. 1995). The observed tolerance cannot be assigned to Kb cross-
presentation by DCs, since the Des-TCR can recognize only an intact Kb molecule and does 
not react with the peptides of a degraded Kb molecule presented by another MHC class I 
molecules. Interestingly, it has been demonstrated that CD8 T cells can pass through the 
endothelium during the neonatal phase and recognize self-antigens on the keratinocytes. 
Contact with parenchymal cells renders these CD8 T cells tolerant (Alferink et al. 1998). 
Tolerant CD8 T cells persist during adulthood and are capable of regulating the reactivity of 
naïve Des-TCR CD8 T cells against Kb positive tumor and skin grafts (Figure 5). The 
molecular mechanism underlying this CD8 T cell tolerance remains to be elucidated and this 
is subject of this study. So far it has been demonstrated that regulatory Des-TCR CD8 T cells 
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upregulate mRNA of molecules, such as TGF-β, that have already been described to play a 
role in the natural Treg mediated suppression (Reibke et al. 2006). 
 
Figure 3-5. CD8 T cell 
tolerance induction by 
keratinocytes during the 
neonatal phase. In 
neonates naïve T cells pass 
through the endothelium 
and are rendered tolerant to 
self-antigens that are 
presented by parenchymal 
cells. Tolerant CD8 T cells 
survive until adulthood and 
can regulate naïve CD8 T 
cells with the same TCR 
specificity. 
 
3.2.4 Immunological privilege 
Described above are the mechanisms that are important for the establishment of a systemic 
immunological tolerance. In addition, certain organs are predisposed to establish an immune-
privileged microenvironment in order to assure local protection. The term immunological 
privilege was first assigned to organs, where prolonged allogeneic graft survival was observed 
(Medawar 1948). In detail, the anterior chamber of the eye, the brain, the hamster cheek 
pouch, the testes and the ovary were all shown to accept allogeneic grafts. Pregnancy is 
another example of immunological privilege, since the fetus, which also carries foreign 
antigens of paternal origin, is not recognized as an allograft and rejected.  
Initially it was proposed that immune privilege is the consequence of the absence of 
lymphatic drainage in the eyes, brain and endometrium, which would lead to ignorance of 
antigens (Medawar 1948). However, peripheral blood contains antibodies against antigen 
injected in the brain (Harling-Berg et al. 1989; Harling-Berg et al. 1991; Gordon et al. 1992), 
allogenic cells transplanted in the eye (Kaplan et al. 1977) or fetal HLAs of paternal origin 
(McLean et al. 1970). Yet, immune privilege is  the result of active regulation, namely local 
suppression or deviation of potentially harmful T cell responses (Niederkorn 2006).  
Numerous mechanisms of local immune suppression have been described. Interestingly, 
MHC I molecules are absent from the neurons (brain) (Lampson et al. 1984), the corneal 
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endothelium and the retina (eye) (Abi-Hanna et al. 1988) as well as from the trophoblast. This 
prevents the CTL responses in the particular tissues. Furthermore, the expression of non-
classical MHC Ib molecules (HLA-G, HLA-E in human and Qa2 in mice) results in the 
inhibition of NK cells and the cell death of activated CD8 T cells (Streilein 2003; Niederkorn 
2006).   
 Apart from the non-classical MHC Ib molecules, some more cell surface proteins have been 
indicated to contribute to the immunological privilege of the eye, the brain and the fetus. For 
example, the FasL is expressed on ocular cells, cytotrophoblasts and the placenta and is 
upregulated on microglia, astrocytes, oligodendrocytes and neurons upon inflammation 
(Askenasy et al. 2005). As already mentioned FasL binds to the Fas receptor on activated T 
cells, thus inducing AICD. Proapoptotic TNF-realted apoptosis inducing ligand (TRAIL) has 
also been found in ocular (Wang et al. 2003) and fetal tissues (Phillips et al. 1999) but not in 
the CNS (Dorr et al. 2002). Yet its function in maintaining immunological privilege is still to 
be established. Finally, some secretory molecules with T cell suppressive role, such as TGF-β, 
soluble FasL and IDO are traced in the anterior chamber of the eye and the placenta 
(Askenasy et al. 2005; Niederkorn 2006). The functional relevance of anti-inflammatory 
molecules in the brain is poorly understood. It has been suggested that the neuropeptides VIP, 
α-MSH and somatostatin are regulating T cell immune responses in the CNS (Reinke et al. 
2006).  
The phenomenon of immune deviation has mainly been described in the anterior chamber of 
the eye and is known as ACAID (anterior chamber associated immune deviation). Upon 
antigen deposition in the anterior chamber unique, tolerogenic F4/80+ APCs in the iris-ciliary 
body are believed to capture it and enter the thymus via blood circulation. There, they induce 
CD4-CD8-NK1.1+ thymocytes, which in turn enter the circulation as recent thymic emigrants 
and home to the spleen, contributing to the generation of splenic suppressor cells. F4/80+ 
APCs are also claimed to migrate directly from the eye to the spleen, where they contribute to 
the development of CD8 regulatory T cells. CD4 regulatory T cells and γδ T cells are also 
involved in ACAID. Soluble antigen introduced to the brain induces an immune deviation that 
bears notable resemblance to ACAID and is therefore called brain-associated immune 
deviation (BRAID). It seems that BRAID does not follow the same splenic pathway as 
described for ACAID, since it could not be induced in splenectomized mice, but it could be 
adoptively transferred by cells isolated from the cervical lymph nodes (Wenkel et al. 2000).  
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3.2.5 Failure of peripheral T cell tolerance: the example of experimental autoimmune 
encephalitis 
Experimental autoimmune encephalitis (EAE) is a model for multiple sclerosis and an 
example of T cell-mediated autoimmunity.  It is an autoimmune disease that is driven mainly 
by CD4 and also by CD8 T cells specific for myelin sheath, a component of the CNS. EAE 
can be induced in mice by active immunization with CNS-self antigens mixed with complete 
Freund’s adjuvant (CFA) and administration of pertussis toxin, which breaks the blood brain 
barrier and provides to the activated autoreactive T cells access to the CNS. The most 
commonly used CNS-derived antigens are the myelin basic protein (MBP), the myelin 
oligodendrocyte glycoprotein (MOG) and the proteolipid protein (PLP). Alternatively EAE 
can be also induced by the adoptive transfer of MBP- or MOG-reactive T cells with 
subsequent pertussis toxin administration.  
In EAE, autoreactive CD4 and CD8 T cells traffic to the CNS parenchyma, resulting in focal 
areas of inflammation and demyelination throughout the CNS. Until recently, research done 
in the EAE model was focused on Th1 CD4 T cells and their resulting cytokines and 
chemokines, which were thought to be involved in the pathogenesis of the disease. The 
cytokine IL-12 was considered to be essential for the development of Th1 mediated 
autoimmunity. However, during the last few years this view has been challenged. It has been 
shown that the cytokine IL-23, which promotes the survival and expansion of Th17 cells, 
plays a major role in the establishment of EAE (Thakker et al. 2007) and that Th17 cells are 
the major disease mediators (Aranami et al. 2008). Moreover, the role of IFN-gamma 
producing CD8 T cells in EAE pathogenesis is not to be overseen, since two independent 
EAE models involve MBP or MOG specific CD8 T cells (Steinman 2001; Ji et al. 2007). 
3.3 Dickkopf 3  
3.3.1 The Dickkopf family of proteins and Dickkopf3 
Dickkopf3 (Dkk3) is a member of  the Dickkopf family of five secreted proteins, DKK1-4 
and Soggy, which share 37-50% sequence identity (Krupnik et al. 1999; Barrantes Idel et al. 
2006). Dkk proteins contain a signal sequence and share two conserved cystein-rich domains, 
separated by a linker domain (Figure 6). Each of the cystein-domains contains ten conserved 
cystein residues (Glinka et al. 1998; Krupnik et al. 1999). The N-terminal cysteine-rich 
domain, Dkk_N (formerly called Cys1) is unique to the Dkk protein family while the C-
terminal cysteine-rich domain (formerly called Cys2) has a pattern of ten cysteines related to 
that of the colipase fold (Niehrs 2006). According to structure-function analysis of vertebrate 
Dkk1,2 and 4, the colipase fold domain alone is sufficient for their biological activity, which 
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is the Wnt pathway modulation. Colipases facilitate the interaction of pancreatic lipases with 
lipid micelles, therefore, it has been suggested that the Cys2 domain may enable Dkk proteins 
to interact with lipids in order to regulate Wnt signaling (Krupnik et al. 1999).  
 
Figure 3-6. Domain 
structure of the Dkk 
family. Dkk1–4, as well as 
DkkL1 (sgy) are shown with 
their domains corresponding 
to DKK_N and colipase 
fold. The sgy-domain is only 
found in DKK3 and DKKL1 
(sgy). Adapted from: 
Function and biological 
roles of the Dickkopf family 
of Wnt modulators, C 
Niehrs, Oncogene, 2006. 
 
 
Contrary to the conserved cysteine-rich domains, the linker region is highly variable between 
Dkk proteins and it is notably larger in Dkk1, 2 and 4 (50-55 amino acids), when compared to 
Dkk3 (12 amino acids). The mammalian Dkk1 possesses one potential N-glycosylation site 
located close to the C-terminus of the protein. Chicken and mammalian Dkk3 displays four 
potential N-glycosylation sites (Krupnik et al. 1999). Additionally, Dkk proteins carry several 
potential proteolytic cleavage sites for furin-type proteases (Nakayuma, 1997), suggesting that 
the proteins may be subject to post-translational proteolytic processing.  
Dkk3 and Soggy (Sgy), which display high sequence similarity, share an N-terminal signal 
peptide, due to which it is predicted that they can be secreted. Sequence homology between 
these two proteins is most pronounced within the N-terminal domain of Dkk3, although 
significant amino-acid identities are seen beyond this domain that extend into the cysteine-
rich domains of Dkk3. The residues shared by Sgy and Dkk3 are poorly conserved in other 
Dkks, implicating that the two proteins are uniquely related (Krupnik et al. 1999). 
3.3.2 Function of the Dkk proteins 
As mentioned above the Dkk family members were characterized as regulators of the Wnt 
signaling pathway. The Wnt pathway has been shown to play an essential role during 
embryonic development (Micsenyi et al. 2004; Nelson et al. 2004). Moreover, during 
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adulthood this pathway has been reported to regulate cell proliferation, motility, cell polarity 
and cell fate (Etheridge et al. 2004). Wnt proteins are secreted molecules that trigger at least 
two (possibly three) pathways that employ Wnt receptors of the frizzled seven transmembrane 
class. These are the canonical or Wnt/b-catenin pathway (Cadigan et al. 2006), the planar cell 
polarity pathway (PCP), which does not involve β-catenin but recruits small GTPases of the 
rho/ cdc42 family to activate JNK and the Wnt/Ca2+ cascade that is still controversial and may 
be partly overlapping with the PCP pathway (Kohn et al. 2005). Of the various pathways 
employed by Wnt proteins, Dkk proteins specifically affect the canonical or Wnt/β-catenin 
cascade. In the canonical Wnt pathway, ligation of the Frizzled and lipoprotein-receptor-
related (LRP5/6) proteins lead to the activation of the cytoplasmic protein Dishevelled, which 
in turn destabilizes the complex formed by APC, Axin and glycogen synthetase kinase 3 
(GSK3). Since APC/Axin/GSK3 complex promotes phosphorylation and degradation of β-
catenin, the Wnt signaling leads to the stabilization and nuclear translocation of β-catenin, 
which in turn forms a complex with TCF transcription factors (Figure 7) (Cadigan et al. 
2006). Dkk1, 4 and occasionaly Dkk2 have been shown to inhibit Wnt signaling by binding 
on LRP5/6 and Kremen coreceptors. This leads to the formation of a ternary complex, which 
is internalized by endocytosis. As a result the Wnt receptors are eliminated from the plasma 
membrane, thus preventing Wnt-LRP5/6 complex formation (Mao et al. 2002).  
All Dkk proteins show distinct and elevated expression patterns in tissues that mediate 
mesechyme-epithelial transitions, indicating that they may participate in the development of 
the heart, tooth, hair follicles, limb and bone (Monaghan et al. 1999). In Xenopus embryos 
Dkk1 is expressed in the Spemann organizer region and is essential for head development 
(Glinka et al. 1998). In the mouse Dkk1 is essential for head development and is involved in 
distal limb patterning (Mukhopadhyay et al. 2001), osteoblast and cardiac myocyte 
proliferation (Kawano et al. 2003). 
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Figure 3-7. The Wnt signalling pathway. Upon activation by the Wnt signal, Dsh inhibits the activity of GSK-
3β. In the absence of the Wnt signal, GSK-3β is thought to phosphorylate and consequently induce the 
degradation of β-catenin. Therefore, the Wnt signal stabilizes and causes the accumulation of β-catenin, which in 
turn associates with TCF/LEF family transcription factors. Adapted from: Regulation of hematopoiesis and 
hematopoietic stem cell niche by Wnt signaling pathways, Michael J Nemeth & David M Bodine, Cell Res, 
2007. 
3.3.3 Dkk3 is a divergent member of the Dickkopf family 
By a number of criteria Dkk3 appears to be a divergent member of the Dkk family. First, by 
DNA sequence similarity, vertebrate Dkk1, 2 and 4 are more related to each other than they 
are to Dkk3 (Glinka et al. 1998). Additionally, Sgy, the distant member of the Dkk family, 
shares sequence similarity with Dkk3 but not with other Dkk family members (Krupnik et al. 
1999).  Two Cnidaria, Hydra and Nematostella, have two Dkk genes only, one related to 
vertebrate Dkk1, 2 and 4 (Guder et al. 2006) and one related to vertebrate Dkk3 (Fedders et 
al. 2004). Human Dkk1, 2 and 4 are located within the well-characterized chromosome 
4/5/8/10 paralogy group (Dkk1 maps to 10q11, Dkk2 to 4q25 and Dkk4 to 8p11). Genes 
within this paralogy region were duplicated early in vertebrate evolution (Pollard et al. 2000). 
In contrast, human Dkk3 maps to 11p15.3, which is not part of the same paralogous 
chromosome group. Taken together, these observations suggest a deep split into Dkk3 and 
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Dkk1/2/4 gene families during early metazoan evolution, and more recent gene duplications 
accompanied by functional divergence of the two Dkk subfamilies (Guder et al. 2006). 
Strikingly, Dkk3 and sgy do not seem to function in Wnt signaling (Glinka et al. 1998; 
Krupnik et al. 1999; Mao et al. 2001). 
3.3.4 The functions of Dkk3 
Like other Dkk members, Dkk3 is expressed during vertebrate development in suggestive 
patterns in many organs. In adult rodents, a prominent expression of Dkk3 is observed in the 
brain and in fibroblasts. Dkk3 protein was also found in the the zona glomerulosa of the 
human adrenal cortex, where it inhibits steroidogenesis (Suwa et al. 2003). Additionally, 
significant Dkk3 expression at the RNA level has been reported for the spinal cord, eye, lung, 
heart, colon, ovary, uterus and hair follicle (Niehrs 2006). Moreover a study using human 
pancreatic tissue revealed Dkk3 mRNA and protein expression in a subpopulation of the 
human pancreatic beta cells (Hermann et al. 2007).  
Dkk3 knockout mice (Dkk3-/-) are, however, viable and fertile, possibly due to 
complementation of the Dkk3 function by the highly homologous Sgy. Dkk3-/- only display 
increased lung ventilation and hyperactivity. It is worth pointing out that minor changes in the 
frequency of NK cells, immunoglobulin M, hemoglobin and hematocrite levels have also 
been reported (Barrantes Idel et al. 2006). 
Dkk3 is also known as ‘REIC’ (Reduced Expression in Immortalized Cells) (Tsuji et al., 
2000), since it has been proposed to act as tumor suppressor. Dkk3 has been claimed to be 
downregulated in a number of tumors, including hepatocellular carcinoma, lymphoblastic 
leukemia, prostate cancer, renal cell carcinoma, lung carcinoma, melanoma, ovarian cancer 
and neuroblastoma (Koppen, 2008). Lack of Dkk3 expression in tumor cells has been 
attributed to hypermethylation of the Dkk3 promoter. For example, the second of the two 
CpG islands in the promoter region is up to 90% methylated in lung carcinoma  (Yue et al. 
2008).  
Dkk3 overexpression suppresses tumor cell proliferation (Abarzua et al. 2005; Lodygin et al. 
2005; Kawano et al. 2006) and induces an apoptotic phenotype (cytoplasm shrinking, 
membrane blebbing and nucleus condensation). In Dkk3-transduced lung carcinoma cells 
proliferation is inhibited by activation of caspase-3. NIH3T3 cells infected with adenovirus 
expressing Dkk3 undergo apoptosis via JNK activation and subsequent mitochondrial 
translocation of the proapoptotic Bax protein (Abarzua et al. 2007) 
Interesingly, Dkk3-transfected RM9 cells exhibit decreased motility due to Dkk3-mediated 
downregulation of metalloproteinase 2 (MMP2), which degrades type IV collagen (Edamura 
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et al. 2007). Kuphal et al. have also indicated that Dkk3 transfected cells upregulate E-
cadherin, which restrains their migratory capacity (Kuphal et al. 2006).  
Although hypermethylation of Dkk3 correlates with certain cancers (Kobayashi et al. 2002; 
Roman-Gomez et al. 2004; Lodygin et al. 2005), the physiological relevance of altered Dkk3 
expression in tumors and its potential growth inhibitory effect are unknown. Notably, Dkk3 
deficient mice show no enhanced tumorigenesis (Barrantes Idel et al. 2006) and the role of 
Dkk3 in the regulation of cell proliferation and migration remains to be studied.  
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3.4 Aim of the study 
Protection of tissues from the devastating effects of immune responses is essential for the 
integrity of the organism. Tolerance mechanisms that are summarized above are controlling 
potentially auto-reactive lymphocytes. In addition, organs that are particularly sensitive to 
damage by inflammation, so called immune privileged sites, are protected by tissue barriers 
and contain an immunosuppressive microenvironment.  
There is increasing evidence that processes establishing immune privilege overlap with those 
associated with tolerance induction. For example, the proapoptotic molecule FasL (Nagata 
1997; Lenardo et al. 1999; Askenasy et al. 2005) and the immunosuppressive enzyme IDO 
(Morelli et al. 2003; Niederkorn 2006; Puccetti et al. 2007) are involved in both the peripheral 
immune regulation by T cells or dendritic cells and in the maintenance of the immune 
privileged status of some tissues. However, there is much yet to learn about the molecules 
with a potential universal role in immune regulation. This knowledge could help in the 
understanding of systemic diseases, such as autoimmunity and cancer, and introduce novel 
principles concerning transplantation tolerance.  
Aim of this study was the identification of novel molecules that are potential mediators of 
both peripheral tolerance and immune privilege. Starting from a transgenic mouse model for 
peripheral CD8 T cell tolerance, identification of such candidate genes was attempted by wide 
range gene expression analysis. Consequently, Dkk3 was chosen for further characterization. 
On the one hand, Dkk3 was found to be upregulated in the tolerant CD8 T cells. On the other 
hand, Dkk3 mRNA was previously shown to be present in peripheral tissues, such as the 
brain, the eye, the spinal cord, the ovary and the uterus (Niehrs 2006). 
The subsequent objective of the study was the functional characterization of Dkk3 in the 
context of immune regulation. First, the role of Dkk3 in the establishment and maintenance of 
peripheral CD8 T cell tolerance was investigated. Moreover the potential of Dkk3 to regulate 
polyclonal T cell responses was examined and its regulatory properties at the cellular and 
molecular level were defined. The study was completed by the determination of the 
importance of Dkk3 in the establishment of immune privilege and in the protection from 
autoimmunity of vital organs, such as the brain.  
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4 MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Chemicals 
• Acrylamide and TEMED were purchased from ROTH. 
• PMA, Ionomycin, Bovine Serum Albumin (BSA) and CFSE were from Sigma.  
• Pertussis Toxin was from Calbiochem.  
• Incomplete Freud’s adjuvant (IFA) and M. Tuberculosis (attenuated) were obtained from 
Dufco. 
• RPMI, Glutamine, Penicillin and Streptavidinwere purchased from Gibco. 
• Fetal calf serum (FCS) was from Biochrom AG. 
• Propidium Iodide was from BD. 
• Protease Inhibitor Cocktail was purchased from Roche. 
• Phosphatase inhibitor cocktail was from Calbiochem. 
• SuperSignal West Dura Extended Duratio Substrate was purchased from PIERCE. 
• Fixation and Permeabilization kit was obtained from BD Biosciences. 
FoxP3 staining kit was from eBioscience. 
4.1.2 Antibodies 
The monoclonal antibodies for FACS are listed on the following table.  
Antigen Conjugate Company 
Annexin V FITC BD 
CD3e PE/Cy7 Natutec 
CD3e FITC BD 
CD3e Biotin BD 
CD3e PE BD 
CD3e purif. Natutec 
CD3e APC BD 
CD3e PerCP/Cy5.5 BD 
CD3e APC-Cy7 BD 
CD4 FITC BD 
CD4 FITC BD 
CD4 PE BD 
CD4 APC BD 
CD4 APC-Cy7 BD 
CD4 PerCP-Cy5.5 BD 
CD8a APC BD 
CD8a FITC BD 
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CD8a PE BD 
CD8a APC BD 
CD8a PE-Cy7 BD 
CD8a PerCP-Cy5.5 BD 
CD11b APC BD 
CD11c PE-Cy7 BD 
CD19 PE BD 
CD19 PerCP/Cy5.5 BD 
CD19 Biotin BD 
CD19 APC BD 
CD25 (IL2Ra) PE BD 
CD45 R (B220) PerCP/Cy5.5 BD 
CD45 R (B220) FITC BD 
CD45 R (B220) PE Natutec 
CD45.1 FITC BD 
CD45.1 Biotin BD 
CD45.1 PE-Cy7 natutec 
CD45.1 PE BD 
CD45.2 FITC BD 
CD45.2 Alexa750-APC natutec 
CD62L FITC BD 
CD62L APC BD 
CD69 FITC BD 
CD69 Biotin BD 
CD103 FITC BD 
CD117 (c-kit) PE-Cy7 Natutec 
CD152 (CTLA-4) Biotin natutec 
CTLA4 Biotin   
DX5 Biotin BD 
Foxp3 PE natutec 
Foxp3 APC natutec 
I-A/I-E FITC BD 
I-A/I-E PE BD 
IFN-g PE BD 
IL-2 PE BD 
      
IL-17a AlxFluor647 Natutec 
Ly6C  Biotin BD 
Ly6C FITC BD 
Ly6G+Ly6C (Gr-1) FITC BD 
Ly-49A&D (sca-1) APC natutec 
NK-1.1 APC BD 
NK-1.1 PerCP/Cy5.5 BD 
NK-1.1 PE-Cy7 BD 
TCR Vb11 PE BD 
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The primary and secondary antibodies for Western blotting are listed below. Unless otherwise 
stated, they were purchased from Cell Signaling. 
• Smad4 (rabbit) 
• phospho-p44/42 MAP Kinase (Thr202/Tyr204) 
• p42 MAP Kinase (3A7) mouse mAb 
• p44/42 MAP Kinase rabbit antibody 
• phospho-MEK1/2 (Ser221) rabbit 
• MEK1/2 (rabbit) 
• phospho-SAPK/JNK (Thr183/Tyr185) mouse mAb 
• SAPK/JNK (rabbit) 
• phospho-p38 MAPK (Thr180/Tyr182)(28B10) mouse mAb 
• p38α  MAP Kinase (L53F8) mouse mAb 
• phospho-PKCθ (Thr538) Rabbit 
• PKCθ (rabbit) 
• phospho-Akt (Thr308)(C31E5) rabbit mAb 
• phospho-IκB-α (Ser32/36)(5A5) mouse mAb 
• IκB (L35A5) mouse mAb (aminoterminal Antigen) 
• antibodies were obtained from Cell Signaling.  
• Ras Activation Assay Kit was purchased from Upstate Biotechnology.  
• Mouse IgG serum (Sigma and Meridian Bioscience) 
• Goat anti-Mouse (Dianova) 
• Goat anti-Rabbit (Dianova) 
4.1.3 Microarrays 
GeneChip Test3 Arrays (Affymetrix) 
GeneChip Mouse Genome 430 2.0 Arrays (Affymetrix) 
4.1.4 Cell lines 
HEK 293T cell line 
P815.Kb.B7 cell line 
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4.1.5  Buffers  
4.1.5.1 Molecular Biology Buffers 
TE:  100 mM Tris, 10 mM EDTA, pH 8.0 
5x Fragmentation 
Buffer:  
20mM Tris Acetate (pH : 8.2), 500mM Potassium Acetate, 150mM 
Magnesium Acetate  
12x MES :  1.22M MES, 0.89M [Na+] 
MES hybridization 
buffer :  
Final 1X concentration is 100 mM MES, 1M [Na+], 20 mM EDTA, 
0.01% Tween-20 
Wash Buffer A :  6X SSPE, 0.01% Tween-20 
Wash Buffer B :  100 mM MES, 0.1M [Na+], 0.01% Tween-20 
2x Stain Buffer:  200 mM MES, 2M [Na+], 0.1% Tween-20 
SAPE Stain solution:  1x Stain Buffer containing 2mg/ml BSA, 10µg/ml SAPE 
(Streptavidin Phycoerythrin) 
Antibody Solution:  1x Stain Buffer containing 3mg/ml BSA, 0.1mg/ml Goat IgG and 
3µg/ml biotynilated antibody 
4.1.5.2 Protein Biochemistry Buffers 
Lysis Buffer:  20mM Tris (pH 7.5), 5mM MgCl2, 1% Novidet P40, protease inhibitor 
cocktail (Roche), phosphatase inhibitor cocktail (Calbiochem) and I-
acetamide 
SDS Running 
Buffer:  
25 mM Tris, pH 8.3, 192 mM Glycin, 0.1 % SDS (w/v) 
6x SDS sample 
Buffer:  
62.5 mM Tris, pH 6.8, 20 % Glycerin, 2 % SDS (w/v), 714 mM β-
Mercaptoethanol, 0.025 % Bromοphenol blue (w/v) 
Transfer 
Buffer:  
48mM Tris, 39mM Glycine, SDS 1.3mM and 20% methanol. pH between 
9-9,4 
Stripping 
buffer:  
62.5mM Tris/HCl (pH 6.7), 10mM β-Mercaptoethanol, 2% SDS 
Blocking 
buffer:  
PBS containing 0,1% Tween20 and 5% Skim Milk powder 
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4.1.5.3 Other Buffers 
Phosphoate Buffered Saline (PBS):  130 mM NaCl, 2.6 mM KCl, 15 mM 
KH2PO4, 4 mM Na2HPO4 
Dubelcco’s PBS (dPBS):  PBS supplied with MgCl2 and CaCl2 was 
purchased by Invitrogen 
dPBS-10:  dPBS containing 10% FCS 
FACS Buffer:   
dPBS containing 0,5% FCS and 0.05% NaN3   
Staining Buffer:  dPBS containing 1%FCS 
Incubation Buffer:  PBS containing 0.5% (w/v) bovine serum 
albumin 
MACS Buffer:  PBS pH 7.2 containing 2mM EDTA and 
0.5% (v/v) FCS 
 
4.1.6 Cell culture Media 
T cell 
medium:  
RPMI 1640 supplemented with 10% (v/v) heat-inactivated FCS, 10 mM 
Hepes, 2 mM L-glutamine, 0.05 mM 2-mercaptoethanol, 100 units/ml 
penicillin, and 100 mg/ml streptomycin 
BMDC 
medium:  
RPMI 1640 containing 10% (v/v) F1/16 cell supernatant containinig GM-CSF; 
10% (v/v) heat-inactivated FCS, 10 mM Hepes, 2 mM L-glutamine, 0.05 mM 
2-mercaptoethanol, 100 units/ml penicillin, and 100 mg/ml streptomycin 
DMEM-full 
medium:  
DMEM containing 10% heat-inactivated FCS, 10 mM Hepes, 2 mM L-
glutamine, 1 mM sodium pyruvate, 0.05 mM 2-mercaptoethanol, 100 units/ml 
penicillin, and 100 mg/ml streptomycin 
Cell-
freezing 
medium:  
heat inactivated FCS supplemented with 10%(v/v) DMSO: 
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4.2 Methods 
4.2.1 Transfected Cell Lines 
The murine mastocytoma cell line P815 (H-2Kd) transfected with the genes encoding for the 
murine MHC class I molecule H-2Kb and the B7-1 gene plus the neomycin resistance gene 
has been described (Alferink et al. 1995). Cells were cultured in full DMEM. For s.c. injection 
the cells were trypsinized (2 ml of 0.25% trypsin plus 2.5 mM EDTA for 5 min at room 
temperature) and washed twice with Dulbecco's PBS.  
4.2.2 Mice  
The Des-TCR mice (H-2Kk) carry a transgene for the Kb-specific TCR. The Des-
TCRx2.4KerIV-Kb mice (H-2Kk or H-2Kd) additionally express the Kb molecule controlled by 
the 2.4KeratinIV-promoter (Alferink et al. 1995). The Des-TCR and Des-TCRx2.4KerIV-Kb 
transgenic mice were crossed to a recombination-activating gene 2-deficient (Rag2-/-) 
background (H-2Kk). The Dickkopf-3 deficient (Dkk3-/-) mice were kindly provided by 
professor C. Niehrs (Barrantes Idel et al. 2006). They were backcrossed to C57BL/6N mice at 
least 15 times. For the experiments Dkk3+/+ littermates from Dkk3+/-x Dkk3+/- breedings were 
used, unless stated otherwise. Dkk3-/- mice were crossed to Des-TCR mice (H-2Kk) and  Der-
TCRx2.4KerIV-Kb mice (H-2Kk or H-2Kd) and only the H-2Kk littermates were used for 
experiments. The C57BL/6 2D2-TCR (MOG35-55 specific TCR) strain is transgenic for the 
mouse T-cell receptor alpha and beta chain (TCRα and TCRβ) transgenes(Bettelli et al. 2003). 
The genotyping of the transgenic mice was performed by PCR or Flow Cytometry, as 
indicated in table 1. C57BL/6 mice were obtained from Charles River Breeding Laboratories 
(Sulzfeld, Germany). The experimental mice used were between six and twelve weeks of age. 
All mice were bred and maintained under specific pathogen-free conditions (SPF) at the 
animal facility of the German Cancer Research Center.  
Mixed bone marrow chimeras were generated by irradiation of the recipient mice with 
950cGray of γ-irradiation via a cesim isotope (127Cs) source and subsequent intravenous 
transfer of 2-5x106 donor bone marrow cells 24 hours later. The chimeric mice were allowed 
to fully reconstitute the peripheral lymphoid tissue for eight weeks before use. 
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Transgene Genotyping method Reagents 
Des-TCR Flow Cytometry anti-clonotypic mAb (Desire-1) binding to the H-2Kb-specific 
alloreactive cytolytic (CTL) clone KB5-C20 (Hua et al. 1986) 
2.4KerIV-Kb Southern Blot  
2D2-TCR Flow Cytometry anti-Vβ11 and anti-CD4  Abs 
Dkk3 knockout Triplex PCR p1 (5'-GATAGCTTTCCGGGACACAC-3'), p2 (5'-
TCCATCAGCTCCTCCACCTCT-3'), p3 (5'-
TAAGTTGGGTAACGCCAGGGT-3') (Barrantes Idel et al. 2006) 
Rag2 knockout FACS anti-CD45.R (B220) Ab, binding on B cells 
Table 4-1. Mouse Genotyping 
4.2.3 T cell and dendritic cell purification ex vivo 
4.2.3.1 T cell isolation 
T cells were isolated from the spleen or the subcutaneous (axilliary and inguinal) lymph 
nodes. A single cell suspension was made by cutting the spleen in two pieces with a scalpel 
and passing the cells through a sieve. Lymph nodes were smashed with frosted-end slides. 
Cells were washed with ice-cold dPBS and centrifuged at 4oC at 1200rpm for 7min. Cell 
pellets were resuspended with dPBS. Lymphocyte numbers were determined by direct 
counting under the microscope using a Neubauer chamber, after suspending a cell aliquot in 
trypan blue (25% in dPBS (v/v)). 
4.2.3.2  CD4 or CD8 T cell purification 
Single-cell suspensions of T cells were washed with ice-cold dPBS and centrifuged at 4oC at 
1200rpm for 7min. For MACS positive selection cell pellets were resuspended with 
90ul/107cells MACS buffer containing 10% (v/v) purified CD4 or CD8-specific microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany). After 20min incubation at 4oC cells were 
washed with ice-cold MACS buffer and centrifuged. Cell pellets were resuspended with 1ml 
MACS buffer and run over Miltenyi LS columns. Columns were washed 4 times with 3ml 
MACS buffer to eliminate non-specifically bound cells. CD4- or CD8-T cells were eluted 
from the column with 5ml MACS buffer and purity was checked with flow cytometry. For the 
microarray experiments, MACS isolated CD8 T cells were stained with Des-TCR- and CD8-
specific antibodies and the Propidium Iodide negative cells were sorted on a FACSVantage 
(BD Biosciences).  
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For CD8 T cell purification with MACS CD8 isolation kit cell pellets were first incubated 
with the biotin-antibody cocktail at 4oC for 15min and additionally with the anti-biotin MACS 
beads for 10min prior to column purification. CD8 T cells were collected with the flow-
through. 
4.2.3.3 CNS-infiltrating T cell isolation 
At day 20 or 29 after EAE induction, Dkk3-/- and Dkk3+/+ mice were lethally anesthetized 
with injection of 0.7 ml of a ketanest (5mg/ml)/ rompun (0.2%) mix i.p.. Followingly, they 
were perfused with 20ml ice cold Hank’s balanced salt solution (HBSS) each. Brain and 
spinal cord were removed and cell suspension was performed after 25min digestion at 37oC 
with 2.5mg/ml collagenase D and 1mg/ml deoxyribonuclease I (Sigma-Aldrich) in dPBS. T 
cells were isolated using Percoll gradient. For cytokine staining T cells were stimulated 
overnight with 5ug/ml anti-CD3 in full RPMI medium at 37oC. Six hours prior to flow 
cytometry stimulated T cells were given Protein Transport Inhibitor (BD GolgiPlugTM) in a 
1:1000 dilution. 
4.2.3.4 Conventional dendritic cell isolation 
Single spleen and lymph node cell suspension was made as described above. After washing 
cell pellets were resuspended with dPBS containing DNAse I and collagenase D. Digestion 
was performed at room temperature for 40min while stirring with a mini magnet. Cells were 
washed with dPBS containing 2mM EDTA to avoid the reassociation of dendritic cells with T 
cells. Where indicated, dendritic cells were further purified using the CD11c MACS beads. 
The protocol for MACS positive selection is described in paragraph 2.3.2. 
4.2.3.5 Expansion of bone marrow derived dendritic cell (BMDC)  
Bone marrow was extracted from the femur and tibiae bones with ice-cold dPBS. Cell 
suspension was made by gently pipetting. Cells were washed and resuspended with BMDC 
medium. 2x106 cells were plated pro each 100mm Petri dish to a final volume of 10ml BMDC 
medium. At day 3 10ml of BMDC medium was added pro dish. At day 6 half of the medium 
was collected, centrifuged at 1200rpm and room temperature for 7 min. The cell pellet was 
resuspunded with fresh medium and replated. At day 10 the non-adherent cells (mostly 
dendritic cells) were collected by gently washing the bottom of the dishes. The resulting 
population was more than 75% CD11c positive, as confirmed by flow cytometry. 
MATERIALS AND METHODS 
 45 
4.2.3.6 BMDC activation with CpG 1668 
Ten days after BMDC expansion DCs were harvested, washed and resuspended with BMDC 
medium at 8x106cells/ml in 15ml TPP tubes. DCs were then incubated with 0.5uM CpG 1668 
for 1 hour at 37oC with periodical mixing. Next they were washed with dPBS containing 
2mM EDTA to avoid formation of cell clumps and cell pellets were frozen in BMDC medium 
plus 10%DMSO. 
4.2.4  Flow Cytometry 
4.2.4.1 Staining of surface antigens for Flow Cytometry 
5-10x106 cells were suspended in 50ul FACS buffer containing fluorochrome-conjugated 
antibodies in a concentration of 2ug/ml each. Cells were incubated with the antibody mixture 
for 20min at 4oC and then washed with FACS buffer. The antibodies that have been used for 
FACS are shown in table 2. Cell pellets were resuspended with 0.1ml FACS buffer. FACS 
buffer was always ice-cold. Flow cytometry was performed on a FACSCalibur with the 
CellQuest software or on a FACS Canto with the Diva software (BD Biosciences, San Diego, 
CA). The FACS data was analysed with the FlowJo software. 
4.2.4.2 Staining of intracellular antigens for Flow Cytometry 
Cells were stained for their surface markers, and then permeabilized using the 
cytofix/cytoperm kit (PharMingen). Briefly cells were gently resuspended in the 
cytofix/cytoperm solution for 20 min at 4oC, washed with the cytoperm/wash buffer and 
stained with fluorochrome-conjugated antibodies for intracellular antigens diluted 1:50 in 
0.1ml cytoperm/wash buffer for 30min at 4oC. Cells were then washed with the 
cytoperm/wash buffer and resuspended in staining buffer. 
To detect Foxp3 protein expression, cells stained with anti-CD4 and anti-CD25 Abs were 
fixed using Fix/Perm Buffer (eBioscience) for 30min at 4oC, then incubated with APC-
conjugated anti-mouse Foxp3 Ab (FJK-16; eBioscience) for 30 min at 4°C. 
To detect phospho-ERK intracellularly, cells stained for surface markers were fixed with 1% 
formaldehyde for 10min at 37oC and permeabilized with 90% ice-cold methanol for 30min at 
4oC.  After washing with incubation buffer cells were stained with 10% anti-phospho-ERK-
APC Ab in staining buffer for 30min at 4oC. 
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4.2.5 Molecular Biology 
4.2.5.1 RNA Isolation 
0.3-0.5x106 Des-TCR CD8 T cells (purity >99%) were used for RNA isolation. Cell lysis and 
RNA isolation were performed with QIAshredder and Qiagen RNeasy Mini Kit.  Up to 
~260ng RNA was isolated from 0,5 x 106 CD8 T cells. RNA was precipitated with 3M 
NH4OAc and pellet paint (dye which binds to RNA pellet, Novagen). RNA concentration was 
determined with Quant-iT RiboGreen RNA Assay kit (Invitrogen) – based on fluorescent dye 
that binds exclusively on RNA. RNA quality was controlled using Agilent RNA Nano Chips.  
4.2.5.2 mRNA amplification 
The mRNA contained in the isolated total RNA was isolated and amplified with two rounds 
of reverse transcription. Therefore the MessageAmpTM mRNA amplification kit (Ambion) 
was used according to manufacturer’s instructions. Briefly, the MessageAmp™ aRNA 
Amplification procedure is based on the RNA amplification protocol developed in the 
laboratory of Dr. James Eberwine (Van Gelder et al. 1990). The procedure consists of reverse 
transcription with an oligo(dT) primer bearing a T7 promoter and in vitro transcription of the 
resulting DNA with T7 RNA Polymerase to generate hundreds to thousands of antisense 
RNA copies of each mRNA in a sample. The antisense RNA is referred to as aRNA and the 
amplification method is referred to as the aRNA amplification procedure. Two rounds of 
amplification were performed. The starting amount of total RNA was 100-200ng in the first 
round and 2ug in the second round, so that a final amount of 20µg aRNA was obtained. 
4.2.5.3 Determination of the RNA concentration by use of the RiboGreen kit 
The RiboGreen® RNA quantification kit was used according to manufacturer’s protocol for 
the low range assays. Briefly, the RiboGreen reagent was 2000-fold diluted with 1x TE 
buffer. Ribosomal RNA standard dilutions ranging from 1ng/ml to 50ng/ml were prepared. 
The isolated or amplified RNA was diluted 1:50 and the RiboGreen-TE solution was added in 
a 1:1 ratio to all samples. Upon 5min incubation in RT in the dark, the fluorescence of the 
samples at 525nm was determined in a fluorescence microplate reader. Blank values were 
extracted and RNA concentration was calculated based on the standard curve. All samples 
were always measured in duplicates.  
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4.2.5.4 aRNA hybridization, microarray scanning and analysis of the microarray 
results 
The hybridization cocktail was prepared at room temperature and consisted of 50pM control 
oligonucleotide B2, 1x eukaryotic hybridization controls (affymetrix), 0.1mg/ml herring 
sperm DNA, 0.5mg/ml acetylated BSA, 1xMES hybridization buffer and 0.5mg/ml 
fragmented aRNA in total volume of 0.1ml. The cocktail was heated up in 99oC for 5min and 
then incubated at 45oC for 5min. After 5min centrifugation at 13000 rpm the supernatant was 
transferred to a fresh tube. The GeneChip was preincubated with 80ul 1xMES hybridization 
buffer for 10min at 45oC while rotating with 60rpm. The buffer was then removed from the 
chip and the hybridization cocktail was added. The chip was left to hybridize at 45oC, 60rpm 
for 16 hours. Prior to processing the mouse GeneChip 430 platforms, the hybridization 
cocktail was tested in test3 Chips for the aRNA integrity. After hybridization the cocktail was 
removed and the chip was washed with the non strigend Wash-Buffer A and the strigend 
Wash Buffer B and stained with the SAPE Stain Solution and Antibody Solution according to 
the following protocol. 
Step Procedure 
Post Hyb Wash 1 10 cycles of 2mixes/cycle with Wash Buffer 
A at 25oC 
Post Hyb Wash 2 8 cycles of 15mixes/cycle with Wash Buffer 
B at 50oC 
Staining Staining of the probe array in SAPE solution 
at 25oC for 10min 
Post Staining Wash 10 cycles of 4mixes/cycle with Wash Buffer 
A at 25oC 
Second Staining Staining of the probe array in antibody 
solution at 25oC for 10min 
Third Staining Staining of the probe array in SAPE solution 
at 25oC for 10min 
Final Wash 15 cycles of 4mixes/cycle with Wash Buffer 
A at 25oC 
4.2.5.5 Real time quantitative PCR 
Isolated RNA was reverse transcribed into cDNA using Oligo(dT)12-18 primers () and 
Superscript II Reverse Transcriptase (Invitrogen). RT-PCR was performed in a Gene Amp 
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5700 Sequence Detection System (Applied Biosystems, Darmstadt, Germany). Relative 
mRNA frequencies were calculated and the experimental samples were normalized to the 
respective calibrator. 
4.2.5.6 Triplex PCR for Dkk3-/- mouse genotyping 
Mouse tails were digested for 2-3 hours at 56oC in 20ul ProteinaseK Buffer (50mM Tris pH 
8.0, 20mM NaCl, 1mM EDTA, 1% SDS and 2mg/ml Proteinase K ().  Following digestion 
the tail-DNA was diluted 1:150 and 3ul were used for PCR with the primers p1 and p2 for the 
detection of the wild type gene and primers p1 and p3 for the detection of the knocked out 
gene (see table 1). PCR-Mix consisted of 10% (v/v) 10xPCR-Mix (Boehringer), 0.2mM 
dNTPs (Boehringer), 0.08U/ul Taq polymerase (Bioron) and 0.4pmol/ul each primer. 
PCR reaction was conducted in total volume 50ul. 
4.2.6 Protein Biochemistry 
4.2.6.1 Dkk3 protein purification 
Dkk3 protein was expressed in the eukaryotic HEK293T cells. Dkk3 expression was 
confirmed by flow cytometric and Western Blot analysis. The cell supernatant, which 
containted the secreted Dkk3 protein, was collected and protein purification was performed. 
Therefore, sepharose columns loaded with the monoclonal anti-Dkk3 antibobody were used. 
After washing with 1x PBS buffer, the HEK293T-Dkk3 supernatant was given through the 
anti-Dkk3 columns. Followingly the columns were washed with 1x PBS and the Dkk3 protein 
was eluted with elution buffer (0.1M glycine, 0.1M NaCl, pH: 3.2). Finaly, the protein was 
dialysed with 1xPBS and protein concentration was measured by photometry, in 280nm. The 
purity of the final protein solution was confirmed by Western Blot analysis.  
4.2.6.2 Western Blotting 
After stimulation the cell pellets were lysed with ice-cold lysis buffer for 20min on ice 
(30ul/106 cells). Protein lysates were diluted with 6x SDS sample buffer, applied to 15% 
acrylamide SDS-PAGE gels, separated at 180 Volt and transferred to PVDF membranes 
(Millipore). The membranes had previously been incubated with methanol for 30sec, destilled 
water for 2 min and transfer buffer for 15min. For the transfer was used. After being blocked 
4 hours with blocking buffer, the membranes were incubated with primary Ab (table 3) 
overnight at 4oC. The protein band of interest were detected with secondary peroxidase-
conjugated Ab-incubation for 1 hour at room temperature and imaged after 1min incubation 
with SuperSignal® WestDura Extended Duration Substrate (Pierce) in Lumi-imager (Roche 
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Boehriger Diagnostics). Membrane reprobing with different primary Ab was performed after 
membrane stripping at 50oC with stripping buffer for 1 hour.  
4.2.7  In vitro assessment of the T cell function 
4.2.7.1 In vitro T cell stimulation for cell signalling studies 
CD4 or CD8 T cells were purified from spleens and lymph nodes of 6-8-week-old mice, using 
MACS CD4 and CD8 beads or MACS CD8 isolation kit as described above. Flow cytometric 
analysis confirmed that the purity of the separated cells was consistently above 80%. CD4 or 
CD8 T cells were stimulated with PMA (250nM) for 15 min at 37oC. Alternatively, purified T 
cells were incubated with 10ug/ml biotinylated anti-CD3ε (Clone 500A2, BD Bioscience) for 
15min on ice, washed with dPBS-10 and cross-linked with prewarmed 20ug/ml streptavidin at 
37oC for the indicated time. Des-TCR CD8 T cells were stimulated in 24-well plates coated 
with 2ug/ml anti-clonotypic Désiré Ab at 37oC for the indicated time. Following T cell 
activation T cells were washed with dPBS-10 and cell pellets were snap frozen with liquid 
nitrogen.  
4.2.7.2 In vitro T cell proliferation assay  
T cells were purified from spleens of 6-8-week-old mice. 200µl (1x106cells ml-1) were 
cultured in 96.well (U-bottom) plate at 37oC for 72 h. The plate was precoated with various 
concentrations of monoclonal mouse CD3ε and CD28 antibodies. 3H (1µCi well-1) was added 
at 72 h after stimulation and its incorporation was measured 24 hours later. For the CFSE 
proliferation assay cells were stained before stimulation with CFSE (20µM) for 15 min at 
37oC. At various time points cells were stained with color conjugated anti- mouse CD3, CD4 
and CD8 antibodies and PI and analyzed in FACS.  
4.2.7.3 IL-2  production assay (ELISA) 
For IL-2 ELISA T cells were purified from spleens of 6-8-week-old mice. 200µl (1x106cells 
ml-1) were cultured in 96.well (U-bottom) plate at 37oC for 72 h. The plate was precoated with 
various concentrations of monoclonal mouse CD3ε and CD28 antibodies. Supernatants were 
collected 24 hours after stimulation with various concentrations of soluble monoclonal mouse 
CD3ε and CD28 antibodies and IL-2 in the culture media was determined using antibodies 
from. The results were obtained from triplicate samples. 
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4.2.8  In vivo experiments 
4.2.8.1 Thymectomy 
 Up to 15-day-old mice were anesthetized with a mixture of ketamine (Fort Dodge 
Laboratories, Fort Dodge, IA) and xylazine (Abbott Laboratories, North Chicago, IL). A 
small incision of the upper thoracic region exposed the thymic lobes. The thymus was 
removed by the application of suction, and the wound was closed thereafter. Mice were kept 
under a heat lamp and observed after the procedure until they had regained consciousness. 
The complete extraction of both thymic lobes was controlled after the adult mice were 
sacrificed. 
4.2.8.2 Tolerance Readout in Des-TCR x „2.4IVKerKb 
Tolerance was assessed by injecting the  mice with Kb and B7-positive P815 tumor cells 
(Alferink et al. 1995). P815.Kb.B7 tumors are rejected by single-transgenic Des-TCR mice 
and accepted by tolerant double-transgenic Des-TCRx2.4KerIV-Kb mice. 
4.2.8.3 In vivo kill assay 
Recipient mice were transferred with 2 x 106 BMDCs; activated with 0.5µM CpG-ODN 1668 
i.v. Seven days after the first immunization, the specific in vivo kill was quantified as 
previously described (Reibke et al. 2006). Briefly, CBK spleen target cells (H-2b) from naïve 
donor mice were loaded with a high CFSE concentration (1.5uM). CBA  naïve splenocytes 
(H-2k) labeled with a low CFSE concentration were used as nonspecific target cells. The two 
target cell populations were mixed in equal ratios, and 20 x 106 cells in total were transferred 
i.v. into effector mice. Four hours later the specific cytotoxic T lymphocyte activity was 
quantified in spleens of effector mice. The ratio between CFSEhi and CFSElo cells recovered 
in nonimmunized Des-TCR mice indicated 0% specific kill activity.  
4.2.8.4 Experimental Autoimmune Encephalitis (EAE) 
Myelin oligodendrocyte glycoprotein (MOG) peptide 35–55 (sequence 
MEVGWYRSPFSRVVHLYRNGK) was synthesized in the Genomics and Proteomics core 
facility of the German Cancer Research center (Im Neuenheimer Feld 580, 69120 Heidelberg, 
Germany), and was 90% pure as assessed by HPLC and mass spectrometry. EAE was 
induced in 8- to 12-week-old mice. Briefly, Dkk3-/- and Dkk3+/+ mice received in the flank a 
subcutaneous injection of  0.1 ml emulsion containing 200 µg MOG peptide in incomplete 
Freund's adjuvant, supplemented with 200 µg of heat-killed Mycobacterium tuberculosis. 
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Pertussis toxin (200 ng in 0.5 ml of dPBS) was injected intra-peritoneally (i.p.) after MOG 
immunization and 48 h later. The mice were observed for clinical signs and EAE scored on a 
scale of 0–5 with gradations of 0.5 for intermediate scores as follows: 0, no overt signs of 
disease; 1, limp tail or hind limb weakness (but not both); 2, limp tail and hind limb 
weakness; 3, partial hind limb paralysis; 4, complete hind limb paralysis and 5, moribund 
state or death by EAE. The average day of disease onset was calculated by averaging the first 
day of clinical signs for each mouse in one group. The average maximum disease score was 
determined by averaging the highest score achieved by each individual mouse.  
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5 RESULTS 
5.1 Gene expression profile of regulatory Des-TCR CD8 T cells 
CD8 T cell tolerance induction by parenchymal cells in the periphery contributes to the 
protection of the host tissues from autoaggressive T cells. The DesTCRxKerKb transgenic 
mouse model used to study keratinocyte-induced CD8 T cell tolerance has already been 
thoroughly described (chapter 1.3.5.2). As mentioned before, the neonatally induced 
regulatory Des-TCR CD8 T cells are long-lived and control rejection of Kb-expressing skin or 
tumor grafts in adult mice. Thus, it was firstly investigated whether they express a specific 
tolerogenic genetic program, by the use of Affymetrix GeneChip microarrays. 
GeneChip microarrays consist of small DNA fragments (probes), chemically synthesized at 
specific locations on a coated quartz surface. Each gene is represented by eleven 25mer probe 
pairs (11 perfect match & 11 mismatch probes, which serve as controls). The precise location 
where each probe is synthesized is called a feature, and millions of features are contained on 
one array. By hybridizing biotin-labeled amplified mRNA (aRNA) to the array, the amount of 
label can be monitored at each feature. The labeled aRNA is obtained upon in vitro reverse 
transcription of the isolated mRNA in the presence of UTP that is conjugated to biotin. 
In this chapter the gene expression analysis of the tolerant CD8 T cell will be described. This 
involves the isolation of total RNA from naïve, activated and tolerant CD8 T cell samples, the 
amplification and labeling of mRNA prior to hybridization with the microarrays and the 
identification of differentially expressed genes by the use of Bioconductor and GCOS 
softwares.  
5.1.1 Isolation of naïve, activated and tolerant CD8 T cells for gene expression analysis 
In order to characterize their gene expression pattern naïve, activated and tolerant CD8 T cells 
were purified. The naïve CD8 T cells were derived from the spleen of thymectomised 
unimmunized Des-TCRxRAG2-/- mice. The activated CD8 T cells were obtained from Kb-
reactive thymectomised Des-TCRxRAG2-/- mice, that had been subcutaneously injected with 
2x105 P815KbB7 tumor cells and rejected the tumor. The tolerant CD8 T cells were isolated 
from P815KbB7-immunized thymectomized Des-TCRxKerKbxRAG2-/- mice that displayed 
tumor growth (Table 1). All mice were thymectomized at 2 weeks of age in order to enrich 
the long lived neonatally induced tolerant CD8 T cells. The RAG2-/- background assured 
isolation of Kb-specific CD8 T cells only. In Table 1 summarized statistics of tumor growth in 
reactive Des-TCR and tolerant Des-TCRxKerKb mice are shown. 
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Experimental Model Observation ISOLATED CD8 T cells 
Des-TCR mice No tumor Naïve CD8 T cells 
Des-TCR mice injected s.c. with 2x10
5
 
P815 K
b
 B7 tumor cells 
Tumor rejection  
(in 15/16 mice) 
Activated CD8 T cells 
Des-TCRxKer K
b
 injected s.c. with 
2x10
5
 P815 K
b
 B7 tumor cells 
Tumor growth  
(in 12/15 mice) 
Tolerant CD8 T cells 
Table 5-1.  Experimental model for the isolation of different CD8 T cell populations.  The experimental 
protocol for the isolation of naïve, activated and tolerant Des-TCR CD8 T cells is presented. The summed 
statistics from the three experiments for the isolation of CD8 T cells for the microarray analysis are shown. 
The isolation of CD8 T cells was performed 15 days after tumor injection with MACS 
purification, followed by CD8 T cell FACS sorting. First CD8 T cells underwent positive 
MACS selection by use of the anti-mouse CD8 magnetic microbeads. Then CD8 T cells were 
stained with fluorochrome-conjugated anti-CD8 antibody and sorted by flow cytometry. The 
dead cells were excluded by propidium iodide (PI) staining. The anti-clonotypic antibody for 
the Des-TCR was not used for the FACS sorting, since it has been shown that crosslinking of 
the TCR leads to CD8 T cell activation. With the above described procedure, the isolation of a 
more than 95% pure CD8 T cell population was achieved (Figure 1). As shown in Figure 1, 
the number of Des-TCR CD8 T cells in the thymectomised Des-TCRxRAG2-/- mice was very 
limited due to the thymectomy and the RAG2-/- background. In average, pooled spleens of 
four to five mice yielded 400.000 CD8 T cells upon MACS and FACS sorting. 
 
Figure 5-1 Isolation of a highly pure naïve Des-TCR CD8 T cell population. (a) Spleen cells were isolated 
and the percentage of CD8-positive T cells was estimated by flow cytometry before and after MACS CD8 T cell 
sorting. (b) Upon MACS purification, CD8-positive and PI-negative T cells were sorted by FACS and the final 
sample contained more than 95% CD8 T cells. The plots shown are representative for the activated and tolerant 
Des-TCR CD8 T cell samples as well. 
5.1.2 Total-RNA isolation and mRNA amplification for the microarray analysis 
Microarray analysis was performed with triplicate RNA samples derived from each CD8 T 
cell population. Every set of replicates was generated at the same time and comparable 
amounts of total RNA were used as templates for the mRNA amplification (Table 2). The 
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exact procedure of mRNA isolation and amplification is described in the material and 
methods chapter (paragraphs 2.5.1 and 2.5.2).  
sample sorted cell 
number 
isolated RNA 
concentration_amount used for 
amplification 
rna yield (1st round 
of amplification) 
rna yield (2nd 
round of 
amplification) 
Naive 1 7x10
5 
29 ng/µl_176 ng 45 ng/µl 8 hrs_1.9 µg/µl 
Naive 2 9 x10
5
 18.8 ng/µl_112 ng 83.9 ng/µl 5 hrs_1.29 µg/µl 
Naive 3 4 x10
5
 60.6 ng/µl_121 ng 41.75 ng/µl 5 hrs_0.46 µg/µl 
Activated 1 4 x10
5
 30 ng/µl_100 ng 39.2 ng/µl 8 hrs_1.8 µg/µl 
Activated 2 5 x10
5
 43.5 ng/µl_100 ng 40.76 ng/µl 5 hrs_0.41 µg/µl 
Activated 3 4 x10
5
 39.7 ng/µl_198.6 ng 30.2 ng/µl 5 hrs_87.3 ng/µl 
Tolerant 1 4 x10
5
 19.6 ng/µl_160 ng 50 ng/µl 8 hrs 1.5 µg/µl 
Tolerant 2 5 x10
5
 29.7 ng/µl_105 mg 71.1 ng/µl 5 hrs_2.13 µg/µl 
Tolerant 3 4 x10
5
 73.2 ng/µl_198 ng 37.54ng/µl 5 hrs_2.15 µg/µl 
Table 5-2. Summary of the total RNA isolation and mRNA amplification data. 
Every total-RNA sample was isolated from pooled CD8 T cells of four to six mice. By doing 
this, enough RNA quantity for mRNA amplification procedure was obtained and the impact 
of biological variability on the gene expression analysis was minimized. The RNA 
concentration was defined with the RiboGreen kit for precise results, since it permits 
quantification of as little as 1ng/ml of RNA (Table 2). The quality of the isolated total RNA 
was checked using the Agilent RNA 6000 nano chip kit in the Agilent 2100 Bioanalyzer. The 
28S:18S rRNA ratio has traditionally been viewed as the primary indicator of RNA quality, 
with a ratio of 2.0 considered to be indicative of high quality, intact RNA. However, with the 
widespread use of the Agilent 2100 bioanalyzer, it has become clear that the standard of a 2.0 
rRNA ratio is difficult to meet, especially if the RNA is derived from ex vivo isolated samples 
(Schroeder et al. 2006). Therefore, the 28S:18S rRNA ratio, two highly structured and long-
lived molecules, is not used as the sole measure of the quality of the underlying mRNA. 
According to manufacturer’s recommendation total RNAs with 28S:18S rRNA ratios of 1.0 
or greater were used as a starting material for mRNA amplification. Additionally, the RNA 
samples that displayed a high baseline between the 28S and 18S rRNA peaks were discarded, 
since the presence high amounts of middle-sized RNA peaks in the RNA plot is indicative or 
RNA degradation (figure 2).  
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Figure 5-2.  Quality control of the isolated total-RNA in Agilent Bioanalyzer 2100. A plot and the respective 
gel, which are representative of the nine RNA samples that were used as templates of mRNA amplification are 
shown. 
The mRNA amplification protocol was established by optimizing a range of different 
parameters. This was done with control total-RNA, derived from MACS isolated CD8 T cells 
from C57.Bl/6 mice. The starting amount of total RNA was fixed at 150ng, due to the low 
RNA yield from the Rag2-/- derived Des-TCR CD8 T cells (see Table 2). The parameters that 
were changed to conclude for the final protocol were the number and the duration of the in 
vitro transcription cycles, as well as the amount of the amplified RNA (aRNA) template for 
the second round of amplification and biotin labeling. Two rounds of amplification were 
necessary to obtain the required amount of labeled aRNA. The best aRNA integrity and 
labeling resulted from the second in vitro transcription rounds that were of the shortest 
duration. The final protocol of the mRNA amplification is depicted in figure 3. 
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Total RNA (≈ 150ng)
Reverse transcription
cDNA
In vitro transcription 14hours
aRNA
Reverse transcription
cDNA
In vitro transcription with 
biotin-11-UTP 5 or 8hours
aRNA (25µg)
 
Figure 5-3. Summary of the mRNA  amplification protocol. 
The first series of samples were initially amplified by a round of 14 hours in vitro 
transcription. Then 1µg of aRNA was used as a template for a second round of 8 hours in 
vitro transcription. To optimize the labeling quality the next two sets of samples were 
generated with a first in vitro transcription round of 14 hours, followed by a second in vitro 
transcription round which lasted 5 hours. Since the duration of the second amplification round 
was shorter, the aRNA yield was maintained in the same level by increasing the amount of the 
template RNA to 2 µg.  
Upon the first and the second amplification round, the mRNA integrity was assessed with the 
Agilent 2100 Bioanalyzer and in an agarose gel (Figure 4). Successfully amplified aRNA 
appears as a smear from 250 to 5000 nt. The average size of the aRNA is approximately 1500 
nt. The aRNA quantity was calculated using the RiboGreen kit and verified by measurement 
of the optical density (OD) at a wavelength of 260nm. An absorbance value at 260nm (A260) 
of 1 is equivalent to 40µg/ml of RNA. Accordingly, the aRNA concentration (µg/ml) was 
calculated from the sample with the formula A260 x dilution factor x 40 µg/ml (Table 2). 
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Figure 5-4. Estimation of the efficiency of the reverse transcription in Agilent Bioanalyser 2100.  One 
representative plot and gel image of the nine samples that were used for the microarray experiment are shown. 
Next, the amplified, labeled aRNA was then fragmented, so that the hybridization with the 
25mer microarray probes is achieved. The quality of the fragmentation was again tested in the 
Agilent Bioanalyzer 2100 and in agarose gels. The mean size of the successfully fragmented 
aRNA is expected to be 100bp (figure 5). 
 
Figure 5-5. Quality control of the labelled fragmented aRNA. One representative plot and gel image of the 
nine samples that were used for the microarray experiment are shown. 
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5.1.3 Gene expression analysis with the Affymetrix mouse GeneChip 430.2 
microarrays 
5.1.3.1 Quality control and data normalization 
The sample preparation, the mRNA amplification and labeling and the microarray 
hybridization and scanning procedures involve numerous steps, in which experimental errors 
and variation could occur. Therefore, before proceeding to gene expression analysis, quality 
control of the microarray experiment is essential, in order to exclude possible artifacts. The 
data normalization is equally important, since it eliminates the exogenous differences between 
the arrays to be compared. 
A first step in the quality control is the performance of test microarrays in order to estimate 
the quality of the labeled fragmented aRNA samples. With the test microarrays, the presence 
or absence of aRNA hybridization to positive and negative controls respectively, provided a 
hint about the integrity of the aRNA and the hybridization efficiency. In detail, the 
hybridization intensity of the fragmented aRNA with the probes of the housekeeping genes 
beta-actin and glyceraldehyde 3-phosphate dehydrogonase was determined and compared 
among the different samples. Samples, where the mRNA of these housekeeping genes was 
not detectable or where the signal ratio was divergent from the mean range of values, were not 
used. Moreover, the average background value of the test arrays and the percentage of present 
and absent gene transcripts in the samples were analyzed. By this means, the good quality of 
the aRNA samples was validated. Samples with average background value that was higher 
than 40 or with a percentage of detectable mRNAs (P) lower than 40% were discarded and are 
not reported in table 2. Representative results of the test microarrays for each of the aRNA 
categories are attached as index tables 3, 4 and 5. 
The results from the microarray experiment also underwent quality control. First, the CEL 
pictures, which result from the chip scanning, were checked for artifacts (such as scratches, 
air bubbles or other spatial inhomogeneities). The percentage of present aRNA fragments and 
the background values were also taken into consideration 
before concluding that the microarray results could further be 
normalized and analyzed. 
 
Figure 5-6. CEL picture of the hybridized microarrays. One 
representative image out of the nine microarrays is shown. All scanned 
chips displayed no image artifacts or damage. 
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Following the image control, the dynamic range and the distribution of gene intensities in 
each array were analyzed. Since many experimental problems occur at the level of a whole 
array or the sample preparation, it was instructive to look at the histogram of intensities from 
every sample. A representative graph of one of the nine samples is shown (Figure 7a). 
Typically, for arrays that contain quasi-random gene selections, a characteristic distribution is 
observed with most of its mass at low intensities, corresponding to the majority of the sample 
genes, which are weakly transcribed or not expressed. The long tail to the right corresponds to 
genes that are transcribed at various levels.  
The intensity distribution in all nine arrays is better summarized in the box plots for each 
sample (Figure 7b). Direct comparison of the gene intensity values of the nine arrays 
demonstrated that they were all in the same range, thus there was only limited experimental 
variation. 
 
 
Figure 5-7. Quality control of the microarrays experiments based on probe intensity distribution. (a) 
Intensity distribution diagram for one representative sample. The plots of all nine samples display the same 
pattern. (b) Intensity box plots for the nine samles of the microarray experiment. 
The second step of data processing prior to gene expression analysis is data normalization. 
The intensities of each microarray display variability, which does not allow direct 
comparison. Data normalization corrects for spatial or data bias and homogenizes the 
variability across arrays. This was performed by the quantile method, which is recommended 
for the affymetrix microarrays. The quantile normalization is a method to equalize the 
distribution of probe intensities for every chip, by averaging each quantile across chips. As a 
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result the gene intensities of all microarrays were corrected so that the independent 
experiments displayed the same intensity means (Figure 8b). 
 
Figure 5-8. Box plots of gene intensity ranges in the nine arrays before and after data normalization. The 
array data were normalized with the quantile method using the rma command in the Bioconductor.  
5.1.3.2 Gene expression data mining from the microarray results 
A first insight into the results of the microarray experiments could be gained by cluster 
analysis of the samples. Hierarchical clustering is an algorithm used in microarray research to 
cluster samples. First, each object is assigned to its own cluster. The two most similar clusters 
are joined, representing a new node of the clustering tree. The same procedure is repeated 
until only one single cluster remains. The closer two nodes (samples) are, the higher is the 
similarity between them. The clustering of the nine independent aRNA samples was 
performed based on the 100 most variably expressed genes. Cluster analysis of the microarray 
results revealed that there were not any diverse expression patterns, characteristic for each of 
the naïve, activated and tolerant CD8 T cells (Figure 9a). This indicated that the tolerant 
status is not attributed to a specialized genetic program, comprising of differential expression 
of plenty of genes, but to differential expression of a limited number of genes which are 
shown as blue and red bars in Figure 9b.  
The differentially expressed genes of tolerant CD8 T cells in comparison to the control 
samples were identified with both the Bioconductor and Affymetrix software tools. 
Bioconductor is an open source and open development software project for the analysis and 
comprehension of genomic data, comprising several R language packages for statistical 
analysis. The Affymetrix GCOS software is used for the scanning and the direct comparison 
of the gene intensities between the GeneChip microarrays. The Affymetrix Data Mining Tool 
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(DMT) software contains a variety of tools for filtering and sorting expression results, 
enabling rapid identification of the most significant results. 
Microarray analysis performed with GCOS and Bioconductor analysis tools gave overlapping 
results. The most significantly up and down regulated genes arising from each analysis tools 
were essentially the same. The resulting genes that are overexpressed in the tolerant CD8 T 
cells as compared to the activated CD8 T cells are listed in appendix 1.  
 
 
Figure 5-9.  The naïve, activated and tolerant CD8 T cells display differential expression only of a limited 
number of genes. (a) Cluster analysis of the nine microarray experiments. The hierarchical clustering method 
was performed based on the 100 most variably expressed genes between the samples. (b) Distribution of the log2 
of the fold change of every transcript between the tolerant and the naïve samples. The few upregulated and down 
regulated genes of the tolerant CD8 T cells are shown as blue and red bars respectively. 
Interestingly, some genes to which the regulatory function of CD4+CD25+FoxP3+ natural 
Treg cells has been attributed (see introduction) were found to be upregulated in the tolerant 
CD8 T cells (Figure 10). This observation confirmed that tolerant Des-TCR CD8 T cells share 
common molecular mechanisms of suppression with natural Treg cells. 
RESULTS 
 62 
 
Figure 5-10. Upregulation of CD4
+
CD25
+
FoxP3
+
 natural Treg associated molecules in the tolerant CD8 T 
cells. Triplicate comparisons of the tolerant and activated T cell microarrays were performed. The list of genes 
found to be more than two fold upregulated in the tolerant samples was scanned for the presence of Treg 
associated molecules. Molecules found to be upregulated in at least two independent comparisons are listed 
above and the mean fold change of upregulation is indicated. (P<0.001) 
5.2 Dkk3 is upregulated in regulatory Des-TCR CD8 T cells and is crucial 
for their regulatory function 
Having a long list of genes which were differentially expressed in the regulatory Des-TCR 
CD8 T cells, it was intriguing to identify some new molecules that could be related to CD8 T 
cell tolerance induction and maintenance. The attention was given to two categories of 
molecules: surface proteins that could be used as markers for the regulatory CD8 T cell 
population and secreted molecules, potential mediators of the T cell suppression. The list of 
secreted molecules was filtered for proteins that bind to cell surface receptors and are 
involved in signal transduction (see Appendix 2). Dkk3 is a secreted molecule that is 
upregulated in regulatory Des-TCR CD8 T cells and could mediate suppression of the 
proximate T cells. It had been shown to inhibit the ERK MAPK signaling (Lodygin et al. 
2005), which is crucial for T cell proliferation and IL-2 production. Moreover, Dkk3 mRNA 
has been reported to be up-regulated in many immune privileged tissues, such as the brain, the 
embryo and the ovaries. All these clues indicated that Dkk3 could be a potential mediator of 
Des-TCR CD8 T cell regulation. 
Therefore, it was further investigated whether the specific upregulation of Dkk3 in the 
tolerant CD8 T cells is connected with the regulatory phenotype of these cells. To address 
this, first Dkk3 upregulation in the regulatory Des-TCR CD8 T cells was confirmed on 
mRNA and protein level. Then the DesTCRxKerKb transgenic mice were crossed to the 
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Dkk3-/- mice and several tolerance readout experimental systems were employed to clarify the 
effect of Dkk3 absence on CD8 T cell tolerance. 
5.2.1 Upregulation of Dkk3 mRNA in the tolerant CD8 T cells 
Microarray analysis identified Dkk3 to be specifically upregulated in the tolerant Des-TCR 
CD8 T cell population (Figure 11a). Dkk3 mRNA was present in all naïve and activated 
triplicates and in two out of three tolerant samples. Presumably the absence of Dkk3 mRNA 
hybridization in the one of the tolerant triplicates was due to experimental error. The 
comparison of the Dkk3 mRNA expression between the nine arrays was performed according 
to the scheme presented in table 3. Only the arrays of the samples that were generated with 
exactly the same mRNA amplification and labeling protocol were directly compared (see also 
Table 2).  
 
Table 5-3. Scheme of comparisons of Dkk3 expression performed between the tolerant and the naïve or 
the activated CD8 T cell samples. The (x) signs indicate the pairs of gene expression comparison. 
Microarray analysis indicated that Dkk3 expression in tolerant CD8 T cells was on average 
4.6 fold and 22.6 fold higher than in naïve and activated CD8 T cells respectively. The 
logarithmical ratios of Dkk3 mRNA in tolerant to naïve and activated CD8 T cells are 
depicted in figure 11a.  
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Figure 5-11.  Upregulation of the Dkk3 mRNA in the tolerant CD8 T cells. (a) The log2 signal ratio for the 
Dkk3 mRNA of the tolerant versus the naïve or activated samples was estimated and the mean +/-s.e.m of  three 
independent comparisons is shown. (P< 0.001) (b) Total RNA was isolated from naïve, activated and tolerant 
Des-TCR CD8 T cells and the Dkk3 mRNA expression was measured by RT-PCR. The fold change of Dkk3 
mRNA expression of tolerant samples in comparison to the naïve and activated samples was calculated. The 
mean +/- s.e.m of nine independent experiments is shown. (P< 0.01) 
The microarray results concerning the transcription of the Dkk3 gene were confirmed by RT-
PCR. Total RNA was isolated from triplicates of naïve, activated and tolerant Des-TCR CD8 
T cells and mRNA was reversely transcribed to cDNA. Dkk3 mRNA was found to be 
upregulated in the regulatory Des-TCR CD8 T cells (Figure 11b). On average, Dkk3 
expression was 11.7 fold higher in tolerant when compared to naïve CD8 T cells. Similarly, 
Dkk3 mRNA amount was 16.7 fold increased in tolerant versus activated CD8 T cells. 
5.2.2 Generation of the molecular tools for the detection of Dkk3 protein in the 
tolerant CD8 T cells 
In order to confirm the mRNA data on the protein level, a mouse Dkk3-specific monoclonal 
antibody was produced. For this, two Dkk3 cDNA constructs were generated. The first 
encoded for a Dkk3-GST fusion protein. The second consisted of the sequence for the mouse 
Dkk3 protein conjugated to the one of the mouse IgG2b. Additionally, HEK 293T cells were 
transfected with plasmids carrying the mouse Dkk3 and GFP genes.  
For the antibody production, Dkk3-/- female mice were immunized with the purified Dkk3-
IgG2b protein and hybridomas were generated, upon fusion of spleen cells that were derived 
from the immunized mice with the myeloma cell line X63-Ag8.653. The hybridomas-
supernatant was first screened for recognition of the Dkk3-GST protein by ELISA. The whole 
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procedure of anti-Dkk3 antibody production was performed by Dr G. Moldenhauer. The 
purified anti-Dkk3 antibody could stain Dkk3 intracellularly in the GFP-positive Dkk3-
transfected HEK 293T cells (Figure 12a). Moreover, the intracellular and secreted Dkk3, 
derived from HEK 293T cells, could be detected by western blot analysis with the newly 
produced anti-Dkk3 antibody (Figure 12b). The secreted and intracellular protein forms were 
found to have different size. Taking into account that there are four glycosylation sites in 
mouse Dkk3, this could be due to differential posttranslational modification. 
 
Figure 5-12. Characterization of the anti-mouse Dkk3 monoclonal antibody. (a) HEK 293T cells that were 
simultaneously transfected with GFP and Dkk3 cDNAs were stained intracellularly with the anti-Dkk3 antibody 
or the isotype control and screened by flow cytometry. Untransfected HEK293T cells were used as a negative 
control. (b) Total protein from supernatant or cell lysates derived from the HEK293T and the transfected Dkk3-
HEK293T cells was analyzed by western blot for the presence of Dkk3 using the monoclonal anti-mouse Dkk3 
antibody. The Dkk3-GST protein was used as a positive control. 
5.2.3 Dkk3 protein expression by the tolerant CD8 T cells 
After the development of a functional anti-Dkk3 antibody the Dkk3 protein level in CD8 T 
cells could be analyzed by flow cytometry. Naïve, activated and tolerant CD8 T cells were 
isolated from thymectomised Des-TCRxRAG2-/- and Des-TCRxKerKbxRAG2-/- mice 15 days 
after subcutaneous P815.Kb.B7 tumor cell injection. Intracellular FACS analysis with the 
monoclonal anti-mouse Dkk3 antibody revealed the presence of Dkk3 in the tolerant Des-
TCR CD8 T cell population on the single cell level (Figure 13). Since Dkk3 mRNA and 
protein are up-regulated in the tolerant CD8 T cells, Dkk3 could be a mediator of CD8 T cell 
regulation. 
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Figure 5-13. Dkk3 protein expression in tolerant Des-TCR CD8 T cells. Naïve (a), activated (b)  and tolerant 
(c) Des-TCR CD8 T cells were isolated as described in paragraph 1.1, stained intracellularly for the Dkk3 
protein and analyzed by FACS. Dkk3 expression in the Des-TCR CD8 populations is shown in histograms. Anti-
human HD20 antibody was used as a negative isotype control. 
5.2.4 The role of Dkk3 in the maintenance CD8 tolerance  
Kb-positive tumor graft acceptance by DesTCR T cell-bearing mice was the first tolerance 
readout system used to investigate the contribution of Dkk3 in tolerance induction and 
maintenance. The Des-TCRxKerKb mice were crossed with the Dkk3 knockout (Dkk3-/-) mice 
to investigate whether lack of Dkk3 was sufficient to reverse tolerance against the Kb antigen. 
Briefly, 2x105 P815KbB7 tumor cells were subcutaneously injected into mice and the tumor 
growth was assessed by measurement of the tumor surface (in cm2). Contrary to the Des-
TCRxKerKb mice the Des-TCR as well the Des-TCRxKerKbxDkk3-/- mice rejected the Kb-
expressing tumor grafts (Figure 14a). The few tumors that had developed in Des-TCR and 
Des-TCRxKerKbxDkk3-/- mice were significantly smaller than those that had grown in Des-
TCRxKerKb mice (Figure 14b).  
RESULTS 
 67 
 
 
Figure 5-14.  Dkk3 is essential for K
b
 – positive tumor graft acceptance mediated by the tolerant Des-TCR 
CD8 T cells. 2x105 P815.Kb.B7 tumor cells were inoculated s.c. into Des-TCR, Des-TCR x KerKb and Dkk3-/- x 
Des-TCR x KerKb mice. Mice were assessed for tumor growth (cm2). (a) The kinetics of tumor growth and (b) 
the tumor sizes at day 21 are indicated. Data represent the mean tumor size +/- s.e.m of two independent 
experiments. (***: P<0.001) 
To strengthen this finding, a second tolerance readout system was used. Des-TCR, Des-
TCRxKerKb and Des-TCRxKerKbxDkk3-/- mice were primed with activated Kb-positive 
dendritic cells, which were derived from B6 bone marrow (see Material and Methods, 
paragraphs 2.3.5 and 2.3.6). In vivo kill of Kb-positive target cells was measured 7 days after 
priming (see Materials and Methods, paragraph 2.8.3) to assess generation of Kb-specific 
cytotoxicity. Whereas the tolerant Des-TCRxKerKb mice displayed less than 15% Kb-specific 
lysis, the Des-TCRxKerKbxDkk3-/- mice showed T cell cytotoxicity comparable to Des-TCR 
mice (Figure 15). The assay was performed three times, twice with mice of the H2kxd 
background and once with mice of the H2kxk background and the pooled results of the three 
experiments are shown. 
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Figure 5-15.  Dkk3 is indispensable for the 
suppression of anti-K
b
 reactivity of CD8 T cells in 
the DesTCR x KerK
b
 mice. Des-TCR, Des-
TCRxKerKb and Dkk3-/-x Des-TCRxKerKb mice 
were immunized with activated C57.Bl6 dendritic 
cells and after 7 days the percentage of specific 
killing of CFSE-labelled Kb-positive target cells in 
vivo was measured by FACS. The mean % lysis +/- 
s.e.m of three independent experiments is shown. 
(***: P<0.001) 
 
Given that it is a secretory molecule it was interesting to clarify whether Dkk3 that is 
expressed by the tolerant CD8 T cells mediates tolerance by suppressing the proximate naive 
T cells. To address this, Des-TCRxKerKb mice were tested for autologous skin graft 
acceptance after Dkk3 blockade by the anti-Dkk3 antibody. Two experimental groups were 
set. The first received the anti-Dkk3 antibody and the second the control mouse serum IgG. 
Each mouse was intraperitoneally injected with 1mg of anti-Dkk3 monoclonal antibody or 
mouse IgG at day 0 and with 0.5mg of antibody every second day. In total each mouse 
received 5mg of blocking or control antibody. Skin from the tail was transplanted to the back 
of the mice and skin graft and both groups were screened for long term skin graft acceptance. 
Interestingly, the Des-TCRxKerKb mice that had received the Dkk3-blocking antibody 
rejected the autologous graft (Figure 16). This indicated that the Dkk3 protein that is secreted 
by the regulatory Des-TCR CD8 T cells is indeed essential for the maintenance of tolerance 
against self antigens and can suppress T cell responses. 
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Figure 5-16. Blocking of the secreted Dkk3 protein abolishes T cell tolerance to autologous skin. Des-
TCRxKerKb mice underwent autologous skin transplantation. In one experimental group, each mouse received in 
total 5mg anti-Dkk3 blocking antibody and in the control group 5mg mouse IgG. Each group consisted of 12 
mice. The mice were screened for skin graft acceptance for a time period of 45 days.. (**: P<0.01) 
To exclude that Dkk3 also binds on the surface of the tolerant CD8 T cells and mediates 
tolerance by cell contact suppression, the Des-TCR CD8 T cells were tested in FACS for 
Dkk3 staining without fixation and permeabilization. However the cell-surface of the naïve, 
activated and tolerant Des-TCR CD8 T cells were all negative for Dkk3 staining (Figure 17). 
Hence, the secreted Dkk3 seems to be the mediator of the suppressive function of the 
regulatory DesTCR CD8 T cells. 
 
Figure 5-17. No presence of Dkk3 can be traced on the tolerant Des-TCR CD8 T cell-surface by flow 
cytometry. Naïve, activated and tolerant Des-TCR CD8 T cells have been isolated from Des-TCR and Des-
TCRxKerKb mice respectively and tested for binding of Dkk3 protein to their cell surface. Dkk3 staining was 
performed with the monoclonal mouse anti-Dkk3 antibody without cell fixation and permeabilization. With 
FACS analysis the CD8 Des-TCR population was gated and Dkk3 expression in each CD8 T cell population was 
depicted by histogram overlay. 
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5.3  Dkk3 affects polyclonal T cell reactivity  
After identifying the regulatory effect of Dkk3 in the Des-TCRxKerKb mouse model, it was 
examined whether Dkk3 is present in wild type regulatory T cell populations and whether it 
could also regulate polyclonal T cell reactivity. Therefore, Dkk3-/- and Dkk3+/+ mice were 
used. First, Dkk3 expression analysis in lymphocytes was performed. Then, the effect of the 
absence of Dkk3 on T cell proliferation in vitro within a splenic cell population was 
addressed. Moreover, the CD4 and CD8 T cell populations were isolated from both mouse 
strains and their proliferation in vitro was measured in order to clarify whether the Dkk3 
effect is T cell intrinsic or a result of the presence of Dkk3 in the splenic microenvironment.  
5.3.1 Dkk3 expression in polyclonal T cells 
It has been reported that the spleen, the lymph nodes and the thymus are negative for Dkk3 
mRNA (Niehrs 2006). This has been confirmed by RT-PCR analysis of lymphatic organ-
lysates that was performed in our lab. However, the Dkk3 mRNA and protein were traced in 
the tolerant Des-TCR CD8 T cells. Moreover, amplified mRNA from naïve and activated 
CD8 T cells were hybridized with the Dkk3 gene probes on the GeneChip microarrays. 
Consequently, it was asked whether a lymphocyte population expressing Dkk3 could be 
found in the spleen of wild type mice by flow cytometry. Therefore, splenocytes were isolated 
from Dkk3+/+ C57.Bl/6 mice and Dkk3-/- mice and stained intracellularly with the monoclonal 
anti-mouse Dkk3 antibody. In each sample 2-4x107 cells were analyzed by flow cytometry for 
the presence of Dkk3. B cells (data not shown) and T lymphocytes were found negative for 
Dkk3 protein. The same held true for NK cells and NK T cells (Figure 18). The above results 
were reproduced in three independent experiments. The observed difference in anti-Dkk3 
binding in the CD8 and NK1.1 negative cell fraction was not reproducible and was attributed 
to unspecific staining, probably due to insufficient blocking of the Fc receptors on 
splenocytes. 
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Figure 5-18. No Dkk3 protein expression can be traced in lymphocytes and NK cells by flow cytometry. 
Splenocytes from C57.Bl6 and Dkk3-/- mice were stained for surface cell markers and with the anti-Dkk3 or with 
the anti-HD-20 isotype control antibodies. 2x107 cells from each spleen were analyzed by flow cytometry for 
Dkk3 expression. The CD8, CD4 T and NK cells were found to be negative for Dkk3. 
In order to screen dendritic cells, monocytes and spleen stromal cells for Dkk3 protein 
expression, the spleens were first digested with DNAse I and collagenase IV in the presense 
of EDTA, so that cell clustering is avoided. In all cases 3-4x107 spleen cells were acquired 
and analyzed by flow cytometry. The Gr1 and CD11b markers were used for the staining of 
the monocytes, whereas the dendritic cells were defined by positively gating the MHC class 
II+ CD11c+ or CD11b+ cells (Figure 19b). The splenic stromal cell gate resulted from 
exclusion of the CD3, CD19, CD11b and CD45.2 positive cells (Figure 19a). No Dkk3 
protein expression was traced in any of the above mentioned populations.  
 
Figure 5-19. No Dkk3 expression can be traced in monocytes, dendritic cells and splenic stromal cells by 
flow cytometry. Spleens from C57.Bl6 and Dkk3-/- mice were enzymatically digested and the resulting cells 
were stained for cell surface markers and intracellular Dkk3 protein. 3-4x107 cells per spleen were analyzed by 
RESULTS 
 72 
flow cytometry. The absence of Dkk3 expression from (a) splenic stromal cells, (b) monocytes and dendritic 
cells is shown. 
5.3.2 Dkk3-/- splenocytes display increased proliferation in vitro 
In order to investigate the impact of Dkk3 on T cell responses, splenocytes were isolated from 
Dkk3+/+ and Dkk3-/- mice and stimulated with titrated amounts of anti-CD3 and anti-CD28 
antibodies. The anti-CD3 and anti-CD28 antibodies provided the signals one and two for the 
T cell stimulation and costimulation. T cell proliferation was measured at day 4 by thymidine 
incorporation. Notably, Dkk3-/- T cell proliferation was increased as compared to wild-type T 
cells (Figure 20).  Thus, the presence of Dkk3 in the wild type mice may set a limit to the T 
cell proliferation.  
 
Figure 5-20. T cell proliferation in vitro is increased in the absence of Dkk3. Dkk3-/- and Dkk3+/+ spleen cells 
were stimulated with varying concentrations of anti-CD3 and anti-CD28 antibodies. Proliferation was measured 
by thymidine incorporation at day 4. A representative of four independent experiments +/- s.e.m is shown. 
To analyze the kinetics of T cell proliferation, splenocytes isolated from Dkk3+/+ and Dkk3-/- 
mice were stained with CFSE, before being stimulated in vitro as described above. 
Proliferation of the CD4 and CD8 T cell subpopulations was screened by FACS at days 4, 5 
and 6 (figure 21). The CD4 and predominantly the CD8 T cell population indicated higher 
proliferation rates in the absence of Dkk3 at days 4 and 5 after stimulation.  
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Figure 5-21. Absence of Dkk3 expression in the spleen results in increased CD4 and CD8 T cell 
proliferation. CFSE labeled Dkk3-/- and Dkk3+/+ spleen cells were stimulated with titrated amounts of anti-CD3 
and anti-CD28 and CFSE-dilution in the CD4 and CD8 T cell subpopulations was determined by flow cytometry 
at days 4, 5 and 6 upon T cell stimulation.  
The CFSE histograms show that the Dkk3-/- CD4 and CD8 T cells proliferate faster than the 
wild type control. The Dkk3-/- T cell proliferation at day 4 was much higher than in wild type. 
This may be attributed to earlier initiation of the T cell proliferation or accelerated cell cycle. 
At day 5, the Dkk3-/- T cells that had been stimulated with lower dose of anti-CD3 and anti-
CD28 still display increased proliferation in comparison to the Dkk3+/+. The wild type T cell 
proliferation level reaches the one Dkk3-/- T cell proliferation at high doses of T cell 
stimulation at day 5 and at low doses of T cell stimulation at day 6. This implies that on later 
time points Dkk3-/- T cell proliferation slows down, possible due to activation induced cell 
death and nutrients’ exhaustion. 
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5.3.3 Dkk3-/- T cell hyperproliferation is not an effect of increased T cell activation 
status or natural Treg deficiency 
In order to clarify the cause of Dkk3-/- T cell hyperproliferation, some control experiments 
were performed. It could be argued that Dkk3-/- T cells are already pre-activated before in 
vitro stimulation and therefore start to proliferate earlier. To exclude this, the proliferation of 
naïve (CD62Lhigh) Dkk3+/+ and Dkk3-/- T cells was compared. Naïve spleen T cells were 
purified from Dkk3+/+ and Dkk3-/- mice by MACS CD62L microbead positive selection. The 
CD62Lhigh Dkk3-/- T cells were stimulated with anti-CD3 (2 µg/ml) and anti-CD28 (1 µg/ml) 
and T cell proliferation was measured four days after stimulation by thymidine incorporation. 
The CD62Lhigh Dkk3-/- T cells proliferated better than the wild type control, suggesting that 
the observed effect is not due to the pre-activation of the Dkk3-/- T cells in the mouse (Figure 
22). At this point, it is worth mentioning that previous studies in the lab had revealed no 
significant up-regulation of T cell activation markers (CD69, CD44, and CD25) on Dkk3-/- 
CD4 and CD8 T cells.  
 
Figure 5-22. Increased Dkk3-/- T cell proliferation in vitro is not a 
result of pre-activation in vivo. MACS sorted CD62L high T cells from 
Dkk3-/- and Dkk3+/+ spleens were stimulated with anti-CD3 (2 ug/ml) 
and anti-CD28 (1 ug/ml) and T cell proliferation in vitro was assessed at 
day 4 by thymidine incorporation. The mean+/- s.e.m from 2 independent 
experiments is shown. 
 
 
 
 
 
It is also possible that the difference in T cell proliferation described above is a result of a 
malfunction of the Dkk3-/- natural Treg cells. However, Treg cells were found to be negative 
for Dkk3 in the mRNA (data not shown) and protein level (Figure 23a). Additionally, the 
Dkk3-/- CD4+CD25+FoxP3+ Tregs were as efficient as the wild type controls in in vitro 
suppression assays (Figure 23b).  
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Figure 5-23.  Increased Dkk3
-/-
 T cell proliferation cannot be attributed to a malfunction of the Dkk3
-/-
 
CD4
+
CD25
+
FoxP3
+
 regulatory T cells. (a) CD4+CD25+ positive T cells were analyzed for Dkk3 expression by 
flow cytometry and found negative. (b) CD4+CD25- T cells were cocultured with Dkk3+/+ or Dkk3-/-CD4+CD25+ 
in different ratios and CD4 T cell proliferation was measured by thymidine incorporation at day 4. The mean+/-
s.e.m of two independent experiments is shown. 
5.3.4 Isolated Dkk3-/- CD8 but not CD4 T cells display increased proliferation in 
comparison to wild type control T cells 
In the previous paragraph it was shown that the absence of Dkk3 from the spleen results in 
stronger CD4 and CD8 T cell proliferation in the total splenocyte cultures. It was then 
reasonable to investigate whether T cell proliferation was influenced by the lack of Dkk3 
expression from the CD4 and CD8 T cells themselves or from the splenic microenvironment. 
To investigate this, CD4 or CD8 T cells were isolated using the respective MACS negative 
selection kits with over 87% purity and were stimulated with anti-CD3 (2µg/ml) and anti-
CD28 (1µg/ml) in the absence of any other spleen cell population. Isolated CD4 T cells 
derived from the Dkk3-/- mice displayed the same proliferation degree as the Dkk3+/+ control 
CD4 T cells. This can be easily explained, since no Dkk3 mRNA or protein expression was 
found in the CD4 T cells (Figure 24a). Unexpectedly, the isolated CD8 T cells showed a 
slightly higher but significant proliferation rate in the absence of Dkk3 (Figure 24b). 
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Figure 5-24. Isolated CD4 but not CD8 T cells derived from Dkk3
-/-
 mice proliferate as much as the wild 
type controls. MACS sorted (a) CD4 and (b) CD8 T cells from Dkk3-/- and Dkk3+/+ spleens were stimulated 
with anti-CD3 (2 ug/ml) and anti-CD28 (1 ug/ml) and T cell proliferation in vitro was assessed at day 4 by 
thymidine incorporation. The mean+/- s.e.m from five independent experiments is shown. ( * P< 0.05) 
This finding could be explained by two arguments. It is possible that there is a regulatory 
CD8 T cell subpopulation that expresses Dkk3, exactly like the tolerant CD8 T cells in the 
transgenic Des-TCRxKerKb mouse system. This subpopulation could be so small that no 
Dkk3 expression can be traced in the total spleen, or in the CD8 T cell fraction. On the other 
hand, the probability that the presence of Dkk3, which is secreted by peripheral tissues in the 
mouse influences permanently the reactivity of the CD8 T cells and temporalily the reactivity 
of the CD4 T cells cannot be excluded. A direct identification of Dkk3-expressing CD8 T 
cells with RT-PCR flow cytometry, ELISA, western blot analysis and histology was not 
feasible. In the next chapter, some experimental approaches that indirectly address this point 
will be described. 
5.4 Attributes of Dkk3-/- T cell hyperproliferation 
5.4.1 Thymic selection is unaltered in Dkk3-/- mice 
The previously described differences in T cell reactivity between the Dkk3-/- and Dkk3+/+ 
mice could have different explanations. First, it could be argued that Dkk3 deficiency results 
in altered thymic selection. In other words, the observed Dkk3-/- T cell hyperproliferation 
could be attributed to a bias of the positive selection towards more reactive T cell clones. To 
address this, bone marrow chimeras were constructed. Wild type mice were irradiated and 
reconstituted with bone marrow from either Dkk3-/- or Dkk3+/+ donor mice. Thus, the thymic 
epithelium of the chimeric mice is Dkk3+/+ and the positively selected T cells are Dkk3-/- and 
Dkk3+/+ respectively. Additionally, Dkk3-/- recipient mice were chimerized with bone marrow 
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from Dkk3+/+ donor mice. The percentages of T cells expressing a spectrum of TCR Vβ 
chains (Vβ8.1, Vβ8.2, Vβ5.1, Vβ5.2, Vβ6, Vβ11, Vβ9, Vβ13, Vβ3, Vβ17A, Vβ14, Vβ7, Vβ2, 
Vβ10B, Vβ12, Vβ4, Vβ8.3) were defined in the chimeric and control Dkk3-/- and Dkk3+/+ 
mice. As shown in table 3, there are no differences in the TCR repertoire derived from Dkk3-
sufficient or deficient thymic epithelium. 
Thymus 
CD4 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.3 
Dkk3 -/- 10.6 2.78 4.56 5.78 6.75 0.95 3.91 3.26 1.1 3.32 0.51 5.11 0.66 4.29 0.33 
B6 8.62 2.78 6.23 4.94 8.02 1.31 4.52 2.97 1.32 3.8 0.47 3.69 1.15 2.43 0.55 
Thymus 
CD8 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.30 
Dkk3 -/- 9.47 4.62 9.48 1.19 6.14 0.21 4.29 1.6 1.62 2.5 0.1 1.56 0.21 3.32 0.36 
B6 8.35 5.84 11.5 0.85 5.82 0.51 5.48 2.11 1.74 1.97 0.14 0.96 0.45 1.37 0.15 
Thymus 
CD4 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.30 
B6 in B6 11.8 5.66 5.49 6.18 7.87 1.33 5.02 3.3 1.24 3.48 0.43 5.88 1.7 4.73 0.3 
B6 in Dkk3 10.7 2.89 3.82 6.16 7.22 1.44 4.54 3.67 1.09 3.43 0.32 4.99 1.75 5.58 0.24 
Dkk3 -/- in 
B6 
11 2.75 5.75 5.64 7.9 1.58 5.01 3.56 1.1 4.48 0.65 4.89 1.69 3.92 0.49 
Thymus 
CD8 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.30 
B6 in B6 8.33 5.39 9.67 1.62 5.47 0.71 3.26 2.59 1.71 2.23 0.23 1.5 0.62 2.15 0.59 
B6 in Dkk3-
/- 
5.91 5.3 6.47 1.47 4.75 0.49 3.7 1.51 1.12 1.29 0.62 1.62 1.15 5.61 0.28 
Dkk3 -/- in 
B6 
9.33 4.57 12 1.34 6.92 0.31 4.75 2.85 1.52 2.65 0.3 1.62 0.51 0.7 0.28 
Spleen 
CD4 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.3 
Dkk3 -/- 6.92 2.23 3.43 3.32 6.26 1 3.61 2.34 1.67 2.15 0.65 4.45 2.94 1.81 0.87 
B6 7.48 2.34 3.07 3.47 8.71 0.95 4.9 2.47 1 3.61 0.62 0.56 0.74 2.62 0.58 
Spleen 
CD8 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.30 
Dkk3 -/- 5.49 5.24 7.95 0.87 4.26 0.64 4.17 0.53 0.64 1.14 0.29 1.05 1.52 0.69 0.56 
B6 6.23 4.69 11.7 0.57 6.71 0.28 5.67 0.94 0.86 1.86 0.16 0.21 0.52 1.6 0.17 
Spleen 
CD4 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.3 
B6 in B6 9.65 2 3.62 4.58 7.04 1.36 4.33 3.39 1.35 3.54 0.72 4.88 1.38 4.97 0.7 
B6 in Dkk3 9.59 1.82 3.02 6 6.52 1.46 3.99 3.65 0.94 3.71 6.45 2.11 0 1.58 0.78 
Dkk3 -/- in 
B6 
10 1.72 2.66 5.16 7.02 1.12 4.74 3.93 0.87 3.43 0.62 1.51 1.92 4.57 0.62 
Spleen 
CD8 
8.1 & 
8.2 
5.1 & 
5.2 
6 11 9 13 3 17a 7 14 2 10b 12 4 8.3 
B6 in B6 7.94 5.81 13.2 0.64 5.3 0.48 3.66 1.47 1.55 2.37 0.15 1.22 0.35 3.72 0.37 
B6 in Dkk3 8.12 5.37 15 0.86 5.32 0.19 3.91 2.05 1.45 2.33 0 0.51 ･ 0.59 0.16 
Dkk3 -/- in 
B6 
7.83 4.59 14.1 0.78 4.99 0.31 4.86 1.31 1.46 2.5 0.14 0.31 0.49 3.65 0.23 
Table 5-4. Absence of Dkk3 from the thymus does not result in altered positive selection. The thymic and 
splenic CD4 and CD8 T cells from Dkk3-/-, Dkk3+/+ mice and Dkk3-/- in Dkk3+/+, Dkk3+/+ in Dkk3-/- and Dkk3+/+ 
in Dkk3+/+ chimeras were screened for the percentage of different Vβ chain populations.   
5.4.2 T cell-extrinsic factors predominantly contribute to Dkk3-/- T cell 
hyperproliferation 
The Dkk3-/- T cell hyperproliferation could be explained in two ways.  One possibility is that 
CD8 T cells or another splenic cell population produce Dkk3. Thus, the absence of local 
Dkk3 production in Dkk3-/- spleen leads to impaired control of T cell proliferation. On the 
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other hand, it cannot be excluded that non-hematopoietic tissue-derived Dkk3 somehow 
influences the proliferative capacity of naïve T cells. In other words, Dkk3-/- T cell 
hyperproliferation could result either from lack of splenocyte-derived Dkk3 or tissue-derived 
Dkk3. To further analyze this point bone marrow chimeras were used, which carried both 
donor-derived and host-derived T cells, due to partial host T cell depletion by irradiation. By 
this means, the proliferation of Dkk3+/+ and Dkk3-/- T cells that are both derived from either a 
Dkk3 deficient or a Dkk3 sufficient mouse could be compared in one host.  
Moreover, if Dkk3 was secreted in a non-detectable amount within in the lymphoid organs, or 
as suggested above by a subpopulation of CD8 T cells, the presence of Dkk3-blocking 
monoclonal anti-mouse Dkk3 antibody during the in vitro T cell stimulation would result in 
increased T cell proliferation, resembling the phenotype of Dkk3-/- T cell. The results of the 
above described experimental approaches will be presented below. 
5.4.2.1 The hyperproliferation of Dkk3-/- T cells is controlled in a Dkk3+/+ mouse 
Wild type mice carrying the CD45.2 congenic marker on lymphocytes or CD45.1 mice 
having the CD45.1 congenic marker were sublethally irradiated. In some mice 40-50 % of the 
host lymphocytes survived upon irradiation and these were chosen as recipients for the 
generation of mixed bone marrow chimeras. The recipient mice were then injected with 
CD45.1 or Dkk3-/- (carrying the CD45.2 congenic marker) bone marrow cells respectively 
(Dkk3+/+Dkk3+/+ and Dkk3-/-Dkk3+/+ chimeric mice). After reconstitution, splenocytes 
were isolated from the chimeric mice, labeled with CFSE and let to proliferate in vitro in the 
presence of anti-CD3 (2µg/ml) and anti-CD28 (1µg/ml) antibodies. The proliferation of the 
host- and donor-derived T cells was then compared by flow cytometry (Figure 25). As shown, 
the two populations displayed around 50 % chimerism in the radioresistant CD8 T cell 
compartment and 70 % chimerism in the more radiosensitive CD4 T cell compartment. 
However, both donor derived CD4 and CD8 T cells proliferated as strong as the host CD4 and 
CD8 T cells. More specifically, the proliferation of the Dkk3-/- T cells was not increased in 
comparison to this of the wild type T cells, when the Dkk3-/- T cells had developed in a Dkk3 
sufficient environment. Since it has been already shown that there are no differences in the 
intrathymic selection between the knockout and control mice, the observed differences 
indicate that external (T cell- or non T cell-derived) Dkk3 can control the T cell reactivity 
(Figure 27a). 
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Figure 5-25. Dkk3 deficient T cells are regulated in chimeric Dkk3
-/-
  Dkk3
+/+
 mice carrying host Dkk3
+/+
 
T cells.  Spleen cells were isolated from the Dkk3-/-  Dkk3+/+ (CD45.1) and control Dkk3+/+ (CD45.1)  
Dkk3+/+ (CD45.2) chimeric mice and labeled with CFSE prior to T cell stimulation with anti-CD3 (2µg/ml) and 
anti-CD28 (1µg/ml). Four days upon stimulation T cell proliferation was assessed by the dilution of the CFSE 
dye. (a) Donor and recipient derived T cells from the Dkk3-/-  Dkk3+/+ chimeric mice were gated according to 
the surface CD45.2 and CD45.1 marker. The dot plots are representative of the Dkk3+/+  Dkk3+/+ chimeric 
mice as well. (b) CD4 and CD8 T cell proliferation in Dkk3-/-  Dkk3+/+ and Dkk3+/+  Dkk3+/+ spleens was 
measured by flow cytometry. One representative of four independent experiments is shown. 
5.4.2.2 Dkk3+/+ T cells reach the Dkk3-/- T cell proliferation rate in a Dkk3-/- mouse 
Dkk3+/+ CD45.1 bone marrow was then transferred into irradiated Dkk3+/+ or Dkk3-/- CD45.2 
recipient mice (Dkk3+/+Dkk3+/+ and Dkk3+/+  Dkk3-/- chimeric mice). Like in the 
experimental setting described before, the chimerism ranged between 30-50%, so the in vitro 
T cell proliferation of both Dkk3+/+ and Dkk3-/- T cells derived from the same mouse could be 
compared. Interestingly, the Dkk3+/+ T cells in the Dkk3-/- host proliferated as much as the 
remaining Dkk3-/- host T cells (Figure 26a). This proliferation rate was increased in 
comparison to Dkk3+/+ T cells derived from a Dkk3 sufficient environment (Figure 26b). Thus 
the production of Dkk3 in the non-hematopoietic tissues is essential for the prevention of T 
cell hyperproliferation (Figure 27b and c). 
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Figure 5-26.  Wild type T cells in chimeric Dkk3
+/+
  Dkk3
-/-
  mice carrying Dkk3
-/-
 T cells display 
elevated proliferation rate. Spleen cells were isolated from the Dkk3+/+ (CD45.1)  Dkk3-/- and control 
Dkk3+/+ (CD45.1)  Dkk3+/+ chimeric mice and labeled with CFSE prior to T cell stimulation with anti-CD3 
(2µg/ml) and anti-CD28 (1µg/ml). Four days upon stimulation, T cell proliferation was assessed by the dilution 
of the CFSE dye. (a) Donor and recipient derived T cells from the Dkk3+/+  Dkk3-/- chimeric mice were gated 
according to the surface CD45.2 and CD45.1 marker. The dot plots are representative of the Dkk3+/+  Dkk3+/+ 
chimeric mice as well. (b) CD4 and CD8 T cell proliferation in Dkk3+/+  Dkk3-/- and Dkk3+/+  Dkk3+/+ 
spleens was measured by flow cytometry. One representative of four independent experiments is shown. (c) The 
proliferation rate of the Dkk3+/+ (CD45.1)  Dkk3-/- chimeras-derived wild type CD4 and CD8 T cells was 
compared to the one of Dkk3+/+ (CD45.1)  Dkk3+/+  chimeras-derived wild type CD4 and CD8 T cells by 
histogram analysis. The results of two independent experiments are shown. 
 
Figure 5-27.  Overview of the experiments with the 50% bone marrow chimeric mice. (a) In order to prove 
that Dkk3-/- T cell proliferation is not a permanent T cell-intrinsic attribute, 50% Dkk3-/-Dkk3+/+ chimeric mice 
were generated so that Dkk3-/- and Dkk3+/+ T cell proliferation could be compared in the same Dkk3 sufficient 
host. In the presence of host non-hematopoietic tissue- or T cell-derived Dkk3 protein, Dkk3-/- T cells did not 
proliferate stronger that Dkk3+/+ T cells. (b) Dkk3+/+ T cell proliferation in Dkk3+/+Dkk3+/+ chimeric mice was 
used as a control. (c) In order to investigate the contribution of non-hematopoietic tissue-derived Dkk3 protein 
50% Dkk3+/+Dkk3-/- chimeric mice were generated so that the proliferation of Dkk3+/+ T cells that were 
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derived from Dkk3 deficient host could be compared with the proliferation of Dkk3+/+ T cells that were derived 
from Dkk3 sufficient host. Dkk3+/+ T cells that had developed in a Dkk3-/- environment proliferated stronger than 
the control. 
5.4.2.3 In vitro Dkk3 blockade is not sufficient for induction of in vitro T cell 
hyperproliferation 
In order to confirm that, unlike tissue-derived Dkk3, potential splenocyte-derived Dkk3 is not 
crucial for the control of T cell responses, in vitro T cell proliferation assays were performed 
in the presence of the anti-Dkk3 blocking antibody. In detail, Dkk3+/+ splenocytes were 
stimulated with titrated amounts of anti-CD3 and anti-CD28 antibodies in the presence of the 
Dkk3-blocking monoclonal anti-Dkk3 antibody (10µg/ml) or the control mouse serum 
derived IgG. T cell proliferation was assessed by thymidine incorporation at day 4 upon T cell 
stimulation. In the presence of the anti-Dkk3 antibody the proliferation of the isolated CD4 
and CD8 T cells was similar to the control (Figure 28).  It was not increased as one would 
expect if the anti-Dkk3 antibody would have neutralized spleen cell derived Dkk3. The 
blocking ability of the anti-Dkk3 monoclonal antibody has been shown in in vivo experiments 
presented in this thesis (Figures 16 and 46). Its inability to induce increased T cell 
proliferation suggests that if any Dkk3 is secreted in the spleen, its amount is not enough to 
regulate T cell responsiveness. It is thus likely that tissue derived Dkk3 is responsible for the 
regulation of T cell proliferation. 
 
Figure 5-28.  T cell proliferation is not increased in the presence of the anti-Dkk3 monoclonal antibody. 
Wild type T cells were stimulated with titrated amounts of anti-CD3 and anti-CD28 antibody in the presence of 
10 µg/ml anti-Dkk3 antibody or mouse serum-derived IgG. T cell proliferation was measured at day 4 upon 
stimulation by thymidine incorporation. The mean+/-s.e.m of triplicate values of one experiment are shown. 
(P>0.1) 
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5.5 Molecular mechanisms of Dkk3-/- T cell hyperproliferation 
In summary, lack of Dkk3 leads to increased T cell proliferation. Very low Dkk3 production 
by splenocytes and its contribution to the observed effect cannot be excluded, but tissue-
derived Dkk3 seems to definitely play a role in the control of T cell proliferation. Since 
isolated Dkk3-/- CD8 T cells display increased proliferation it could be proposed that the 
absence of Dkk3 permanently alters the biochemistry of T cell stimulation and proliferation. 
In this chapter the changes in CD8 T cell signaling pathways resulting from the lack of Dkk3 
will be investigated. 
5.5.1 Dkk3 does not interfere with the TGF-β pathway in T cells 
The TGF-β signaling pathway is known to restrain T cell proliferation. Upon binding of TGF-
β to its receptor on the T cell membrane, the Smad2 and Smad3 proteins are phosphorylated. 
This leads to the formation of the Smad2/3 complex, which in turn binds to the cytoplasmic 
protein Smad4. The Smad2/3/4 complex translocates to the nucleus, where it regulates gene 
transcription (Nakao et al. 1997; Derynck et al. 2003). The induced genes limit T cell 
proliferation.  
Smad4 has been shown to be degraded by ubiquitination upon Ras activation (Saha et al. 
2001). It should be noted that T cell stimulation involves Ras activation and therefore Smad4 
degradation. At this point it is interesting to mention that Dkk3 was reported to be required 
for TGF-β signaling in the Xenopus laevis embryo since it stabilizes Smad4 by 
downregulating the ubiquitin ligase ectodermin (Pinho et al. 2007).  
Therefore, it was analyzed whether the increase of T cell proliferation in the absence of Dkk3 
could be attributed to unresponsiveness of T cells to TGF-β due to Smad4 proteolytic 
degradation. First, TGF-β was added to in vitro proliferating Dkk3+/+ and Dkk3-/- T cells and 
the percentage of inhibition of T cell proliferation was calculated. Both at high and low TGF-
β doses there was no decrease in the percentage of inhibition (Figure 29). In detail, the mean 
Dkk3-/- T cell proliferation was decreased from 120,020 to 5,555 thymidine counts by the 
presence of 5ng/ml TGF-β. Similarly, the mean Dkk3+/+ T cel proliferation was decreased 
from 67,561 to 2,175 counts by TGF-β. Therefore it seems unlikely that absence of Dkk3 
leads to Smad4 degradation and TGF-β unresponsiveness. 
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Figure 5-29. TGF-β signaling is not deficient in the absence of Dkk3. Dkk3+/+ and Dkk3-/- T cells were 
stimulated with anti-CD3 (2 µg/ml) and anti-CD28(1 µg/ml) in the presence of TGF-β and T cell proliferation 
was measured at day 4 upon stimulation by thymidine incorporation. The percentage of TGF-β-mediated 
inhibition of T cell proliferation was calculated as the difference of thymidine counts in the absence and the 
presence of TGF-β divided by the counts in the absence of TGF-β. (a) A high dose (5 ng/ml) of TGF-β was 
added to the T cell proliferation assay. Mean+/-s.e.m of two independent experiments are shown. (b) a low dose 
(2 ng/ml) of TGF-β was added to the T cell proliferation assay. Mean+/- of triplicates of one experiment are 
shown.  
Moreover, Western Blot analysis of the cytoplasmic levels of Smad4 in CD8 T cells derived 
from Dkk3-/- and Dkk3+/+ mice was performed. CD8 T cells were stimulated with anti-CD3 
(2µg/ml) and anti-CD28 (1µg/ml) for the indicated time, varying from 2 to 48 hours (Figure 
30). The CD8 T cell protein lysates were analyzed for the relative amount of Smad4 by 
western blot analysis. The levels of the calnexin protein were used as a reference, since it is 
not newly synthesized or degraded during T cell stimulation. There was no increase in Smad4 
degradation noticed in the Dkk3-/- CD8 T cells.  
 
Figure 5-30. Smad4 degradation is not decreased in the absence of Dkk3 from CD8 T cells. MACS isolated 
Dkk3-/- and Dkk3+/+ CD8 T cells were stimulated with anti-CD3 (2µg/ml) and anti-CD28 (1µg/ml) for the 
indicated times. The stimulated CD8 T cell protein lysates were then tested for the levels of Smad4 protein by 
western blot analysis. The levels of calnexin were used as a control for the protein loading amount. One 
representative of three independent experiments is shown. 
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5.5.2 Lack of Dkk3 leads to an altered ERK pathway activity upon CD8 T cell 
stimulation 
The next CD8 T cell signaling pathway to be examined was the ERK MAPK pathway. TCR 
triggering leads to the activation in the one hand of the Src-type tyrosine kinases Lck and Fyn, 
followed by ZAP-70 and on the other hand the activation of phospholipase C-γ (PLCγ) (Noh 
et al. 1995; Pacholczyk et al. 2007). The tyrosine kinases are responsible for the 
phosphorylation and recruitment of the LAT adaptor protein (Pitkanen et al. 2003). PLC-γ 
mediates the generation of DAG (Crabtree 1989). The LAT adaptor protein and the DAG 
messenger initiate two independent signaling pathways that both lead to the activation of Ras 
GTPase (van Leeuwen et al. 1999; Stone 2006). The active Ras-GTP in turn phosphorylates 
the c-Raf kinase, thus initiating the ERK pathway. Activated c-Raf catalyses MEK 
phosphorylation. Phosphorylated MEK then activates ERK1 and ERK2. ERK activation upon 
T cell stimulation leads to Fos protein activation which together with c-Jun forms the AP-1 
transcription factor. AP-1 nuclear translocation and transcriptional function are essential for T 
cell proliferation. Thereby, the transcription of IL-2 is induced, which in turn leads to the 
survival and proliferation of T cells (Cantrell 1996). Since ERK inhibition is a feature of T 
cell anergy and tolerance, it was reasonable to study the effect of the absence of Dkk3 on this 
particular signaling pathway. 
5.5.2.1 In the absence of Dkk3 IL-2 production upon T cell stimulation is increased 
The first hint that the activation of the ERK pathway could be altered in the absence of Dkk3 
was the fact that Dkk3-/- T cells not only proliferated stronger, but that they also produced 
higher levels of IL-2. The supernatants of the proliferating Dkk3-/- and Dkk3+/+ T cells was 
tested for IL-2 at day 1 upon stimulation. The increased proliferative capacity of the Dkk3-/- 
splenocytes was found to be accompanied by an increase in IL-2 production (Figure 31) 
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Figure 5-31. In the absence of Dkk3 splenocyte IL-2 production is increased. Dkk3-/- and Dkk3+/+ spleen 
cells were stimulated with varying concentrations of anti-CD3 and anti-CD28 antibodies. IL-2 production was 
measured by ELISA 24 hours upon stimulation. A representative of three independent experiments +/- s.e.m is 
shown. 
5.5.2.2 In the absence of Dkk3 the ERK MAPK pathway activity is increased 
Knowing that Dkk3-/- T cells produce higher amounts of IL-2, the activation state of  the 
upstream p42 and p44 kinases, following Dkk3-/- and wild type CD8 T cell stimulation was 
examined. MACS purified CD8 T cells were stimulated with the DAG analogue PMA 
(250nM) for 15min at 37˚C. Alternatively, TCR signaling was simulated by CD8 T cell 
incubation with anti-CD3 -biotin followed by streptavidin cross-linking for 1, 3 and 5 minutes 
at 37˚C. Western blot analysis showed that lack of Dkk3 in CD8 T cells leads in higher ERK 
activation (Figure 32a, 32b).  
MEK phosphorylation was also increased in Dkk3-/- CD8 T cells, indicating that the phospho-
ERK inhibition takes place upstream of MEK. On the other hand, Ras-GTP levels remained 
unchanged in the absence of Dkk3 (Figure 31b). This data suggest that Dkk3 specifically 
inhibits ERK activation by acting on the level of the c-Raf kinase. It inhibits either the 
phosphorylation of MEK by the activated c-Raf kinase of the phosphorylation of c-Raf itself. 
However, the analysis of the phospho c-Raf kinase levels in ex-vivo isolated CD8 T cells by 
immune precipitation and western blotting was technically difficult with the available 
antibodies. 
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Figure 5-32. Dkk3 specifically inhibits the ERK-MAPK signaling pathway. (a) MACS isolated Dkk3+/+ and 
Dkk3-/- CD8 T cells were stimulated with biotynilated anti-CD3 which was crosslinked to streptavidin for the 
indicated time and the levels of phosphorylated and total ERK-MAPK were detected by Western Blot analysis. 
The blot and the quantitative results of one out of 3 independent experiments are shown. (b) MACS isolated (2) 
Dkk3+/+ and (3) Dkk3-/- CD8 T cells were stimulated with PMA 250nM for 15min and the activation levels of 
ERK, MEK and Ras were detected by Western Blot analysis. In series (1) non-stimulated control CD8 T cells 
were analyzed. Representative results of three independent experiments are shown. (c) Schematic representation 
of the signalling events that are initiated after TCR triggering. The central role of ERK MAPK pathway in TCR 
signal transduction is highlighted. 
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5.5.3 Dkk3-/- CD8 T cells display no changes in the p38 MAPK and PKCθ/NF-κΒ 
signaling 
Next, it was investigated whether the lack of Dkk3 affected other signaling molecules apart 
from the ERK pathway. In detail, the p38, JNK, phospho-Akt and NF-κB signaling pathway 
activities were examined. The p38 MAPK is induced upon TCR stimulation and 
costimulation. Additionally, some cytokine receptors, such as IL-12R, IL-18R and TNFR, can 
activate p38 MAPK. In CD8 T cells, p38 MAPK phosphorylation has been reported to induce 
increased IFNγ production and caspase-mediated apoptosis. However, p38 triggering upon 
TCR stimulation of isolated CD8 T cells in the absence of Dkk3 was not altered (Figure 33). 
 
Figure 5-33. Dkk3 deficiency does not influence the p38-MAPK signaling pathway. MACS isolated Dkk3+/+ 
and Dkk3-/- CD8 T cells were stimulated with PMA (250nM) and ionomycin (10µΜ) for the indicated time at 
37˚C and the levels of phosphorylated and total p38-MAPK protein were assessed by Western Blot analysis. One 
representative of two independent experiments is shown. 
The IκBα phosphorylation status was then investigated, since IκBα is a specific inhibitor of 
the nuclear factor NF-κB. NF-κB activation is induced upon TCR stimulation accompanied 
by costimulatory signals. TCR triggering leads to the activation of the PKCθ, which 
cooperates with Akt1 to induce IKK activity. IKK is the complex of two catalytic subunits 
(IKKα and IKKβ) and the regulatory IKKγ (NEMO) protein. The IKK complex 
phosphorylates the IκB proteins, thus allowing their subsequent polyubiquitination and 
proteasomal degradation. Upon IκΒ degradation, NF-κB is released and phosphorylated and 
translocates to the nucleus, where it regulates gene expression. To test whether the absence of 
Dkk3 affects the NF-κΒ pathway, the IκΒα phosphorylation status and integrity was analyzed 
by western blot analysis. If Dkk3-/- CD8 T cells display NF-κΒ hyperactivation, IκΒα 
phosphorylation upon TCR triggering should be increased and the total IκΒα levels should be 
reduced due to its proteolytic degradation. However, the lack of Dkk3 does not seem to affect 
the NF-κΒ pathway (Figure 34). 
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Figure 5-34. Dkk3 deficiency does not influence the NF-κΒ signaling pathway. MACS isolated Dkk3+/+ and 
Dkk3-/- CD8 T cells were stimulated with biotynilated anti-CD3 which was crosslinked to streptavidin for the 
indicated times. The levels of phosphorylated and total IκB protein were assessed by Western Blot analysis. One 
representative of two independent experiments is shown. 
 
5.6 Dkk3 is secreted by immune privileged tissues and contributes to the 
control of T cell reactivity 
In the previous paragraphs Dkk3 was shown to be involved in the maintenance of peripheral 
tolerance in the Des-TCR transgenic mouse model and to regulate polyclonal T cell reactivity. 
As mentioned in the introduction though, apart from the mechanisms of systemic peripheral T 
cell tolerance, immune homeostasis is preserved by the establishment of a local 
immunosuppressive microenvironment in non-regenerative tissues that are vital for host 
survival. Therefore it was interesting to investigate whether Dkk3 expression also contributes 
to the immunosuppressive environment detected in immune privileged organs. 
5.6.1 Dkk3 is expressed by immune privileged tissues 
It has been reported that Dkk3 mRNA is present in peripheral tissues, including the brain, 
spinal cord, eye, heart, ovary, uterus and liver (Niehrs 2006). By using the monoclonal anti-
Dkk3 antibody in ELISA Dkk3 protein could be traced in the tissues of two different inbred 
mouse strains. It is worth mentioning that Dkk3 protein was found to be present in the brain, 
the spinal cord and the eye. Additionally, the lung and the heart also expressed a significant 
level of Dkk3 (Table 5). The liver produced Dkk3 protein as well (Table 5). Finally, the 
embryo and the ovary, uterus and placenta all contained Dkk3 (Table 5). On the other hand, 
Dkk3 was absent from the skin, spleen, lymph nodes, thymus and serum. These results were 
confirmed by histological analysis. 
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Table 5-5.  Dkk3 protein expression in peripheral tissues.  Organs were isolated from C57.Bl6 and CBA mice 
and the protein lysates were titrated and screened for Dkk3 by ELISA. Organ lysates from Dkk3-/- mice 
displayed no Dkk3 antibody binding (data not shown). A representative of three independent experiments is 
shown for the C57.Bl6 mouse. The CBA mouse organs were tested in ELISA in a single experiment. 
In order to define the cell type in the central nervous system that expresses Dkk3, brain 
sections were analyzed for Dkk3 expression pattern using the markers Neurofilament N and 
Glial fibrillary acidic protein (GFAP). Neurofilament N is a specific marker for the neuronal 
cells and was found to be co-localized with Dkk3 protein (Figure 35). On the other hand, 
GFAP positive cells, which are the astrocytes, were not found to express Dkk3 in the steady 
state or during EAE. However, astrocytes isolated from the neonatal brain and expanded by in 
vitro culture were found to be positive for Dkk3 mRNA in RT-PCR. Apparently, the cell 
activation upon culture, which resembles strong inflammatory signals, induced the expression 
of Dkk3 in astrocytes. 
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Figure 5-35. Dkk3 expression in the brain is to neurons but not to astrocytes.  The brain of C57Bl6 mice 
that had been perfused with formaldehyde was analyzed for Dkk3 expression by confocal microscopy. The cell 
markers Neurofilament N for neuronal cells and GFAP for astrocytes were also used for the determination of the 
Dkk3-producing cell type. 
5.6.2 Secretory Dkk3 protein suppresses CD4 and CD8 T cell proliferation 
It was shown that lack of Dkk3 leads to increased T cell proliferation. Dkk3 expression was 
found to be prevalent in the immune privileged tissues. The reasonable question was then 
whether the presence of Dkk3 in peripheral tissues is important for the control of T cell 
responses. To address this, the direct effect of secreted Dkk3 on T cells was investigated with 
a series of in vitro assays. 
5.6.2.1 Dkk3 protein has a direct effect on CD4 and CD8 T cell proliferation 
In order to study the direct effect of Dkk3 on T cell proliferation, the Dkk3-secreting HEK 
293T-Dkk3 cells were used (see also paragraph 5.2.2). The HEK 293T-Dkk3 and the control 
HEK 293T cells were irradiated with 300 Gray and plated in 96-well plates in a concentration 
of 105cells/well. After irradiation the HEK 293T cells were living, thus expressed and 
secreted Dkk3, but were not able to proliferate. Either splenocytes or MACS-isolated CD8 T 
cells were added to the plate, at a final concentration of 105cells/well. The T cell proliferation 
was measured by thymidine incorporation at day 4 and the results of 3 independent 
experiments are shown in figures 36 and 37.  
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Figure 5-36.  Dkk3 protein secreted by the HEK293T-Dkk3 cells suppresses T cell proliferation in vitro. 
Spleenocytes from Dkk3+/+ (a) and Dkk3-/- (b) mice were stimulated with anti-CD3 (2µg/ml) and anti-CD28 
(1µg/ml) in the presence of irradiated HEK293T or HEK293T-Dkk3 T cells. T cell proliferation was measured 
by thymidine incorporation at day 4 upon stimulation. Mean+/- s.e.m from three independent experiments is 
shown. ( * P<0.05, *** P<0.001) 
The secreted Dkk3 could down-regulate total spleen T cell proliferation as well as CD8 T cell 
proliferation. The effect was observed in both Dkk3+/+ and Dkk3-/- groups, but was more 
pronounced with the knockout T cells (Figures 36b and 37b). It seems that the secreted Dkk3 
can bind to a yet unknown receptor on the T cells and directly suppress their proliferation. 
 
Figure 5-37. Dkk3 protein secreted by the HEK293T-Dkk3 cells suppresses CD8 T cell proliferation in 
vitro. MACS isolated CD8 T cells from Dkk3+/+ (a) and Dkk3-/- (b) mice were stimulated with anti-CD3 
(2µg/ml) and anti-CD28 (1µg/ml) in the presence of irradiated HEK23T or HEK293T-Dkk3 T cells. T cell 
proliferation was measured by thymidine incorporation at day 4 upon stimulation. Mean+/- s.e.m from three 
independent experiments is shown. ( * P<0.05, *** P<0.001) 
 
Furthermore, it was tested whether the observed effect of Dkk3-HEK 293T cells on T cell 
proliferation was exclusively due to the presence of secreted Dkk3. Purified recombinant 
mouse Dkk3 protein was added to in vitro proliferating T cells. The recombinant mouse Dkk3 
inhibited CD4 and CD8 T proliferation in a concentration dependent manner (Figure 38).  
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Figure 5-38.  Recombinant mouse Dkk3 protein suppresses CD4 and CD8 T cell proliferation in vitro. The 
proliferation of MACS isolated wild type CD4 and CD8 T cells in the presence of titrated concentrations of 
recombinant mouse Dkk3 protein was measured by thymidine incorporation at day 4 after anti-CD3 (2µg/ml) 
and anti-CD28 (1µg/ml) stimulation. One representative of three independent experiments +/-s.e.m is shown. 
5.6.2.2 Dkk3 protein regulates activated T cells by suppressing their proliferation in 
vitro 
Up to this point the effect of Dkk3 protein on T cell proliferation was studied by 
administration of the recombinant mouse Dkk3 to naïve T cells. Nonetheless, it was intriguing 
to investigate whether the suppressive function of Dkk3 could also be exerted on pre-
activated T cells. Therefore, recombinant mouse Dkk3 protein (3.5µg/ml) was added to 
activated CD4 or CD8 T cells, that had been stimulated in vitro with anti-CD3 (2µg/ml) and 
anti-CD28 (1µg/ml) for two days. T cell proliferation was measured 4 days upon T cell 
stimulation and 2 days upon addition of recombinant mouse Dkk3 protein to the proliferating 
T cell medium. Indeed, Dkk3 protein could inhibit further proliferation of the pre-activated 
CD4 and CD8 T cells (Figure 39).  
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Figure 5-39. Recombinant mouse Dkk3 protein can inhibit activated T cells from proliferating. MACS 
isolated CD4 or CD8 T cells were stimulated with anti-CD3 (2µg/ml) and anti-CD28 (1µg/ml). Recombinant 
mouse Dkk3 was added to the T cell medium at day two upon stimulation and T cell proliferation was assessed 
at day 4 after T cell stimulation by thymidine incorporation. Means of triplicates +/- s.e.m of one experiment are 
shown (*** P<0.001) 
5.6.2.3 Dkk3-mediated regulation of T cell proliferation involves an increase in T cell 
apoptosis 
Various mechanisms may lie behind the observed inhibitory effect of Dkk3 on T cell 
proliferation. One possibility is that Dkk3 induces early apoptosis of the activated T cells. To 
address this, C57.Bl/6 splenocytes or MACS isolated CD8 T cells were stimulated with anti-
CD3 (2µg/ml) and anti-CD28 (1µg/ml) antibodies in the absence or the presence of 3.5µg/ml 
Dkk3 protein. It has been reported that Dkk3 induces tumor cell apoptosis in a cell-density 
dependent manner (Hsieh et al. 2004). Therefore, titrated cell numbers were stimulated in the 
presence of Dkk3 in a constant volume of 0.2ml in a 96-well plate.  
In order to screen T cell apoptosis, the binding of annexin V to the cell surface was used as an 
early apoptotic marker. One of the earliest indications of apoptosis is the translocation of the 
membrane phospholipid phosphatidylserine (PS) from the inner to the outer leaflet of the 
plasma membrane. Once exposed to the extracellular environment, binding sites on PS 
become available for Annexin V, a 35-36 kDa, Ca2+-dependent, phospholipid binding protein 
with a high affinity for PS. Annexin V-binding cells can then be detected by flow cytometry. 
The proapoptotic cells are the annexin V positive, propidium iodide (PI) negative fraction and 
the late apoptotic or dead cells are within the annexin V positive PI positive fraction. 
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Figure 5-40.  Activation induced cell death is increased in the presence of recombinant mouse Dkk3 
protein. Titrated densities of Splenocytes or MACS isolated CD8 T cells from C57.Bl6 mice were stimulated 
with anti-CD3 (2µg/ml) and anti-CD28 (1µg/ml) in the presence or absence of recombinant mouse Dkk3 protein 
(3.5µg/ml). The percentage of apoptotic (annexin and propidium iodide positive) T cells was assessed by flow 
cytometry 24 hours upon stimulation.   
 
As shown in Figure 40, rmDkk3 protein resulted in increased percentages of apoptotic T cells. 
In detail, in CD4 and CD8 T cells in total spleen recombinant mouse Dkk3 induced a mean 
1.6 fold upregulation of apoptosis. The effect of rmDkk3 on the isolated CD8 T cells was 
more pronounced, with an average 2.2 fold increase in the percentage of apoptotic cells. 
5.7 Dkk3 regulates T cell responses in Experimental Autoimmune 
Encephalitis  
Up to this point, it has been shown that Dkk3 protein is secreted by immune privileged tissues 
and can control T cell reactivity in vitro, partially through the induction of T cell apoptosis. 
Obviously, it was intriguing to investigate the role of tissue-secreted Dkk3 in the regulation of 
T cell responses in vivo. Knowing that high amounts of Dkk3 are produced in the brain, the 
model of EAE was the ideal experimental system to address this point.  
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5.7.1 Dkk3-/- mice display more severe and persistent EAE 
To determine whether the clinical course of EAE was altered in the absence of Dkk3, Dkk3-/- 
and Dkk3+/+ mice were immunized with MOG35-55 peptide in CFA and additionally received 
two doses of pertussis toxin at days 0 and 2.  
 
Figure 5-41. Absence of Dkk3 results in more severe and persistent EAE. Dkk3+/+ and Dkk3-/- mice were      
immunized with MOG33-55 in CFA plus pertussis toxin and the EAE symptoms were assessed every second day. 
Mean +/- s.e.m of three independent experiments are shown. 
 
The clinical data from more than 60 days of observation of three independent experiments 
(Figure 41 and Table 6) indicated that lack of Dkk3 leads to more severe and persistent EAE. 
The disease onset (days 10-14) was similar in wild type and Dkk3-/- animals. At the peak of 
the disease, however, at day 15, the Dkk3-/- mice displayed more severe symptoms. The mean 
maximum disease score remained higher for the Dkk3-/- group throughout the 60 days of 
observation. As shown in table 6 four Dkk3-/- mice and only one wild type mouse died from 
severe EAE. 
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 Incidence Mean Onset 
(Day) 
Mean Maximum score Dead mice 
DKK3 
+/+
 24/26 11.1+/-2.6 2.4+/-1.1 1 
DKK3 
-/-
 25/25 10.8+/-2.3 3.1+/-1.1 (P<0.05) 4 
Table 5-6. Clinical data from three independent EAE experiments. The mean onset refers to the mean+/-
s.e.m day upon immunization that the first symptoms were observed. The mean maximum score refers to the 
mean+/-s.e.m disease maximum of each mouse. 
The EAE graph shows that the wild type mice recovered from the disease after day 22, but the 
mice lacking Dkk3 remained ill and their clinical state did not ameliorate during the 
observation time. The increased disease chronicity in the Dkk3-/- group is more apparent in 
figure 42, where the mice that have died from the disease are excluded from the analysis. The 
disease duration in the living mice is shown. 
 
 Figure 5-42. EAE diseased Dkk3
-/-
 mice display increased EAE disease 
chronicity.  The disease duration of each Dkk3+/+ and Dkk3-/- mouse in 
two independent EAE experiments is shown. The mice that died from the 
disease were excluded from the analysis.  
 
5.7.2  
 
 
5.7.3  
 
5.7.4 The increased EAE chronicity in the Dkk3-/- mice is accompanied by persistence 
of activated CD8 T cells in the CNS. 
In order to clarify why Dkk3-/- mice do not recover from EAE, CNS-infiltrating T cells were 
isolated from the brain and spinal cord of the mice at days 20 and 29. FACS analysis 
suggested that the severe disease phenotype of Dkk3-/- mice was due to persistence of IFNγ-
producing activated CD8 T cells in the CNS (Figure 43). The percentage of TNF-α and IL-17 
producing CD4 T cells in the Dkk3-/- mice suffering from EAE were comparable with the 
ones  found in recovered Dkk3+/+ mice. Moreover, there was no difference in the cell number 
and representation of the CNS infiltrating leukocyte types. 
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Figure 5-43.  In the absence of Dkk3 IFNγ-producing CD8 T cells persist in the CNS of  mice suffering 
from EAE. (a) CNS-infiltrating T cells were isolated from EAE-diseased mice and stained intracellularly for the 
IFNγ,IL-17, TNFα cytokine expression. Representative results of five independent experiments are shown. (b) 
The mean +/- s.e.m of the percentage of IFNγ-producing CD8 T cells in the CNS of EAE diseased mice, at day 
29 upon EAE immunization. (**P<0.01) 
 
5.7.5 Neuron-derived Dkk3 is crucial for the control of EAE 
As already mentioned, Dkk3 production by T cells could not be proven, neither in this thesis 
nor by others (Krupnik et al. 1999; Niehrs 2006). However, it can not be formally excluded 
that T cells express undetectable amounts of Dkk3, which modify their function, or that T cell 
development in a Dkk3-/- host has an effect on T cell reactivity. Thus, the last question asked 
was whether the observed severe EAE phenotype in Dkk3-/- mice was strictly a T cell-intrinsic 
effect or due to the absence of the neuron-derived Dkk3.  
To address this point, bone marrow chimeras were constructed. Bone marrow from wild type 
mice was transferred to irradiated Dkk3-/- mice and conversely Dkk3-/- bone marrow was 
injected to wild type recipients. A control group of irradiated wild type mice that received 
Dkk3+/+ bone marrow was also included in the experimental setup. Eight weeks after the 
reconstitution of the mice, the chimerism was checked by defining the percentage of donor 
derived B and T cells in the blood and EAE was induced as described. All mice developed 
very severe symptoms (all displayed an EAE score of 4 or higher), probably because of the 
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damage induced in the CNS by the extended inflammation caused by the irradiation (Zehntner 
et al. 2004).  
However, there was a difference in the onset of the disease. The Dkk3+/+ Dkk3-/- chimeras 
developed EAE symptoms earlier, indicating that absence of Dkk3 from the tissues is the 
main cause of severe EAE. Indeed, the presence of neuron-derived Dkk3 in the brain could 
partially control T cell responses in the Dkk3-/- Dkk3+/+ and Dkk3+/+ Dkk3+/+ chimeric 
mice (Figure 44). 
 
Figure 5-44. Lack of Dkk3 in the brain rather than in T cells leads to more severe EAE. Lethally irradiated 
Dkk3-/- and Dkk3+/+ mice were injected with Dkk3+/+ and Dkk3-/- bone marrow cells respectively. Additionally 
control Dkk3+/+  Dkk3+/+ chimeric mice were generated. The chimeras were immunized with MOG33-55 in CFA 
and received two doses of pertussis toxin i.p. The EAE onset is depicted in the graph. The mean+/-s.e.m from 
each group is shown. All experimental groups consisted of eight mice. 
 
The result obtained in the bone marrow chimeras EAE experiment was confirmed using T cell 
transfer studies. The aim was to induce passive EAE in Dkk3+/+ and Dkk3-/- donor mice by 
adoptive transfer of pre-activated MOG-specific T cells. Donor Dkk3+/+ and Dkk3-/- mice 
were immunized with MOG33-55 peptide (200µg/mouse) in CFA (500ng M. 
tuberculosis/mouse) in the presence of pertussis toxin (250ng/mouse). Ten days upon 
immunization T cells were isolated from the spleen and the draining lymph nodes of the 
diseased mice and cultured for 4 days in vitro in the presence of the MOG33-55 peptide 
(10µg/ml) and IL-12 (2.5ng/ml), or the MOG33-55 peptide (10µg/ml) and IL-12 (25ng/ml) plus 
IL-2 (0.5ng/ml and upon day 2 of culture 2.5ng/ml) and IL-18 (25ng/ml). After their in vitro 
expansion, MOG33-55-specific T cells were intravenously injected to the recipient mice (1-
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2x107/mouse), which also received pertussis toxin (250ng/mouse) intraperitoneally. 
Unfortunately, the mice displayed only weak disease symptoms (EAE sores ranged from 0.5 
to 1.5) (Figure 45). Therefore, it was not possible to draw a conclusion concerning the role of 
Dkk3-/- T cells in EAE severity and persistence from this experiment. 
Figure 5-45. Passive EAE induction by adoptive 
transfer. Activated MOG-specific Dkk3+/+ and Dkk3-/- 
T cells were isolated from immunized donors and 
expanded in vitro in the presence of MOG peptide 
(10µg/ml) and IL-12 (2.5µg/ml). Dkk3-/- and Dkk3+/+ 
mice received 2x107 activated MOG-specific Dkk3+/+ 
and Dkk3-/- T cells respectively. The disease course 
was followed. The mean EAE score+/- s.e.m of eight 
mice per group is shown. 
 
Additionally, transgenic 2D2 mice, carrying the MOG33-55-specific Vβ11 TCR chain, were 
used as donor mice. However, there was again only slight disease occurrence. The passive 
immunization was also attempted with simultaneous subcutaneous administration of DCs, 
which had previously been activated with CpG and loaded with the MOG33-35 peptide. 2x10
7 
activated and peptide-loaded DCs were intraperitoneally and subcutaneously injected to the 
recipient mice. However, again the mice only developed mild EAE symptoms. 
It was then considered that adoptive transfer of pre-activated MOG-specific T cells could 
induce high disease score, when combined with host immunization. Since the simultaneous 
activation of host T cells by the immunization was not desired, Rag1-/- mice were used as 
recipient mice. The MOG-specific activated T cells were obtained as described above. The 
Rag1-/- were transferred with 2x107 T cells and at the same time received pertussis toxin 
(250ng/mouse) intraperitoneally. One day after the adoptive transfer, the recipient mice were 
immunized with MOG33-55 peptide in CFA. At day two the mice received an extra dose of 
pertussis toxin. The disease symptoms started at day 4, as the MOG specific T cells were 
already activated. The disease course mediated by Dkk3-/- T cells was comparable with the 
one induced by Dkk3+/+ T cells (Figure 46). This strongly suggests that the presence or 
absence of Dkk3 in T cells is not the decisive factor for the protection against autoimmunity. 
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Figure 5-46. Dkk3
-/-
 and Dkk3
+/+
 T cells cause equally severe EAE symptoms in Rag1
-/-
 host mice. Activated 
MOG-specific Dkk3+/+ and Dkk3-/- T cells were isolated from immunized donors and expanded in vitro in the 
presence of MOG peptide (10µg/ml) and IL-12 (2.5µg/ml). Rag1-/- mice received 2x107 activated MOG-specific 
Dkk3+/+ and Dkk3-/- T cells and pertussis toxin. One day after transfer the mice were immunized with MOG in 
CFA. At day 2 upon adoptive T cell transfer the Rag1-/- were injected with pertussis toxin. The disease course 
was followed. The mean EAE score+/- s.e.m of five mice per group is shown. 
 
Finally, the Dkk3-blocking monoclonal antibody was employed to prove that the presence of 
secreted Dkk3 in CNS is important for the regulation of the autoimmune response. 
Additionally by this approach it was possible to confirm that the altered EAE phenotype of 
the Dkk3-/- mice cannot be attributed to different thymic selection of the developing T cells or 
to another yet undefined T cell-intrinsic effect of Dkk3.  
EAE was induced in wild type mice by immunization with the MOG33-55 peptide in CFA and 
injection of pertussis toxin (250ng/mouse) as described above. Additionally the mice received 
intraperitoneally 1 mg of anti-Dkk3 monoclonal antibody or control mouse IgG at day 7. 
Administration of 0.5mg of antibody per mouse was repeated at days 10, 15, 20, 25, 35 and 
50.  
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Figure 5-47. Dkk3 blockade by the monoclonal anti-Dkk3 antibody leads to increased EAE chronicity.  
C57.Bl/6 mice were immunized with MOG peptide in CFA and pertussis toxin. Additionally, one experimental 
group received anti-Dkk3 and the other control mouse IgG at days 7 (1mg/mouse), 10, 15, 20, 25 and 35 
(0.5mg/mouse). (a) The mean disease score+/-s.e.m of  seven mice pro group is shown.  The results are from one 
representative out of three independent experiments. (***P<0.001). (b) The disease duration of each EAE-
immunized mouse is shown. Pooled data from two independent experiments are presented. (*P<0.05) 
 
Blockade of the secreted Dkk3 by the anti-Dkk3 monoclonal antibody resulted in slightly 
elevated and longer lasting EAE scores in C57.Bl/6 mice (Figure 47a and 47b). The disease 
onset was similar in both groups. Importantly, the disease chronicity was significantly 
increased in mice that received the anti-Dkk3 antibody in each of the three experiments.  
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6 DISCUSSION 
The main point of the current thesis is the identification of Dickkopf 3 protein as a universal 
immune regulator. Briefly, Dkk3 was shown to be expressed and secreted by tolerant CD8 T 
cells in a transgenic mouse model of parenchymal cell-induced CD8 T cell tolerance. In this 
mouse model, secretory Dkk3 was proved to be essential for the mediation of T cell 
suppression in a paracrine function. Moreover, studies carried out with polyclonal T cells of 
the C57.BL/6 background indicated the crucial role of Dkk3 in controlling T cell reactivity. 
Last but not least, Dkk3 was shown to contribute to the protection of immune privileged 
organs from the devastating consequences of extended immune responses. The 
characterization of Dkk3 as a mediator of immune suppression in more than one contexts, e.g. 
in the Des-TCR CD8 T cell tolerance, in T cell responses in the secondary lymphoid organs 
and in immune privileged organs, is of importance, considering that there are not many 
molecules reported to have such a wide spectrum of function. The detailed aspects of Dkk3 
function as well as the significance of these findings will be discussed below. 
6.1 Characterization of the gene expression profile of the Des-TCR 
regulatory CD8 T cells 
The characterization of the gene expression profile of the tolerant CD8 T cells could give 
insight into novel molecular mechanisms of immune suppression. Indeed, gene expression 
analysis of the regulatory Des-TCR CD8 T cells has revealed the upregulation of genes, 
which encode either for markers of the CD4+CD25+FoxP3+ natural Treg cells, or for 
mediators of the regulatory function of natural Treg cells. The pronounced expression of 
TGF-β, CTLA-4, CCR5, neuropilin-1, Epstein-Barr virus-induced gene 3 (EBI3) and 
granzyme B indicates that regulatory Des-TCR CD8 T cells display common markers and 
suppressive mechanisms with natural Treg cells (Figure 5-10). 
TGF-β is a well characterized immune suppressive cytokine. It has been shown to induce the 
differentiation of adaptive Treg cells and is crucial for the suppressive function of both natural 
and induced Tregs (Wan et al. 2007). Moreover, TGF-β has been shown to contribute to the 
immunosuppressive microenvironment of the immune privileged tissues (Niederkorn 2006). 
The expression of TGF-β underlies the observed regulatory function of Des-TCR CD8 T cells 
in the tolerant Des-TCRxKerKb mice. 
CTLA-4 is a surface molecule, expressed by all activated T cells but not by the naïve T cells. 
Like CD28, CTLA-4 is a receptor for the B7 costimulatory molecules that are expressed on 
APCs and provide the signal 2 for T cell stimulation. However, unlike CD28, its ligation leads 
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to the suppression of T cell activation and proliferation (Greenwald et al. 2005). CTLA-4 was 
also found to be expressed by natural Treg cells and was shown to be indispensible for their 
suppressive function (Itoh et al. 1999; Kingsley et al. 2002; Read et al. 2006). CTLA-4 has 
been found to mediate Treg suppressive function, by stimulating the APCs to upregulate the 
immunosuppressive enzyme IDO (Puccetti et al. 2007). Notably, CTLA-4, together with 
TGF-β, are the sole Treg-related genes whose disruption results in a severe phenotype, similar 
to the phenotype of Treg deficient mice (Tang et al. 2008). Thus CTLA-4 might also 
contribute to the regulatory function of the Des-TCR CD8 T cells. 
The chemokine receptor CCR5 is expressed on activated CD4 and CD8 T cells, NK cells, 
macrophages, and dendritic cells (Murphy et al. 2000). The ligands for this receptor, CCL3, 
CCL4, and CCL5, are expressed at sites of inflammation. Thus, CCR5 may play a role in the 
migration of effector cells to the tissues (Huffnagle et al. 1999; Glass et al. 2001; Murai et al. 
2003; Deaglio et al. 2007). Interestingly however, multiple studies in CCR5-deficient mice 
demonstrate enhanced cell-mediated immune responses during pathogen infection (Sato et al. 
1999; Algood et al. 2004), delayed-type hypersensitivity (Liu et al. 2007), and tumor 
vaccination (Ng-Cashin et al. 2003) suggesting an immunoregulatory role for CCR5. 
Expression of CCR5 by Treg cell is critical for the suppression of immune responses in vivo, 
since it directs Treg cells to the sites of inflammation (Wysocki et al. 2005; Yurchenko et al. 
2006). Subsequently, CCR5 may be of importance for the suppressive capacity of the tolerant 
Des-TCR CD8 T cells, by enabling their migration to the inflamed tumor or skin grafts. 
Neuropilin 1 (Nrp1) was first identified as a receptor for the class 3 semaphorins and 
members of the vascular endothelial growth factor (VEGF) family (Romeo et al. 2002). It has 
been shown to be constitutively expressed by the natural Treg cells and to promote regulatory 
T cell activity (Bruder et al. 2004). In detail, Nrp1 has been reported to bind the latency-
associated peptide (LAP)-TGF-β, which is the latent form of TGF-β, as well as free LAP and 
active TGF-β (Glinka et al. 2008). Moreover, Nrp1 was demonstrated to prolong the contact 
between Treg cells and immature DCs in steady state conditions (Sarris et al. 2008). 
Importantly, increased expression of Nrp1 in the tolerant CD8 T cells is an additional hint for 
their regulatory role. In the future Nrp1 could be studied as a marker for the regulatory CD8 T 
cells, since it is a surface molecule that is not expressed on naïve and activated CD8 T cells. 
EBI-3 molecule is a member of the IL-12 family of proteins. It is homologous to the p40 
subunit of the IL-12 cytokine and until recently it was only known to heterodimerize with p28 
subunit to form the cytokine IL-27 (Holscher 2004). Interestingly, it was lately shown to form 
a heterodimer with the p35 subunit of IL-12, which was given the name IL-35. EBI-3 and p35 
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are both expressed by natural Treg cells and IL-35 has been reported to contribute to their 
regulatory function in vitro and in vivo (Collison et al. 2007). Moreover, EBI-3 has been 
shown to be expressed by the placenta, where it has been suggested to exert an immune 
suppressive role (Devergne et al. 1997). Interestingly, EBI-3, but not p35 or p40, is expressed 
by the regulatory Des-TCR CD8 T cells. This indicates that it may be a mediator of immune 
regulation upon binding to an unknown subunit of the IL-12 family or by forming 
homodimers.  
Granzyme B is a caspase-like serine protease released from cytotoxic CD8 T cells and NK 
cells within granules against virus-infected host cells and tumor cells (Andrade et al. 2004). 
Once in the target cells, it activates the caspases and the proapoptotic molecule Bid by 
proteolytic cleavage, thereby inducing apoptosis (Lord et al. 2003). Its upregulation in the 
tolerant Des-TCR CD8 T cells, which are not able to reject the P815 tumor carrying their 
cognate Kb antigen, is however not a paradox, since granzyme B has been lately reported to 
be expressed by natural Treg and to mediate their suppressive function. Interestingly, 
granzyme B has been shown to be upregulated in natural Treg cells and to mediate cell 
contact-dependent suppression in vitro, by inducing apoptosis of effector CD4 T cells 
(Gondek et al. 2005). Additionally, in in vivo studies Treg cells have been reported to 
suppress tumor clearance in a granzyme B-dependent fashion, which involves the death of 
NK and CD8 T cells (Cao et al. 2007). Granzyme B has also been implied to mediate the 
suppressive function of CD4 and CD8 double positive CD25+ regulatory T cells that are 
isolated from the lymph nodes of diabetic NOD mice (Qin et al. 2006). Importantly, 
granzyme B has been demonstrated to be expressed by other CD8 regulatory T cell 
populations (Mahic et al. 2008). Thus, it is reasonable to suggest that granzyme B 
upregulation in the Des-TCR tolerant CD8 T cells it may contribute to their suppressive 
function. 
Interestingly, FoxP3, the transcription factor that is crucial for natural Treg differentiation and 
function is not upregulated in the tolerant CD8 T cells. This finding differentiates the 
regulatory Des-TCR CD8 T cells from other FoxP3+CD8 T cell regulatory populations which 
are either induced in vitro (Kapp et al. 2006) or in vivo, during ACAID (Jiang et al. 2007) or 
murine lupus (Sharabi et al. 2008). This suggests that the development of self antigen-specific 
tolerant CD8 T cells in the neonatal mouse follows distinct molecular proccess from the 
development of FoxP3+ regulatory T cells in the thymus (natural Treg cells) or in the 
periphery (adaptive Treg cells). However, the occurring suppressive T cells may employ 
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common mechanisms of regulatory function, such as expression of TGF-β, CTLA-4, EBI-3, 
Nrp1 and granzyme B. 
6.2 Dkk3 is up-regulated in tolerant CD8 T cells and is crucial for their 
regulatory function 
Having identified numerous genes that are differentially regulated in the Des-TCR regulatory 
CD8 T cells, a decision had to be made, which candidate gene product should be studied in 
detail to establish a causal link between enhanced gene expression and the observed in vivo 
tolerance. Among the differentially expressed genes Dickkopf 3 was chosen for further 
investigation. Importantly Dkk3 is a secreted molecule that could mediate regulation of the 
proximate T cells. Moreover, it had been shown to inhibit the ERK MAPK signaling 
(Lodygin et al. 2005), which is crucial for T cell proliferation and IL-2 production. Finaly, 
Dkk3 mRNA has been reported to be up-regulated in many immune privileged tissues, such 
as the brain, the embryo and the ovaries. All these clues indicated that Dkk3 could be a 
potential mediator of Des-TCR CD8 T cell regulation. 
Dkk3, mRNA was found to be induced in the tolerant CD8 T cell population by RT-PCR 
(Figure 5-11). Interestingly, Dkk3 protein was also traced by intracellular staining of tolerant 
CD8 T cells by flow cytometry (Figure 5-13). In summary, tolerant CD8 T cells express the 
secretory molecule Dkk3 on the mRNA and protein level.  
Studies using Des-TCRxKerKb mice lacking Dkk3 expression (Dkk3-/-xDes-TCRxKerKb 
mice) revealed that Dkk3 is not just an intracellular marker of tolerant Des-TCR CD8 T cells 
but also contributes to their function. In the absence of Dkk3, the Des-TCR CD8 T cells that 
develop in a mouse expressing the Kb cognate antigen in the skin are not suppressive. Kb-
positive P815 tumor cells tumor grafts were rejected with the same kinetics as in the Des-
TCR control mice (Figure 5-14).  
The role of Dkk3 in Des-TCR CD8 T cell tolerance was also tested upon priming of the 
Dkk3-/-xDes-TCRxKerKb mice with CpG-activated Kb-positive dendritic cells. The cytotoxic 
T cells were challenged 7 days after with Kb-positive target cells and the cytotoxicity was 
measured by FACS. The tolerant Des-TCRx KerKb mice exhibited no effector cell responses. 
On the contrary, the Dkk3-/-xDes-TCRxKerKb mice displayed elevated cytotoxicity as 
compared to the control Des-TCRxKerKb mice (Figure 5-15).  
Thus, Dkk3 is thus indispensable for CD8 T cell tolerance as shown in two independent test 
systems. From the findings mentioned above it does not become clear whether the presence of 
Dkk3 is essential for the induction of tolerance by parenchymal cells in the neonatal mice or 
for the mediation of tolerance during an immune response in the adult individuals. To 
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examine this, Des-TCRxKerKb mice, which have been shown to develop tolerant CD8 T cells 
during the neonatal phase, were tested for autologous skin graft acceptance in the presence of 
Dkk3-blocking antibody.  Interestingly, administration of Dkk3-blocking antibody resulted in 
the rejection of the transplants (Figure 5-16). This indicates that Dkk3 mediates CD8 T cell 
tolerance upon secretion, therefore blocking of the secreted molecule inhibits immune 
suppression. Additionally, it is apparent that absence of tolerance is not an artifact of the 
Dkk3-/-xDes-TCRxKerKb mice but it is essential for CD8 T cell tolerance maintenance during 
the adult phase of wild type Des-TCRxKerKb mice. 
Dkk3 is suggested to mediate tolerance upon secretion and binding on target cells rather than 
by a cell contact-dependent manner. FACS analysis after extracellular staining of Dkk3 on 
naïve, activated and tolerant Des-TCR CD8 T cells revealed that there is no Dkk3 protein 
bound on their membrane (Figure 5-17). Since the amounts of membrane-bound Dkk3 were 
under the detection limit, it is reasonable to propose that the mechanism of Dkk3-dependent 
tolerance is the secretion of Dkk3 and the paracrine suppression of non-tolerant CD8 T cells. 
In summary, Dkk3 protein is expressed by the tolerant Des-TCR CD8 T cells and is 
indispensable for their suppressive function. Lack of Dkk3 from the Des-TCRxKerKb mice 
results in the activation of naïve Des-TCR CD8 T cells after encountering their cognate 
antigen. It is suggestive that the suppressive function of the tolerant Des-TCR CD8 T cell is 
mediated by the secreted Dkk3, since administration of the blocking anti-Dkk3 antibody in 
adult mice is sufficient to reverse tolerance against Kb-expressing autologous skin grafts. It 
seems that Dkk3 does not mediate cell-contact dependent suppression, since surface-bound 
Dkk3 cannot be traced on tolerant Des-TCR CD8 T cells by FACS. 
6.3 Dkk3 affects polyclonal T cell reactivity  
Dkk3 apparently plays a major role in the establishment of peripheral Des-TCR CD8 T cell 
tolerance in the transgenic mouse model carrying a single T cell receptor. However, its 
regulatory role is not limited to this transgenic model of peripheral CD8 T cell tolerance. 
Dkk3 affects polyclonal T cell reactivity as well. This was shown by a series of experiments 
with mice of C57.Bl/6 background lacking Dkk3 (Dkk3-/-) and in studies of the direct effect of 
Dkk3 protein on T cell proliferation, which are discussed in paragraph 6.6. 
Comparison of the in vitro proliferation of Dkk3+/+ and Dkk3-/- splenocytes showed that 
Dkk3-/- CD4 and CD8 T cells proliferate significantly more than the control Dkk3+/+ T cells 
(Figure 5-20). Analysis of the kinetics of Dkk3-/- T cell proliferation by FACS revealed that in 
the absence of Dkk3, T cells had undergone more proliferation rounds on day 4 (Figure 5-21). 
DISCUSSION 
 107 
Wild type T cell proliferation reached the Dkk3-/- T cell proliferation level at later time points. 
This could mean that Dkk3-/- T cells started proliferating earlier or that in the absence of Dkk3 
the rate of T cell proliferation was increased. Therefore Dkk3-/- T cells may have died by day 
5, due to activation induced cell death and nutrient exhaustion. In general, it seems that Dkk3 
expression in mice with polyclonal repertoire sets a limit to T cell reactivity.  
The observed hyperproliferation of Dkk3-/- T cells was not an effect of T cell in vivo pre-
activation. Unpublished work in our lab had shown that the levels of the activation markers on 
T cells derived from naïve Dkk3-/- are comparably low with these of wild type naïve T cells. 
Moreover, it was here shown that isolated CD62Lhigh Dkk3-/- naïve T cell proliferation was 
stronger than the proliferation of Dkk3+/+ controls (Figure 5-22), thereby confirming the 
assumption that the presence of Dkk3 in the wild type mice suppresses the proliferation of T 
cells upon their stimulation. 
The Dkk3-mediated suppression is not related to CD4+CD25+FoxP3+ regulatory T cells. It 
could be possible that such a hyperproliferative Dkk3-/- T cell phenotype was due to Treg 
malfunction, since Treg cells have been reported to play a major role in the control of T cell 
reactivity. However, neither was Dkk3 expression found in CD4+CD25+FoxP3+ regulatory T 
cells, nor was the suppressive function of Dkk3-/- Treg cells compromised (Figure 5-23). 
To summarize, Dkk3 is indispensable for the control of T cell reactivity in mice with 
polyclonal TCR repertoire. Absence of Dkk3 leads to T cell hyperproliferation upon 
stimulation of naïve T cells through T cell receptor. Expression analysis accompanied by 
functional studies suggests that Dkk3 is not a mediator of natural Treg function, but controls 
activated T cell proliferation via a Treg-independent mechanism. 
The observed effect of Dkk3 on polyclonal T cell reactivity contradicts the reports, according 
to which Dkk3 is not expressed by lymphoid organs, e.g. spleen, lymph nodes and thymus. 
These data were validated in our lab both by RT-PCR and ELISA (Table 5-5). However, 
Dkk3 mRNA and protein were traced in the tolerant Des-TCR CD8 T cells (Figures 5-11 and 
5-13). Moreover, only after mRNA amplification naïve and activated Des-TCR CD8 T cell 
samples displayed hybridization with the Dkk3 gene probes on the GeneChip microarrays. 
Similarly, in a microarray study done by Kaech et al., it was reported that Dkk3 expression 
levels in P14 transgenic CD8 T cells were decreased during the peak as well as the late phase 
of the immune response (days 8-22 post LCMV viral infection) and then increased as the 
memory CD8 T cell population was stabilized (Kaech et al. 2002). This suggests that in the 
particular study Dkk3 mRNA was also present in the naïve, activated and memory CD8 T cell 
samples in tiny amounts that could be traced only upon mRNA amplification.  
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FACS analysis of the Dkk3 protein levels in lymphocytes from wild type mice was not 
efficient in detecting a CD8 T cell population expressing the Dkk3 protein. Similarly, CD4 T 
cells, NK cells, dendritic cells, monocytes and stromal spleen cells were also negative for 
Dkk3 (Figures 5-18 and 5-19).  
Generally, it cannot be excluded by the FACS analysis that a tiny undetectable spleen cell 
population expresses Dkk3. Indeed, considering the consequences of the extended expression 
of a negative regulator of T cell responses in the spleen of naïve mice, it is reasonable to 
suggest that if there is any Dkk3 expression in spleen or in other lymphoid organs, it is so 
limited that it cannot be traced by RT-PCR, FACS and ELISA analysis of the total organ. 
Based on the Des-TCRxKerKb transgenic model it could be hypothesized that only few self 
antigen-specific T cells may upregulate Dkk3 expression upon encountering their cognate 
antigen in the periphery under steady state conditions, probably during the neonatal phase, 
when they have access to peripheral tissues. 
However, it is possible to prove Dkk3 expression by T cells indirectly, through functional 
assays. Moreover, in future studies single cell RT-PCR could be employed to trace the few 
spleen cells that could possibly express Dkk3 mRNA.  
6.4 Cellular mechanisms of Dkk3-/- T cell hyperproliferation 
In total spleen proliferation assays both CD4 and CD8 T cells were hyperproliferative in the 
absence of Dkk3 when compared to wild type controls. However, isolated Dkk3-/- CD4 T cells 
proliferated as much as isolated Dkk3+/+ CD4 T cells (Figure 5-24). This suggests that the 
difference observed in the proliferation of Dkk3-/- and Dkk3+/+ CD4 T cell in total spleen 
cultures can be attributed to the role of CD4 T cell-extrinsic Dkk3 protein. Apparently, CD4 T 
cells can respond to the presence of Dkk3 but do not produce Dkk3 themselves.  
On the contrary, isolated Dkk3-/- CD8 T cells displayed hyperproliferation, exactly like in 
total spleen assays (Figure 5-24). This suggests that CD8 T cells not only are able to respond 
to Dkk3 but they also are influenced by its absence. One hypothesis is that Dkk3 is expressed 
by a small regulatory CD8 T cell population that is untraceable by FACS analysis. Thereby, 
CD8-derived Dkk3 can further regulate CD8 T cell proliferation and its absence results in 
CD8 T cell hyperproliferation. However, it cannot be excluded that tissue-derived Dkk3 
affects permanently CD8 T cell reactivity and CD8 T cells that develop in a Dkk3 deficient 
environment are hyperproliferative. 
For example, the differential Dkk3-/- CD8 T cell reactivity could be a consequence of altered 
thymic selection in the absence of Dkk3, which could favor more reactive T cell clones. 
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Analysis of the TCR repertoire in Dkk3-/- and Dkk3+/+ mice as well as in Dkk3-/-Dkk3+/+, 
Dkk3+/+Dkk3-/- and control Dkk3+/+Dkk3+/+ chimeras revealed that the absence of Dkk3 
from the thymic epithelium or from cells of hematopoietic origin that play a role in thymic 
selection does not affect T cell development in the thymus (Table 5-4).  
However, studies carried out with Dkk3-/-Dkk3+/+ and Dkk3+/+Dkk3-/- chimeras revealed 
the importance of tissue-derived Dkk3 for the control of T cell reactivity. Wild type T cells 
that developed in Dkk3-/- host displayed increased proliferation when compared to wild type T 
cells that developed in Dkk3 sufficient environment (Figure 5-27). Consequently, although 
Dkk3 expression in a CD8 T cell subpopulation cannot be excluded, it is undisputable that 
Dkk3 production by cells of non-hematopoietic origin influences T cell reactivity. 
6.5 Molecular mechanisms of Dkk3-/- T cell hyperproliferation 
Taking into account that Dkk3-/- T cell responses are different from the wild type ones, it was 
intriguing to investigate which signaling pathways are modified in the absence of Dkk3 
molecule. Dkk3 belongs to the Dickkopf family of mediators of the Wnt signaling pathway. 
However, it is widely accepted that it does not interact with the known receptors that initiate 
Wnt signaling (Krupnik et al. 1999; Mao et al. 2002; Wu et al. 2006). Interestingly, no 
receptor has been identified to bind secretory Dkk3.  
Although Dkk3 is involved in the TGF-β pathway by maintaining normal levels of Smad4 in 
the Xenopus laevis embryo (Pinho et al. 2007), there is no evidence that it affects the TGF-β 
pathway in T cells. TGF-β exerted the same suppressive effect on both Dkk3-/- and Dkk3+/+ T 
cells (Figure 5-29). Additionally, the levels of intracellular Smad4 protein were not found to 
be decreased despite the absence of Dkk3 from activated T cells (Figure 5-30). 
The activation of the ERK pathway is essential for T cell survival and proliferation since it 
leads to IL-2 production by T cells. Inhibition of ERK phosphorylation leads to T cell anergy. 
It is characteristic that in tolerant Des-TCR CD8 T cells that were obtained from 
thymectomized Des-TCRxKerKbxRAG2-/- mice the levels of phosphorylated ERK upon T 
cell stimulation were highly decreased in comparison to activated Des-TCR CD8 T cells. 
In the absence of Dkk3, polyclonal T cells display an increased proliferation rate and elevated 
IL-2 production (Figures 5-31 and 5-32). The molecular mechanism lying behind this effect 
seems to be the increased activity of the ERK pathway. TCR stimulation as well as direct 
signaling via the DAG analogue PMA led to increased ERK activation in the Dkk3-/- CD8 T 
cells.  
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This suggests that Dkk3 is an inhibitor of the ERK pathway. It seems that it inhibits 
downstream of Ras and upstream of the MEK kinase, most possibly at the level of the c-Raf 
kinase. The conclusion that Dkk3 is an inhibitor of the ERK pathway is also consistent with 
the observation that Dkk3 overexpression in the prostate cancer cell line PC3 prevents ERK 
phosphorylation (Lodygin et al. 2005).  
The observed effect of the lack of Dkk3 on the ERK pathway in CD8 T cells could explain 
Dkk3-/- T cell hypereactivity. However, what remains to be investigated is whether the 
presence of secreted Dkk3 inhibits directly the ERK pathway, since the above experiments 
cannot exclude the possibility that lack of Dkk3 indirectly affects the ERK signaling in T 
cells. 
6.6 Dkk3 is secreted by immune privileged tissues and contributes to the 
control of T cell reactivity 
6.6.1 Dkk3 is expressed by immune privileged tissues 
It has previously been reported that Dkk3 mRNA is present in peripheral tissues, including 
the brain, the spinal cord, the eye, the heart, the ovary, the uterus and the liver. By using the 
monoclonal anti-Dkk3 antibody in ELISA and histology staining, Dkk3 could indeed be 
detected in those tissues (Table 5-5 and Figure 5-35). Interestingly, Dkk3 is present in the 
brain, the spinal cord and the eye, which are characterized as immune privileged organs. As 
mentioned before, immune privileged organs are known to express the immune suppressive 
molecules Fas, IDO and the TGF-β cytokine. Thus, the presence of Dkk3 secretory molecule 
in the CNS and the eye could be an additional mechanism of active control of the immune 
responses in these tissues, where aberrant immunity and extended inflammation are 
detrimental for the host.  
The exact cell type producing Dkk3 in the brain and the spinal cord was investigated by 
histological studies. In the steady state the neurons were shown to express considerable 
amounts of Dkk3. On the contrary, the astrocytes and the microglia were negative for Dkk3 
protein. However, Dkk3 mRNA was traced in primary astrocyte cultures. It is suggested that 
the in vitro culture conditions, which resemble the in vivo inflammatory conditions, activate 
the astrocytes and possibly then induce Dkk3 expression. Accordingly, brain sections derived 
from diseased EAE C57.Bl/6 mice were also tested for Dkk3 expression by histology. The 
neuronal cells were found positive, displaying no apparent up-regulation of Dkk3 expression. 
However, Dkk3 expression was not traced in the astrocytes. Thus the induction of Dkk3 
expression in activated astrocytes in vitro does not reflect the in vivo EAE situation. 
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Additionally, the lung and the heart, where even transient autoimmunity, such as pulmonary 
fibrosis and rheumatic fever, might be of a severe risk for the individual, also express a 
significant level of Dkk3. The liver, an organ important for the induction of T cell tolerance, 
produces Dkk3 protein as well. Finally, the embryo and the ovary, uterus and placenta, where 
a tolerogenic milieu is needed, all secrete Dkk3. On the other hand, it is interesting that all the 
lymphoid tissues, such as the thymus, the spleen and the lymph nodes do not express Dkk3 
protein. This observation is meaningful, since the presence of high amounts of a potent 
suppressor of T cell responses in the above lymphoid organs would be deleterious for the 
protection of the host against infections. 
6.6.2 Secretory Dkk3 protein suppresses CD4 and CD8 T cell proliferation 
The in vivo effect of the Dkk3, which is secreted by the immune privileged tissues, on T cell 
responses was investigated by using cells that secreted Dkk3 protein in in vitro proliferation 
assays. HEK 293T cells, transfected with Dkk3, were shown to express Dkk3 by RT-PCR. 
Moreover, they were demonstrated to secrete Dkk3 protein by ELISA and Western blot 
analysis of their supernatant. Thus these cells were employed to reproduce the model of Dkk3 
secretion by neuronal cells in the brain. Interestingly, secreted Dkk3 could down regulate total 
spleen T cell proliferation as well as CD8 T cell proliferation. The effect was observed in both 
Dkk3+/+ and Dkk3-/- groups, but was more pronounced with the knockout T cells (Figures 5-
36 and 5-37).  
The direct proof for the regulatory capacity of Dkk3 came from the use of purified 
recombinant mouse Dkk3 protein in the in vitro T cell proliferation assays. Indeed, 
recombinant mouse Dkk3 inhibited CD4 and CD8 T cell proliferation in a concentration 
dependent manner (Figure 5-38).   
The main hypothesis is that activated T cells express the receptor for Dkk3 on their surface 
and thereby respond to secreted Dkk3. To verify this hypothesis, Dkk3 was administered to 
proliferating T cells two days after their stimulation. The suppressive effect on their 
proliferation was as potent as in the case of Dkk3 being present in the proliferation assay from 
the first day of stimulation (Figure 5-39). Thus, the activated T cells respond to the presence 
of soluble Dkk3, possibly via a specific Dkk3 receptor, and loose their proliferative capacity. 
In more detail, preliminary experiments indicated that Dkk3 acts on activated T cells by 
inducing early apoptosis. 
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6.7 Dkk3 regulates T cell responses in Experimental Autoimmune 
Encephalitis (EAE) 
EAE is an autoimmune disease resembling human demyelinating diseases and in particular 
multiple sclerosis. It is initiated upon the priming of T cells with CNS-derived antigens in the 
presence of potent adjuvants. Like in multiple sclerosis, EAE is accompanied by the presence 
of multiple CNS lesions, which are distributed by time and in the site of occurence. Most 
pronounced lesions are found in the brain stem and the spinal cord.  
The inflammatory process involves the disruption of the blood-brain barrier and the 
recruitment of blood-born macrophages and microglia. Additionally, cytokines are locally up-
regulated and released. The CNS tissue-cells and the infiltrating lymphocytes release IFN-γ, 
IL-23, TNF-α, as well as the death ligands TRAIL and Fas. As a consequence, 
oligodendrocytes and neurons within the lesions undergo cell death. Furthermore, axons 
become demyelinated and dissected, leading to the blockade of nerve conduction and thus the 
clinical symptoms of paresis and paralysis (Aktas et al. 2006). However, EAE in mice is 
reversible. Inflammation is controlled and gradually recedes, permitting partial remyelination 
and recovery from the EAE symptoms. 
6.7.1 Dkk3-/- mice display more severe and persistent EAE 
Here, it was demonstrated that Dkk3 contributes to the control of the immune response which 
occurs during the course of EAE. Lack of Dkk3 does not affect the onset of the disease, but 
importantly the later stages, thus resulting in more severe and persistent EAE symptoms 
(Figure 5-41).  
The MOG33-55-specific naïve CD4 and CD8 T cells are normally primed in the absence of 
Dkk3. They then pass through the blood-brain barrier, thus initiating the inflammation in the 
CNS. Apparently their priming and migration to the brain and spinal cord are independent of 
Dkk3.  
Nevertheless, the mean maximum score of the disease is higher and the severe symptoms are 
more persistent in the absence of Dkk3 (Table 5-6). This leads to the hypothesis that secretory 
Dkk3 may bind on activated CNS-infiltrating T cells, thereby suppressing them. 
Consequently, the effect of Dkk3-mediated suppression is seen during the recovery phase. 
Therefore, absence of the suppressor Dkk3 leads to increased EAE chronicity. 
Histological analyses revealed that Dkk3 expression in the brain is unaltered during the 
course of the disease. Thus, it is possible that the observed relevance of Dkk3 for the control 
of the disease during the recovery phase is not due to protein-overexpression at this stage but 
might be due to up-regulation of the respective Dkk3-receptor on T cells. The possibility that 
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T cell-derived Dkk3 contributes to the control of inflammation at late stages of EAE is 
partially excluded by experiments that will be addressed later. At this point, it is important to 
stress out that the observed difference between the EAE Dkk3+/+ and Dkk3-/- mice cannot be 
attributed to altered thymic selection, since the MOG-specific CD4 and CD8 T cells, carrying 
the TCR-Vβ11 chain, are present in the same percentages in both mouse strains (Table 5-4). 
Interestingly, Dkk3 is expressed in the brain and other immune privileged sites and can 
control immune responses, possibly by inducing apoptosis (Figure 4-40), without harming the 
nervous tissues. Noticeably, other molecules expressed in the brain and known to induce 
apoptosis in T cells, such as Fas and its ligand have a dual role in EAE and multiple sclerosis. 
They have been shown to exacerbate the disease symptoms, because they do not specifically 
induce apoptosis of activated T cells, but also of oligodendrocytes, thereby contributing to the 
demyelination (Aktas et al. 2006). Additionally, the immunosuppressive enzyme IDO, which 
is also expressed by the tissue cells during EAE, suppresses T cell proliferation, but also 
induces the production of side products of the kyanourine pathway, which are toxic for the 
nervous system (Kwidzinski et al. 2007). It seems that Dkk3 suppresses T cell responses 
without damaging the CNS tissue. However it remains to be clarified whether Dkk3-receptor 
is induced on CNS tissue cells upon inflammation. 
6.7.2 The increased EAE chronicity in the Dkk3-/- mice is accompanied by activated 
CD8 T cell-persistence in the CNS. 
A more detailed investigation of the effect of Dkk3 deficiency on EAE was achieved by 
analyzing the CNS-infiltrating T cell populations shortly after the disease peak (day 20) and 
during the recovery phase (day 29). At day 20 both Dkk3+/+ and Dkk3-/- experimental groups 
exhibited severe EAE symptoms. On the contrary, at day 29 the Dkk3+/+ mice had already 
recovered from EAE, whereas the Dkk3-/- mice still suffered from high EAE score (Figure 5-
43).  
Strikingly, the absolute numbers and percentages of activated CD4 and CD8 T cells in the 
CNS of EAE-diseased Dkk3-/- and Dkk3+/+ were comparable. However, it is possible that 
Dkk3 regulates CNS-infiltrating T cell subsets with characteristic cytokine profile that are 
responsible for the persistence of inflammation during EAE. Therefore CD4 and CD8 T cells 
derived from the brain and spinal cord of diseased Dkk3+/+ and Dkk3-/- mice were analyzed by 
flow cytometry for their cytokine profile. Interestingly, there were no differences between the 
EAE-diseased Dkk3+/+ and Dkk3-/- mice in the percentages of TNF-α, IL-17 and IFN-γ 
producing CD4 T cells.  
DISCUSSION 
 114 
IL-17 mRNA has been shown to be induced on day 6 after immunization of C57.Bl/6 mice 
with MOG33-55 peptide. IL-17 expression by CD4 T cells is increased at the EAE onset and 
declines upon the peak of the disease. IFN-γ expression by CD4 T cells displays the same 
pattern (Sonobe et al. 2007). Both IL-17- and IFN-γ-producing CD4 T cell subsets have been 
implied to play a crucial role in the induction of EAE (Langrish et al. 2005; Sonobe et al. 
2007). Thus, it is expectable that these particular CD4 T cell populations are not involved in 
the chronic disease phase that is observed in the Dkk3-/- experimental group. On the contrary, 
TNF-α production by CD4 and CD8 T cells is intensified during the late disease stages 
(Sonobe et al. 2007) and has been suggested to contribute to the pathophysiology of the 
disease, by inducing apoptosis of oligodendrocytes and neuronal degeneration (reviewed in 
(Aktas et al. 2006)). However, Dkk3 does not seem to regulate CD4 T cells, which are the 
main producers of TNF-α during the late EAE stages. 
On the other hand, the subpopulation of CD8 T cells expressing IFN-γ appears to be much 
more expanded in Dkk3-/- mice when compared to Dkk3+/+ mice. CD8 T cells have been 
reported to produce IFN-γ later on in the disease course than CD4 T cells and have been 
suggested to play a role in the maintenance of the EAE late stages (Sonobe et al. 2007).  
This finding contradicts former reports concerning the regulatory role of CD8 T cells and 
IFN-γ in the EAE. It has previously been shown that CD8 T cells isolated from EAE-
recovered mice specifically inhibited MBP-activated CD4 T cell clones in vitro and their 
depletion was followed by recurrence of EAE. Additionally, mice reconstituted with EAE-
experienced CD8 T cells were resistant to MBP vaccination-induced EAE (Jiang et al. 2003). 
The proposed mechanism of CD8 T cell-suppression involved the non-classical MHC I 
molecules Qa-1, shown to be expressed by some pathogenic CD4 T cells. It was suggested 
that suppressor CD8 T cells recognize a peptide from the auto-reactive CD4 T cell-TCR, 
presented by the Qa-1 molecules (Madakamutil et al. 2003; Kumar 2004). Therefore the auto-
reactive CD4 T cells are depleted by the suppressor CD8 T cells in wild type but not in Qa-1 
deficient mice (Hu et al. 2004). Nonetheless, Qa-1 mediated suppression is controversial, 
since it was observed during secondary, but not primary responses (Friese et al. 2005).  
Furthermore, another study has identified a distinct population of suppressor CD8 T cells that 
lack CD28 expression and render the APCs tolerogenic (Najafian et al. 2003). However, the 
exact function of these CD8 T cells in vivo is not clear. In general, it cannot be excluded that a 
regulatory CD8 T cell population can be identified in EAE diseased mice. The same holds 
true for CD4 regulatory T cells.  
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Actually, during the last few years many reports concerning the effector function of CD8 T 
cells during EAE have been published. It has been shown that MBP and MOG immunizations 
lead to the expansion of CD8 T cells which are specific for the MBP and MOG peptides 
respectively, when presented by the MHC I molecules (Huseby et al. 1999; Huseby et al. 
2001; Sun et al. 2001). Isolation of the expanded CD8 T cells followed by their adoptive 
transfer into naïve recipients induced EAE. The severe clinical symptoms were accompanied 
by extended lesion formation in the brain and to a lesser extend in the spinal cord, massive 
CD8 T cell infiltration, increased demyelination and perivascular cell death. In general, the 
disease profile resembled more to multiple sclerosis than conventional EAE with a relapsing-
remitting course. Interestingly, co-injection of anti-IFN-γ antibodies markedly reduced the 
disease severity, whereas blocking TNF with a TNF receptor-Fc fusion did not have such an 
effect (Huseby et al. 2001). These results contradict the previously suggested regulatory role 
of IFN-γ in EAE, which was based on the observation that IFN-γ-/- mice displayed EAE of 
increased severity (Krakowski et al. 1996; Willenborg et al. 1996). This discrepancy remains 
yet to be clarified. However, this study points out the contribution of IFN-γ, which is 
produced by CD8 T cells only,  at the late stages of the disease course, to the persistence of 
the EAE symptoms.  
In conclusion, it seems that the presence of Dkk3 in the brain during EAE has a suppressive 
effect on the disease course, and more particularly it contributes to the recovery from the 
disease. Lack of Dkk3 leads to the increase of IFN-γ-producing CD8 T cells, which may be 
responsible for the inhibition of EAE recovery. Potential mechanisms of IFN-γ mediated 
disease chronicity are the induction of blood brain barrier permeability (Oshima et al. 2001) 
and the up-regulation of MHC I and II molecules in the CNS (Neumann et al. 2002; Horwitz 
et al. 2003). Moreover, IFN-γ promotes the cytotoxic function of T cells (Horwitz et al. 2003), 
activates the macrophages, astrocytes (Nikcevich et al. 1997) and microglia (Takeuchi et al. 
2006) and directly induces the cell death of oligodendrocytes (Popko et al. 1999). 
6.7.3 Neuron-derived but not T cell-derived Dkk3 is crucial for the control of EAE 
Having shown that Dkk3 contributes to the immune regulation of EAE by suppressing the 
IFN-γ-producing CD8 T cells, it was challenging to investigate whether the main source of 
Dkk3 were the neurons or the CNS-infiltrating T cells. As already mentioned, Dkk3 is 
secreted in considerable amounts by neuronal cells in steady state and in inflammation. On 
the contrary, Dkk3 expression by T cells is not detectable in the polyclonal repertoire. 
However, it cannot be excluded that a small subpopulation of CD8 regulatory T cells secretes 
Dkk3.  
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The contribution of CNS- and T cell-derived Dkk3 to EAE recovery was studied in bone 
marrow chimeras. On one hand, Dkk3-/- recipient mice were reconstituted with Dkk3+/+ bone 
marrow, in order to study the contribution of the brain to the Dkk3-mediated control of EAE. 
On the other hand, Dkk3+/+ irradiated mice received Dkk3-/- bone marrow and it was 
investigated whether the lack of Dkk3 from T cells is sufficient to lead to more severe EAE 
symptoms.  
It has been reported that the extended inflammation, which is induced upon lethal irradiation 
of the recipient mice, results in severe and non-reversible EAE in chimeric mice (Zehntner et 
al. 2004). This effect was also observed after active immunization of Dkk3+/+  Dkk3-/- and 
Dkk3-/-  Dkk3+/+ chimeric mice. However, the kinetics of the disease onset could give a hint 
about the differential control of autoimmune disease. More specifically, it could be 
investigated whether an earlier disease onset is mediated by wild type T cells in a Dkk3-/- 
CNS microenvironment or by Dkk3-/- T cells in a Dkk3-sufficient CNS background. T cells 
that develop in the previously irradiated chimeric mice have an activated phenotype. Thus, 
since it suppresses activated T cells, the expected suppressive effect of Dkk3 during EAE can 
theoretically be observed from the first days upon disease induction.  
Dkk3 was indeed shown to exert a suppressive effect on activated T cells during the disease 
onset. In chimeric mice lacking Dkk3 expression in the brain and spinal cord, activated CD4 
and CD8 T cells, which passed through the permeabilized blood-brain barrier, induced the 
disease earlier (Figure 5-44). Possibly, on days 6-12 the amount of Dkk3 secreted by the 
neurons is sufficient to suppress the already activated CNS-infiltrating T cells. Nonetheless, 
after day 12 the influx of activated T cells may be so increased that the amount of Dkk3 
present in the CNS is not sufficient to suppress their inflammatory capacity. Moreover, the 
induced cytokine expression by tissue cells may also contribute to demyelination and to 
occurrence of severe clinical symptoms.  
In the Dkk3-/-  Dkk3+/+ chimeras, lack of Dkk3 from T cells did not result in early disease 
onset. Apparently, the presence of Dkk3 that is secreted by the neurons is sufficient to inhibit 
early disease onset. 
The results obtained upon the induction of EAE in the chimeric mice could be used to draw 
conclusions concerning the importance of the brain-derived Dkk3 for the control of 
autoimmune encephalitis. However, in order to directly exclude the thymic influence from the 
experimental system, an alternative approach was used. In this approach, Dkk3 was blocked 
in C57.Bl/6 mice with the monoclonal anti-Dkk3 antibody, after the induction of the disease. 
Dkk3 blockade resulted in increased disease chronicity, thereby confirming the initial 
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hypothesis that Dkk3 is crucial for T cell suppression during the late stages of EAE (Figure 5-
47). The anti-Dkk3 and control IgG antibodies were administered intraperitoneally and are 
thought to access the brain, since the blood-brain barrier was permeabilized upon 
administration of pertussis toxin. IgG has been also previously described to access the CNS 
during EAE and has been shown to inhibit the disease course, as indicated by milder clinical 
symptoms (Jorgensen et al. 2005; Jorgensen et al. 2007). In the case of the anti-Dkk3 mouse 
IgG administration, it neither ameliorated the disease course nor increased the mean disease 
duration.  
The suppressive role of Dkk3 during EAE recovery was shown by the use of the blocking 
antibody. Thus, combining the results obtained from the analysis of the cytokine profile of 
CNS-infiltrating T cells, it could be argued that blocking of secreted Dkk3 by the monoclonal 
anti-Dkk3 antibody inhibits binding of Dkk3 on effector CD8 T cells and thereby increases 
the chronicity of the disease. 
6.8 Conclusions and Outlook 
Dkk3 is a newly identified modulator of the immune responses. It is expressed by transgenic 
regulatory Des-TCR CD8 T cells and is the mediator of their function. Regulatory Des-TCR 
CD8 T cells were shown to secrete the suppressive Dkk3 molecule, which then presumably 
binds to an unknown receptor on target T cells.  
The immune regulatory function of Dkk3 was not found to be limited to the Des-TCR 
transgenic mouse model. Lack of Dkk3 from polyclonal T cells results in hyperproliferation 
and increased IL-2 production. This effect could be explained by the fact that the ERK MAPK 
is over activated in the absence of Dkk3. It seems that Dkk3 specifically inhibits the ERK 
pathway activation on the level of the Raf kinase in CD8 T cells. 
Dkk3 expression could not be detected in the lymphoid organs. Yet, it is unclear whether a 
limited CD8 T cell population secretes Dkk3, but tissue-derived Dkk3 was shown to 
permanently affect CD8 T cell reactivity. Thymic selection does not seem to be altered in the 
absence of Dkk3.  
Among the tissues that express Dkk3 in high amounts are all immune privileged organs 
(CNS, ovaries, placenta), the liver, which is a crucial site for the establishment of T cell 
tolerance to oral antigens, the heart and the lung. It seems that Dkk3 secreted by the above 
organs can control potentially harmful T cell responses by inducing T cell apoptosis. 
Specifically, the immune regulatory role of Dkk3 in the CNS is apparent in the context of 
EAE. Absence of neuron-derived Dkk3 leads to severe and persistent EAE, due to lack of 
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suppression of activated CD8 T cells. Interestingly, blockade of the secreted Dkk3 at the site 
of inflammation results in increased disease chronicity as well.  
In conclusion, Dkk3 is an immune regulator, employed by both transgenic regulatory CD8 T 
cells and immune privileged tissues. The above finding is of importance, since except from its 
assumed role in embryonic development no other function has been assigned to Dkk3. It 
seems that Dkk3’s primary function is unrelated to the immune system, since genes, with 
great homology to Dkk3 first appeared in invertebrates such as the cnidaria, before the 
evolution of the adaptive immune system (Fedders et al. 2004). However, Dkk3, like other 
molecules which are vital for the functionality of the adaptive immune system, may have 
acquired a second function throughout evolution, which is this of an immune modulator. 
Taking the immune regulatory role of Dkk3 into consideration, future research investigating 
the role of Dkk3 in antiviral responses and autoimmune diseases would be fascinating. Most 
intriguing is the role of Dkk3 in anti-tumor immunity, since it has been recently shown that it 
is strongly expressed by endothelial cells on the tumor blood vessels (Hermann et al. 2007). It 
is thus possible that blockade of Dkk3 by the monoclonal anti-Dkk3 antibody may inhibit not 
only tumor angiogenesis but also the suppression of anti-tumor immune responses. On the 
other hand, the importance of the identification of the Dkk3 specific receptor is not to be 
overseen. 
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Appendix 1: The 1000 first most up-regulated genes in regulatory Des-TCR CD8 T cells 
as compared to activated Des-TCR CD8 T cells 
Probe Set 
Name 
Signal 
Log 
Ratio 
Change 
p-value 
Gene Symbol 
1447096_at 8.64 0.00002 --- 
1455986_at 8.33 0.001651 Zdhhc17 
1449603_at 7.72 0.00002 AI594671 
1451463_at 6.48 0.000046 Arhgap8 
1438945_x_at 6.35 0.001077 Gja1 
1441630_at 6.34 0.00003 Ep400 
1439397_at 6.33 0.000241 Fmn1 
1429943_at 6.28 0.000052 Ctbs 
1437707_at 6.13 0.001077 Slmo1 
1415855_at 6.11 0.000346 Kitl 
1441964_at 5.94 0.000552 1110003F05Rik 
1458103_at 5.94 0.00004 Ncor1 
1456940_at 5.84 0.000214 Slc43a2 
1450037_at 5.76 0.000692 Usp9x 
1421173_at 5.75 0.00002 Irf4 
1452388_at 5.71 0.000046 Hspa1a 
1427127_x_at 5.62 0.00002 Hspa1b 
1423842_a_at 5.59 0.000068 Rnf41 
1454232_at 5.55 0.000147 9430027B09Rik 
1416579_a_at 5.44 0.000052 Tacstd1 
1416687_at 5.42 0.001486 Plod2 
1427126_at 5.4 0.00002 Hspa1b 
1452318_a_at 5.31 0.00002 Hspa1b 
1434559_at 5.25 0.00002 Stx3 
1423700_at 5.23 0.000865 Rfc3 
1428749_at 5.22 0.001336 Dmxl2 
1442463_at 5.22 0.001336 --- 
1443153_at 5.22 0.00002 --- 
1457247_at 5.13 0.000101 --- 
1438377_x_at 5.09 0.000147 Slc13a3 
1428609_at 5.07 0.000346 LOC100048581 /// LOC621579 /// Mylc2b 
1423178_at 5.05 0.000774 Abi1 
1420549_at 4.99 0.00003 Gbp1 
1425380_at 4.96 0.000774 Rasgrp4 
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1436690_at 4.93 0.001651 Lrba 
1448943_at 4.92 0.000147 Nrp1 
1433496_at 4.77 0.001201 Glt25d1 
1436672_at 4.75 0.000389 Grk5 
1440325_at 4.73 0.00002 --- 
1445749_at 4.73 0.001832 --- 
1435128_at 4.72 0.000865 Baiap2 
1437445_at 4.72 0.000052 Trpm1 
1459810_at 4.71 0.000273 1110008F13Rik 
1436916_at 4.66 0.000692 Tmem108 
1434572_at 4.65 0.00002 Hdac9 
1431133_at 4.63 0.000492 Arhgap18 
1422252_a_at 4.61 0.001077 Cdc25c 
1417704_a_at 4.58 0.000147 Arhgap6 
1451013_at 4.56 0.000189 Slc29a3 
1428578_s_at 4.52 0.000035 Ppfia4 
1419094_at 4.51 0.000307 Cyp2c37 
1418455_at 4.5 0.000865 Copz2 
1455970_at 4.5 0.00002 --- 
1457295_at 4.49 0.001832 Tnrc6a 
1431867_a_at 4.47 0.000618 1700007B13Rik 
1422160_at 4.33 0.000692 H2-T24 
1422781_at 4.32 0.00002 Tlr3 
1438349_at 4.32 0.00002 BC043476 
1434599_a_at 4.3 0.00002 Tjp2 
1437950_at 4.27 0.000023 BC035537 
1455180_at 4.27 0.000389 AA407270 
1454803_a_at 4.26 0.000692 Hdac11 
1437762_at 4.24 0.000027 Rab39 
1442971_at 4.24 0.000046 Baz2b 
1458399_at 4.24 0.000189 Lrrc3 
1437186_at 4.23 0.000023 BC055324 
1427376_a_at 4.21 0.000438 Map4k5 
1429427_s_at 4.2 0.00003 Tcf7l2 
1432472_a_at 4.2 0.001201 Mccc2 
1441887_x_at 4.2 0.00002 EG622976 
1430955_at 4.18 0.000273 2810403A07Rik 
1449310_at 4.18 0.00002 Ptger2 
1417073_a_at 4.17 0.00002 Qk 
1418086_at 4.16 0.00002 Ppp1r14a 
1439214_a_at 4.15 0.00003 Api5 
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1417172_at 4.13 0.001486 Ube2l6 
1419821_s_at 4.13 0.00002 Idh1 
1435542_s_at 4.13 0.00002 Cttnbp2nl 
1435771_at 4.12 0.00002 Plcb4 
1448944_at 4.12 0.00004 Nrp1 
1416467_at 4.09 0.000492 Ddx3x 
1458662_at 4.07 0.000552 Daam1 
1441423_at 4.06 0.00013 Ece1 
1425878_at 4.03 0.000147 Cabp4 
1429466_s_at 4.02 0.00002 Aph1b /// Aph1c 
1428856_at 4.01 0.000167 H13 
1429527_a_at 4 0.000492 Plscr1 
1422411_s_at 3.99 0.00002 Ear1 /// Ear12 /// Ear2 /// Ear3 
1441344_at 3.98 0.000346 Erlin1 
1453985_at 3.98 0.000692 0610007P08Rik 
1416188_at 3.96 0.000035 Gm2a 
1422964_at 3.96 0.000027 Rad23a 
1416236_a_at 3.94 0.00003 Mpzl2 
1439127_at 3.94 0.00002 AI314180 
1448627_s_at 3.94 0.001201 Pbk 
1450883_a_at 3.93 0.00002 Cd36 
1452487_x_at 3.93 0.000552 Pira2 
1460329_at 3.93 0.001077 B4galt6 /// LOC675709 
1422824_s_at 3.92 0.00002 Eps8 
1443336_at 3.92 0.001486 --- 
1425513_at 3.91 0.000774 Map2k7 
1434277_a_at 3.9 0.00002 Ypel2 
1437502_x_at 3.9 0.000023 Cd24a /// EG621324 
1426301_at 3.88 0.001201 Alcam 
1457753_at 3.87 0.000114 Tlr13 
1429332_at 3.86 0.000273 4632427E13Rik 
1436329_at 3.86 0.00002 Egr3 
1428034_a_at 3.85 0.000552 Tnfrsf9 
1434955_at 3.84 0.00002 1-Mar 
1435679_at 3.84 0.000167 Optn 
1427170_at 3.83 0.000552 Psma8 
1430439_at 3.83 0.000027 Mctp1 
1431645_a_at 3.83 0.001201 Gdi2 
1439790_at 3.83 0.00002 Serpinb9 
1455796_x_at 3.83 0.00002 Olfm1 
1453135_at 3.82 0.00002 Fndc5 
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1455621_at 3.82 0.001201 BC066107 
1421955_a_at 3.81 0.00002 Nedd4 
1447914_x_at 3.8 0.00002 2600010E01Rik 
1436080_at 3.79 0.000618 AW011738 
1448460_at 3.79 0.00002 Acvr1 
1451243_at 3.79 0.00002 Rnpep 
1428260_at 3.78 0.00002 Spg3a 
1428517_at 3.78 0.000046 Wdfy3 
1429428_at 3.78 0.00002 Tcf7l2 
1449858_at 3.78 0.00002 Cd86 
1451867_x_at 3.78 0.000088 Arhgap6 
1422294_at 3.77 0.000027 Xcr1 
1438030_at 3.77 0.00002 Rasgrp3 
1456174_x_at 3.76 0.00002 Ndrg1 
1429656_at 3.75 0.000774 Rhobtb1 
1449670_x_at 3.75 0.000023 Gpr137b /// LOC100044979 
1423319_at 3.74 0.000241 Hhex 
1450070_s_at 3.74 0.00002 Pak1 
1436397_at 3.73 0.000167 Tifab 
1437921_x_at 3.73 0.00002 Zfp516 
1423569_at 3.71 0.00002 Gatm 
1434442_at 3.71 0.00002 Stbd1 
1438463_x_at 3.71 0.000438 Zdhhc6 
1421137_a_at 3.69 0.00002 Pkib 
1438306_at 3.69 0.00002 Rnf180 
1432466_a_at 3.68 0.00003 Apoe 
1433452_at 3.68 0.00002 B630019K06Rik 
1451386_at 3.68 0.00002 Blvrb 
1452411_at 3.68 0.00002 Lrrc1 
1455009_at 3.68 0.00013 Cpd 
1434061_at 3.67 0.00002 Rp2h 
1438068_at 3.67 0.00002 --- 
1453181_x_at 3.67 0.00002 Plscr1 
1452301_at 3.66 0.00003 Aldh3b1 
1424902_at 3.65 0.00002 Plxdc1 
1435064_a_at 3.65 0.00002 Tmem27 
1438313_at 3.65 0.000692 --- 
1419627_s_at 3.63 0.00002 Clec4n 
1424413_at 3.63 0.00002 Ogfrl1 
1438169_a_at 3.63 0.00002 Frmd4b 
1452458_s_at 3.63 0.000147 Ppil5 
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1416034_at 3.62 0.00002 Cd24a /// EG621324 
1423378_at 3.62 0.00002 Adam23 /// LOC100046035 
1428097_at 3.62 0.000241 2510009E07Rik 
1447040_at 3.62 0.00002 --- 
1458802_at 3.62 0.00002 Hivep3 
1416120_at 3.61 0.000618 Rrm2 
1423166_at 3.61 0.00002 Cd36 
1426775_s_at 3.61 0.00002 Scamp1 
1449846_at 3.61 0.00002 Ear2 
1425951_a_at 3.6 0.00003 Clec4n 
1427081_at 3.6 0.00002 A630072M18Rik 
1435029_at 3.6 0.00002 --- 
1416645_a_at 3.59 0.00002 Afp 
1424367_a_at 3.59 0.000023 Homer2 
1429775_a_at 3.59 0.00002 Gpr137b /// Gpr137b-ps /// LOC100044979 
1429909_at 3.59 0.00002 2600010E01Rik 
1437467_at 3.59 0.000035 Alcam 
1439622_at 3.59 0.00002 Rassf4 
1459804_at 3.59 0.000068 Crebbp 
1416165_at 3.58 0.00002 Rab31 
1418084_at 3.58 0.000552 Nrp1 
1419829_a_at 3.58 0.000023 --- 
1425597_a_at 3.58 0.001336 Qk 
1430886_at 3.58 0.00003 1700112E06Rik 
1434695_at 3.58 0.00004 Dtl 
1456574_at 3.57 0.000618 Zfp800 
1458438_at 3.57 0.00002 Ccdc122 
1429228_at 3.55 0.00002 4930534B04Rik 
1448233_at 3.55 0.00002 Prnp 
1439833_at 3.54 0.00002 3-Sep 
1449348_at 3.54 0.00002 Mpp6 
1458406_at 3.54 0.00002 --- 
1419853_a_at 3.53 0.00003 P2rx7 
1424124_at 3.53 0.00002 Mospd2 
1429520_a_at 3.53 0.00002 Phca 
1453069_at 3.53 0.00002 Pik3cb 
1457307_at 3.53 0.000346 Apol11b 
1427996_at 3.52 0.000346 BC028528 
1429417_at 3.52 0.000147 Chsy3 
1453416_at 3.52 0.00002 Gas2l3 
1415973_at 3.51 0.00002 Marcks 
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1421855_at 3.5 0.00002 Fgl2 
1422468_at 3.5 0.00002 Ppt1 
1428574_a_at 3.5 0.000027 Chn2 
1434447_at 3.5 0.00002 Met 
1425214_at 3.49 0.000241 P2ry6 
1433908_a_at 3.49 0.00002 Cttn 
1428385_at 3.48 0.000189 8-Mar 
1425496_at 3.47 0.00004 Abca3 
1431394_a_at 3.47 0.000068 Lrrk2 
1438672_at 3.47 0.001486 Parvb 
1440209_at 3.47 0.00002 1-Mar 
1451623_at 3.47 0.000438 Mrpl15 
1424046_at 3.46 0.000023 Bub1 
1425583_at 3.46 0.00003 --- 
1435517_x_at 3.46 0.00002 Ralb 
1436265_at 3.46 0.00004 ENSMUSG00000072769 
1439489_at 3.46 0.000101 Gpr120 
1422499_at 3.45 0.00002 Lima1 
1422823_at 3.45 0.00002 Eps8 /// LOC632638 
1429055_at 3.45 0.00002 4930506M07Rik 
1435372_a_at 3.45 0.000068 Pa2g4 
1435939_s_at 3.45 0.000023 AI987662 
1436519_a_at 3.45 0.00002 1110057K04Rik 
1448788_at 3.45 0.000023 Cd200 
1451604_a_at 3.45 0.00002 Acvrl1 
1424292_at 3.44 0.000068 Depdc1a 
1440799_s_at 3.44 0.00002 Farp2 
1424356_a_at 3.43 0.00002 Metrnl 
1427456_at 3.43 0.000214 Wdfy3 
1440927_x_at 3.43 0.000114 Apol11b 
1451416_a_at 3.43 0.000552 Tgm1 
1451929_a_at 3.43 0.000052 Vrk2 
1447363_s_at 3.42 0.00003 Bub1b 
1450496_a_at 3.42 0.000966 2810433K01Rik 
1422412_x_at 3.41 0.000068 Ear3 
1425315_at 3.41 0.00003 Dock7 
1435490_at 3.41 0.000023 Hk3 
1436913_at 3.41 0.00002 Cdc14a 
1451451_at 3.41 0.000035 Gca 
1428167_a_at 3.4 0.000027 Mpzl1 
1437378_x_at 3.4 0.00002 Scarb1 
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1439153_at 3.4 0.00002 Rnf144b 
1448558_a_at 3.4 0.001832 Pla2g4a 
1422011_s_at 3.39 0.000023 3830403N18Rik /// Xlr 
1425530_a_at 3.39 0.00002 Stx3 
1457662_x_at 3.39 0.000774 Tpk1 
1426952_at 3.38 0.00002 Arhgap18 
1427912_at 3.38 0.00013 Cbr3 
1433735_a_at 3.38 0.00002 Tmem64 
1434437_x_at 3.38 0.00002 Rrm2 
1443245_at 3.38 0.001832 --- 
1416431_at 3.37 0.00002 Tubb6 
1418379_s_at 3.37 0.00002 Gpr124 
1425477_x_at 3.37 0.000023 H2-Ab1 /// Rmcs2 /// Rmcs5 
1435664_at 3.37 0.000214 Zfp397 
1416441_at 3.36 0.00002 Pgcp 
1416558_at 3.36 0.000046 Melk 
1420980_at 3.36 0.00002 Pak1 
1424733_at 3.36 0.00002 P2ry14 
1426260_a_at 3.36 0.00002 LOC632297 /// Ugt1a1 /// Ugt1a10 /// Ugt1a2 /// Ugt1a5 /// Ugt1a6a /// 
Ugt1a6b /// Ugt1a7c /// Ugt1a9 
1426530_a_at 3.36 0.00002 Klhl5 
1448265_x_at 3.36 0.001832 Mpzl2 
1454838_s_at 3.36 0.00002 AW548124 /// LOC100048505 
1454884_at 3.36 0.00002 Zbtb46 
1456475_s_at 3.36 0.00002 Prkar2b 
1417938_at 3.35 0.00002 Rad51ap1 
1422620_s_at 3.35 0.00002 Ppap2a 
1423596_at 3.35 0.00002 Nek6 
1435386_at 3.35 0.000035 Vwf 
1439787_at 3.35 0.00002 P2rx7 
1449453_at 3.35 0.00002 Bst1 
1460431_at 3.35 0.000147 Gcnt1 
1425536_at 3.34 0.000147 Stx3 
1428568_at 3.34 0.000088 B230217C12Rik 
1435332_at 3.34 0.000088 Htr7 
1437466_at 3.34 0.000052 Alcam 
1448732_at 3.34 0.00002 Ctsb 
1449309_at 3.34 0.001651 Cyp8b1 
1450884_at 3.34 0.000035 Cd36 
1452410_a_at 3.34 0.00002 Fes 
1422782_s_at 3.33 0.00002 Tlr3 
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1428573_at 3.33 0.00002 Chn2 
1435703_at 3.33 0.00004 LOC677224 
1438893_at 3.33 0.000966 5530601H04Rik 
1448213_at 3.33 0.00006 Anxa1 
1448600_s_at 3.33 0.00002 Vav3 
1451708_at 3.33 0.000088 Gpr33 
1451721_a_at 3.33 0.00002 H2-Ab1 /// Rmcs2 /// Rmcs5 
1453361_at 3.33 0.001651 Hells 
1455333_at 3.33 0.00002 Tns3 
1419249_at 3.32 0.00004 Pftk1 
1425053_at 3.32 0.00004 Isoc1 
1430570_at 3.32 0.00002 Kynu 
1434705_at 3.32 0.000023 Ctbp2 
1434929_at 3.32 0.00002 BC035044 
1435477_s_at 3.32 0.000052 Fcgr2b 
1441667_s_at 3.32 0.001077 Smyd1 
1447106_at 3.32 0.00013 --- 
1450702_at 3.32 0.000068 Hfe 
1451716_at 3.32 0.000492 Mafb 
1454875_a_at 3.32 0.00002 Rbbp4 
1421813_a_at 3.31 0.00002 Psap 
1422789_at 3.31 0.000088 Aldh1a2 
1426501_a_at 3.31 0.00002 LOC637082 /// Tifa 
1427311_at 3.31 0.000307 Bptf 
1448226_at 3.31 0.000023 Rrm2 
1424698_s_at 3.3 0.00002 Gca 
1428369_s_at 3.3 0.00002 Arhgap21 
1436633_at 3.3 0.00003 --- 
1438664_at 3.3 0.00002 Prkar2b 
1455260_at 3.3 0.00002 Lcorl 
1434781_at 3.29 0.000189 Dnajc16 
1450896_at 3.29 0.00002 Arhgap5 
1453317_a_at 3.29 0.00002 Khdrbs3 
1434171_at 3.28 0.000774 C330011K17Rik 
1435825_at 3.28 0.00002 Acvrl1 
1437831_at 3.28 0.000167 Zcchc4 
1442320_at 3.28 0.00002 LOC553096 
1444884_at 3.28 0.000189 Ppt1 
1416537_at 3.27 0.000389 Creld1 
1420544_at 3.27 0.00003 Gcet2 
1425294_at 3.27 0.00003 Slamf8 
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1425544_at 3.27 0.00002 Plekha5 
1425784_a_at 3.27 0.00002 Olfm1 
1428069_at 3.27 0.000966 Cdca7 
1440790_x_at 3.27 0.00002 --- 
1451986_s_at 3.27 0.00002 Lrrk1 
1454966_at 3.27 0.000078 Itga8 
1416167_at 3.26 0.00002 Prdx4 
1418258_s_at 3.26 0.000189 Dynll2 
1419144_at 3.26 0.000052 Cd163 
1422430_at 3.26 0.00002 Fignl1 
1434089_at 3.26 0.00002 Synpo 
1451043_at 3.26 0.00002 Nek6 
1455843_at 3.26 0.000046 Fut4 
1422601_at 3.25 0.00002 Serpinb9 
1427151_at 3.25 0.000034 Qser1 
1427682_a_at 3.25 0.000088 Egr2 
1428577_at 3.25 0.000147 Ppfia4 
1428579_at 3.25 0.00002 Fmnl2 
1429831_at 3.25 0.00002 Pik3ap1 
1434945_at 3.25 0.00002 Lpcat2 
1454816_at 3.25 0.000147 Rp2h 
1416309_at 3.24 0.00002 Nusap1 
1422671_s_at 3.24 0.000273 Naalad2 
1430598_at 3.24 0.001201 Crem 
1435748_at 3.24 0.001832 Gda 
1437306_at 3.24 0.000346 C130092O11Rik 
1442582_at 3.24 0.00002 Gcet2 
1448316_at 3.24 0.00002 Cmtm3 /// LOC100046883 
1449580_s_at 3.24 0.00002 H2-DMb1 /// H2-DMb2 
1452398_at 3.24 0.000147 Plce1 
1460304_a_at 3.24 0.000774 Ubtf 
1426452_a_at 3.23 0.00002 Rab30 
1451246_s_at 3.23 0.000023 Aurkb 
1419470_at 3.22 0.000035 Gnb4 
1419587_s_at 3.22 0.000167 Rp2h 
1435115_at 3.22 0.001336 Fndc5 
1435330_at 3.22 0.00002 BC094916 /// LOC100048304 /// LOC637605 /// Pyhin1 
1452074_at 3.22 0.000114 Tmem135 
1418776_at 3.21 0.000035 5830443L24Rik 
1438434_at 3.21 0.00002 Arhgap11a 
1450939_at 3.21 0.000273 Entpd1 
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1417695_a_at 3.2 0.00002 Soat1 
1419838_s_at 3.2 0.00002 Plk4 
1433716_x_at 3.2 0.00004 Gfra2 
1434272_at 3.2 0.000035 Cpeb2 
1447458_at 3.2 0.000774 --- 
1448923_at 3.2 0.000078 Prkra 
1449308_at 3.2 0.000389 C6 
1455849_at 3.2 0.00002 Nav1 
1457035_at 3.2 0.00003 AI607873 
1415971_at 3.19 0.00002 Marcks 
1417162_at 3.19 0.00002 Tmbim1 
1418057_at 3.19 0.00002 Tiam1 
1418365_at 3.19 0.00002 Ctsh 
1435727_s_at 3.19 0.00002 Lima1 
1448176_a_at 3.19 0.00002 Hnrpk 
1455162_at 3.19 0.00002 4922503N01Rik 
1416527_at 3.18 0.000052 Rab32 
1420522_at 3.18 0.00002 Ccdc50 
1422645_at 3.18 0.00002 Hfe 
1423557_at 3.18 0.00002 Ifngr2 
1426915_at 3.18 0.000101 Dapk1 
1438610_a_at 3.18 0.00002 Cryz 
1448761_a_at 3.18 0.00002 Copg2 
1416418_at 3.17 0.000052 Gabarapl1 
1417392_a_at 3.17 0.00002 Slc7a7 
1417932_at 3.17 0.00002 Il18 
1418123_at 3.17 0.00002 Unc119 
1423889_at 3.17 0.000189 EG434402 
1427488_a_at 3.17 0.000078 Birc6 
1434369_a_at 3.17 0.000035 Cryab 
1434988_x_at 3.17 0.000389 Aldh2 
1437154_at 3.17 0.00003 Cep170 
1440037_at 3.17 0.000027 Pbx1 
1448892_at 3.17 0.00002 Dock7 
1450744_at 3.17 0.00002 Ell2 
1455761_at 3.17 0.000552 2310009B15Rik 
1455820_x_at 3.17 0.00002 Scarb1 
1459316_at 3.17 0.000023 --- 
1460341_at 3.17 0.00002 Plekhb2 
1416111_at 3.16 0.00002 Cd83 
1417312_at 3.16 0.00004 Dkk3 
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1422619_at 3.16 0.00002 Ppap2a 
1437119_at 3.16 0.000035 Ern1 
1437208_at 3.16 0.001486 10-Sep 
1442798_x_at 3.16 0.00002 Hk3 
1455665_at 3.16 0.001651 LOC631639 /// Lonrf1 
1415922_s_at 3.15 0.00002 Marcksl1 
1428603_at 3.15 0.00002 LOC100036521 
1436025_at 3.15 0.000552 Ccdc88a 
1447360_at 3.15 0.00002 Tsc22d1 
1447640_s_at 3.15 0.00002 Pbx3 
1450731_s_at 3.15 0.00002 Tnfrsf21 
1416968_a_at 3.14 0.00002 Hsd3b7 
1419586_at 3.14 0.000214 Rp2h 
1420463_at 3.14 0.00002 Clnk 
1422881_s_at 3.14 0.000273 Sypl 
1427683_at 3.14 0.000046 Egr2 
1429954_at 3.14 0.00002 Clec4a3 
1439555_at 3.14 0.000023 Rlf 
1448143_at 3.14 0.000035 Aldh2 
1449164_at 3.14 0.00002 Cd68 
1415677_at 3.13 0.00002 Dhrs1 
1425108_a_at 3.13 0.000052 BC004728 
1426914_at 3.13 0.00002 Marveld2 
1429649_at 3.13 0.000035 Slc35a3 
1438834_at 3.13 0.000023 Mospd2 
1452279_at 3.13 0.00002 Cfp 
1453299_a_at 3.13 0.00002 LOC100045567 /// Pnp1 /// Pnp2 
1458341_x_at 3.13 0.00004 --- 
1417019_a_at 3.12 0.00002 Cdc6 
1419081_at 3.12 0.000023 Atg10 
1422535_at 3.12 0.000078 Ccne2 
1426794_at 3.12 0.00002 Ptprs 
1436907_at 3.12 0.00002 Nav1 
1441075_at 3.12 0.00002 Nostrin 
1441974_at 3.12 0.000068 Camk4 
1452700_s_at 3.12 0.00002 Kbtbd7 
1455425_at 3.12 0.00002 BB001228 
1455901_at 3.12 0.00006 Chpt1 
1421818_at 3.11 0.00002 Bcl6 
1423621_a_at 3.11 0.00002 Slc33a1 
1424650_at 3.11 0.00002 Pdia5 
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1435244_at 3.11 0.00002 Vav2 
1440490_at 3.11 0.000046 --- 
1452514_a_at 3.11 0.00002 Kit 
1455418_at 3.11 0.00002 --- 
1456772_at 3.11 0.00002 Ncf1 
1415948_at 3.1 0.00002 Creg1 
1415972_at 3.1 0.00002 Marcks 
1419907_s_at 3.1 0.00002 Fcrla 
1423170_at 3.1 0.000088 Taf7 
1427345_a_at 3.1 0.00002 Sult1a1 
1429468_at 3.1 0.00002 1110018F16Rik 
1430419_at 3.1 0.00002 2310031A07Rik 
1448669_at 3.1 0.000114 Dkk3 
1449947_s_at 3.1 0.000046 Zfhx3 
1416735_at 3.09 0.00006 Asah1 
1418774_a_at 3.09 0.000023 Atp7a 
1419883_s_at 3.09 0.00013 Atp6v1b2 
1427161_at 3.09 0.00002 Cenpf 
1435306_a_at 3.09 0.00004 Kif11 
1436508_at 3.09 0.000273 2410014A08Rik 
1438750_at 3.09 0.00002 Atrx 
1444367_at 3.09 0.000035 Fndc7 
1451318_a_at 3.09 0.00002 LOC676654 /// Lyn 
1454736_at 3.09 0.000088 Ankrd57 
1415897_a_at 3.08 0.000023 Mgst1 
1416304_at 3.08 0.000023 Litaf 
1424766_at 3.08 0.000167 Ercc6l 
1432606_at 3.08 0.000346 2610012C04Rik 
1435774_at 3.08 0.00002 AV024533 
1437215_at 3.08 0.001201 LOC100047504 /// Nudt15 
1460231_at 3.08 0.00002 Irf5 
1422542_at 3.07 0.000273 Gpr34 
1429206_at 3.07 0.000027 Rhobtb1 
1444778_at 3.07 0.00002 3-Sep 
1449454_at 3.07 0.00003 Bst1 
1458159_at 3.07 0.00003 --- 
1416934_at 3.06 0.00002 Mtm1 
1422804_at 3.06 0.000023 Serpinb6b 
1429189_at 3.06 0.00002 Arsb 
1439189_at 3.06 0.00002 Fnip2 
1452858_at 3.06 0.001832 Elavl1 
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1460014_at 3.06 0.00002 Treml4 
1418506_a_at 3.05 0.00002 Prdx2 
1423160_at 3.05 0.000389 Spred1 
1428468_at 3.05 0.00002 3110043O21Rik 
1436826_at 3.05 0.000774 Tmtc3 
1436921_at 3.05 0.00002 Atp7a 
1440883_at 3.05 0.00002 Usp6nl 
1457682_at 3.05 0.00002 9030420J04Rik 
1457824_at 3.05 0.00002 Plscr1 
1416046_a_at 3.04 0.00002 Fuca2 
1416299_at 3.04 0.000078 Shcbp1 
1426356_at 3.04 0.00002 6330578E17Rik 
1427040_at 3.04 0.00002 Mdfic 
1434014_at 3.04 0.00006 Atg4c 
1434789_at 3.04 0.001486 Depdc1b 
1438855_x_at 3.04 0.00002 Tnfaip2 
1447946_at 3.04 0.000023 Adam23 
1449976_a_at 3.04 0.00002 Gpr35 
1420898_at 3.03 0.00003 Snap23 
1435129_at 3.03 0.00002 --- 
1437401_at 3.03 0.001201 Igf1 
1438435_at 3.03 0.00002 Phca 
1443104_at 3.03 0.00004 --- 
1449590_a_at 3.03 0.000052 Mras 
1453573_at 3.03 0.00002 Hist1h3b /// Hist1h3c /// Hist1h3d /// Hist1h3e /// Hist1h3f /// Hist2h3b /// 
Hist2h3c1 /// Hist2h3c2 
1455102_at 3.03 0.00002 Larp4 
1418715_at 3.02 0.00003 Pank1 
1435644_at 3.02 0.00003 Sh3pxd2b 
1436915_x_at 3.02 0.00002 Laptm4b 
1460006_at 3.02 0.00002 Zfhx3 
1416258_at 3.01 0.00002 Tk1 
1419538_at 3.01 0.000023 Flt3 
1420760_s_at 3.01 0.000307 Ndrg1 
1430073_at 3.01 0.000035 2900016B01Rik 
1431182_at 3.01 0.00013 Hspa8 /// LOC624853 /// LOC641192 /// LOC666031 
1433568_at 3.01 0.00004 Papd4 
1433853_at 3.01 0.000052 Mib1 
1435564_at 3.01 0.000052 C230078M08Rik 
1443141_at 3.01 0.00002 --- 
1454783_at 3.01 0.00004 Il13ra1 
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1415871_at 3 0.00002 Tgfbi 
1419585_at 3 0.000052 Rp2h 
1420664_s_at 3 0.000114 Procr 
1420979_at 3 0.00002 Pak1 
1421534_at 3 0.00002 LOC14210 
1422755_at 3 0.00002 Btk 
1430291_at 3 0.00002 Dock5 
1431146_a_at 3 0.000046 Cpne8 
1434911_s_at 3 0.000046 Arhgap19 
1436853_a_at 3 0.000023 Snca 
1438609_x_at 3 0.000114 Tnni2 
1451133_s_at 3 0.000088 Tmem168 
1454701_at 3 0.00002 4930503L19Rik 
1419905_s_at 2.99 0.00002 Hpgd 
1420398_at 2.99 0.00002 Rgs18 
1424303_at 2.99 0.000966 Depdc7 
1424412_at 2.99 0.00002 Ogfrl1 
1427442_a_at 2.99 0.000035 App 
1429347_at 2.99 0.00002 Bcl2l14 
1437286_x_at 2.99 0.000273 1110020G09Rik 
1443777_at 2.99 0.00003 --- 
1448405_a_at 2.99 0.000023 Eid1 
1455885_at 2.99 0.00002 Amz1 
1418243_at 2.98 0.000307 Fcna 
1421223_a_at 2.98 0.00002 Anxa4 
1424588_at 2.98 0.000068 Srgap3 
1424603_at 2.98 0.00002 Sumf1 
1428562_at 2.98 0.000241 2210403K04Rik 
1437187_at 2.98 0.000438 E2f7 
1440615_at 2.98 0.00002 Dusp16 
1445440_at 2.98 0.000438 Ccdc88a 
1448698_at 2.98 0.000078 Ccnd1 
1422891_at 2.97 0.000167 H2-Ea 
1424987_at 2.97 0.000346 5430435G22Rik 
1430386_at 2.97 0.000101 E030024N20Rik 
1431323_at 2.97 0.00002 Lztfl1 
1434310_at 2.97 0.000023 Bmpr2 
1446497_at 2.97 0.00002 --- 
1448205_at 2.97 0.000023 Ccnb1 /// Ccnb1-rs1 
1456599_at 2.97 0.000023 Nxt2 
1415789_a_at 2.96 0.000189 LOC100045709 /// Ublcp1 
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1415904_at 2.96 0.00002 Lpl 
1419171_at 2.96 0.000023 Tmem157 
1422612_at 2.96 0.00002 Hk2 
1426552_a_at 2.96 0.000189 Bcl11a 
1430534_at 2.96 0.000167 Rnase6 
1430557_at 2.96 0.000167 4930434J08Rik 
1433696_at 2.96 0.000035 Hn1l 
1433741_at 2.96 0.00002 Cd38 
1439234_a_at 2.96 0.00002 Tm2d2 
1444546_at 2.96 0.00002 Tifab 
1460597_at 2.96 0.00002 Asxl2 
1417122_at 2.95 0.000035 Vav3 
1419469_at 2.95 0.000023 Gnb4 
1420132_s_at 2.95 0.000167 Pttg1ip 
1422743_at 2.95 0.000068 Phka1 
1427368_x_at 2.95 0.00002 Fes 
1436759_x_at 2.95 0.00002 Cnn3 /// LOC100047856 
1440911_at 2.95 0.00004 Col23a1 
1452473_at 2.95 0.000389 Prr15 
1453748_a_at 2.95 0.000189 Kif23 
1456700_x_at 2.95 0.00002 Marcks 
1423555_a_at 2.94 0.00002 Ifi44 
1428284_at 2.94 0.00004 8430427H17Rik 
1435777_at 2.94 0.00003 E030018N11Rik 
1437854_at 2.94 0.000023 --- 
1437956_at 2.94 0.000068 Pik3r6 
1448566_at 2.94 0.000492 Slc40a1 
1452123_s_at 2.94 0.00002 Frmd4b 
1454740_at 2.94 0.00002 Mib1 
1454896_at 2.94 0.00002 Rbpj 
1455053_a_at 2.94 0.000023 Dcun1d1 
1456210_at 2.94 0.000389 5430407P10Rik 
1417124_at 2.93 0.00004 Dstn 
1418638_at 2.93 0.000147 H2-DMb1 
1419153_at 2.93 0.00002 2810417H13Rik 
1421221_at 2.93 0.000027 Bco2 
1421410_a_at 2.93 0.000023 Pstpip2 
1422141_s_at 2.93 0.000214 Csprs 
1423702_at 2.93 0.000027 H1f0 
1428572_at 2.93 0.00002 Basp1 /// LOC100045716 
1433623_at 2.93 0.00002 Zfp367 
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1436999_at 2.93 0.00002 5033414K04Rik 
1449645_s_at 2.93 0.000088 Cct3 
1454728_s_at 2.93 0.00002 Atp8a1 
1456886_at 2.93 0.000027 --- 
1417716_at 2.92 0.001077 Got2 
1419453_at 2.92 0.00002 Uchl5 
1424923_at 2.92 0.00002 Serpina3g 
1425546_a_at 2.92 0.00002 Trf 
1426594_at 2.92 0.000241 Frmd4b 
1426716_at 2.92 0.000147 Tdrd7 
1434549_at 2.92 0.00002 Rab11a 
1434875_a_at 2.92 0.00002 Hmgn3 
1438310_at 2.92 0.000114 --- 
1441546_at 2.92 0.00002 LOC624524 
1447277_s_at 2.92 0.000027 Pcyox1 
1452011_a_at 2.92 0.00002 Uxs1 
1456712_at 2.92 0.00003 Lcorl 
1416166_a_at 2.91 0.000078 Prdx4 
1417266_at 2.91 0.000618 Ccl6 
1424615_at 2.91 0.00002 Frag1 
1426817_at 2.91 0.00002 Mki67 
1427084_a_at 2.91 0.000052 Map4k5 
1439775_at 2.91 0.000114 Brwd3 
1444516_at 2.91 0.000438 --- 
1448318_at 2.91 0.00004 Adfp 
1452203_at 2.91 0.00002 Obfc2a 
1452210_at 2.91 0.00013 Dna2 
1452912_at 2.91 0.000078 Dscc1 
1453122_at 2.91 0.000114 4921533L14Rik 
1455468_at 2.91 0.00013 --- 
1416021_a_at 2.9 0.00003 Fabp5 /// LOC620603 
1419565_a_at 2.9 0.001832 Zfx 
1420064_s_at 2.9 0.000023 Tktl1 
1422567_at 2.9 0.00002 Niban 
1423597_at 2.9 0.00002 Atp8a1 
1428938_at 2.9 0.000027 Gnaq 
1435702_s_at 2.9 0.00002 Ywhae 
1443814_x_at 2.9 0.00002 Ctsh 
1449216_at 2.9 0.00002 Itgae 
1449585_at 2.9 0.000966 Il1rap 
1454938_at 2.9 0.000068 Snx13 
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1460359_at 2.9 0.00002 Armcx3 /// LOC100044266 
1419123_a_at 2.89 0.000023 Pdgfc 
1428450_at 2.89 0.001486 2610034B18Rik 
1429190_at 2.89 0.00013 Arsb 
1432042_a_at 2.89 0.00002 Smu1 
1440736_at 2.89 0.000027 AI131651 
1446861_at 2.89 0.00002 Gns 
1448770_a_at 2.89 0.00002 Atpif1 
1449195_s_at 2.89 0.000027 Cxcl16 
1451667_at 2.89 0.00004 C530043G21Rik 
1452655_at 2.89 0.000774 Zdhhc2 
1455292_x_at 2.89 0.00003 --- 
1456790_at 2.89 0.000618 Zfp800 
1460623_at 2.89 0.00002 Skap2 
1419456_at 2.88 0.00002 Dcxr 
1419754_at 2.88 0.00006 Myo5a 
1420920_a_at 2.88 0.00002 Arf1 
1421210_at 2.88 0.000114 Ciita 
1422892_s_at 2.88 0.00002 H2-Ea 
1427306_at 2.88 0.000052 Ryr1 
1428323_at 2.88 0.00002 Gpd2 
1430163_at 2.88 0.00002 Rab43 
1435240_at 2.88 0.000027 Baz2b 
1435467_at 2.88 0.000346 Fgd6 
1448670_at 2.88 0.00002 LOC100047012 /// Ube2e3 
1449401_at 2.88 0.00002 C1qc 
1450036_at 2.88 0.000241 Sgk3 
1450882_s_at 2.88 0.00002 Gpr137b /// Gpr137b-ps /// LOC100044979 
1417588_at 2.87 0.000273 Galnt3 
1417925_at 2.87 0.000035 Ccl22 
1421274_at 2.87 0.000101 Socs4 
1426580_at 2.87 0.000046 Plk4 
1428374_at 2.87 0.00002 Glce 
1428939_s_at 2.87 0.000027 Gnaq 
1429761_at 2.87 0.000114 Rtn1 
1430125_s_at 2.87 0.00002 Pqlc1 
1433847_at 2.87 0.000147 D330017J20Rik 
1434860_at 2.87 0.00002 Narg3 
1435665_at 2.87 0.00006 AI451617 
1441892_x_at 2.87 0.000023 --- 
1442059_at 2.87 0.00002 Fxr1 
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1449193_at 2.87 0.000101 Cd5l 
1451563_at 2.87 0.00002 Emr4 
1452408_at 2.87 0.00002 --- 
1455729_at 2.87 0.00002 Gnaq 
1459682_at 2.87 0.00002 EG434249 
1416168_at 2.86 0.00002 Serpinf1 
1416303_at 2.86 0.000046 Litaf 
1416412_at 2.86 0.00002 Nsmaf 
1417541_at 2.86 0.00002 Hells 
1427619_a_at 2.86 0.000189 Sh3tc1 
1429172_a_at 2.86 0.000692 Ncapg 
1429642_at 2.86 0.001336 Anubl1 
1434285_at 2.86 0.00002 Frmd4a 
1434828_at 2.86 0.000101 B430201A12Rik 
1435058_x_at 2.86 0.000035 Stxbp3a 
1435914_at 2.86 0.000088 Ncor1 
1439256_x_at 2.86 0.00002 Gpr137b-ps 
1448123_s_at 2.86 0.00002 Tgfbi 
1448182_a_at 2.86 0.00002 Cd24a /// EG621324 
1448720_at 2.86 0.00002 Lrrc40 
1448839_at 2.86 0.001336 Kank3 
1452016_at 2.86 0.000027 Alox5ap 
1415834_at 2.85 0.00002 Dusp6 
1430038_at 2.85 0.00002 --- 
1430077_at 2.85 0.00002 Sfrs11 
1437989_at 2.85 0.00002 Pde8b 
1447849_s_at 2.85 0.00002 Maf 
1418895_at 2.84 0.000114 Skap2 
1419097_a_at 2.84 0.00002 Stom 
1422013_at 2.84 0.000189 Clec4a2 
1423774_a_at 2.84 0.000214 Prc1 
1425229_a_at 2.84 0.000774 Tcf7l2 
1428259_at 2.84 0.000114 Pxdn 
1434502_x_at 2.84 0.000552 Slc4a1 
1435745_at 2.84 0.00002 5031439G07Rik 
1436330_x_at 2.84 0.00002 EG631624 
1437226_x_at 2.84 0.00002 Marcksl1 
1438910_a_at 2.84 0.00002 Stom 
1448314_at 2.84 0.00002 Cdc2a 
1449874_at 2.84 0.001832 Ly96 
1450876_at 2.84 0.001486 Cfh /// LOC100048018 
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1452759_s_at 2.84 0.000438 Ppfibp1 
1458077_at 2.84 0.00002 --- 
1418736_at 2.83 0.000618 B3galnt1 
1430981_s_at 2.83 0.00004 Gpbp1 
1435597_at 2.83 0.00002 Atad5 
1439235_x_at 2.83 0.000035 Tm2d2 
1440179_x_at 2.83 0.000865 Rnf217 
1441556_at 2.83 0.00002 --- 
1443858_at 2.83 0.00003 EG667823 
1447873_x_at 2.83 0.000966 Bid 
1452190_at 2.83 0.000189 Prcp 
1452445_at 2.83 0.000438 Slc41a2 
1416330_at 2.82 0.00002 Cd81 
1416419_s_at 2.82 0.000023 Gabarapl1 
1417376_a_at 2.82 0.000023 Cadm1 
1417462_at 2.82 0.001651 Cap1 
1417980_a_at 2.82 0.00002 Insig2 
1418301_at 2.82 0.001651 Irf6 
1418512_at 2.82 0.000052 Stk3 
1420908_at 2.82 0.00002 Cd2ap 
1424604_s_at 2.82 0.00002 Sumf1 
1428192_at 2.82 0.00002 Kbtbd7 
1436686_at 2.82 0.000068 LOC100046449 /// Zfp706 
1437611_x_at 2.82 0.000273 Kif2c 
1439255_s_at 2.82 0.00002 Gpr137b /// Gpr137b-ps /// LOC100044979 
1449049_at 2.82 0.00002 Tlr1 
1449429_at 2.82 0.000078 Fkbp1b 
1452061_s_at 2.82 0.00002 Strbp 
1452191_at 2.82 0.000068 LOC100048391 /// Prcp 
1453076_at 2.82 0.00002 Batf3 
1454086_a_at 2.82 0.00004 Lmo2 /// LOC100048263 
1417508_at 2.81 0.00002 Rnf19a 
1424574_at 2.81 0.00002 LOC100046567 /// Tmed5 
1429436_at 2.81 0.00002 Prpf40a 
1432478_a_at 2.81 0.000046 Rnf19b 
1433965_at 2.81 0.000035 Atp8a1 
1438329_at 2.81 0.00002 Tlr12 
1445984_at 2.81 0.00002 --- 
1452352_at 2.81 0.001486 Ctla2b 
1453228_at 2.81 0.000023 Stx11 
1453783_at 2.81 0.00003 6330411E07Rik 
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1459888_at 2.81 0.000241 LOC545261 
1415822_at 2.8 0.00002 Scd2 
1416337_at 2.8 0.000035 Uqcrb 
1417045_at 2.8 0.00002 Bid 
1417061_at 2.8 0.00002 Slc40a1 
1417910_at 2.8 0.00002 Ccna2 
1420693_at 2.8 0.00013 Myom1 
1423608_at 2.8 0.000023 Itm2a 
1425028_a_at 2.8 0.00013 Tpm2 
1431777_a_at 2.8 0.00002 Hmgn3 
1433920_at 2.8 0.001077 Sema4c 
1433995_s_at 2.8 0.00002 Ccdc50 
1440201_at 2.8 0.000189 C130026L21Rik /// Slc8a1 
1452054_at 2.8 0.000023 Ube2w 
1418150_at 2.79 0.000346 Mtmr4 
1422491_a_at 2.79 0.000114 Bnip2 
1423306_at 2.79 0.000346 2010002N04Rik 
1426221_at 2.79 0.00002 Loh11cr2a 
1426649_at 2.79 0.000692 LOC100045217 /// Tmeff1 
1429270_a_at 2.79 0.000189 Syce2 
1433750_at 2.79 0.000023 Slc31a1 
1433894_at 2.79 0.000068 Jazf1 
1435327_at 2.79 0.00002 AW112037 /// Lpgat1 
1438606_a_at 2.79 0.00002 Clic4 
1442739_at 2.79 0.00002 BC031441 
1460639_a_at 2.79 0.00002 Atox1 
1416109_at 2.78 0.00002 Fuca1 
1417377_at 2.78 0.00002 Cadm1 
1418209_a_at 2.78 0.000101 Pfn2 
1419513_a_at 2.78 0.00002 Ect2 
1424438_a_at 2.78 0.00002 Leprot 
1428484_at 2.78 0.00002 Osbpl3 
1434260_at 2.78 0.00002 Fchsd2 
1438796_at 2.78 0.00002 Nr4a3 
1439426_x_at 2.78 0.00002 Lyz1 
1448731_at 2.78 0.00002 Il10ra 
1449043_at 2.78 0.00002 Naga 
1457671_at 2.78 0.00003 9330120H11Rik 
1418436_at 2.77 0.00002 Stx7 
1418747_at 2.77 0.00003 Sfpi1 
1421211_a_at 2.77 0.00002 Ciita 
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1422449_s_at 2.77 0.00002 Rcn2 
1430569_at 2.77 0.00004 Ttc9c 
1448149_at 2.77 0.00002 Ctnna1 
1449661_at 2.77 0.000492 Suz12 
1457676_at 2.77 0.00002 Tirap 
1460203_at 2.77 0.000027 Itpr1 
1417170_at 2.76 0.00002 Lztfl1 
1426774_at 2.76 0.00002 Parp12 
1433751_at 2.76 0.00002 Slc39a10 
1437807_x_at 2.76 0.00002 Ctnna1 
1449602_at 2.76 0.00002 --- 
1450044_at 2.76 0.00002 Fzd7 
1456898_at 2.76 0.00003 --- 
1459906_at 2.76 0.000492 --- 
1416525_at 2.75 0.00002 Spop 
1417622_at 2.75 0.000101 Slc12a2 
1423613_at 2.75 0.000167 Ssfa2 
1424926_at 2.75 0.000035 Sec63 
1425705_a_at 2.75 0.000078 Ero1lb 
1428094_at 2.75 0.00002 Lamp2 
1429209_at 2.75 0.00002 Col23a1 
1434547_at 2.75 0.000438 Cpd 
1437111_at 2.75 0.00002 Zc3h12c 
1438379_x_at 2.75 0.000023 2310007F21Rik 
1442465_s_at 2.75 0.000241 Strbp 
1442865_at 2.75 0.000101 Dgkk 
1449198_a_at 2.75 0.00002 St3gal5 
1449268_at 2.75 0.000078 Gfpt1 
1449746_s_at 2.75 0.000027 Glipr1 
1451161_a_at 2.75 0.000307 Emr1 
1455241_at 2.75 0.000023 BC037703 
1460076_x_at 2.75 0.000307 --- 
1460335_at 2.75 0.00002 Lysmd3 
1416666_at 2.74 0.00004 Serpine2 
1417190_at 2.74 0.00002 Nampt 
1417378_at 2.74 0.000552 Cadm1 
1418652_at 2.74 0.000241 Cxcl9 
1426461_at 2.74 0.00002 Ugp2 
1435492_at 2.74 0.000101 Socs6 
1436991_x_at 2.74 0.00002 Gsn 
1437404_at 2.74 0.000273 Mast4 
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1443629_at 2.74 0.000147 Nav1 
1444559_at 2.74 0.001651 Phtf2 
1446104_at 2.74 0.000273 --- 
1449187_at 2.74 0.000147 Pdgfa 
1450792_at 2.74 0.000046 Tyrobp 
1452092_at 2.74 0.00002 4631426J05Rik 
1452717_at 2.74 0.00002 Slc25a24 
1459991_at 2.74 0.001486 Myo9a 
1416094_at 2.73 0.00002 Adam9 
1417898_a_at 2.73 0.00002 Gzma 
1418585_at 2.73 0.000346 Ccnh 
1419254_at 2.73 0.00002 Mthfd2 
1422573_at 2.73 0.00002 Ampd3 
1426850_a_at 2.73 0.000114 Map2k6 
1428480_at 2.73 0.000865 Cdca8 
1434339_at 2.73 0.000101 Fnbp1l 
1434557_at 2.73 0.00004 Hip1 
1436509_at 2.73 0.000023 2410014A08Rik 
1437495_at 2.73 0.000966 LOC100047187 /// Mbtps2 /// Yy2 
1441600_at 2.73 0.000027 C920021A13 
1443184_at 2.73 0.000068 Cdc14a /// LOC100047731 
1447593_x_at 2.73 0.000307 Gnaq 
1448339_at 2.73 0.00002 Tmem30a 
1456592_at 2.73 0.00003 --- 
1415788_at 2.72 0.00002 Ublcp1 
1417811_at 2.72 0.000023 Slc24a6 
1426687_at 2.72 0.000552 Map3k3 
1428481_s_at 2.72 0.00002 Cdca8 
1428930_at 2.72 0.00002 Tmem29 
1429295_s_at 2.72 0.000027 Trip13 
1430700_a_at 2.72 0.000078 Pla2g7 
1435069_at 2.72 0.001486 BC064078 
1436890_at 2.72 0.000241 Uap1l1 
1436997_x_at 2.72 0.00002 Sh3bgrl 
1437033_a_at 2.72 0.00002 Skp2 
1438511_a_at 2.72 0.000088 1190002H23Rik 
1439845_at 2.72 0.000438 Hp1bp3 
1444437_at 2.72 0.001077 Usp34 
1452213_at 2.72 0.00006 Tex2 
1452242_at 2.72 0.00002 Cep55 
1452598_at 2.72 0.000046 Gins1 
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1455101_at 2.72 0.00002 Phactr2 
1455618_x_at 2.72 0.000101 Tspan33 
1420507_a_at 2.71 0.000023 Sfrs12ip1 
1423804_a_at 2.71 0.00002 Idi1 
1424852_at 2.71 0.000078 Mef2c 
1427144_at 2.71 0.00002 Hnrpll 
1429432_at 2.71 0.000078 Bat2d 
1433655_at 2.71 0.00002 Rnf141 
1436911_at 2.71 0.000078 Ss18l1 
1440954_at 2.71 0.000618 --- 
1449221_a_at 2.71 0.000035 Rrbp1 
1452885_at 2.71 0.000035 Sfrs2ip 
1456533_at 2.71 0.000023 Dpy19l1 
1456936_at 2.71 0.000214 Cabp4 
1459874_s_at 2.71 0.00002 Mtmr4 
1417590_at 2.7 0.00002 Cyp27a1 
1419300_at 2.7 0.000027 Flt1 
1420814_at 2.7 0.00002 Gdi2 
1421525_a_at 2.7 0.000307 Naip5 
1423543_at 2.7 0.000023 Swap70 
1425019_at 2.7 0.000114 Ubxd4 
1428194_at 2.7 0.00002 Usp9x 
1433678_at 2.7 0.000088 Pld4 
1433985_at 2.7 0.00002 Abi2 
1438930_s_at 2.7 0.00002 Mecp2 
1442560_at 2.7 0.001336 --- 
1451608_a_at 2.7 0.000692 Tspan33 
1454809_at 2.7 0.000167 Ncoa7 
1454880_s_at 2.7 0.000189 Bmf 
1458630_at 2.7 0.00002 --- 
1416066_at 2.69 0.00002 Cd9 
1417744_a_at 2.69 0.000114 Ralb 
1418100_at 2.69 0.000023 A030009H04Rik 
1419253_at 2.69 0.00002 Mthfd2 
1423195_at 2.69 0.00002 Hiat1 
1424128_x_at 2.69 0.000046 Aurkb 
1428018_a_at 2.69 0.000492 AF251705 
1430530_s_at 2.69 0.00002 Nmral1 
1433159_at 2.69 0.000088 Kif13b 
1434687_at 2.69 0.000068 C730026J16 
1437009_a_at 2.69 0.00002 Zfp364 
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1447985_s_at 2.69 0.000023 Ankib1 
1448162_at 2.69 0.00002 Vcam1 
1449014_at 2.69 0.00002 Lactb /// LOC677144 
1449116_a_at 2.69 0.000241 Dtymk 
1449708_s_at 2.69 0.00002 Chek1 
1454947_a_at 2.69 0.00002 Ublcp1 
1416062_at 2.68 0.000241 Tbc1d15 
1416514_a_at 2.68 0.00002 Fscn1 
1417381_at 2.68 0.00002 C1qa 
1420404_at 2.68 0.00002 Cd86 
1420618_at 2.68 0.00002 Cpeb4 
1420650_at 2.68 0.000307 Zfhx3 
1420907_at 2.68 0.00002 Cd2ap 
1420915_at 2.68 0.00002 Stat1 
1420989_at 2.68 0.000214 4933411K20Rik 
1421056_at 2.68 0.000027 Dnase1l3 
1422467_at 2.68 0.00002 Ppt1 
1423266_at 2.68 0.00003 2810405K02Rik 
1423326_at 2.68 0.000046 Entpd1 
1424383_at 2.68 0.000023 Tmem51 
1428700_at 2.68 0.000618 P2ry13 
1429171_a_at 2.68 0.000307 Ncapg 
1430332_a_at 2.68 0.00002 Gusb 
1433796_at 2.68 0.00002 Endod1 
1448620_at 2.68 0.000068 Fcgr3 
1448960_at 2.68 0.000046 Cxxc5 
1451730_at 2.68 0.000101 Zfp62 
1452115_a_at 2.68 0.001651 Plk4 
1455852_at 2.68 0.001486 Nsl1 
1456435_at 2.68 0.000023 Morn1 
1460586_at 2.68 0.000147 Megf8 
1416344_at 2.67 0.000027 Lamp2 
1416802_a_at 2.67 0.00002 Cdca5 
1416957_at 2.67 0.00002 Pou2af1 
1419519_at 2.67 0.000389 Igf1 
1419603_at 2.67 0.000438 Ifi204 
1420819_at 2.67 0.00002 Sla 
1420919_at 2.67 0.000114 Sgk3 
1421871_at 2.67 0.00002 Sh3bgrl 
1422201_at 2.67 0.000088 H2-Ob 
1422476_at 2.67 0.000114 Ifi30 
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1424210_at 2.67 0.000035 Erlin1 
1428653_x_at 2.67 0.000241 Elavl1 
1433592_at 2.67 0.00002 Calm1 
1436186_at 2.67 0.000189 E2f8 
1437461_s_at 2.67 0.00002 Rnpc3 
1447694_x_at 2.67 0.000774 Neo1 
1448075_at 2.67 0.000438 AA408251 
1451584_at 2.67 0.00002 Havcr2 
1453595_at 2.67 0.00003 2900064B18Rik 
1456312_x_at 2.67 0.00002 Gsn 
1416728_at 2.66 0.00002 Csnk2b 
1417870_x_at 2.66 0.00002 Ctsz 
1418681_at 2.66 0.000241 Alg13 
1420072_s_at 2.66 0.000101 --- 
1422433_s_at 2.66 0.00002 Idh1 
1423796_at 2.66 0.00002 Sfpq 
1427434_at 2.66 0.00002 Birc1f 
1427567_a_at 2.66 0.000046 Tpm3 
1430460_at 2.66 0.00006 2310047O13Rik 
1434767_at 2.66 0.000214 C79407 
1434835_at 2.66 0.00002 Wapal 
1435632_at 2.66 0.00002 Nufip2 
1441727_s_at 2.66 0.00003 Zfp467 
1443136_at 2.66 0.000046 LOC432459 
1449360_at 2.66 0.00002 Csf2rb2 
1450350_a_at 2.66 0.000147 Jdp2 
1450386_at 2.66 0.00002 Kpna3 
1451313_a_at 2.66 0.00002 1110067D22Rik 
1452504_s_at 2.66 0.000068 Ctbs 
1454901_at 2.66 0.000492 Ypel2 
1456236_s_at 2.66 0.00002 Commd10 
1415995_at 2.65 0.00002 Casp6 
1418219_at 2.65 0.000046 Il15 
1419130_at 2.65 0.00002 Adat2 
1421968_a_at 2.65 0.00002 Nipa2 
1424389_at 2.65 0.000307 Nupl1 
1442606_at 2.65 0.00002 --- 
1449345_at 2.65 0.000167 Ccdc34 
1451134_a_at 2.65 0.00002 Tm2d2 
1455130_at 2.65 0.00002 Spty2d1 
1456822_at 2.65 0.000438 Rad23b 
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1416035_at 2.64 0.00003 Hif1a 
1416964_at 2.64 0.000046 Eefsec 
1417668_at 2.64 0.000774 Rtn4ip1 
1417878_at 2.64 0.00002 E2f1 
1418483_a_at 2.64 0.00002 Ggta1 
1420475_at 2.64 0.00002 Mtpn 
1423568_at 2.64 0.00002 Psma7 
1424095_at 2.64 0.00002 Rtcd1 
1428107_at 2.64 0.00002 Sh3bgrl 
1430088_at 2.64 0.001336 Zfp619 
1438385_s_at 2.64 0.00002 Gpt2 
1447757_x_at 2.64 0.000167 Inpp5f 
1454942_at 2.64 0.00002 Niban 
1457672_at 2.64 0.00002 Chd9 
1417450_a_at 2.63 0.00002 Tacc3 
1418204_s_at 2.63 0.000027 Aif1 
1420361_at 2.63 0.00002 Slc11a1 
1421679_a_at 2.63 0.000966 Cdkn1a 
1422527_at 2.63 0.000027 H2-DMa 
1426398_at 2.63 0.000046 Ube2w 
1426936_at 2.63 0.00002 BC005512 /// EG641366 /// LOC215866 /// LOC629242 
1428715_at 2.63 0.00002 2810423A18Rik /// Gfpt1 
1434714_at 2.63 0.00003 Ero1lb 
1435059_at 2.63 0.000492 --- 
1435554_at 2.63 0.00002 Tmcc3 
1436303_at 2.63 0.00004 Mllt4 
1439520_at 2.63 0.00003 Dtl 
1441867_x_at 2.63 0.000027 4930534B04Rik 
1448148_at 2.63 0.00002 Grn 
1452007_at 2.63 0.00002 Vamp7 
1455054_a_at 2.63 0.000167 Dcun1d1 
1455089_at 2.63 0.000865 Gng12 
1456060_at 2.63 0.000046 Maf 
1457434_s_at 2.63 0.00002 Ptpla 
1416076_at 2.62 0.001336 Ccnb1 /// Ccnb1-rs1 /// EG434175 /// LOC667005 
1418188_a_at 2.62 0.000046 Malat1 
1421936_at 2.62 0.00002 Dapp1 
1422948_s_at 2.62 0.00002 Hist1h4a /// Hist1h4b /// Hist1h4c /// Hist1h4d /// Hist1h4f /// Hist1h4h /// 
Hist1h4i /// Hist1h4j /// Hist1h4k /// Hist1h4m /// Hist2h4 /// Hist4h4 /// 
LOC100041230 
1423775_s_at 2.62 0.000035 Prc1 
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1424431_at 2.62 0.00002 Csgalnact2 
1426785_s_at 2.62 0.000068 Mgll 
1441972_at 2.62 0.000307 6230424C14Rik 
1449222_at 2.62 0.00004 Ebi3 
1450430_at 2.62 0.00002 Mrc1 
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Appendix 2: Overrepresentation analysis of the genes that are upregulated in the tolerant Des-TCR CD8 T cells as compared to the 
activated Des-TCR CD8 T cells 
 
System Gene 
Category 
Population 
Hits 
Population 
Total 
Official Gene Symbol 
GO 
Cellular 
Compo
nent 
cytoplasm 874 1672 ABCB7; ABCD1; ABL1; ABR; ACAA2; ACADL; ACADVL; ACAT1; ACO1; ACOX1; ACP1; ACP2; ACTB; ACTR10; ACTR8; ADA; ADAR; ADD1; 
ADD3; ADFP; ADK; AHCYL1; AIF1; AIM1; AK2; AK3; AKAP9; ALDH1A2; ALDH2; ALDH3A2; ALDH9A1; ALDOC; ALS2; AMD1; ANP32A; 
ANP32E; ANXA4; ANXA5; ANXA6; ANXA7; AP1G1; AP1GBP1; AP1S2; AP3B1; AP3D1; AP3M1; AP3S1; AP3S2; APAF1; APC; APOE; APP; 
APPBP2; ARF1; ARF3; ARF4; ARFGAP3; ARFRP1; ARHGAP5; ARHGAP6; ARHGEF10; ARHGEF7; ARIH2; ARL1; ARL3; ARL6; ARPC4; 
ARPC5; ARRB1; ASAH1; ASAH2; ASL; ASNA1; ATF6; ATP2A2; ATP5A1; ATP5C1; ATP5E; ATP6V0D1; ATP6V1A; ATP6V1B2; ATP6V1D; 
ATP6V1H; ATP7A; ATPIF1; AUH; AXIN1; B4GALT4; B4GALT6; BAD; BAG5; BAIAP2; BASP1; BBX; BECN1; BID; BIRC5; BLMH; BMI1; 
BNIP3L; BTK; BUB1; BZW1; BZW2; CALM1; CALM2; CAMTA2; CANX; CAPZA1; CAPZA2; CAPZB; CARD10; CARHSP1; CASK; CASP7; CAT; 
CBFA2T3; CBR3; CCNA2; CCNB1; CCNB2; CCND1; CCND2; CCR5; CCT3; CCT7; CD2AP; CD68; CDC16; CDC20; CDC6; CDK2AP1; CDK4; 
CDK5; CDK8; CENPE; CENPF; CETN2; CFL2; CHFR; CHUK; CKB; CLASP1; CLK1; CLN3; CLN8; CLPP; CLTA; CLTB; CLTC; CNN3; COPZ2; 
COQ3; CORO2A; COX15; COX5B; COX7C; CRK; CROT; CRYAB; CRYZ; CS; CSK; CSNK1D; CSNK1G1; CSRP1; CSRP2; CTBS; CTDP1; 
CTNNA1; CTPS; CTSB; CTSC; CTSH; CTSL; CTSS; CTSZ; CUGBP2; CXCR3; CYBA; CYC1; CYCS; CYP27A1; CYP8B1; DAPK1; DAPK3; 
DBI; DBN1; DBT; DCK; DCXR; DDX6; DEK; DFFA; DFFB; DGUOK; DLG1; DMXL1; DNAJB11; DNAJB4; DNAJB6; DNAJB9; DNMT3A; DNPEP; 
DPAGT1; DPM1; DPP8; DRG1; DSTN; DTYMK; DUSP1; DUSP16; DUSP22; DUSP6; DUSP7; DUT; DYRK1A; EBP; ECT2; EGLN1; EHD1; 
EHD2; EHD4; EHHADH; EIF1A; EIF1AY; EIF2AK3; EIF2B2; EIF2B4; EIF4B; EIF4E; EIF4G1; EIF4G2; EIF4G3; ELAC1; ENO2; EPC1; EPHX1; 
EPRS; EPS15; EPS8; ERBB2IP; ERO1L; ESD; ETF1; EVL; EXTL2; EXTL3; FABP5; FECH; FEM1B; FEN1; FES; FGD2; FIGNL1; FKBP1A; 
FKBP1B; FKBP2; FKBP4; FKBP9; FLII; FLNB; FNTA; FPR1; FRAP1; FSCN1; FUCA1; FUCA2; FUSIP1; FXC1; FXR1; FYCO1; GABARAPL2; 
GADD45B; GADD45G; GALC; GALNT1; GALNT11; GALNT3; GATM; GBA; GBP1; GBP2; GBP3; GCA; GCH1; GCSH; GDI1; GDI2; GLG1; 
GLRX; GLRX2; GLUD1; GM2A; GNAI3; GNPAT; GNS; GOLGA4; GOLPH3; GOT1; GOT2; GPD2; GPHN; GPX4; GRPEL1; GSN; GSPT1; 
GUSB; GZMA; GZMB; GZMK; HABP4; HADHB; HARS; HARS2; HAT1; HCCS; HCK; HDAC11; HDAC2; HDAC5; HERPUD1; HEXA; HEXB; 
HFE; HIBADH; HIP1; HK2; HLCS; HMGCL; HMGCR; HMGCS1; HMOX1; HOMER2; HRBL; HSD17B4; HSPA1A; HSPA1B; HSPA4; HSPA5; 
HSPA8; HSPH1; HUS1; IARS; ICMT; IDH1; IDH2; IDI1; IDS; IER5; IFI30; IFI35; IFI44; IFIT1; IFIT2; IGF2R; IKBKG; IL15; ILK; INPP1; INPP4A; 
INPP5D; INPPL1; IPO7; IQGAP1; IREB2; IRF3; IRF4; IRF5; IRF6; IRF7; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; ITPR1; 
ITPR2; JAK1; JAK2; JAK3; KARS; KATNA1; KHK; KIF11; KIF1B; KIF1C; KIF20A; KIF23; KIF2C; KIF3B; KIF5B; KLHL2; KLHL5; KPNA1; 
KPNA2; KPNB1; KRT17; KTN1; LACTB; LAMP2; LAMP3; LANCL2; LAP3; LARGE; LASP1; LCMT1; LCP1; LGMN; LIMK1; LIPA; LMAN1; 
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LRMP; LRRFIP1; LRRFIP2; LSP1; LYN; LYPLA1; LZTFL1; M6PR; MAD2L1; MADD; MAN1A2; MAN2A1; MAN2B1; MANBA; MAP3K3; 
MAP3K4; MAP3K8; MAP4K5; MAPK14; MAPRE2; MARCKS; MBP; MCL1; MDH1; MELK; METAP2; MFHAS1; MGAT2; MGLL; MGST1; 
MKI67IP; MKLN1; MLF2; MLH3; MMAA; MRPL1; MRPL11; MRPL15; MRPL16; MRPL17; MRPL22; MRPL27; MRPL3; MRPL46; MRPL48; 
MRPL49; MRPL50; MRPS14; MRPS15; MRPS2; MRPS21; MRPS25; MRPS28; MRPS9; MTAP; MTHFD2; MTHFS; MTM1; MTMR1; MTMR6; 
MTX2; MVP; MX1; MYCBP; MYL6; MYO1C; MYO5A; MYO6; MYO9A; MYOM1; NAGA; NAGLU; NARS; NCBP2; NCF1; NCOA1; NDRG1; 
NDST1; NDST2; NDUFA5; NDUFA9; NDUFAB1; NDUFB4; NDUFB7; NDUFC2; NDUFS4; NDUFS5; NDUFV1; NEDD9; NFAT5; NFATC1; NFIX; 
NFKB1; NFKBIE; NGLY1; NMI; NNT; NOLA2; NOLC1; NPEPPS; NR3C1; NSF; NSMAF; NT5C2; NUCB2; NUDT1; NUMB; NUP50; NUP54; 
NUTF2; OAT; ODC1; OGT; OLFM1; OSGEP; P4HA1; P4HB; PA2G4; PACSIN1; PAFAH1B2; PAFAH1B3; PAPOLG; PAPSS1; PCCA; PCM1; 
PCMT1; PDCL; PDK1; PDK3; PDLIM2; PDPK1; PEX11A; PEX13; PEX3; PEX6; PEX7; PFDN2; PFKFB3; PFKL; PFKP; PFN2; PFTK1; PGD; 
PGLS; PHYH; PIGC; PIGF; PIGH; PIGS; PIK3C2A; PIK3CD; PLA2G4A; PLCE1; PLCG2; PLDN; PLEC1; PLEK; PLEKHA1; PLEKHA2; 
PLEKHF2; PLOD2; PLP2; PLS3; PMAIP1; PMM2; PMPCB; PMVK; PNN; PPAT; PPFIA4; PPID; PPIF; PPP1R2; PPP1R7; PPP2R1B; PPP4R2; 
PPT1; PPT2; PRC1; PRCP; PRDX2; PRKAG2; PRKCB1; PRKCD; PRKCH; PRKRA; PRNP; PSAP; PSEN1; PSMA4; PSMA6; PSMA7; PSMB3; 
PSMB4; PSMB5; PSMB7; PSMB8; PSMB9; PSMC1; PSMC2; PSMC6; PSMD10; PSMD13; PSMD14; PSMD2; PSMD4; PSMD8; PSME3; 
PTEN; PTGIS; PTPN11; PTPN6; PTPRE; PTTG1IP; PUM1; PUM2; PURA; PVR; PXN; PYGB; QARS; RAB24; RAB2B; RAB30; RAB31; RAB32; 
RAB33B; RAB5A; RAB6B; RAB7; RAD51; RAD51L1; RAD51L3; RANBP2; RANBP9; RAP1GDS1; RASSF5; RBBP8; RBM4; RCN2; RDBP; 
RDH11; RDX; RERE; REV3L; RFC3; RFC4; RFX5; RGS18; RGS19; RGS2; RGS3; RNASEH1; RNF14; RNF7; ROCK1; ROCK2; RPL11; 
RPL13; RPL14; RPL15; RPL23; RPL30; RPL31; RPL5; RPN1; RPS10; RPS13; RPS24; RPS6; RPS6KA2; RPS6KB1; RPS6KB2; RPS9; 
RRAS2; RRBP1; RREB1; RRM2; RTN1; RTN3; RTN4; RUNX1; RYR1; SC4MOL; SCARB2; SCP2; SDCBP; SDCCAG3; SDCCAG8; SDHA; 
SDHC; SEC14L1; SEC23A; SEC24B; SEC24C; SEC24D; SEC63; SERPINB9; SERPINF1; SF1; SFXN2; SGCB; SGPL1; SH3BGRL; SH3GLB1; 
SHMT1; SHOC2; SIAH2; SIRT2; SLC25A11; SLC25A13; SLC25A14; SLC25A20; SLC25A5; SLC30A4; SLC33A1; SLC35A1; SLC35B1; 
SLC37A3; SLMAP; SNCA; SNX10; SNX2; SNX3; SNX4; SNX5; SNX6; SOAT1; SOCS4; SOCS5; SOLH; SPIB; SPTLC1; SPTLC2; SQSTM1; 
SREBF2; SRI; SRP14; SSR2; SSR3; SSR4; SSX2IP; STAM2; STARD3; STAT1; STAT3; STAT5A; STAT6; STK17B; STK3; STK39; STMN1; 
STOM; STRBP; STRN; STRN3; STX18; STX5A; STX6; STX7; STX8; SUCLG1; SULT1A1; SUOX; SURF4; SYK; SYNJ2BP; SYPL; SYT11; 
TACC3; TALDO1; TANK; TAP2; TAPBP; TAX1BP1; TBCD; TBK1; TCF19; TEC; TES; TGOLN2; TIA1; TIAL1; TIMM17B; TIMM22; TK1; TLR1; 
TM9SF2; TMEM1; TMOD3; TNIP2; TNNI2; TOMM70A; TOP1; TOR3A; TPI1; TPM1; TPM2; TPM3; TPM4; TPP2; TPR; TPST1; TRAF3; TRAM1; 
TRIM17; TRIM3; TRIM32; TRIM33; TRIM34; TRIP12; TRIP13; TRNT1; TSG101; TTK; TUBGCP5; TUFM; TXK; TXN2; TXNDC4; TXNRD1; 
TYK2; UAP1; UCHL5; UCP2; UGCGL1; UGP2; UGT1A5; ULK1; UMPS; UNC119; UQCRB; UQCRFS1; USP4; UXT; VAMP4; VAMP8; VASP; 
VAV1; VAV3; VCL; VDAC1; VDAC3; VPS35; VPS4B; WASF2; WASL; WDR1; XPO1; XPO7; YME1L1; YWHAB; YWHAQ; YWHAZ; ZAP70; 
ZDHHC3; ZFP36L1; ZFYVE16; ZFYVE21 
GO 
Cellular 
membrane 599 1672 ABCA3; ABCB7; ABCD1; ABCF1; ABCF3; ABHD3; ACP2; ACVR1; ACVRL1; ADAM10; ADAM17; ADAM19; ADAM23; ADAM8; ADAM9; 
ADCY7; ADD1; ADD3; ADFP; ADK; AGPAT3; ALCAM; ALDH3A2; ALOX5AP; AMD1; AMPD3; ANPEP; AP1G1; AP1S2; APOE; APP; ARF1; 
ARHGAP12; ARHGAP5; ARHGAP9; ARRB1; ASB13; ASNA1; ATF6; ATOX1; ATP11A; ATP11B; ATP1B1; ATP2A2; ATP2C1; ATP5A1; 
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ATP5C1; ATP5E; ATP6V0A2; ATP6V0B; ATP6V0D1; ATP6V1A; ATP6V1B2; ATP6V1C1; ATP6V1D; ATP6V1H; ATP7A; ATP8A1; AXL; 
B4GALT4; B4GALT6; BAD; BAIAP2; BASP1; BCL11A; BCL11B; BCL2L11; BECN1; BFAR; BNIP2; BNIP3L; BRI3; BST1; C6; CABP4; 
CACNA1S; CACNB3; CALCRL; CALM1; CALM2; CANX; CASK; CAST; CCR5; CCR9; CD14; CD163; CD36; CD38; CD44; CD48; CD5; CD5L; 
CD68; CD74; CD80; CD81; CD83; CD86; CD8A; CD9; CD96; CD97; CD99L2; CDC42; CDCA7; CEBPG; CHD6; CHN2; CHPT1; CHRNB1; 
CKLF; CLCN3; CLDN1; CLIC4; CLN3; CLN8; CLTA; CLTB; CLTC; CNOT2; CNP; CNR2; COPZ2; COX15; COX5B; CPD; CPNE1; CPNE3; 
CRAMP1L; CRIM1; CRLF2; CRLF3; CSF1R; CSF2RA; CSF2RB; CSNK2A1; CTNNA1; CXCL16; CXCR3; CYB561; CYBA; CYC1; CYCS; 
CYP27A1; CYP8B1; CYSLTR1; DDEF1; DDR1; DEK; DGCR2; DLG1; DLG3; DNAJA1; DNAJC5; DPAGT1; DPP4; DPP8; DSCR3; EBI3; EBP; 
ECE1; EEF1E1; EIF2AK3; EIF2AK4; ELF1; ELK3; EMD; EMR1; ENPP4; ENTPD1; EPHX1; ERBB2IP; ERO1L; ETS2; ETV3; ETV6; EVI2A; 
EVI2B; EVI5; EVL; EXTL2; EXTL3; EZH2; FADS1; FCGR2B; FCGRT; FLI1; FLNB; FLT1; FLT3; FMO5; FPR1; FTH1; FXC1; FZD7; 
GABARAPL1; GABBR1; GABPA; GALNT1; GALNT3; GBA; GCA; GHITM; GIT2; GJA1; GLG1; GMFB; GNA13; GNAI3; GNB2; GNB4; GNG10; 
GNG12; GNG2; GNPAT; GP2; GPR124; GPR34; GPR35; GPR65; GPRC5B; GPSN2; GTPBP2; GYPC; HABP4; HADHB; HCCS; HERPUD1; 
HFE; HK2; HMGCR; HRB; HRBL; HRH2; HS2ST1; HS6ST1; ICAM1; ICMT; ICOS; IFITM3; IFNAR1; IFNAR2; IFNGR2; IGF2R; IL10RA; 
IL13RA1; IL15; IL15RA; IL1RAP; IL2RG; IL6ST; ILK; INPP5B; IPO7; IRAK1; IRAK4; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; 
ITGB2; ITM2A; ITM2B; ITM2C; ITPR1; ITPR2; JAG2; JTB; KATNA1; KCNJ10; KCNN4; KHDRBS1; KHDRBS3; KHK; KIF1B; KIT; KLRC1; KMO; 
KPNA1; KPNA3; KPNB1; KTN1; LAMP2; LAMP3; LANCL2; LAPTM4A; LAPTM4B; LARGE; LEPROTL1; LGALS3; LGALS3BP; LIFR; LILRB3; 
LIMD1; LIMS1; LIN7C; LITAF; LMAN1; LPP; LRMP; LRP4; LRRC1; LST1; LY75; LY86; LY96; M6PR; MADD; MAN1A2; MAN2A1; MARCKS; 
MCL1; MDM2; MDM4; MERTK; METAP1; MGAT2; MGST1; MKRN1; MPP6; MRAS; MRC1; MS4A1; MTX2; MYCL1; MYD88; NAALAD2; 
NDFIP1; NDFIP2; NDST1; NDST2; NDUFV1; NNT; NOTCH1; NOTCH2; NOTCH4; NRP1; NUCB2; NUDT4; NUFIP1; NUMB; NUP153; NUP50; 
NUP54; NUP62; NUTF2; ODC1; OLFM1; ORMDL2; P2RX4; P2RY6; PAK1; PAK2; PCNX; PCNXL3; PDGFA; PDGFC; PDPK1; PEPD; PEX11A; 
PEX13; PEX3; PIGC; PIGF; PIGM; PIGN; PIGQ; PIGS; PIP5K1C; PITPNM1; PLA2G4A; PLCE1; PLEC1; PLOD2; PLP2; PLSCR1; PLSCR3; 
PLXNB2; PLXNC1; PNN; PPAP2A; PPAP2B; PPAP2C; PPP2R1B; PREB; PRKCB1; PRKCD; PRKCI; PRKRIR; PRNP; PROCR; PRRG2; 
PSAP; PSCD2; PSEN1; PSME4; PTDSS1; PTGER1; PTGER2; PTGER4; PTGIS; PTGS1; PTPN6; PTPN9; PTPRE; PTPRJ; PTPRS; PTTG1IP; 
PVR; RAB6IP1; RAC1; RALA; RALB; RAMP1; RANBP2; RAP1B; RAP2A; RASGRP4; RDH11; RDX; RECQL; RGS19; RNF121; RNF44; RNMT; 
RPN1; RRAS2; RRBP1; RTN1; RTN3; RTN4; RYR1; SACM1L; SC4MOL; SCAMP1; SCAMP2; SCARB1; SCARB2; SDC3; SDCBP; SDHC; 
SEC14L1; SEC24B; SEC63; SEMA4D; SEMA4F; SFRS1; SFRS9; SFXN2; SGCB; SGPL1; SGPP1; SH3GLB1; SIN3B; SLC11A1; SLC12A2; 
SLC13A3; SLC14A1; SLC15A2; SLC1A5; SLC22A5; SLC25A11; SLC25A13; SLC25A14; SLC25A20; SLC25A5; SLC2A9; SLC30A4; SLC30A5; 
SLC30A7; SLC31A1; SLC31A2; SLC33A1; SLC35A1; SLC35A5; SLC35B1; SLC35E1; SLC4A1; SLC4A7; SLC6A6; SLC7A6; SLC7A7; 
SLC8A1; SLC9A3R2; SLMAP; SNAP23; SOAT1; SON; SPAG5; SPINT2; SPTLC1; SPTLC2; SQLE; SREBF2; SRF; SSFA2; SSR2; SSR3; 
SSR4; STARD3; STARD3NL; STOM; STX12; STX17; STX18; STX5A; STX6; STX7; STX8; SURF4; SYNGR2; SYNJ2BP; SYPL; SYT11; 
TACSTD1; TAP1; TAP2; TAPBP; TBC1D8; TBXAS1; TCIRG1; TGFBR1; TGFBR2; TGM1; TGOLN2; TIAM1; TIMM17B; TIMM22; TJP2; TLE3; 
TLR1; TLR2; TLR3; TLR4; TM6SF1; TM9SF2; TMEFF1; TMEM1; TMEM8; TMPO; TNFAIP1; TNFRSF1A; TNFRSF21; TNFRSF9; TOMM70A; 
TPD52; TPR; TPST1; TRAM1; TREX1; TRIM37; TRIO; TRIP6; TRPM7; TRPV2; TULP3; TXNDC4; TYROBP; UBE2J1; UBE3A; UCP2; 
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UGT1A1; UGT1A10; UGT1A5; UGT1A9; UNC93B1; UPF2; UQCRB; UQCRFS1; UTX; VAMP3; VAMP4; VAPB; VCAM1; VCL; VDAC1; VDAC3; 
VPS18; VPS41; VRK2; WASF2; XBP1; XCR1; XPNPEP1; XPO1; XPO7; YME1L1; ZDHHC14; ZDHHC2; ZDHHC3; ZDHHC6; ZDHHC9; 
ZFYVE21; ZFYVE26; ZYX 
GO 
Cellular 
Compo
nent 
nucleus 506 1672 ABL1; ADAR; ADNP; AHR; AIF1; ANAPC11; ANP32A; ANP32E; AP3D1; API5; ARFGAP3; ARHGAP6; ARIH2; ASF1B; ASNA1; ASXL1; ATF1; 
ATF2; ATF3; ATF6; ATF7IP; ATM; ATRX; BACH1; BAD; BASP1; BAZ1B; BAZ2A; BAZ2B; BCAS2; BCL3; BCL6; BCL9; BLMH; BMI1; BRD8; 
BUB1; BUB3; BXDC1; CAPN7; CBFA2T3; CBFB; CBL; CBX6; CCM2; CCNA2; CCNB1; CCNB2; CCNC; CCND1; CCND2; CCNE2; CCNG1; 
CCNG2; CCNH; CCNI; CCNT2; CDC25C; CDC6; CDK2AP1; CDK7; CDKN1A; CDYL; CEBPG; CENPA; CENPE; CENPF; CENTA2; CENTD1; 
CENTD2; CFL2; CHD1; CHD6; CHEK1; CITED2; CLK1; CNOT2; CNOT7; CNOT8; COPS4; CPSF2; CPSF3; CRAMP1L; CREB3; CREM; CRK; 
CRNKL1; CRYAB; CSNK2A1; CSRP1; CSRP2; CSTF2; CSTF3; CTBP2; CTCF; CTNNBIP1; CTNNBL1; CUL1; CUL3; CUL4A; CUL4B; DAPK3; 
DCK; DDB2; DDEF1; DDX6; DEK; DFFA; DFFB; DMTF1; DNAJB9; DNASE1L3; DNMT3A; DR1; DTX2; DUSP11; DUSP16; DUT; DYRK1A; 
E2F1; EED; EGR1; EGR2; EHD2; ELF1; ELK3; EMD; EPC1; ERBB2IP; ETS2; ETV3; ETV6; EZH2; FBL; FEN1; FKBP1A; FKBP1B; FKBP4; 
FLI1; FNBP1; FUBP1; FUS; FUSIP1; FXR1; GABPA; GABPB1; GIT2; GLRX2; GPS1; GSPT1; GTF2A1; GTF2B; GTF2E2; GTF2F2; GTF2H1; 
GTF2H2; GTF2I; GTF3C4; H1F0; H2AFZ; H3F3B; HABP4; HAT1; HCLS1; HDAC11; HDAC2; HDAC5; HELLS; HHEX; HIF1A; HIST1H1C; 
HIST1H2AB; HIST1H2AC; HIST1H2AD; HIST1H2AE; HIST1H3D; HIST1H4A; HIST2H2AC; HIST3H2A; HIVEP1; HIVEP2; HMGB3; HMGN3; 
HNRPA3; HNRPAB; HNRPDL; HNRPF; HNRPH2; HNRPK; HRB; HRBL; HSBP1; HSPA1A; HSPA1B; ID2; ID3; IFI35; IKBKG; INCENP; IPO7; 
IRF3; IRF4; IRF5; IRF6; IRF7; KHDRBS3; KIF23; KIF2C; KLF3; KPNA1; KPNA2; KPNA3; KPNB1; LGALS3; LIG1; LIMD1; LITAF; LMO2; LPIN2; 
LRRFIP1; LSM3; LYL1; MAD2L1; MAFB; MAPK14; MAPK8; MAPK9; MAPKAPK2; MBD4; MBNL3; MBP; MCM2; MCM3; MCM4; MCM6; MDM2; 
MDM4; MEF2A; MEF2C; MFHAS1; MITF; MKI67; MKI67IP; MKL1; MLF2; MLH3; MNDA; MTAP; MVP; MXI1; MYB; MYCBP; MYCL1; MYNN; 
NAP1L1; NCBP2; NCOA1; NCOA3; NDRG1; NEDD9; NFAT5; NFATC1; NFIX; NFKB1; NFKB2; NFYA; NFYB; NMNAT1; NOLC1; NOTCH2; 
NOTCH4; NPEPPS; NR2C2; NR3C1; NUFIP1; NUP153; NUP50; NUP54; NUP62; NUPL1; NUTF2; NVL; OGT; ORC4L; PA2G4; PAPOLG; 
PCAF; PCNXL3; PDCD7; PDGFA; PES1; PFTK1; PHTF2; PIAS1; PKNOX1; PLAGL2; PLRG1; PML; PNN; POLB; POLD4; POLE4; POLR2B; 
POLR2F; POLR2H; POLR3K; POU2AF1; PPARG; PPIH; PPIL2; PPP1CC; PPP1R7; PPP2R1B; PPP2R5C; PRC1; PREB; PRPF39; PRPF4B; 
PRPF8; PRRG2; PSEN1; PSMA4; PSMA6; PSMA7; PSMB3; PSMB4; PSMB5; PSMB7; PSMB8; PSMB9; PSMC1; PSMC2; PSMC6; PSMD10; 
PSMD14; PSMD2; PSMD4; PSMD8; PSME3; PTP4A1; PTTG1IP; PURA; PXN; RAD17; RAD23A; RAD23B; RAD51; RAD51L1; RAD51L3; 
RAD54L; RANBP2; RASA1; RB1; RBBP4; RBBP8; RBL1; RBM12; RBM5; RBMS1; RBMX; RECQL; RELB; RERE; REV3L; RFC1; RFC3; RFC4; 
RFX5; RFXAP; RNF103; RNF12; RNF13; RNF14; RNF6; RNF7; RNMT; ROD1; RPA3; RPS6KA2; RREB1; RRS1; RTCD1; RTN4; RUNX1; 
RUVBL1; RXRA; SALL2; SAP30; SDCBP; SEC63; SF1; SF3A2; SF3A3; SF3B1; SF3B2; SFPQ; SFRS1; SFRS10; SFRS11; SFRS2; SFRS2IP; 
SFRS3; SFRS7; SFRS9; SHPRH; SIAH2; SIN3B; SIRT2; SLC9A3R2; SMARCA5; SMARCB1; SMARCC1; SMARCE1; SNAPC3; SNRPA1; 
SNRPB2; SNRPD1; SON; SP100; SPIB; SPOP; SREBF2; SRF; SRPK2; SRRM1; SSB; SSBP3; SSNA1; STAT1; STAT3; STAT5A; STAT6; 
STK17B; STK39; STRN3; SUPT4H1; TAF13; TAF1B; TAF7; TAF9; TARDBP; TBPL1; TCEA1; TCEB1; TCEB3; TCERG1; TCF19; TCF4; TCF7; 
TCF7L2; TDG; TDP1; TEP1; TFDP1; TFPT; TGFBR2; THOC2; TJP2; TLE3; TLK2; TMPO; TOB2; TOP2A; TOP2B; TPR; TREX1; TRIM32; 
TRIM33; TRIP13; TTC3; TTF1; TULP3; UBE2A; UBE2B; UBE2J1; UBE2V1; UBE2V2; UBE3A; UBP1; UBTF; UCHL5; USP18; USP4; UTX; 
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VAV1; WBP4; WDR13; XBP1; XPO1; XPO7; XRN2; YAF2; YY1; ZBTB1; ZBTB2; ZDHHC14; ZDHHC2; ZDHHC3; ZDHHC6; ZDHHC9; ZFP161; 
ZFP36L1; ZFR; ZFX; ZNRD1; ZWINT 
GO 
Cellular 
Compo
nent 
integral to 
membrane 
402 1672 ABCA3; ABCB7; ABCD1; ABHD3; ACP2; ACVR1; ACVRL1; ADAM10; ADAM17; ADAM19; ADAM23; ADAM8; ADAM9; ADCY7; AGPAT3; 
ALCAM; ALDH3A2; ALOX5AP; AMPD3; ANPEP; APP; ATF6; ATP11A; ATP11B; ATP1B1; ATP2A2; ATP2C1; ATP5A1; ATP5C1; ATP5E; 
ATP6V0A2; ATP6V0B; ATP6V1A; ATP6V1B2; ATP6V1C1; ATP7A; ATP8A1; AXL; B4GALT4; B4GALT6; BFAR; BNIP3L; BRI3; C6; CACNA1S; 
CACNB3; CALCRL; CANX; CAST; CCR5; CCR9; CD163; CD36; CD38; CD44; CD48; CD5; CD68; CD74; CD80; CD81; CD83; CD86; CD8A; 
CD9; CD96; CD97; CD99L2; CHRNB1; CKLF; CLCN3; CLDN1; CLN3; CLN8; CNR2; CPD; CRIM1; CRLF2; CSF1R; CSF2RA; CSF2RB; 
CXCL16; CXCR3; CYB561; CYC1; CYP8B1; CYSLTR1; DDR1; DEK; DGCR2; DPAGT1; DPP4; DSCR3; EBP; ECE1; EEF1E1; EIF2AK3; 
EIF2AK4; EMD; EMR1; ENPP4; ENTPD1; EPHX1; ERO1L; ETV6; EVI2A; EVI2B; EXTL2; EXTL3; FADS1; FCGR2B; FCGRT; FLNB; FLT1; 
FLT3; FMO5; FPR1; FZD7; GABBR1; GALNT1; GALNT3; GHITM; GJA1; GLG1; GPR34; GPR35; GPR65; GPSN2; GYPC; HABP4; HERPUD1; 
HFE; HMGCR; HRB; HRBL; HRH2; HS2ST1; HS6ST1; ICAM1; ICMT; ICOS; IFITM3; IFNAR1; IFNAR2; IFNGR2; IGF2R; IL10RA; IL13RA1; 
IL15; IL15RA; IL1RAP; IL2RG; IL6ST; INPP5B; IPO7; IRAK1; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; ITM2A; ITM2B; 
ITM2C; ITPR1; ITPR2; JAG2; JTB; KCNJ10; KCNN4; KIT; KLRC1; KMO; KPNA1; KPNA3; KPNB1; KTN1; LAMP2; LANCL2; LAPTM4A; 
LAPTM4B; LARGE; LEPROTL1; LIFR; LILRB3; LIMD1; LMAN1; LPP; LRMP; LST1; LY75; M6PR; MAN1A2; MAN2A1; MCL1; MERTK; 
METAP1; MGAT2; MRC1; MS4A1; NAALAD2; NDFIP1; NDFIP2; NDST1; NDST2; NNT; NOTCH1; NOTCH2; NOTCH4; NRP1; NUMB; 
NUP153; NUP50; NUP54; NUP62; NUTF2; ORMDL2; P2RX4; P2RY6; PCNX; PCNXL3; PEPD; PEX13; PEX3; PIGC; PIGF; PIGM; PIGN; 
PIGQ; PIGS; PITPNM1; PLA2G4A; PLP2; PLSCR1; PLSCR3; PLXNC1; PPAP2A; PPAP2B; PREB; PRKRIR; PROCR; PRRG2; PSAP; PSEN1; 
PSME4; PTDSS1; PTGER1; PTGER2; PTGER4; PTGIS; PTGS1; PTPN9; PTPRE; PTPRJ; PTPRS; PTTG1IP; PVR; RAB6IP1; RAMP1; 
RANBP2; RDH11; RECQL; RNF121; RNF44; RPN1; RRBP1; RTN1; RTN3; RTN4; RYR1; SACM1L; SC4MOL; SCAMP1; SCAMP2; SCARB1; 
SCARB2; SDC3; SDCBP; SDHC; SEC63; SEMA4D; SEMA4F; SFXN2; SGCB; SGPL1; SGPP1; SLC11A1; SLC12A2; SLC13A3; SLC14A1; 
SLC15A2; SLC1A5; SLC22A5; SLC25A11; SLC25A13; SLC25A14; SLC25A20; SLC25A5; SLC2A9; SLC30A4; SLC30A5; SLC31A1; SLC31A2; 
SLC33A1; SLC35A1; SLC35A5; SLC35B1; SLC4A1; SLC4A7; SLC6A6; SLC7A6; SLC7A7; SLC8A1; SLMAP; SOAT1; SPINT2; SPTLC1; 
SPTLC2; SQLE; SREBF2; SSR2; SSR3; SSR4; STARD3; STARD3NL; STOM; STX17; STX18; STX5A; STX6; STX7; STX8; SURF4; SYNGR2; 
SYNJ2BP; SYPL; SYT11; TACSTD1; TAP1; TAP2; TAPBP; TBXAS1; TCIRG1; TGFBR1; TGFBR2; TGOLN2; TIMM17B; TIMM22; TJP2; TLR1; 
TLR2; TLR3; TLR4; TM6SF1; TM9SF2; TMEFF1; TMEM1; TMEM8; TMPO; TNFAIP1; TNFRSF1A; TNFRSF21; TNFRSF9; TOMM70A; TPR; 
TPST1; TRAM1; TRIM37; TRIP6; TRPM7; TRPV2; TYROBP; UBE3A; UCP2; UGT1A1; UGT1A10; UGT1A5; UGT1A9; UNC93B1; UPF2; 
UQCRFS1; VAMP3; VAMP4; VAPB; VCAM1; VDAC1; VDAC3; VPS41; VRK2; WASF2; XCR1; XPO1; XPO7; ZDHHC14; ZDHHC2; ZDHHC3; 
ZDHHC6; ZDHHC9; ZYX 
GO 
Cellular 
Compo
plasma 
membrane 
261 1672 ACVR1; ACVRL1; ADAM10; ADAM17; ADAM23; ADAM8; ADAM9; ADCY7; ALCAM; ANPEP; AP1G1; AP1S2; APP; ARF1; ARRB1; ATP1B1; 
ATP2A2; ATP6V1A; ATP6V1C1; ATP7A; AXL; BAIAP2; BASP1; BFAR; BST1; CABP4; CACNA1S; CACNB3; CALCRL; CALM1; CALM2; 
CANX; CASK; CCR5; CCR9; CD14; CD163; CD36; CD38; CD44; CD48; CD5; CD80; CD81; CD83; CD86; CD8A; CD9; CD96; CD97; CDC42; 
CDCA7; CHRNB1; CLDN1; CLTA; CLTB; CLTC; CNR2; CSF1R; CSF2RA; CSF2RB; CSNK2A1; CTNNA1; CXCR3; CYB561; CYSLTR1; DDR1; 
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 XXVII 
nent DLG1; DLG3; EBI3; EBP; EMR1; ENTPD1; ERBB2IP; ETV6; EVI2B; EVL; EZH2; FCGR2B; FLNB; FLT1; FLT3; FPR1; FTH1; FZD7; 
GABARAPL1; GABBR1; GCA; GIT2; GJA1; GNA13; GNAI3; GNB2; GNB4; GNG10; GNG12; GNG2; GPR34; GYPC; HFE; HRH2; HS6ST1; 
ICAM1; IFNAR1; IFNAR2; IFNGR2; IGF2R; IL10RA; IL13RA1; IL15; IL15RA; IL2RG; IL6ST; ILK; IRAK1; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; 
ITGAX; ITGB1; ITGB2; ITM2B; ITPR2; JAG2; JTB; KATNA1; KCNJ10; KCNN4; KLRC1; LAMP2; LANCL2; LGALS3; LIFR; LIMD1; LIMS1; 
LIN7C; LPP; LRMP; LRRC1; LST1; LY75; LY86; LY96; M6PR; MADD; MARCKS; MERTK; METAP1; MRAS; MRC1; MS4A1; NOTCH1; 
NOTCH2; NOTCH4; NUCB2; NUMB; P2RX4; P2RY6; PAK1; PAK2; PCNXL3; PDPK1; PEX3; PIP5K1C; PLCE1; PLEC1; PLSCR1; PLSCR3; 
PLXNC1; PNN; PPAP2A; PRKCB1; PRKCI; PRNP; PROCR; PRRG2; PSCD2; PSEN1; PTGER1; PTGER2; PTPN9; PTPRE; PTPRJ; PTPRS; 
RAC1; RALA; RALB; RAMP1; RASGRP4; RDX; RECQL; RGS19; RNF44; RRAS2; RYR1; SC4MOL; SCARB2; SDCBP; SEMA4F; SGCB; 
SLC11A1; SLC12A2; SLC14A1; SLC15A2; SLC1A5; SLC22A5; SLC25A11; SLC25A13; SLC25A14; SLC25A5; SLC30A5; SLC31A1; SLC31A2; 
SLC33A1; SLC35A1; SLC4A1; SLC6A6; SLC7A6; SLC7A7; SLC8A1; SLC9A3R2; SLMAP; SNAP23; SSFA2; STOM; STX6; STX7; STX8; 
SYNGR2; SYPL; SYT11; TACSTD1; TAP1; TAP2; TCIRG1; TGFBR1; TJP2; TLE3; TLR3; TLR4; TM9SF2; TMEM8; TNFAIP1; TNFRSF1A; 
TNFRSF9; TRIM37; TRIO; TRIP6; TRPV2; TULP3; TYROBP; UBE3A; UPF2; VAPB; VCAM1; VCL; VDAC3; XCR1; ZYX 
GO 
Cellular 
Compo
nent 
integral to 
plasma 
membrane 
171 1672 ACVR1; ACVRL1; ADAM10; ADAM17; ADAM23; ADAM8; ADAM9; ADCY7; ALCAM; ANPEP; APP; ATP1B1; ATP2A2; ATP6V1A; ATP7A; AXL; 
BFAR; CACNA1S; CACNB3; CALCRL; CANX; CCR5; CCR9; CD163; CD36; CD44; CD48; CD5; CD81; CD83; CD8A; CD9; CD96; CD97; 
CHRNB1; CLDN1; CNR2; CSF1R; CSF2RA; CSF2RB; CXCR3; CYB561; CYSLTR1; DDR1; EBP; EMR1; ENTPD1; ETV6; EVI2B; FLNB; FLT1; 
FLT3; GABBR1; GJA1; GPR34; GYPC; HFE; HRH2; HS6ST1; ICAM1; IFNAR1; IFNAR2; IFNGR2; IGF2R; IL13RA1; IL15; IL15RA; IL2RG; 
IL6ST; IRAK1; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; ITM2B; JAG2; JTB; KCNJ10; KCNN4; KLRC1; LAMP2; LANCL2; 
LIFR; LIMD1; LPP; LRMP; LST1; LY75; M6PR; MERTK; METAP1; MRC1; MS4A1; NOTCH1; NOTCH2; NOTCH4; NUMB; P2RX4; P2RY6; 
PCNXL3; PEX3; PROCR; PRRG2; PSEN1; PTGER1; PTGER2; PTPN9; PTPRE; PTPRJ; PTPRS; RAMP1; RECQL; RNF44; RYR1; SCARB2; 
SDCBP; SEMA4F; SGCB; SLC11A1; SLC12A2; SLC14A1; SLC15A2; SLC1A5; SLC25A11; SLC25A13; SLC25A14; SLC25A5; SLC30A5; 
SLC31A1; SLC31A2; SLC33A1; SLC35A1; SLC4A1; SLC6A6; SLC7A6; SLC7A7; SLC8A1; SLMAP; STOM; STX6; STX7; STX8; SYNGR2; 
SYPL; SYT11; TAP1; TAP2; TCIRG1; TGFBR1; TJP2; TLR3; TLR4; TM9SF2; TMEM8; TNFAIP1; TNFRSF1A; TNFRSF9; TRIM37; TRIP6; 
TRPV2; TYROBP; UBE3A; UPF2; VAPB; VDAC3; XCR1; ZYX 
GO 
Cellular 
Compo
nent 
nucleoplas
m 
108 1672 AHR; ASF1B; ATF1; ATF2; ATF3; ATF6; BACH1; BCL3; BCL6; CBFB; CCM2; CCNH; CDK7; CPSF2; CPSF3; CSTF2; CSTF3; CTCF; DDB2; 
DR1; E2F1; EGR1; EGR2; FBL; FUS; FUSIP1; GTF2A1; GTF2B; GTF2E2; GTF2F2; GTF2H1; GTF2H2; GTF3C4; HCLS1; HDAC11; HDAC2; 
HDAC5; HELLS; HHEX; HIF1A; HIVEP1; HIVEP2; HNRPA3; HNRPK; ID2; ID3; KLF3; KPNA2; LMO2; LYL1; MCM4; MCM6; MEF2A; MEF2C; 
MITF; MKI67IP; MXI1; MYNN; NAP1L1; NFKB2; NFYA; NFYB; NUP54; PHTF2; PKNOX1; PLAGL2; POLD4; POLR2B; POLR2F; POLR2H; 
POLR3K; POU2AF1; PPP1CC; RAD54L; RASA1; RBBP4; RELB; REV3L; RNF103; RNF12; RNF6; ROD1; RREB1; RTCD1; RXRA; SAP30; 
SFPQ; SFRS2IP; SIRT2; SMARCA5; SMARCB1; SMARCC1; SNAPC3; SPIB; TAF13; TAF7; TAF9; TBPL1; TCF4; TDG; TFDP1; TTC3; UBP1; 
UBTF; XPO1; YAF2; YY1; ZFX 
GO 
Cellular 
cytosol 108 1672 ALDH1A2; ALDH9A1; ALS2; APAF1; ARFGAP3; ARHGEF7; BAG5; BID; BZW1; BZW2; CBR3; CCNA2; CCNB1; CCNB2; CCND1; CCND2; 
CCT3; DFFA; DFFB; DNAJB9; EGLN1; EIF4B; ENO2; FRAP1; GATM; GBP1; GBP2; GBP3; GOT1; GSN; GSPT1; IDH1; LCMT1; LCP1; 
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 XXVIII 
Compo
nent 
MAP3K8; MDH1; MTAP; MTHFS; NCF1; NPEPPS; NT5C2; NUCB2; NUTF2; OGT; PDCL; PFDN2; PFKFB3; PFKL; PFKP; PIK3C2A; PIK3CD; 
PLA2G4A; PLCE1; PLCG2; PLEKHA1; PLEKHA2; PPP2R1B; PSMA4; PSMA6; PSMA7; PSMB3; PSMB4; PSMB5; PSMB7; PSMB8; PSMB9; 
PSMC1; PSMC2; PSMC6; PSMD10; PSMD13; PSMD14; PSMD2; PSMD4; PSMD8; PSME3; RGS2; RGS3; RPL11; RPL13; RPL14; RPL30; 
RPL31; RPL5; RPS10; RPS13; RPS24; RPS6; RPS9; SEC23A; SERPINB9; SH3GLB1; SHMT1; SQSTM1; STMN1; STRN3; SYK; TAP2; 
TBCD; TPI1; TRIP12; TSG101; UCHL5; ULK1; UNC119; UXT; VPS35; ZAP70 
GO 
Cellular 
Compo
nent 
extracellu
lar 
97 1672 ADAM17; ADFP; AFP; AGL; APOE; APP; BRE; BTG2; C1QA; C1QB; C6; CASP8AP2; CCL22; CD163; CD5L; CNOT7; CNOT8; COL14A1; 
COL9A3; CRIM1; CRTAP; CST3; CXCL10; CXCL16; CXCL9; DKK3; DNASE1L1; DNASE1L3; EBI3; ERBB2IP; FGL2; FLT1; GLIPR1; GRN; 
GSN; HSBP1; IBSP; IFI30; IFNAR2; IGF1; IK; IL15; IL16; IL18; INSL3; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; KLK1; 
LGALS3; LGALS3BP; LPL; LTBP2; LYPLA3; MAP2K1; MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K7IP2; MAPKAP1; MATN2; MFAP3; 
MGEA5; MST1; NAB2; NUCB2; PDGFA; PDGFC; PLA2G7; PRDX4; PRRG2; PSAP; PTPLA; PVR; QPCT; RTN3; SERPINE2; SGCB; SLPI; 
SPINT1; SPINT2; SYT11; TGFB3; TGFBI; TGM2; TIMP2; TNFAIP2; TNFRSF1A; TOB2; VAMP3; VWF 
GO 
Cellular 
Compo
nent 
membrane 
fraction 
91 1672 ABCA3; ALCAM; ALDH3A2; ALDH3B1; ALOX5AP; ALS2; ARFRP1; ATP2A2; ATP5A1; ATP5C1; BCL2L11; BFAR; BID; CACNA1S; CACNB3; 
CD36; CD38; CD68; CERK; CHPT1; CLCN3; CPD; CRIM1; CYP8B1; CYSLTR1; ECE1; EPHX1; FMO5; GALNT3; GOLGA4; GP2; HIP1; 
HMGCR; HMOX1; HSD17B12; ICMT; IL15; ITM2B; JTB; KCNN4; LYPLA1; MAN1A2; MAN2A1; MGAT2; MGST1; NDUFAB1; NDUFB4; 
NDUFB7; NDUFC2; NDUFS4; NDUFS5; NDUFV1; NRP1; PEX13; PITPNM1; PLCE1; PLP2; PPAP2A; PPIF; PSCD2; PSEN1; RASGRP4; 
RGS19; SCAMP1; SCAMP2; SCARB2; SEC63; SEMA4F; SLC11A1; SLC12A2; SLC1A5; SLC30A5; SLC33A1; SLC35B1; SNAP23; SPINT1; 
SQLE; SSR3; STRN3; TAP1; TAP2; TAPBP; TGM1; TPST1; UCP2; UGT1A1; UGT1A10; UGT1A5; UGT1A9; VAMP3; VAMP8 
GO 
Cellular 
Compo
nent 
transcripti
on factor 
complex 
61 1672 AHR; ATF1; ATF2; ATF3; BACH1; BCL3; CBFB; CCM2; CCNH; CDK7; CTCF; E2F1; EGR1; EGR2; FUS; GTF2A1; GTF2B; GTF2E2; GTF2F2; 
GTF2H1; GTF2H2; GTF3C4; HDAC11; HDAC2; HDAC5; HHEX; HIF1A; HIVEP1; HIVEP2; ID2; ID3; KLF3; LMO2; LYL1; MITF; MXI1; MYNN; 
NFKB2; NFYA; NFYB; PHTF2; PKNOX1; PLAGL2; POLD4; POU2AF1; RELB; RXRA; SAP30; SFPQ; SNAPC3; SPIB; TAF13; TAF7; TAF9; 
TBPL1; TCF4; TFDP1; UBP1; UBTF; YY1; ZFX 
GO 
Cellular 
Compo
nent 
soluble 
fraction 
36 1672 ACP1; ANXA1; ARRB1; ASNA1; CXCL10; DUSP6; EPRS; GYG; HMGCS1; IARS; IK; INSL3; IPO7; KARS; MATK; MERTK; NARS; NCF1; 
NSMAF; PAFAH1B2; PAFAH1B3; PDE4B; PPP1R11; PPP2R1B; PPP2R4; PPP4R1; PPP4R1L; PTP4A1; PTPN2; PTPRE; QARS; RASGRP4; 
SPINT2; STMN3; UGCGL1; UNC119 
GO 
Cellular 
Compo
nent 
extrinsic to 
plasma 
membrane 
11 1672 ALCAM; ARRB1; GNA13; GNB2; GNB4; GNG10; GNG12; GNG2; NUMB; RGS19; TLE3 
Appendix 2 
 XXIX 
GO 
Cellular 
Compo
nent 
caspase 
complex 
7 1672 BIRC3; CASP2; CASP3; CASP6; CASP7; CASP9; CFLAR 
GO 
Biologi
cal 
Proces
s 
cell growth 
and/or 
maintenan
ce 
624 1702 ABCA3; ABCB7; ABCD1; ABCF1; ABCF3; ABL1; ACO1; ACP2; ADD1; ADD3; AFP; AHR; AIF1; AKAP9; ALS2; ANAPC11; ANLN; AP1G1; 
AP1GBP1; AP1S2; AP3B1; AP3D1; AP3M1; AP3S1; AP3S2; APC; APOE; APP; APPBP2; ARF1; ARF3; ARF4; ARFGAP3; ARHGAP12; 
ARHGAP6; ARHGAP9; ARL3; ARL6; ARPC5; ASF1B; ASNA1; ATM; ATOX1; ATP11A; ATP11B; ATP1B1; ATP2A2; ATP2C1; ATP5A1; 
ATP5C1; ATP5E; ATP6V0A2; ATP6V0B; ATP6V0D1; ATP6V1A; ATP6V1B2; ATP6V1C1; ATP6V1D; ATP6V1H; ATP7A; ATP8A1; ATRX; 
AXIN1; AXL; BAZ2A; BCL10; BCL3; BCL6; BCL9; BIRC5; BMI1; BRI3; BTG2; BUB1; BUB3; CACNA1S; CACNB3; CALM2; CAPZA1; CAPZA2; 
CAPZB; CBFA2T3; CBFB; CBL; CBX6; CCNA2; CCNB1; CCNB2; CCNC; CCND1; CCND2; CCNDBP1; CCNE2; CCNG1; CCNG2; CCNH; 
CCNI; CCNT2; CCT7; CD14; CD36; CD5; CD68; CD81; CD86; CD99L2; CDC16; CDC20; CDC25A; CDC25C; CDC37; CDC42; CDC6; 
CDK2AP1; CDK4; CDK5; CDK5RAP1; CDK7; CDK8; CDKN1A; CDYL; CENPA; CENPE; CENPF; CETN2; CHD1; CHD6; CHEK1; CHFR; 
CHPT1; CHRNB1; CKS1B; CKS2; CLASP1; CLCN3; CLIC4; CLK1; CLTA; CLTB; CLTC; COPG2; COPZ2; CPNE1; CPNE3; CRIM1; CRK; 
CROT; CRTAP; CSF1R; CSK; CSNK2A2; CSRP1; CSRP2; CTBP2; CTCF; CTNNBIP1; CUL1; CUL3; CUL4A; CUL4B; CXCL10; CXCL16; DBI; 
DBN1; DDX6; DEK; DLEU2; DLG3; DSCR3; DSTN; DTYMK; DUSP1; DUSP16; DUSP22; DUSP6; DUT; E2F1; ECT2; EHD1; EHD2; EHD4; 
EHHADH; EIF2AK4; EIF4G2; ELK3; EMD; ENSA; EPS15; EPS8; ERBB2IP; ETS2; ETV6; EVI2A; EVI2B; EVI5; EVL; EXTL2; EXTL3; EZH2; 
FABP5; FBL; FCGR2B; FEN1; FES; FLI1; FLNB; FLT1; FLT3; FRAP1; FSCN1; FTH1; FUS; FUSIP1; FXC1; FYCO1; GABARAPL1; 
GABARAPL2; GBA; GDI1; GDI2; GFPT1; GJA1; GLG1; GLRX2; GMNN; GNA13; GNAI3; GOLGA4; GPS1; GRN; GRPEL1; GSN; GSPT1; 
GTF2H1; H1F0; H2AFZ; H3F3B; HDAC11; HDAC2; HDAC5; HFE; HIST1H1C; HIST1H2AB; HIST1H2AC; HIST1H2AD; HIST1H2AE; 
HIST1H3D; HIST1H4A; HIST2H2AC; HIST3H2A; HK2; HNRPA3; HRB; HSPA1B; HUS1; ICMT; IFI44; IGF1; IGF2R; IL15; IL15RA; IL18; IL2RG; 
ILK; INCENP; IPO7; IRF5; ITPR1; ITPR2; ITSN1; ITSN2; JAG2; JAK2; JAK3; KATNA1; KCNJ10; KCNN4; KHDRBS1; KIF11; KIF1B; KIF1C; 
KIF20A; KIF23; KIF2C; KIF3B; KIF5B; KIT; KLHL2; KLHL5; KPNA1; KPNA2; KPNA3; KPNB1; LAMP3; LAPTM4A; LAPTM4B; LIG1; LIMD1; 
LIMK1; LMAN1; LMO2; LPL; LRMP; LTBP2; LY75; LY86; LYL1; LYN; LZTFL1; M6PR; MAD2L1; MAP2K6; MAP2K7; MAP3K7IP2; MAP3K8; 
MAPK1; MAPK13; MAPK6; MAPRE1; MAPRE2; MATK; MCL1; MCM2; MCM3; MCM4; MCM6; MDM2; MDM4; MERTK; MKI67; MKL1; MLH3; 
MRAS; MRC1; MRPL49; MTM1; MTPN; MTX2; MVP; MXI1; MYB; MYCL1; MYL6; MYO1C; MYO5A; MYO6; NAB2; NAP1L1; NCBP2; NDUFA9; 
NEDD4L; NEDD9; NEK9; NFIX; NFKB2; NFKBIE; NNT; NOLC1; NOTCH2; NRP1; NSF; NUBP1; NUCB2; NUDT4; NUP153; NUP50; NUP54; 
NUP62; NUPL1; NUTF2; ORC4L; OSBPL11; OSBPL9; P2RX4; PA2G4; PACSIN1; PCAF; PDAP1; PDGFA; PDGFC; PDPK1; PEX11A; PEX13; 
PEX3; PEX6; PEX7; PFN2; PITPNM1; PLCE1; PLDN; PLEC1; PLP2; PLSCR1; PLSCR3; PML; POLB; POLD4; POU2AF1; PPAP2A; PPAP2B; 
PPIH; PPP1CC; PPP2R1B; PPP3CB; PPP6C; PRC1; PRKRA; PRKRIR; PRNP; PSAP; PSCD2; PSEN1; PSMD8; PTEN; PTPN6; PTPN9; 
PTTG1IP; PURA; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; RAB32; RAB33B; RAB5A; RAB6B; RAB6IP1; RAB7; RABIF; 
RAC1; RAD17; RAD51; RAD51L1; RAD51L3; RAD54L; RAMP1; RANBP2; RANBP9; RAP1A; RAP1B; RASA1; RASGRP4; RB1; RBBP4; 
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RBBP6; RBBP8; RBL1; RBM5; RBMS1; RDX; REV3L; RFC1; RFC3; RFC4; RGS19; RGS2; ROCK1; ROCK2; RPA3; RPL13; RPL23; RPL5; 
RPS6KA2; RPS6KB2; RRAS2; RRBP1; RRM1; RRM2; RRS1; RUNX1; RYR1; SAP30; SCAMP1; SCAMP2; SCP2; SDCBP; SDCCAG3; 
SEC14L1; SEC23A; SEC24B; SEC24C; SEC24D; SEC63; SERPINF1; SFRS9; SFXN2; SHPRH; SIRT2; SKP2; SLC11A1; SLC12A2; SLC13A3; 
SLC14A1; SLC15A2; SLC1A5; SLC22A5; SLC25A11; SLC25A13; SLC25A14; SLC25A20; SLC25A5; SLC2A9; SLC30A4; SLC30A5; SLC30A7; 
SLC31A1; SLC31A2; SLC33A1; SLC35A1; SLC35A5; SLC35B1; SLC35E1; SLC37A3; SLC41A1; SLC4A1; SLC4A7; SLC6A6; SLC7A6; 
SLC7A7; SLC8A1; SMARCA5; SMARCB1; SMARCC1; SMARCE1; SNAP23; SNX10; SNX2; SNX3; SNX4; SNX5; SNX6; SOCS4; SOCS5; 
SRF; SRI; SRP14; SSFA2; SSR2; SSR4; STAM2; STARD3; STARD4; STARD5; STAT1; STMN1; STRN3; STX12; STX17; STX18; STX5A; 
STX6; STX7; STX8; SUPT4H1; SYK; SYNGR2; SYPL; SYT11; TACC3; TAP1; TAP2; TAPBP; TARDBP; TBC1D8; TBCD; TCF19; TCIRG1; 
TEP1; TFDP1; TGFB3; TGFBI; TGFBR2; THOC2; TIMM17B; TIMM22; TLK2; TM9SF2; TMEM1; TNFAIP1; TNFAIP2; TNFRSF9; TOB2; TOP1; 
TOP2A; TOP2B; TPR; TRAM1; TREX1; TRNT1; TRPM7; TRPV2; TSG101; TTK; TUBGCP5; TXNDC4; UBE2C; UBE2D1; UBE2D3; UBE2V1; 
UBE2V2; UCP2; USP4; USP8; VAMP3; VAMP8; VAPB; VAV1; VDAC1; VDAC3; VPS18; VPS35; VPS41; VPS4B; WASF2; WASL; XPO1; 
XPO7; XRN2; YWHAQ; ZFP36L1; ZFYVE16 
GO 
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Proces
s 
cell 
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cation 
447 1702 ABL1; ABR; ACVR1; ACVRL1; ADAM10; ADAM17; ADAM9; ADCY7; AHR; AIM1; AKAP9; ALCAM; ANP32A; ANXA1; AP3S1; APC; APOE; 
APP; ARF1; ARF3; ARF4; ARFRP1; ARHGAP5; ARHGAP6; ARHGEF7; ARL1; ARL3; ARL6; ARRB1; ASAH2; ASB13; ATF6; ATM; ATP2A2; 
AXIN1; AXL; BAIAP2; BCL3; BCL9; BIRC3; BRD8; BRE; BTK; C1QA; CABP4; CALCRL; CALM1; CALM2; CAMK1; CARD10; CARHSP1; CASK; 
CASP8AP2; CBL; CCL22; CCR5; CCR9; CD14; CD2AP; CD36; CD38; CD44; CD5; CD80; CD83; CD86; CD8A; CD9; CD96; CD97; CDC42; 
CENTD1; CENTD2; CERK; CFL2; CHN2; CHRNB1; CHUK; CLDN1; CNOT7; CNP; CNR2; CORO2A; CREM; CRK; CSF1R; CSF2RB; CSK; 
CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; CSNK2B; CTNNA1; CTNNBIP1; CXCL10; CXCL9; CXCR3; CYSLTR1; DAPK1; DAPK3; DAPP1; 
DBN1; DDR1; DEK; DFFA; DFFB; DGCR2; DKK3; DUSP16; DUSP22; DUSP6; DUSP7; ECE1; ECT2; ELK3; EMR1; ENSA; ENTPD1; EPS15; 
EPS8; ERBB2IP; EVL; FCGR2B; FES; FLNB; FLT1; FLT3; FNBP1; FNTA; FPR1; FXC1; FZD7; GABBR1; GADD45B; GADD45G; GALNT1; 
GCH1; GDI1; GDI2; GIT2; GJA1; GLRX2; GMFB; GNA13; GNAI3; GNB2; GNB4; GNG10; GNG12; GNG2; GPR124; GPR34; GPR35; GPR65; 
GPS1; GRN; GTF2I; GTPBP2; HABP4; HCK; HCLS1; HIF1A; HIVEP2; HOMER2; HRH2; IBSP; ICAM1; IFNAR1; IFNAR2; IFNGR2; IGF1; 
IGF2R; IK; IKBKG; IL10RA; IL13RA1; IL15; IL15RA; IL18; IL2RG; IL6ST; ILK; IMPA1; INPP1; INPP4A; INPP5D; INPPL1; INSL3; IPO7; IQGAP1; 
IRAK1; IRF7; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; ITPR1; ITPR2; JAG2; JAK1; JAK2; JAK3; KHDRBS1; KIF1B; KIT; 
KLRC1; LANCL2; LARGE; LGALS3; LGALS3BP; LIFR; LIMD1; LIMK1; LMAN1; LSP1; LTBP2; LY75; LY86; LY96; LYN; MADD; MAN1A2; 
MAP2K1; MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K3; MAP3K4; MAP3K7; MAP4K1; MAP4K3; MAP4K4; MAP4K5; MAPK1; MAPK13; 
MAPK14; MAPK6; MAPK8; MAPK9; MAPKAPK2; MAPRE2; MATK; MBP; MERTK; MFAP3; MFHAS1; MKLN1; MKNK1; MRAS; MRC1; MX1; 
MYD88; MYO9A; NCF1; NCOA1; NCOA3; NEDD9; NFAT5; NFKB1; NFKB2; NMI; NOTCH1; NOTCH2; NOTCH4; NR3C1; NRP1; NSMAF; 
NUDT4; OGT; OSTF1; P2RX4; P2RY6; PAK1; PAK2; PDAP1; PDCD6IP; PDCL; PDE1B; PDE4B; PDE8A; PDGFA; PDK1; PDK3; PDPK1; 
PELI1; PEX11A; PIAS1; PIK3C2A; PIK3CD; PLCE1; PLCG2; PLDN; PLEK; PLXNC1; PNN; PPAP2A; PPARG; PPFIA4; PPP2R1B; PPP2R2A; 
PPP2R5C; PPP3CB; PPP4R1; PPP4R1L; PRDX4; PRKCB1; PRKCD; PRKCH; PRKCI; PRKRA; PRKRIR; PRNP; PSCD2; PSEN1; PTGER1; 
PTGER2; PTGER4; PTPLA; PTPN11; PTPN6; PTPRE; PTPRJ; PTPRS; PXN; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; 
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RAB32; RAB33B; RAB5A; RAB6B; RAB7; RAC1; RALA; RALB; RAMP1; RAP1A; RAP1B; RAP2A; RASA1; RASGRP4; RASSF3; RASSF5; 
RGS10; RGS18; RGS19; RGS2; RGS3; RNF14; ROCK1; ROCK2; RPS6KA2; RPS6KB1; RPS6KB2; RPS6KC1; RRAS2; RRBP1; RREB1; 
RTN1; RXRA; SCARB1; SCARB2; SDCBP; SEMA4D; SEMA4F; SHOC2; SIAH2; SLA; SLC9A3R2; SNX10; SNX2; SNX3; SNX4; SNX5; SNX6; 
SOCS4; SOCS5; SQSTM1; SRF; SRI; STAT1; STAT3; STAT5A; STAT6; STK17B; STK3; STMN1; STMN3; SULT1A1; SYK; SYPL; TANK; 
TBK1; TCF7; TCF7L2; TEC; TGFB3; TGFBI; TGFBR1; TGFBR2; TGM2; TIAM1; TLE3; TLK2; TLR1; TLR3; TLR4; TMEM8; TNFAIP2; 
TNFRSF1A; TNFRSF21; TRAF3; TRAF5; TRIM37; TRIO; TULP3; TXK; TXNRD1; TYK2; TYROBP; ULK1; UNC119; VAV1; VAV3; VCAM1; 
VCL; VWF; WASF2; XCR1; YWHAB; YWHAE; YWHAQ; YWHAZ; ZAP70; ZFYVE16; ZFYVE21; ZYX 
GO 
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392 1702 ABL1; ABR; ACVR1; ACVRL1; ADAM9; ADCY7; AHR; AKAP9; ALCAM; ANP32A; ANXA1; AP3S1; APC; APP; ARF1; ARF3; ARF4; ARFRP1; 
ARHGAP5; ARHGAP6; ARHGEF7; ARL1; ARL3; ARL6; ARRB1; ASAH2; ASB13; ATF6; ATM; AXIN1; AXL; BAIAP2; BCL3; BCL9; BIRC3; 
BRD8; BRE; BTK; CABP4; CALCRL; CALM1; CALM2; CAMK1; CARD10; CARHSP1; CASP8AP2; CBL; CCL22; CCR5; CCR9; CD14; CD2AP; 
CD38; CD80; CD83; CD8A; CD97; CDC42; CENTD1; CENTD2; CERK; CFL2; CHN2; CHRNB1; CHUK; CNOT7; CNR2; CORO2A; CREM; 
CRK; CSF1R; CSF2RB; CSK; CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; CSNK2B; CTNNBIP1; CXCL10; CXCL9; CXCR3; CYSLTR1; 
DAPK1; DAPK3; DAPP1; DBN1; DDR1; DEK; DFFA; DFFB; DKK3; DUSP16; DUSP22; DUSP6; DUSP7; ECT2; ELK3; EMR1; EPS15; EPS8; 
ERBB2IP; EVL; FCGR2B; FES; FLNB; FLT1; FLT3; FNBP1; FNTA; FPR1; FZD7; GABBR1; GADD45B; GADD45G; GDI1; GDI2; GIT2; GLRX2; 
GMFB; GNA13; GNAI3; GNB2; GNB4; GNG10; GNG12; GNG2; GPR124; GPR34; GPR35; GPR65; GPS1; GRN; GTF2I; GTPBP2; HABP4; 
HCK; HCLS1; HIF1A; HIVEP2; HOMER2; HRH2; IFNAR1; IFNAR2; IFNGR2; IGF1; IGF2R; IKBKG; IL10RA; IL13RA1; IL15; IL15RA; IL2RG; 
IL6ST; ILK; IMPA1; INPP1; INPP4A; INPP5D; INPPL1; IPO7; IQGAP1; IRAK1; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; 
ITPR1; ITPR2; JAG2; JAK1; JAK2; JAK3; KHDRBS1; KIT; KLRC1; LANCL2; LGALS3BP; LIFR; LIMD1; LIMK1; LSP1; LTBP2; LY86; LY96; 
LYN; MADD; MAN1A2; MAP2K1; MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K3; MAP3K4; MAP3K7; MAP4K1; MAP4K3; MAP4K4; 
MAP4K5; MAPK1; MAPK13; MAPK14; MAPK6; MAPK8; MAPK9; MAPKAPK2; MAPRE2; MATK; MERTK; MFAP3; MFHAS1; MKLN1; MKNK1; 
MRAS; MX1; MYD88; MYO9A; NCF1; NCOA1; NCOA3; NEDD9; NFAT5; NFKB1; NFKB2; NMI; NOTCH1; NOTCH2; NOTCH4; NR3C1; NRP1; 
NSMAF; NUDT4; OGT; OSTF1; P2RX4; P2RY6; PAK1; PAK2; PDAP1; PDCD6IP; PDCL; PDE1B; PDE4B; PDE8A; PDGFA; PDK1; PDK3; 
PDPK1; PELI1; PEX11A; PIAS1; PIK3C2A; PIK3CD; PLCE1; PLCG2; PLEK; PPAP2A; PPARG; PPP2R1B; PPP2R2A; PPP2R5C; PPP3CB; 
PPP4R1; PPP4R1L; PRDX4; PRKCB1; PRKCD; PRKCH; PRKCI; PRKRA; PRKRIR; PRNP; PSCD2; PSEN1; PTGER1; PTGER2; PTGER4; 
PTPLA; PTPN11; PTPN6; PTPRE; PTPRJ; PXN; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; RAB32; RAB33B; RAB5A; 
RAB6B; RAB7; RAC1; RALA; RALB; RAMP1; RAP1A; RAP1B; RAP2A; RASA1; RASGRP4; RASSF3; RASSF5; RGS10; RGS18; RGS19; 
RGS2; RGS3; RNF14; ROCK1; ROCK2; RPS6KA2; RPS6KB1; RPS6KB2; RPS6KC1; RRAS2; RRBP1; RREB1; RTN1; RXRA; SDCBP; 
SHOC2; SIAH2; SLA; SLC9A3R2; SNX10; SNX2; SNX3; SNX4; SNX5; SNX6; SOCS4; SOCS5; SQSTM1; SRF; SRI; STAT1; STAT3; STAT5A; 
STAT6; STK17B; STK3; STMN1; STMN3; SYK; TANK; TBK1; TCF7; TCF7L2; TEC; TGFB3; TGFBR1; TGFBR2; TGM2; TIAM1; TLE3; TLK2; 
TLR1; TLR3; TLR4; TNFRSF1A; TNFRSF21; TRAF3; TRAF5; TRIM37; TRIO; TULP3; TXK; TXNRD1; TYK2; TYROBP; ULK1; VAV1; VAV3; 
WASF2; XCR1; YWHAB; YWHAE; YWHAQ; YWHAZ; ZAP70; ZFYVE16; ZFYVE21; ZYX 
GO transcripti 265 1702 ABL1; ADNP; AHR; AP3D1; ARHGAP6; ASF1B; ASXL1; ATF1; ATF2; ATF3; ATF6; ATF7IP; ATRX; BACH1; BAD; BASP1; BAZ1B; BAZ2A; 
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on BAZ2B; BBX; BCL11A; BCL11B; BCL3; BCL6; BMI1; BRD8; CARHSP1; CBFA2T3; CBFB; CBX6; CCNC; CCNH; CCNT2; CD80; CD86; CDK7; 
CDK8; CEBPG; CHD1; CITED2; CNOT2; CNOT7; CNOT8; CRAMP1L; CREB3; CREM; CRK; CTCF; CTDP1; CTNNBIP1; CTNNBL1; DEK; 
DMTF1; DNMT3A; DR1; DRG1; E2F1; EED; EGR1; EGR2; ELF1; ELK3; EPC1; ETS2; ETV3; ETV6; EZH2; FBXO3; FKBP1A; FKBP1B; FLI1; 
FNBP1; FUBP1; FUSIP1; FXR1; GABPA; GABPB1; GLRX2; GSPT1; GTF2A1; GTF2B; GTF2E2; GTF2F2; GTF2H1; GTF2H2; GTF2I; GTF3C4; 
H1F0; HABP4; HCLS1; HDAC11; HDAC2; HDAC5; HHEX; HIF1A; HIST1H1C; HIVEP1; HIVEP2; HMGB3; HMGN3; HSBP1; IKBKG; IRAK1; 
IRF3; IRF4; IRF5; IRF6; IRF7; KLF3; LIMD1; LITAF; LRRFIP1; LYL1; MAFB; MBP; MCM2; MCM3; MCM4; MCM6; MEF2A; MEF2C; MFHAS1; 
MITF; MKI67IP; MKL1; MNDA; MRPS25; MXI1; MYB; MYCBP; MYCL1; MYD88; MYNN; NAB2; NAP1L1; NCOA1; NCOA3; NFAT5; NFATC1; 
NFIX; NFKB1; NFKB2; NFYA; NFYB; NMI; NOTCH1; NOTCH2; NOTCH4; NR2C2; NR3C1; PAPOLG; PCAF; PCNXL3; PDCD7; PDGFA; 
PHF10; PKNOX1; PLAGL2; PML; POLR2B; POLR2F; POLR2H; POLR3K; POU2AF1; PPARG; PPP2R1B; PPP3CB; PREB; PRKCBP1; PRNP; 
PRPF4B; PRRG2; PURA; PXN; RAD51L1; RB1; RBBP8; RBL1; RBMX; RELB; RERE; RFC1; RFX5; RFXAP; RNF12; RNF14; RREB1; RRS1; 
RUNX1; RUVBL1; RXRA; SALL2; SF1; SFRS1; SFRS11; SFRS3; SFRS9; SHPRH; SIN3B; SIRT2; SMARCA5; SMARCB1; SMARCC1; 
SMARCE1; SNAPC3; SNRPD1; SP100; SPIB; SREBF2; SRF; SRRM1; SSB; SSBP3; SSX2IP; STAT1; STAT3; STAT5A; STAT6; SUPT4H1; 
TAF13; TAF1B; TAF7; TAF9; TARDBP; TBPL1; TCEA1; TCEB1; TCEB3; TCERG1; TCF19; TCF4; TCF7; TCF7L2; TFDP1; TFPT; TGFBR2; 
TIAL1; TJP2; TLE3; TOP2B; TRIM33; TRIP13; TTF1; TULP3; UBE2V1; UBP1; UBTF; UBXD2; UGP2; UHRF1; VPS4B; XBP1; YAF2; YME1L1; 
YY1; ZBTB1; ZBTB2; ZDHHC14; ZDHHC2; ZDHHC3; ZDHHC6; ZDHHC9; ZFP161; ZFX; ZNRD1 
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241 1702 ABL1; ADNP; AHR; AP3D1; ARHGAP6; ASF1B; ASXL1; ATF1; ATF2; ATF3; ATF6; ATF7IP; ATRX; BACH1; BAD; BASP1; BAZ1B; BAZ2A; 
BAZ2B; BBX; BCL11A; BCL11B; BCL3; BCL6; BMI1; BRD8; CARHSP1; CBFA2T3; CBX6; CCNC; CCNH; CCNT2; CD80; CD86; CDK7; CDK8; 
CEBPG; CHD1; CITED2; CNOT2; CNOT7; CNOT8; CRAMP1L; CREB3; CREM; CRK; CTCF; CTNNBIP1; CTNNBL1; DEK; DMTF1; DNMT3A; 
DR1; E2F1; EED; EGR1; EGR2; ELF1; ELK3; ETS2; ETV3; ETV6; EZH2; FKBP1A; FKBP1B; FLI1; FNBP1; FUBP1; FUSIP1; FXR1; GABPA; 
GABPB1; GLRX2; GSPT1; GTF2A1; GTF2B; GTF2E2; GTF2F2; GTF2H1; GTF2H2; GTF2I; H1F0; HABP4; HCLS1; HDAC11; HDAC2; HDAC5; 
HHEX; HIF1A; HIST1H1C; HIVEP1; HIVEP2; HMGB3; HSBP1; IKBKG; IRAK1; IRF3; IRF4; IRF5; IRF6; IRF7; KLF3; LIMD1; LITAF; LRRFIP1; 
LYL1; MAFB; MBP; MCM2; MCM3; MCM4; MCM6; MEF2A; MEF2C; MFHAS1; MITF; MKL1; MNDA; MRPS25; MXI1; MYB; MYCBP; MYCL1; 
MYD88; NAB2; NCOA3; NFAT5; NFATC1; NFIX; NFKB1; NFKB2; NFYA; NFYB; NOTCH1; NOTCH2; NOTCH4; NR2C2; NR3C1; PCAF; 
PCNXL3; PDCD7; PDGFA; PHF10; PKNOX1; PLAGL2; PML; POLR3K; POU2AF1; PPARG; PPP2R1B; PREB; PRKCBP1; PRNP; PRPF4B; 
PRRG2; PURA; PXN; RB1; RBBP8; RBL1; RBMX; RELB; RERE; RFC1; RFX5; RNF12; RNF14; RREB1; RRS1; RUNX1; RUVBL1; RXRA; 
SALL2; SF1; SFRS1; SFRS11; SFRS3; SFRS9; SHPRH; SIN3B; SIRT2; SMARCA5; SMARCB1; SMARCC1; SMARCE1; SNAPC3; SNRPD1; 
SP100; SPIB; SREBF2; SRF; SRRM1; SSBP3; SSX2IP; STAT1; STAT3; STAT5A; STAT6; SUPT4H1; TAF13; TAF7; TAF9; TARDBP; TBPL1; 
TCEA1; TCEB1; TCEB3; TCF19; TCF4; TCF7; TCF7L2; TFDP1; TFPT; TGFBR2; TIAL1; TJP2; TLE3; TOP2B; TRIM33; TULP3; UBE2V1; 
UBP1; UBTF; UBXD2; UGP2; UHRF1; VPS4B; XBP1; YAF2; YME1L1; YY1; ZBTB1; ZBTB2; ZDHHC14; ZDHHC2; ZDHHC3; ZDHHC6; 
ZDHHC9; ZFP161; ZFX; ZNRD1 
GO 
Biologi
cell 
proliferatio
237 1702 ABL1; ACP2; AHR; AIF1; ANAPC11; ANLN; APC; ATM; AXIN1; AXL; BCL10; BCL3; BCL6; BIRC5; BTG2; BUB1; BUB3; CALM2; CBFA2T3; 
CCNA2; CCNB1; CCNB2; CCNC; CCND1; CCND2; CCNE2; CCNG1; CCNG2; CCNH; CCNI; CCNT2; CCT7; CD5; CD68; CD81; CD86; 
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cal 
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n CD99L2; CDC16; CDC20; CDC25A; CDC25C; CDC37; CDC6; CDK2AP1; CDK4; CDK5; CDK5RAP1; CDK7; CDK8; CDKN1A; CENPE; 
CENPF; CETN2; CHEK1; CHFR; CKS1B; CKS2; CLK1; CRK; CRTAP; CSF1R; CSK; CSNK2A2; CSRP2; CTBP2; CTCF; CTNNBIP1; CUL1; 
CUL3; CUL4A; CUL4B; CXCL10; DLEU2; DLG3; DTYMK; DUSP1; DUSP22; DUSP6; DUT; E2F1; EIF2AK4; EIF4G2; ELK3; EPS15; EPS8; 
ERBB2IP; ETS2; EVI2A; EVI5; FEN1; FES; FLT1; FLT3; FRAP1; FSCN1; FTH1; GMNN; GPS1; GRN; GSPT1; GTF2H1; HDAC5; HK2; 
HSPA1B; HUS1; IGF1; IL15; IL15RA; IL18; IL2RG; ILK; INCENP; JAG2; JAK2; KATNA1; KHDRBS1; KIF11; KIF23; KIF2C; KPNA2; LAMP3; 
LIG1; LTBP2; LY86; LYN; MAD2L1; MAP2K6; MAP2K7; MAP3K8; MAPK1; MAPK13; MAPK6; MAPRE1; MAPRE2; MATK; MCM2; MCM3; 
MCM4; MCM6; MDM2; MDM4; MKI67; MLH3; MVP; MXI1; MYB; NAB2; NAP1L1; NEDD9; NEK9; NFIX; NOLC1; NOTCH2; NRP1; NUBP1; 
ORC4L; PA2G4; PCAF; PDAP1; PDGFA; PLCE1; POLB; POLD4; PPAP2A; PPP1CC; PPP2R1B; PPP3CB; PPP6C; PRC1; PRKRA; PRKRIR; 
PSEN1; PSMD8; PTEN; PTPN6; PURA; RAB6IP1; RAC1; RAD17; RAD51; RAD51L1; RAD51L3; RAD54L; RAP1A; RAP1B; RASGRP4; RB1; 
RBBP4; RBBP6; RBBP8; RBL1; RBM5; RBMS1; REV3L; RFC1; RFC3; RFC4; RGS2; ROCK2; RPA3; RPS6KB2; RRM1; RRM2; SAP30; 
SERPINF1; SIRT2; SKP2; SMARCB1; STAT1; STRN3; SYK; TARDBP; TBC1D8; TCF19; TCIRG1; TEP1; TFDP1; TGFB3; TGFBI; TGFBR2; 
TLK2; TNFRSF9; TOB2; TOP1; TOP2A; TOP2B; TREX1; TTK; UBE2C; UBE2D1; UBE2D3; UBE2V1; UBE2V2; USP8; VAV1; YWHAQ; 
ZFP36L1 
GO 
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dependent 
234 1702 ABL1; ADNP; AHR; AP3D1; ARHGAP6; ASF1B; ASXL1; ATF1; ATF2; ATF3; ATF6; ATF7IP; ATRX; BACH1; BAD; BASP1; BAZ1B; BAZ2A; 
BAZ2B; BBX; BCL11A; BCL11B; BCL3; BCL6; BMI1; BRD8; CARHSP1; CBFA2T3; CBX6; CCNC; CCNH; CCNT2; CDK7; CDK8; CEBPG; 
CHD1; CITED2; CNOT2; CNOT7; CNOT8; CRAMP1L; CREB3; CREM; CRK; CTCF; CTNNBIP1; CTNNBL1; DEK; DMTF1; DNMT3A; DR1; 
E2F1; EGR1; EGR2; ELF1; ELK3; ETS2; ETV3; ETV6; EZH2; FKBP1A; FKBP1B; FLI1; FNBP1; FUBP1; FXR1; GABPA; GABPB1; GSPT1; 
GTF2A1; GTF2B; GTF2E2; GTF2F2; GTF2H1; GTF2H2; GTF2I; H1F0; HABP4; HCLS1; HDAC11; HDAC2; HDAC5; HHEX; HIF1A; HIST1H1C; 
HIVEP1; HIVEP2; HMGB3; HSBP1; IKBKG; IRF3; IRF4; IRF5; IRF6; IRF7; KLF3; LIMD1; LITAF; LRRFIP1; LYL1; MAFB; MBP; MCM2; MCM3; 
MCM4; MCM6; MEF2A; MEF2C; MFHAS1; MITF; MKL1; MNDA; MRPS25; MXI1; MYB; MYCBP; MYCL1; MYD88; NAB2; NCOA3; NFAT5; 
NFATC1; NFIX; NFKB1; NFKB2; NFYA; NFYB; NOTCH1; NOTCH2; NOTCH4; NR2C2; NR3C1; PCAF; PCNXL3; PDCD7; PDGFA; PHF10; 
PKNOX1; PLAGL2; PML; POLR3K; POU2AF1; PPARG; PREB; PRKCBP1; PRNP; PRPF4B; PRRG2; PURA; PXN; RB1; RBBP8; RBL1; RBMX; 
RELB; RERE; RFC1; RFX5; RNF12; RNF14; RREB1; RRS1; RUNX1; RUVBL1; RXRA; SALL2; SF1; SFRS1; SFRS11; SFRS3; SFRS9; 
SHPRH; SIN3B; SIRT2; SMARCA5; SMARCB1; SMARCC1; SMARCE1; SNAPC3; SNRPD1; SP100; SPIB; SREBF2; SRF; SRRM1; SSBP3; 
SSX2IP; STAT1; STAT3; STAT5A; STAT6; SUPT4H1; TAF13; TAF7; TAF9; TARDBP; TBPL1; TCEA1; TCEB1; TCEB3; TCF19; TCF4; TCF7; 
TCF7L2; TFDP1; TFPT; TGFBR2; TIAL1; TJP2; TLE3; TOP2B; TRIM33; TULP3; UBE2V1; UBP1; UBTF; UBXD2; UGP2; UHRF1; VPS4B; 
XBP1; YAF2; YME1L1; YY1; ZBTB1; ZBTB2; ZDHHC14; ZDHHC2; ZDHHC3; ZDHHC6; ZDHHC9; ZFP161; ZFX; ZNRD1 
GO 
Biologi
cal 
Proces
developm
ent 
200 1702 ADAM23; ALAD; ALDH3A2; ANPEP; AP3D1; APAF1; APOE; ARIH2; ASF1B; ATF7IP; ATP2A2; ATP2C1; ATRX; AXIN1; BAIAP2; BMI1; BST1; 
BTK; CCNI; CD80; CD86; CDK5; CDK5RAP1; CDYL; CHEK1; CHUK; CLN8; CRAMP1L; CRIM1; CRLF3; CRYAB; CSF1R; CSF2RA; 
CSNK2A2; CSRP2; CTNNBIP1; CUGBP2; CXCL10; DBN1; DFFA; DFFB; DGCR2; DICER1; DKK3; DNMT3A; DRG1; DUSP22; DYRK1A; EBP; 
EGR2; ELAVL1; EMD; ETS2; EVI5; EVL; FABP5; FECH; FES; FLI1; FLII; FLNB; FLT1; FZD7; GADD45B; GADD45G; GJA1; GLRX2; GMFB; 
GNA13; GNPAT; GPX4; GYPC; HCCS; HCK; HDAC5; HELLS; HHEX; HMBS; HMGB3; HMGCR; HMOX1; IBSP; ID2; ID3; IGF1; IL18; INSL3; 
Appendix 2 
 XXXIV 
s IRF4; ITGAX; ITGB1; ITGB2; ITM2B; JAG2; JAK2; JAK3; KHDRBS3; KIF1B; KIF3B; KLF3; KRT17; LARGE; LIG1; LIMD1; LIMK1; LIMS1; 
LMO2; LRMP; LRRC1; MAFB; MAP4K1; MAPK14; MATK; MBNL3; MBP; MCL1; MEF2A; MEF2C; MITF; MRAS; MTM1; MTPN; MYD88; MYL6; 
MYOM1; NAB2; NAGLU; NDRG1; NDUFB7; NOTCH1; NOTCH2; NOTCH4; NR2C2; NRP1; NUMB; OLFM1; OSTF1; PAFAH1B3; PAPSS1; 
PCNXL3; PDGFC; PES1; PHYH; PITPNM1; PLCE1; PLXNB2; PLXNC1; PPAP2A; PPAP2B; PPAP2C; PPP2R1B; PPT1; PTEN; PTPLA; 
PTTG1IP; RAC1; RASGRP4; RNF103; ROD1; RREB1; RTN1; RTN3; RTN4; RUNX1; RUVBL1; SACM1L; SCMH1; SEMA4D; SEMA4F; 
SERPINF1; SGCB; SIAH2; SIRT2; SNCA; SOCS5; SRI; STAT3; STMN3; STRBP; SYK; TCF4; TGFB3; TLE3; TLR3; TLR4; TNFAIP2; TNNI2; 
TOB2; TOP2B; TPD52; TPM1; TPM2; TPM3; TPM4; TRIM3; UBE2V1; UBE3A; UFD1L; USP9X; XRN2; YAF2 
GO 
Biologi
cal 
Proces
s 
intracellula
r signaling 
cascade 
180 1702 ABL1; ABR; ADAM9; ADCY7; ANP32A; ARF1; ARF3; ARF4; ARFRP1; ARHGAP5; ARHGAP6; ARL1; ARL3; ARL6; ASB13; BCL3; BTK; 
CALCRL; CALM2; CARD10; CARHSP1; CD80; CDC42; CFL2; CHN2; CHUK; CNR2; CORO2A; CRK; CSK; DAPK1; DAPK3; DAPP1; DBN1; 
DFFA; DFFB; DUSP16; DUSP22; DUSP6; DUSP7; ECT2; FES; FPR1; GABBR1; GADD45B; GADD45G; GDI2; GNA13; GNAI3; GPS1; 
GTPBP2; HCK; HCLS1; HRH2; IFNAR1; IFNAR2; IGF1; IKBKG; INPP5D; INPPL1; IQGAP1; IRAK1; JAK1; JAK2; JAK3; KHDRBS1; LIMK1; 
LYN; MAP2K4; MAP3K3; MAP3K4; MAP4K1; MAP4K3; MAP4K4; MAP4K5; MAPK13; MAPK14; MAPK8; MAPK9; MAPKAPK2; MATK; 
MFHAS1; MKNK1; MRAS; MYO9A; NCF1; NMI; NOTCH2; NUDT4; PAK1; PDK1; PIAS1; PIK3C2A; PLCE1; PLCG2; PLEK; PPAP2A; 
PPP2R1B; PRDX4; PRKCB1; PRKCD; PRKCH; PRKCI; PSEN1; PTGER4; PTPN11; PTPN6; RAB10; RAB11A; RAB14; RAB24; RAB2B; 
RAB30; RAB31; RAB32; RAB33B; RAB5A; RAB6B; RAB7; RAC1; RALA; RALB; RAP1A; RAP1B; RAP2A; RASA1; RASGRP4; RASSF5; 
RGS19; RGS3; RNF14; ROCK1; ROCK2; RPS6KA2; RPS6KC1; RRAS2; RREB1; SDCBP; SHOC2; SIAH2; SLA; SLC9A3R2; SNX10; SNX2; 
SNX3; SNX4; SNX5; SNX6; SOCS4; SOCS5; SRI; STAT1; STAT3; STAT5A; STAT6; STK17B; STMN1; STMN3; SYK; TBK1; TEC; TGM2; 
TIAM1; TLK2; TLR1; TLR3; TLR4; TXK; TYK2; TYROBP; VAV1; VAV3; WASF2; XCR1; YWHAB; YWHAE; YWHAQ; YWHAZ; ZAP70; ZFYVE21 
GO 
Biologi
cal 
Proces
s 
cell cycle 179 1702 ABL1; ACP2; AHR; AIF1; ANAPC11; ANLN; APC; ATM; AXIN1; AXL; BCL10; BCL3; BIRC5; BUB1; BUB3; CALM2; CCNA2; CCNB1; CCNB2; 
CCNC; CCND1; CCND2; CCNE2; CCNG1; CCNG2; CCNH; CCNI; CCNT2; CCT7; CD99L2; CDC16; CDC20; CDC25A; CDC25C; CDC37; 
CDC6; CDK2AP1; CDK4; CDK5; CDK5RAP1; CDK7; CDK8; CDKN1A; CENPE; CENPF; CETN2; CHEK1; CHFR; CKS1B; CKS2; CLK1; CRK; 
CRTAP; CSK; CSNK2A2; CTCF; CUL1; CUL3; CUL4A; CUL4B; DLEU2; DTYMK; DUSP1; DUSP6; DUT; E2F1; EIF2AK4; EIF4G2; ELK3; 
ERBB2IP; ETS2; FEN1; FRAP1; GMNN; GPS1; GSPT1; GTF2H1; HDAC5; HK2; HUS1; IGF1; INCENP; JAG2; JAK2; KATNA1; KHDRBS1; 
KIF11; KIF23; KIF2C; KPNA2; LIG1; LTBP2; LYN; MAD2L1; MAP2K6; MAP2K7; MAP3K8; MAPK1; MAPK13; MAPK6; MAPRE1; MATK; MCM2; 
MCM3; MCM4; MCM6; MKI67; MLH3; MVP; MYB; NAP1L1; NEDD9; NEK9; NFIX; NOLC1; NOTCH2; ORC4L; PA2G4; PCAF; PDGFA; POLB; 
POLD4; PPP2R1B; PPP3CB; PPP6C; PRC1; PSEN1; PSMD8; PTEN; PURA; RAB6IP1; RAD17; RAD51; RAD51L1; RAD51L3; RAD54L; 
RAP1A; RAP1B; RB1; RBBP4; RBBP6; RBBP8; RBL1; RBM5; RBMS1; REV3L; RFC1; RFC3; RFC4; RGS2; RPA3; RPS6KB2; RRM1; RRM2; 
SAP30; SIRT2; SKP2; SMARCB1; STAT1; STRN3; TARDBP; TCF19; TEP1; TFDP1; TGFB3; TLK2; TOB2; TOP1; TOP2A; TOP2B; TREX1; 
TTK; UBE2C; UBE2D1; UBE2D3; UBE2V1; UBE2V2; VAV1; YWHAQ 
GO 
Biologi
defense 
response 
134 1702 ABCF1; ADA; ADAR; AFP; AIF1; ALCAM; ALOX5AP; ANXA1; APAF1; APOE; ATP6V0A2; BCL6; BECN1; BMI1; BST1; C1QA; C1QB; C6; 
CCL22; CCR5; CCR9; CD14; CD48; CD5L; CD74; CD80; CD81; CD83; CD86; CD8A; CD96; CD97; CHUK; CNR2; CSF1R; CSF2RB; CTSC; 
CTSS; CXCL10; CXCL16; CXCL9; CXCR3; CYSLTR1; DPP4; DPP8; EBI3; ENTPD1; FCGR2B; FCGRT; FPR1; FTH1; GBP1; GBP2; GBP3; 
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 XXXV 
cal 
Proces
s 
GZMA; HDAC5; HFE; HHEX; HRH2; HSPA1B; ICOS; IFI30; IFI35; IFIT1; IFIT2; IFITM3; IK; IKBKG; IL15; IL16; IL18; IL2RG; IL6ST; IRAK1; 
IRF4; IRF7; ITGB1; ITGB2; JAG2; KCNN4; KLRC1; LGALS3; LGALS3BP; LILRB3; LSP1; LST1; LY75; LY86; LY96; MAPK13; MAPK14; 
MAPRE2; MBP; MGLL; MNDA; MS4A1; MX1; MYD88; NCF1; NFKB1; NMI; NOTCH1; NR3C1; PLA2G7; POU2AF1; PRKRA; PROCR; PSMB8; 
PSMB9; PTGER4; RAC1; SAMHD1; SEMA4D; SOCS4; SOCS5; STAT3; STAT5A; TACSTD1; TAP1; TAP2; TAPBP; TCF7; TCIRG1; TLR1; 
TLR2; TLR3; TLR4; TNFRSF9; TPST1; TYROBP; XBP1; XCR1; YY1; ZAP70 
GO 
Biologi
cal 
Proces
s 
cell 
surface 
receptor 
linked 
signal 
transducti
on 
131 1702 ACVR1; ACVRL1; ANXA1; AP3S1; APC; ARL3; AXIN1; BAIAP2; BCL9; BIRC3; BRD8; CALCRL; CALM1; CALM2; CBL; CCR5; CCR9; CD14; 
CD8A; CD97; CENTD1; CENTD2; CERK; CNR2; CSF1R; CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; CTNNBIP1; CXCL10; CXCL9; CXCR3; 
CYSLTR1; DDR1; DKK3; EMR1; EPS15; EPS8; ERBB2IP; EVL; FLT1; FLT3; FNTA; FPR1; FZD7; GABBR1; GIT2; GNA13; GNAI3; GNB2; 
GNB4; GNG10; GNG12; GNG2; GPR124; GPR34; GPR35; GPR65; HOMER2; HRH2; IFNAR1; IFNAR2; IFNGR2; IL10RA; IL13RA1; IL6ST; 
ILK; IRAK1; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; JAG2; KIT; KLRC1; LANCL2; LIFR; LTBP2; LY96; MADD; MAP3K7; 
MAPK14; MERTK; MYD88; MYO9A; NEDD9; NOTCH2; NOTCH4; P2RY6; PDGFA; PDPK1; PLCE1; PLCG2; PPAP2A; PPP2R1B; PTGER1; 
PTGER2; PTGER4; PTPN6; PTPRE; PTPRJ; PXN; RAMP1; RASGRP4; RASSF3; RASSF5; RGS19; RGS2; RGS3; SHOC2; SNX6; SOCS5; 
SQSTM1; SYK; TCF7; TCF7L2; TGFBR1; TGFBR2; TGM2; TLE3; TRIM37; TRIO; TULP3; WASF2; XCR1; ZFYVE16 
GO 
Biologi
cal 
Proces
s 
immune 
response 
126 1702 ABCF1; ADA; ADAR; AFP; AIF1; ALCAM; ALOX5AP; ANXA1; APOE; ATP6V0A2; BCL6; BECN1; BMI1; BST1; C1QA; C1QB; C6; CCL22; 
CCR5; CCR9; CD14; CD5L; CD74; CD80; CD83; CD86; CD8A; CD96; CD97; CHUK; CNR2; CSF1R; CSF2RB; CTSC; CTSS; CXCL10; 
CXCL16; CXCL9; CXCR3; DPP4; DPP8; EBI3; ENTPD1; FCGR2B; FCGRT; FPR1; FTH1; GBP1; GBP2; GBP3; GZMA; HDAC5; HFE; HHEX; 
HRH2; HSPA1B; ICOS; IFI30; IFI35; IFIT1; IFIT2; IFITM3; IK; IKBKG; IL15; IL16; IL18; IL2RG; IL6ST; IRF4; IRF7; ITGB1; ITGB2; JAG2; 
KLRC1; LGALS3; LGALS3BP; LILRB3; LSP1; LST1; LY75; LY86; LY96; MAPK13; MAPK14; MAPRE2; MBP; MGLL; MNDA; MS4A1; MX1; 
MYD88; NCF1; NFKB1; NMI; NOTCH1; NR3C1; PLA2G7; POU2AF1; PRKRA; PROCR; PSMB8; PSMB9; PTGER4; RAC1; SAMHD1; 
SEMA4D; SOCS5; STAT3; STAT5A; TAP1; TAP2; TAPBP; TCF7; TCIRG1; TLR1; TLR2; TLR3; TLR4; TNFRSF9; TPST1; TYROBP; XBP1; 
XCR1; YY1; ZAP70 
GO 
Biologi
cal 
Proces
s 
phosphory
lation 
123 1702 ABL1; ACVR1; ACVRL1; AXL; BTK; BUB1; CAMK1; CASK; CD80; CDK2AP1; CDK4; CDK5; CDK7; CDK8; CHEK1; CHUK; CLK1; CSF1R; 
CSK; CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; DAPK1; DAPK3; DDR1; DYRK1A; EIF2AK3; EIF2AK4; FES; FLT1; FLT3; GMFB; HCK; ILK; 
IRAK1; IRAK4; JAK1; JAK2; JAK3; KIT; LATS2; LIMK1; LYN; MAP2K1; MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K3; MAP3K4; MAP3K7; 
MAP3K8; MAP4K1; MAP4K3; MAP4K4; MAP4K5; MAPK1; MAPK13; MAPK14; MAPK6; MAPK8; MAPK9; MAPKAPK2; MATK; MELK; MERTK; 
MKNK1; NDUFB4; NDUFS4; NDUFS5; NDUFV1; NEK6; NEK7; NEK9; PAK1; PAK2; PDPK1; PFTK1; PIK3CD; PIM2; PIP5K1C; PKIB; PKIG; 
PLCE1; PMVK; PPP2R1B; PRDX4; PRKCB1; PRKCD; PRKCH; PRKCI; PRKRA; PRKX; PRPF4B; ROCK1; ROCK2; RPS6KA2; RPS6KB1; 
RPS6KB2; RPS6KC1; SAP30; SRPK2; STAT1; STK17B; STK3; STK39; SYK; TBK1; TEC; TGFBR1; TGFBR2; TLK2; TRIO; TRPM7; TTK; TXK; 
TYK2; UGP2; ULK1; UQCRB; VRK2; ZAP70 
GO 
Biologi
morphoge
nesis 
122 1702 ADAM23; ALDH3A2; ANPEP; APAF1; APOE; ATP2A2; ATP2C1; BAIAP2; BMI1; BTK; CD80; CD86; CDK5; CDK5RAP1; CHUK; CLN8; CRIM1; 
CRYAB; CSRP2; CUGBP2; CXCL10; DBN1; DGCR2; DKK3; DYRK1A; EBP; EGR2; EMD; ETS2; EVL; FABP5; FLI1; FLNB; FLT1; GJA1; 
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cal 
Proces
s 
GMFB; GNA13; GNPAT; GYPC; HCCS; HCK; HDAC5; HELLS; HHEX; HMGCR; IBSP; ID2; IGF1; IL18; IRF4; ITGAX; ITM2B; JAG2; JAK2; 
JAK3; KRT17; LARGE; LIG1; LIMK1; LRMP; LRRC1; MAFB; MAP4K1; MAPK14; MATK; MBP; MEF2A; MEF2C; MRAS; MTM1; MTPN; MYL6; 
MYOM1; NAB2; NAGLU; NOTCH1; NOTCH2; NOTCH4; NR2C2; NRP1; NUMB; OLFM1; OSTF1; PAFAH1B3; PAPSS1; PCNXL3; PDGFC; 
PES1; PHYH; PITPNM1; PLCE1; PPT1; RAC1; RASGRP4; RNF103; ROD1; RTN3; RTN4; SCMH1; SEMA4D; SEMA4F; SERPINF1; SGCB; 
SNCA; SOCS5; SRI; STAT3; STMN3; SYK; TGFB3; TLE3; TNFAIP2; TNNI2; TOP2B; TPD52; TPM1; TPM2; TPM3; TPM4; TRIM3; UBE3A; 
UFD1L 
GO 
Biologi
cal 
Proces
s 
regulation 
of cell 
cycle 
107 1702 ABL1; ACP2; AIF1; ANAPC11; ANLN; APC; ATM; AXIN1; AXL; BCL10; BCL3; BUB1; BUB3; CCNA2; CCNB1; CCNB2; CCNC; CCND1; 
CCND2; CCNE2; CCNG1; CCNG2; CCNH; CCNI; CCNT2; CCT7; CDC16; CDC20; CDC25A; CDC25C; CDC37; CDC6; CDK2AP1; CDK4; 
CDK5RAP1; CDK7; CDK8; CDKN1A; CENPF; CHEK1; CHFR; CKS1B; CKS2; CLK1; CRK; CSK; CSNK2A2; CTCF; CUL1; CUL3; CUL4A; 
DLEU2; DUSP6; E2F1; EIF4G2; ELK3; ETS2; FRAP1; GMNN; GSPT1; GTF2H1; HDAC5; HK2; HUS1; JAK2; KHDRBS1; LTBP2; LYN; 
MAD2L1; MAP2K6; MAP2K7; MAP3K8; MAPRE1; MATK; MKI67; MYB; NEDD9; NOTCH2; PA2G4; PCAF; PDGFA; PPP2R1B; PPP3CB; 
PSMD8; PTEN; RAD17; RAP1A; RAP1B; RB1; RBBP6; RBBP8; RBL1; RBM5; RPS6KB2; SKP2; SMARCB1; STAT1; TCF19; TFDP1; TGFB3; 
TOB2; TTK; UBE2C; UBE2V1; UBE2V2; VAV1; YWHAQ 
GO 
Biologi
cal 
Proces
s 
intracellula
r protein 
transport 
101 1702 AP1G1; AP1GBP1; AP1S2; AP3B1; AP3D1; AP3M1; AP3S1; AP3S2; APPBP2; ARF1; ARF3; ARF4; ARFGAP3; BCL3; CDC37; CLTA; CLTB; 
CLTC; COPZ2; CROT; DEK; DSCR3; DUSP16; FXC1; GABARAPL2; GRPEL1; ICMT; IPO7; KIF20A; KLHL2; KPNA1; KPNA2; KPNA3; KPNB1; 
LPL; LTBP2; M6PR; MTX2; MXI1; NFKBIE; NSF; NUP50; NUTF2; PEX13; PEX6; PEX7; PPIH; PRNP; PTTG1IP; RAB10; RAB11A; RAB14; 
RAB24; RAB2B; RAB30; RAB33B; RAB5A; RAB6B; RAB7; RABIF; RANBP2; RPL23; RRBP1; SCAMP1; SCAMP2; SDCBP; SEC23A; SEC24B; 
SEC24C; SEC24D; SEC63; SNAP23; SNX10; SNX2; SNX3; SNX4; SNX5; SNX6; SRP14; SSR2; SSR4; STAM2; STX12; STX17; STX18; 
STX5A; STX6; STX7; STX8; TAP2; TIMM17B; TIMM22; TPR; TRAM1; TRNT1; TSG101; VPS18; VPS35; XPO1; XPO7; ZFYVE16 
GO 
Biologi
cal 
Proces
s 
mitotic cell 
cycle 
96 1702 ABL1; ANAPC11; ANLN; BIRC5; BUB1; BUB3; CCNA2; CCNB1; CCNB2; CCND1; CCNE2; CCNG1; CCNG2; CCNH; CCNT2; CD99L2; 
CDC16; CDC20; CDC25A; CDC25C; CDC37; CDC6; CDK2AP1; CDK4; CDK5RAP1; CDK7; CDKN1A; CENPE; CENPF; CETN2; CHEK1; 
CHFR; CKS1B; CKS2; CUL1; CUL3; CUL4A; DUT; E2F1; EIF2AK4; FEN1; GMNN; GSPT1; GTF2H1; IGF1; INCENP; KATNA1; KHDRBS1; 
KIF11; KIF23; KIF2C; KPNA2; LIG1; MAD2L1; MCM2; MCM3; MCM4; MCM6; MLH3; MVP; NAP1L1; NEDD9; NEK9; NFIX; NOLC1; ORC4L; 
POLB; POLD4; PPP2R1B; PPP6C; PRC1; PTEN; PURA; RAB6IP1; RAD17; RBBP4; RBMS1; REV3L; RFC1; RFC3; RFC4; RPA3; RRM1; 
RRM2; SAP30; SIRT2; SKP2; TARDBP; TOP1; TOP2A; TOP2B; TREX1; TTK; UBE2C; UBE2D1; UBE2D3 
GO 
Biologi
cal 
Proces
s 
cell death 95 1702 ABL1; AHR; APAF1; API5; APOE; APP; AXIN1; BAD; BAG5; BCL10; BCL2L11; BECN1; BFAR; BID; BIRC3; BIRC5; BIRC6; BNIP2; BNIP3L; 
BTK; C6; CARD10; CASP2; CASP3; CASP6; CASP7; CASP8AP2; CASP9; CD14; CD38; CD5L; CDKN1A; CFLAR; CUL1; CUL3; CUL4A; 
CYCS; DAPK1; DAPK3; DFFA; DFFB; DNASE1L3; DUSP22; DUSP6; E2F1; EIF4G2; FAIM; FEM1B; FGL2; FXR1; GADD45B; GADD45G; 
GLRX2; GPR65; GZMA; GZMB; IKBKG; IL18; LIMS1; LY86; MAPK1; MCL1; MOAP1; MX1; NFKB1; NOTCH2; PAK1; PDCD6IP; PDCD7; 
PDE1B; PMAIP1; PPP2R1B; PRDX2; PSEN1; PTPN6; RNF7; RTN4; SEMA4D; SGPL1; SH3GLB1; SNCA; SON; STAT1; STK17B; STK3; 
TAX1BP1; TGM2; TIA1; TIAL1; TNFRSF1A; TNFRSF21; TNFRSF9; TRAF3; TRAF5; VDAC1 
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GO 
Biologi
cal 
Proces
s 
lipid 
metabolis
m 
95 1702 ACAA2; ACADL; ACADVL; ACAT1; ACOX1; AGPAT3; ALDH3A2; ALDH3B1; ALOX5AP; ANXA1; APOE; ASAH1; ASAH2; B4GALT4; 
B4GALT6; CD36; CERK; CHPT1; CPNE1; CPNE3; CROT; CRYL1; DDHD1; DPAGT1; EBP; EHHADH; FABP5; FADS1; GALC; GBA; GM2A; 
GNPAT; GPD1; GPD2; GPX4; GRN; HADHB; HEXA; HEXB; HMGCR; HMGCS1; HPGD; HSD17B4; HSD3B7; IDI1; IMPA1; LARGE; LIPA; LPL; 
LYPLA3; MGLL; MGST1; NDUFAB1; NSMAF; OSBPL11; OSBPL9; PAFAH1B2; PAFAH1B3; PCCA; PHYH; PIGC; PIGF; PIGH; PIK3C2A; 
PITPNM1; PLA2G4A; PLA2G7; PLCE1; PLCG2; PMVK; PPAP2A; PPAP2B; PPARG; PPP2R1B; PRKAG2; PSAP; PTDSS1; PTGIS; PTGS1; 
SC4MOL; SCP2; SGPL1; SOAT1; SPTLC1; SQLE; SREBF2; STARD3; STARD4; STARD5; SULT1A1; TBXAS1; TMPO; TPI1; UGCGL1; 
UGT1A1 
GO 
Biologi
cal 
Proces
s 
death 95 1702 ABL1; AHR; APAF1; API5; APOE; APP; AXIN1; BAD; BAG5; BCL10; BCL2L11; BECN1; BFAR; BID; BIRC3; BIRC5; BIRC6; BNIP2; BNIP3L; 
BTK; C6; CARD10; CASP2; CASP3; CASP6; CASP7; CASP8AP2; CASP9; CD14; CD38; CD5L; CDKN1A; CFLAR; CUL1; CUL3; CUL4A; 
CYCS; DAPK1; DAPK3; DFFA; DFFB; DNASE1L3; DUSP22; DUSP6; E2F1; EIF4G2; FAIM; FEM1B; FGL2; FXR1; GADD45B; GADD45G; 
GLRX2; GPR65; GZMA; GZMB; IKBKG; IL18; LIMS1; LY86; MAPK1; MCL1; MOAP1; MX1; NFKB1; NOTCH2; PAK1; PDCD6IP; PDCD7; 
PDE1B; PMAIP1; PPP2R1B; PRDX2; PSEN1; PTPN6; RNF7; RTN4; SEMA4D; SGPL1; SH3GLB1; SNCA; SON; STAT1; STK17B; STK3; 
TAX1BP1; TGM2; TIA1; TIAL1; TNFRSF1A; TNFRSF21; TNFRSF9; TRAF3; TRAF5; VDAC1 
GO 
Biologi
cal 
Proces
s 
apoptosis 91 1702 ABL1; AHR; APAF1; API5; APOE; APP; AXIN1; BAD; BAG5; BCL10; BCL2L11; BECN1; BFAR; BID; BIRC3; BIRC5; BIRC6; BNIP2; BNIP3L; 
BTK; CARD10; CASP2; CASP3; CASP6; CASP7; CASP8AP2; CASP9; CD14; CD38; CD5L; CDKN1A; CFLAR; CUL1; CUL3; CUL4A; CYCS; 
DAPK1; DAPK3; DFFA; DFFB; DNASE1L3; DUSP22; DUSP6; E2F1; FAIM; FEM1B; FXR1; GADD45B; GADD45G; GLRX2; GPR65; GZMA; 
GZMB; IKBKG; IL18; LY86; MAPK1; MCL1; MOAP1; MX1; NFKB1; NOTCH2; PAK1; PDCD6IP; PDCD7; PDE1B; PMAIP1; PPP2R1B; PRDX2; 
PSEN1; PTPN6; RNF7; RTN4; SEMA4D; SGPL1; SH3GLB1; SNCA; SON; STAT1; STK17B; STK3; TAX1BP1; TGM2; TIA1; TIAL1; 
TNFRSF1A; TNFRSF21; TNFRSF9; TRAF3; TRAF5; VDAC1 
GO 
Biologi
cal 
Proces
s 
programm
ed cell 
death 
91 1702 ABL1; AHR; APAF1; API5; APOE; APP; AXIN1; BAD; BAG5; BCL10; BCL2L11; BECN1; BFAR; BID; BIRC3; BIRC5; BIRC6; BNIP2; BNIP3L; 
BTK; CARD10; CASP2; CASP3; CASP6; CASP7; CASP8AP2; CASP9; CD14; CD38; CD5L; CDKN1A; CFLAR; CUL1; CUL3; CUL4A; CYCS; 
DAPK1; DAPK3; DFFA; DFFB; DNASE1L3; DUSP22; DUSP6; E2F1; FAIM; FEM1B; FXR1; GADD45B; GADD45G; GLRX2; GPR65; GZMA; 
GZMB; IKBKG; IL18; LY86; MAPK1; MCL1; MOAP1; MX1; NFKB1; NOTCH2; PAK1; PDCD6IP; PDCD7; PDE1B; PMAIP1; PPP2R1B; PRDX2; 
PSEN1; PTPN6; RNF7; RTN4; SEMA4D; SGPL1; SH3GLB1; SNCA; SON; STAT1; STK17B; STK3; TAX1BP1; TGM2; TIA1; TIAL1; 
TNFRSF1A; TNFRSF21; TNFRSF9; TRAF3; TRAF5; VDAC1 
GO 
Biologi
cal 
Proces
s 
response 
to 
pest/patho
gen/parasi
te 
81 1702 ABCF1; ADA; ADAR; AIF1; ALCAM; ALOX5AP; ANXA1; BCL6; BECN1; BMI1; BST1; C1QA; C1QB; C6; CCL22; CCR5; CCR9; CD14; CD5L; 
CD80; CD83; CD86; CD8A; CD97; CSF1R; CSF2RB; CXCL10; CXCL9; CXCR3; EBI3; ENTPD1; FPR1; HDAC5; HHEX; HSPA1B; IFI44; 
IFNAR1; IFNAR2; IFNGR2; IL18; IRF4; IRF7; ITGB1; ITGB2; KLRC1; LGALS3; LGALS3BP; LSP1; LST1; LY75; LY86; LY96; MAPK13; 
MAPK14; MAPRE2; MGLL; MNDA; MYD88; NCF1; NFKB1; NMI; NR3C1; PLA2G7; POU2AF1; PROCR; RAC1; SAMHD1; SLC11A1; STAT1; 
STAT3; TAP1; TAP2; TCIRG1; TLR1; TLR2; TLR3; TLR4; TPST1; TYROBP; XCR1; YY1 
Appendix 2 
 XXXVIII 
GO 
Biologi
cal 
Proces
s 
cell 
motility 
69 1702 AAMP; ACTB; ANXA1; APOE; ARPC4; ARPC5; ATP2A2; CABP4; CACNA1S; CAPZA1; CAPZA2; CD2AP; CD97; CHRNB1; CKB; CNN3; CRK; 
CRYAB; CXCL10; CXCR3; EMD; EVL; FKBP1B; FLII; FPR1; GJA1; GNA13; HMGCR; HMMR; IGF1; JAG2; JAK2; LIMK1; LSP1; MAP2K1; 
MAPK14; MAPK8; MARCKS; MKLN1; MYO6; MYOM1; NRP1; PAFAH1B2; PLCE1; PPAP2A; PPAP2B; PPAP2C; PXN; RAC1; RNF121; 
ROCK2; RTN3; RTN4; RYR1; SDCBP; SEMA4F; SERPINE2; SLC8A1; SLMAP; SPINT2; SRI; STAT3; STRBP; TNNI2; TPM1; TPM2; TPM3; 
VASP; WASL 
GO 
Biologi
cal 
Proces
s 
ion 
transport 
60 1702 ASNA1; ATOX1; ATP11A; ATP11B; ATP1B1; ATP2A2; ATP2C1; ATP5A1; ATP5C1; ATP5E; ATP6V0A2; ATP6V0B; ATP6V0D1; ATP6V1A; 
ATP6V1B2; ATP6V1C1; ATP6V1D; ATP6V1H; ATP7A; ATP8A1; CACNA1S; CACNB3; CHRNB1; CLCN3; CLIC4; FTH1; HFE; ITPR1; ITPR2; 
KCNJ10; KCNN4; NDUFA9; NEDD4L; NNT; P2RX4; PLP2; RYR1; SFXN2; SLC11A1; SLC12A2; SLC13A3; SLC1A5; SLC22A5; SLC30A4; 
SLC30A5; SLC30A7; SLC31A1; SLC31A2; SLC41A1; SLC4A1; SLC4A7; SLC8A1; TCIRG1; TMEM1; TNFAIP1; TRPM7; TRPV2; UCP2; 
VDAC1; VDAC3 
GO 
Biologi
cal 
Proces
s 
cell 
adhesion 
58 1702 AIM1; ALCAM; APC; APP; ARHGAP5; ATP2A2; CASK; CD36; CD44; CD5; CD9; CD96; CD97; CLDN1; CTNNA1; CXCR3; DDR1; DGCR2; 
EMR1; ENTPD1; ERBB2IP; FXC1; GALNT1; IBSP; ICAM1; IL18; ILK; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; KLRC1; 
LGALS3; LMAN1; LY75; MKLN1; MRC1; NEDD9; NRP1; PLXNC1; PNN; PPP2R1B; PTPRS; PXN; RAC1; SCARB1; SCARB2; SEMA4D; 
TGFBI; TMEM8; VCAM1; VCL; VWF; ZYX 
GO 
Biologi
cal 
Proces
s 
protein 
kinase 
cascade 
54 1702 ADAM9; BCL3; CARD10; CHUK; DAPK1; DAPK3; DBN1; DUSP16; DUSP22; DUSP6; DUSP7; FPR1; GADD45B; GADD45G; GNA13; GPS1; 
IFNAR1; IFNAR2; IKBKG; IRAK1; JAK2; MAP2K4; MAP3K3; MAP3K4; MAP4K1; MAP4K3; MAP4K4; MAP4K5; MAPK13; MAPK14; MAPK8; 
MAPK9; MAPKAPK2; MKNK1; NMI; PAK1; PIAS1; PLCE1; PPP2R1B; PRDX4; RGS3; RPS6KA2; SOCS4; SOCS5; STAT1; STAT3; STAT5A; 
STK17B; TBK1; TEC; TLR1; TLR3; TLR4; ZAP70 
GO 
Biologi
cal 
Proces
s 
small 
GTPase 
mediated 
signal 
transducti
on 
54 1702 ABR; ARF1; ARF3; ARF4; ARFRP1; ARHGAP5; ARHGAP6; ARL1; ARL3; ARL6; CDC42; CFL2; GDI2; GNA13; GNAI3; GTPBP2; IGF1; 
IQGAP1; KHDRBS1; LIMK1; MFHAS1; MRAS; NOTCH2; PDK1; PLCE1; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; RAB32; 
RAB33B; RAB5A; RAB6B; RAB7; RAC1; RALA; RALB; RAP1A; RAP1B; RAP2A; RASGRP4; RGS19; ROCK1; RRAS2; RREB1; SHOC2; 
SIAH2; VAV3; YWHAB; YWHAQ; YWHAZ 
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 XXXIX 
GO 
Biologi
cal 
Proces
s 
G-protein 
coupled 
receptor 
protein 
signaling 
pathway 
53 1702 ARL3; CALCRL; CALM1; CALM2; CCR5; CCR9; CD97; CENTD1; CENTD2; CERK; CNR2; CXCL9; CXCR3; CYSLTR1; EMR1; FPR1; FZD7; 
GABBR1; GIT2; GNA13; GNAI3; GNB2; GNB4; GNG10; GNG12; GNG2; GPR124; GPR34; GPR35; GPR65; HOMER2; HRH2; LANCL2; 
MYO9A; P2RY6; PLCE1; PPAP2A; PTGER1; PTGER2; PTGER4; PTPN6; RAMP1; RASGRP4; RASSF3; RASSF5; RGS19; RGS2; RGS3; 
SYK; TGM2; TULP3; WASF2; XCR1 
GO 
Biologi
cal 
Proces
s 
regulation 
of 
biological 
process 
52 1702 AIF1; BCL6; BTG2; CD86; CDC6; CDKN1A; CHEK1; CHPT1; CRIM1; CTBP2; CUL1; CUL3; CUL4A; CXCL10; DLG3; FLT1; FLT3; FTH1; 
GLRX2; GRN; IGF1; IL15; IL18; JAG2; MATK; MDM2; MDM4; MXI1; NAP1L1; NEDD9; NOTCH2; NRP1; PCAF; PLCE1; PPAP2A; PPP2R1B; 
PRKRA; PRKRIR; PTPN6; RBBP4; SOCS4; SOCS5; TBC1D8; TCIRG1; TGFBR2; TNFRSF9; TNIP2; TOB2; TSG101; TTK; TXNDC4; UBE2C 
GO 
Biologi
cal 
Proces
s 
regulation 
of 
apoptosis 
52 1702 ABL1; API5; APOE; BAD; BCL10; BCL2L11; BECN1; BFAR; BID; BIRC3; BIRC5; BIRC6; BNIP2; BNIP3L; BTK; CASP2; CASP3; CASP6; 
CASP8AP2; CD38; CDKN1A; CFLAR; CUL1; CUL3; CUL4A; CYCS; DAPK1; DAPK3; FEM1B; IKBKG; IL18; MAPK1; MCL1; MX1; NFKB1; 
NOTCH2; PMAIP1; PPP2R1B; PRDX2; PSEN1; RNF7; RTN4; SEMA4D; SNCA; SON; STK17B; TAX1BP1; TGM2; TIA1; TIAL1; TNFRSF9; 
TRAF3 
GO 
Biologi
cal 
Proces
s 
response 
to 
wounding 
52 1702 ABCF1; AIF1; ALOX5AP; ANXA1; BCL6; BECN1; CCL22; CCR5; CCR9; CD14; CD5L; CD80; CD86; CD8A; CD97; CXCL10; CXCL9; EBI3; 
FPR1; HDAC5; IL18; IRF4; IRF7; ITGB1; LGALS3; LGALS3BP; LSP1; LST1; LY75; LY86; LY96; MAPRE2; MGLL; MNDA; MYD88; NCF1; 
NFKB1; NMI; NR3C1; PLA2G7; PROCR; RAC1; TAP1; TAP2; TCIRG1; TLR1; TLR2; TLR3; TLR4; TPST1; TYROBP; XCR1 
GO 
Biologi
cal 
Proces
s 
response 
to 
endogeno
us 
stimulus 
47 1702 ABL1; ATM; ATRX; BTG2; CCNH; CDK7; CHEK1; CSNK1D; DCLRE1A; DDB2; FEN1; FRAP1; GADD45G; GTF2H1; GTF2H2; HUS1; IRF7; 
LIG1; MAP2K6; MBD4; MLH3; NUDT1; POLB; POLK; RAD17; RAD23A; RAD23B; RAD51; RAD51L1; RAD51L3; RAD54L; RBBP4; RBBP8; 
RECQL; REV3L; RFC1; RPA3; TDG; TDP1; TLK2; TREX1; UBE2A; UBE2B; UBE2C; UBE2V1; UBE2V2; XRN2 
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 XL 
GO 
Biologi
cal 
Proces
s 
protein 
amino acid 
dephosph
orylation 
36 1702 ACP1; CDC25A; CDC25C; CTDP1; DUSP1; DUSP11; DUSP16; DUSP19; DUSP22; DUSP6; DUSP7; ILKAP; KIT; MTM1; MTMR1; MTMR4; 
MTMR6; PPEF2; PPM1A; PPM1B; PPP2R1B; PPP2R2A; PPP2R4; PPP3CA; PPP3CB; PPP6C; PTEN; PTP4A1; PTPLA; PTPN11; PTPN2; 
PTPN6; PTPN9; PTPRE; PTPRJ; PTPRS 
GO 
Biologi
cal 
Proces
s 
positive 
regulation 
of 
programm
ed cell 
death 
35 1702 ABL1; APOE; BAD; BCL10; BCL2L11; BID; BNIP3L; BTK; CASP2; CASP3; CASP6; CASP8AP2; CD38; CDKN1A; CFLAR; CUL1; CUL3; 
CUL4A; CYCS; DAPK1; DAPK3; FEM1B; IKBKG; IL18; MAPK1; MX1; NOTCH2; PMAIP1; PPP2R1B; RNF7; STK17B; TIA1; TIAL1; TNFRSF9; 
TRAF3 
GO 
Biologi
cal 
Proces
s 
regulation 
of 
programm
ed cell 
death 
35 1702 ABL1; APOE; BAD; BCL10; BCL2L11; BID; BNIP3L; BTK; CASP2; CASP3; CASP6; CASP8AP2; CD38; CDKN1A; CFLAR; CUL1; CUL3; 
CUL4A; CYCS; DAPK1; DAPK3; FEM1B; IKBKG; IL18; MAPK1; MX1; NOTCH2; PMAIP1; PPP2R1B; RNF7; STK17B; TIA1; TIAL1; TNFRSF9; 
TRAF3 
GO 
Biologi
cal 
Proces
s 
induction 
of 
apoptosis 
35 1702 ABL1; APOE; BAD; BCL10; BCL2L11; BID; BNIP3L; BTK; CASP2; CASP3; CASP6; CASP8AP2; CD38; CDKN1A; CFLAR; CUL1; CUL3; 
CUL4A; CYCS; DAPK1; DAPK3; FEM1B; IKBKG; IL18; MAPK1; MX1; NOTCH2; PMAIP1; PPP2R1B; RNF7; STK17B; TIA1; TIAL1; TNFRSF9; 
TRAF3 
GO 
Biologi
cal 
Proces
s 
positive 
regualtion 
of 
apoptosis 
35 1702 ABL1; APOE; BAD; BCL10; BCL2L11; BID; BNIP3L; BTK; CASP2; CASP3; CASP6; CASP8AP2; CD38; CDKN1A; CFLAR; CUL1; CUL3; 
CUL4A; CYCS; DAPK1; DAPK3; FEM1B; IKBKG; IL18; MAPK1; MX1; NOTCH2; PMAIP1; PPP2R1B; RNF7; STK17B; TIA1; TIAL1; TNFRSF9; 
TRAF3 
Appendix 2 
 XLI 
GO 
Biologi
cal 
Proces
s 
inflammat
ory 
response 
32 1702 ABCF1; AIF1; ALOX5AP; ANXA1; BCL6; CCL22; CCR5; CD14; CD97; CXCL10; CXCL9; FPR1; HDAC5; IRF7; LGALS3; LY75; LY86; LY96; 
MGLL; MYD88; NFKB1; NMI; NR3C1; PLA2G7; PROCR; RAC1; TLR1; TLR2; TLR3; TLR4; TPST1; XCR1 
GO 
Biologi
cal 
Proces
s 
innate 
immune 
response 
32 1702 ABCF1; AIF1; ALOX5AP; ANXA1; BCL6; CCL22; CCR5; CD14; CD97; CXCL10; CXCL9; FPR1; HDAC5; IRF7; LGALS3; LY75; LY86; LY96; 
MGLL; MYD88; NFKB1; NMI; NR3C1; PLA2G7; PROCR; RAC1; TLR1; TLR2; TLR3; TLR4; TPST1; XCR1 
GO 
Biologi
cal 
Proces
s 
enzyme 
linked 
receptor 
protein 
signaling 
pathway 
31 1702 ACVR1; ACVRL1; AP3S1; BAIAP2; CD8A; CSF1R; DDR1; EPS15; EPS8; ERBB2IP; FLT1; FLT3; FNTA; IRAK1; KIT; LTBP2; MAP3K7; 
PDPK1; PLCE1; PTPRE; PTPRJ; PXN; RASGRP4; SHOC2; SNX6; SQSTM1; SYK; TGFBR1; TGFBR2; TRIO; ZFYVE16 
GO 
Biologi
cal 
Proces
s 
humoral 
immune 
response 
30 1702 ADA; ADAR; ALCAM; BMI1; BST1; C1QA; C1QB; C6; CCL22; CD83; CD86; CSF1R; CSF2RB; CXCR3; EBI3; ENTPD1; HHEX; HSPA1B; IL18; 
IRF4; ITGB2; KLRC1; LY86; LY96; MAPK13; MAPK14; NFKB1; POU2AF1; XCR1; YY1 
GO 
Biologi
cal 
Proces
s 
antimicrobi
al humoral 
response 
17 1702 ADA; ADAR; ALCAM; CCL22; CSF1R; CSF2RB; CXCR3; ENTPD1; HHEX; ITGB2; KLRC1; LY96; MAPK13; MAPK14; NFKB1; XCR1; YY1 
Appendix 2 
 XLII 
GO 
Biologi
cal 
Proces
s 
chemotaxi
s 
16 1702 CCL22; CCR5; CCR9; CKLF; CXCL10; CXCL16; CXCL9; CXCR3; FPR1; IL16; MAN1A2; MAP2K1; MAPK1; MAPK14; RALA; XCR1 
GO 
Biologi
cal 
Proces
s 
second-
messenge
r-mediated 
signaling 
14 1702 CALCRL; CALM2; CNR2; FPR1; GABBR1; GNAI3; HRH2; NUDT4; PLCE1; PPP2R1B; PTGER4; TGM2; WASF2; XCR1 
GO 
Biologi
cal 
Proces
s 
Wnt 
receptor 
signaling 
pathway 
14 1702 APC; AXIN1; BCL9; CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; CTNNBIP1; DKK3; FZD7; PPP2R1B; TCF7; TCF7L2; TLE3 
GO 
Biologi
cal 
Proces
s 
cell-cell 
adhesion 
14 1702 AIM1; CD44; DGCR2; GALNT1; ICAM1; ITGA8; ITGAE; ITGB1; KLRC1; LGALS3; LMAN1; LY75; MRC1; VCAM1 
GO 
Biologi
cal 
Proces
s 
embryoge
nesis and 
morphoge
nesis 
14 1702 AK2; CAMTA2; CST3; CUL1; DKK3; HIST1H2AB; HIST1H2AD; HIST1H2AE; HIST1H3D; HIST3H2A; PSME4; SCMH1; SMARCC1; TPD52 
Appendix 2 
 XLIII 
GO 
Biologi
cal 
Proces
s 
cell 
migration 
14 1702 APOE; CD2AP; EVL; HMGCR; JAG2; NRP1; PPAP2A; PPAP2B; PPAP2C; RTN3; RTN4; SDCBP; SEMA4F; SERPINE2 
GO 
Biologi
cal 
Proces
s 
negative 
regulation 
of cell 
cycle 
14 1702 APC; ATM; AXIN1; BCL10; CDK2AP1; CDK5RAP1; CTCF; DLEU2; PTEN; RAP1A; RB1; RBL1; RBM5; SMARCB1 
GO 
Biologi
cal 
Proces
s 
apoptotic 
program 
12 1702 BAD; BID; CASP2; CASP7; CASP9; CYCS; DFFA; DFFB; MCL1; SH3GLB1; STAT1; VDAC1 
GO 
Biologi
cal 
Proces
s 
hemopoie
sis 
11 1702 CD80; CD86; HDAC5; IRF4; JAG2; LRMP; MAP4K1; NOTCH2; NOTCH4; RASGRP4; SOCS5 
GO 
Biologi
cal 
Proces
s 
immune 
cell 
activation 
11 1702 CD80; CD86; CD8A; HDAC5; IL18; IRF4; JAG2; MS4A1; SOCS5; TLR1; TLR4 
Appendix 2 
 XLIV 
GO 
Biologi
cal 
Proces
s 
lymphocyt
e 
activation 
9 1702 CD80; CD86; CD8A; HDAC5; IL18; IRF4; JAG2; MS4A1; SOCS5 
GO 
Biologi
cal 
Proces
s 
pathogene
sis 
8 1702 CCR5; GLIPR1; IFI44; MX1; SNCA; TTC3; UBE2D1; UBE2D3 
GO 
Biologi
cal 
Proces
s 
secretion 7 1702 ARFGAP3; CANX; LTBP2; PLDN; RAB14; TNFAIP2; UNC93B1 
GO 
Biologi
cal 
Proces
s 
induction 
of 
apoptosis 
by 
extracellul
ar signals 
7 1702 BID; BTK; CASP8AP2; CD38; CFLAR; DAPK1; IL18 
GO 
Biologi
cal 
Proces
s 
inactivatio
n of MAPK 
7 1702 DUSP16; DUSP22; DUSP6; DUSP7; GPS1; PPP2R1B; RGS3 
Appendix 2 
 XLV 
GO 
Biologi
cal 
Proces
s 
T-cell 
activation 
7 1702 CD80; CD86; CD8A; IL18; IRF4; JAG2; SOCS5 
GO 
Biologi
cal 
Proces
s 
cytokine 
biosynthes
is 
7 1702 CD80; CD86; IL18; IRF4; TLR1; TLR3; TLR4 
GO 
Biologi
cal 
Proces
s 
cytokine 
metabolis
m 
7 1702 CD80; CD86; IL18; IRF4; TLR1; TLR3; TLR4 
GO 
Biologi
cal 
Proces
s 
TGFbeta 
receptor 
signaling 
pathway 
7 1702 ACVRL1; FNTA; LTBP2; MAP3K7; TGFBR1; TGFBR2; ZFYVE16 
GO 
Biologi
cal 
Proces
s 
induction 
of 
apoptosis 
by 
intracellula
r signals 
6 1702 ABL1; CDKN1A; CUL1; CUL3; CUL4A; RNF7 
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 XLVI 
GO 
Biologi
cal 
Proces
s 
cAMP-
mediated 
signaling 
6 1702 FPR1; GABBR1; GNAI3; PTGER4; TGM2; WASF2 
GO 
Biologi
cal 
Proces
s 
lymphocyt
e 
differentiat
ion 
6 1702 CD80; CD86; HDAC5; IRF4; JAG2; SOCS5 
GO 
Biologi
cal 
Proces
s 
regulation 
of cytokine 
biosynthes
is 
6 1702 CD80; CD86; IRF4; TLR1; TLR3; TLR4 
GO 
Biologi
cal 
Proces
s 
protein 
ubiquitinati
on 
6 1702 FBXO4; NEDD4L; TGM2; TRIP12; UBE2V1; UBE2V2 
GO 
Biologi
cal 
Proces
s 
embryonic 
developm
ent 
5 1702 BMI1; JAG2; KIF1B; LRRC1; NOTCH4 
Appendix 2 
 XLVII 
GO 
Biologi
cal 
Proces
s 
T-cell 
differentiat
ion 
5 1702 CD80; CD86; IRF4; JAG2; SOCS5 
GO 
Biologi
cal 
Proces
s 
frizzled 
signaling 
pathway 
3 1702 AXIN1; FZD7; TLE3 
GO 
Molecul
ar 
Functio
n 
signal 
transduce
r activity 
274 1716 ACVR1; ACVRL1; ADAM23; ADAM9; ADFP; AHR; AKAP9; ALCAM; ANPEP; ANXA1; APOE; ARF1; ARHGAP6; ARL3; AXIN1; AXL; BAIAP2; 
BID; BRD8; CALCRL; CARD10; CARHSP1; CBL; CCL22; CCR5; CCR9; CD14; CD163; CD36; CD44; CD5; CD5L; CD74; CD80; CD86; CD8A; 
CD97; CDK2AP1; CHD6; CHN2; CHRNB1; CHUK; CKLF; CNOT7; CNR2; CRIM1; CRK; CRLF2; CRLF3; CRTAP; CSF1R; CSF2RA; CSF2RB; 
CXCL10; CXCL16; CXCL9; CXCR3; CYSLTR1; DBI; DDR1; DGCR2; DKK3; DUSP1; EBI3; EBP; EEF1E1; EMR1; ENSA; EPS8; ERBB2IP; 
EVI2A; EXTL3; FCGR2B; FCGRT; FEM1B; FGL2; FKBP1A; FLT1; FLT3; FPR1; FZD7; GABARAPL1; GABBR1; GLG1; GMFB; GNA13; GNAI3; 
GNB2; GNB4; GNG10; GNG12; GNG2; GPR124; GPR34; GPR35; GPR65; GPRC5B; GRINL1A; GRN; HABP4; HAVCR2; HFE; HIF1A; 
HMGN3; HOMER2; HRH2; ICAM1; IFITM3; IFNAR1; IFNAR2; IFNGR2; IGF1; IGF2R; IK; IKBKG; IL10RA; IL13RA1; IL15; IL15RA; IL16; IL18; 
IL1RAP; IL2RG; IL6ST; INSL3; IRAK1; IRAK4; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; ITPR1; ITPR2; ITSN2; JAG2; 
JAK1; JAK2; JAK3; KIT; KLRC1; LANCL2; LASP1; LGALS3BP; LIFR; LILRB3; LSP1; LY75; LY86; LY96; LYN; M6PR; MADD; MAN1A2; 
MAP2K7; MAP3K3; MAP3K4; MAP3K7; MAPK1; MAPK13; MAPK14; MAPK6; MAPK8; MAPK9; MAPKAPK2; MERTK; MRC1; MS4A1; MYD88; 
NCOA1; NCOA3; NEDD9; NOTCH1; NOTCH2; NOTCH4; NR2C2; NR3C1; NRP1; NSMAF; OLFM1; P2RX4; P2RY6; PDCL; PDE8A; PDGFA; 
PDGFC; PEX11A; PEX7; PLCE1; PLCG2; PLRG1; PLXNB2; PLXNC1; PPARG; PPFIA4; PRKCB1; PRKCD; PRKCH; PRKCI; PRKRA; PROCR; 
PTGER1; PTGER2; PTGER4; PTPN6; PTPN9; PTPRE; PTPRJ; PTPRS; PTTG1IP; PVR; RAMP1; RGS10; RGS18; RGS19; RGS2; RGS3; 
RNF121; RRBP1; RTN1; RXRA; RYR1; SCARB1; SCARB2; SDCBP; SEMA4D; SEMA4F; SH3BGRL; SLA; SLC1A5; SRI; SSR4; STAM2; 
STAT1; STAT3; STAT5A; STAT6; STK39; STMN1; SYK; TACSTD1; TAP2; TAPBP; TGFB3; TGFBI; TGFBR1; TGFBR2; TIAM1; TLR1; TLR2; 
TLR3; TLR4; TNFRSF1A; TNFRSF21; TNFRSF9; TOB2; TOMM70A; TRAF3; TRAM1; TRIP12; TRIP13; TRIP6; TRPV2; TYK2; TYROBP; 
VAV3; WASF2; WBP1; XCR1; XPO7; ZYX 
GO 
Molecul
transcripti
on 
174 1716 ADNP; AHR; ATF1; ATF2; ATF3; ATF6; ATF7IP; ATRX; BACH1; BAZ1B; BAZ2A; BCL11A; BCL3; BCL6; BRD8; BTG2; CAMTA2; CBFA2T3; 
CBFB; CBL; CD80; CD86; CEBPG; CITED2; CNOT2; CNOT7; CNOT8; CREB3; CREM; CTCF; DEK; DMTF1; DR1; E2F1; EED; EGR1; ELF1; 
ELK3; EPC1; ETS2; ETV3; ETV6; FLI1; FUS; GABPA; GABPB1; GTF2A1; GTF2B; GTF2E2; GTF2F2; GTF2H1; GTF2I; GTF3C4; HCLS1; 
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 XLVIII 
ar 
Functio
n 
regulator 
activity 
HDAC2; HDAC5; HHEX; HIF1A; HMGN3; HSBP1; ID3; IER5; IRAK1; IRF3; IRF4; IRF5; IRF6; IRF7; KLF3; LITAF; LMO2; LRRFIP1; MEF2A; 
MEF2C; MITF; MRPS25; MXI1; MYB; MYCBP; MYCL1; MYNN; NAB2; NCOA1; NCOA3; NFAT5; NFATC1; NFIX; NFKB1; NFKB2; NFYA; 
NFYB; NMI; NOTCH2; NR2C2; NR3C1; PCAF; PIAS1; PKNOX1; PLAGL2; PLRG1; PML; POLR3K; POU2AF1; PPARG; PURA; RB1; RELB; 
RERE; RFX5; RFXAP; RNF12; RNF14; RREB1; RUNX1; RXRA; SALL2; SAP30; SCMH1; SF1; SIAH2; SIN3B; SMARCA5; SMARCB1; 
SMARCC1; SMARCE1; SOLH; SPIB; SQSTM1; SREBF2; SRF; SSBP3; STAT1; STAT3; STAT5A; STAT6; SUPT4H1; TAF13; TAF1B; TAF7; 
TAF9; TARDBP; TBPL1; TCEA1; TCEB1; TCEB3; TCERG1; TCF19; TCF4; TCF7; TFDP1; TIAL1; TRIM32; TRIM33; TRIP13; TSG101; TTF1; 
UBE2V1; UBP1; UBTF; UBXD2; UGP2; UTX; VAV1; XBP1; YAF2; YY1; ZDHHC14; ZDHHC2; ZDHHC3; ZDHHC6; ZDHHC9; ZFP36L1; ZFX; 
ZNRD1 
GO 
Molecul
ar 
Functio
n 
kinase 
activity 
169 1716 ABL1; ACVR1; ACVRL1; ADK; AK2; AK3; ATM; AXL; BAIAP2; BTK; BUB1; CALM2; CAMK1; CASK; CDK4; CDK5; CDK7; CDK8; CDKN1A; 
CERK; CHEK1; CHUK; CKB; CKS1B; CKS2; CLK1; CPNE3; CRIM1; CSF1R; CSK; CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; CSNK2B; 
DAPK1; DAPK3; DCK; DDR1; DGUOK; DLG1; DLG3; DTYMK; DUSP1; DUSP22; DYRK1A; EIF2AK3; EIF2AK4; FES; FLT1; FLT3; FRAP1; 
GTF2H1; HCK; HK2; IGF2R; ILK; ILKAP; IRAK1; IRAK4; JAK1; JAK2; JAK3; KHK; KIT; LATS2; LIMK1; LIN7C; LRMP; LYN; MADD; MAP2K1; 
MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K3; MAP3K4; MAP3K7; MAP3K7IP2; MAP3K8; MAP4K1; MAP4K3; MAP4K4; MAP4K5; MAPK1; 
MAPK13; MAPK14; MAPK6; MAPK8; MAPK9; MAPKAPK2; MATK; MELK; MERTK; MKNK1; NAGK; NEK6; NEK7; NEK9; NRP1; NSF; 
PACSIN1; PAK1; PAK2; PANK1; PANK3; PAPSS1; PCM1; PDK1; PDK3; PDPK1; PDXK; PFKFB3; PFKL; PFKP; PFTK1; PHKA1; PHKB; 
PIK3C2A; PIK3CD; PIM2; PIP5K1C; PKIG; PMVK; PRKAG2; PRKCB1; PRKCD; PRKCH; PRKCI; PRKRA; PRKX; PRPF4B; PRPSAP2; 
PSMB7; ROCK1; ROCK2; RPS6KA2; RPS6KB1; RPS6KB2; RPS6KC1; SAP30; SLC9A3R2; SRPK2; STK17B; STK3; STK39; SYK; TBK1; 
TEC; TGFBR1; TGFBR2; TJP2; TK1; TLE3; TLK2; TPD52; TPK1; TPR; TRIO; TRPM7; TTK; TXK; TYK2; TYROBP; UGP2; ULK1; VRK2; 
ZAP70 
GO 
Molecul
ar 
Functio
n 
receptor 
activity 
160 1716 ACVR1; ACVRL1; ADFP; AHR; ANPEP; AXL; BAIAP2; BRD8; CALCRL; CCR5; CCR9; CD14; CD163; CD36; CD44; CD5; CD5L; CD74; CD80; 
CD86; CD8A; CD97; CHD6; CHRNB1; CNR2; CRIM1; CRLF2; CRLF3; CRTAP; CSF1R; CSF2RA; CSF2RB; CXCL16; CXCR3; CYSLTR1; 
DDR1; DGCR2; DUSP1; EBI3; EBP; EEF1E1; EMR1; EVI2A; EXTL3; FCGR2B; FCGRT; FEM1B; FKBP1A; FLT1; FLT3; FPR1; FZD7; 
GABARAPL1; GABBR1; GPR124; GPR34; GPR35; GPR65; GPRC5B; GRINL1A; HABP4; HAVCR2; HFE; HRH2; ICAM1; IFNAR1; IFNAR2; 
IFNGR2; IGF2R; IL10RA; IL13RA1; IL15RA; IL1RAP; IL2RG; IL6ST; IRAK1; IRAK4; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; 
ITGB2; ITPR1; ITPR2; KIT; KLRC1; LANCL2; LGALS3BP; LIFR; LILRB3; LY75; LY96; M6PR; MERTK; MRC1; MYD88; NCOA1; NOTCH1; 
NOTCH2; NOTCH4; NR2C2; NR3C1; NRP1; OLFM1; P2RX4; P2RY6; PEX11A; PEX7; PLXNB2; PLXNC1; PPARG; PRKCB1; PRKCD; 
PRKCH; PRKCI; PROCR; PTGER1; PTGER2; PTGER4; PTPN6; PTPN9; PTPRE; PTPRJ; PTPRS; PTTG1IP; PVR; RAMP1; RNF121; RRBP1; 
RXRA; RYR1; SCARB1; SCARB2; SEMA4D; SEMA4F; SLC1A5; SSR4; SYK; TACSTD1; TGFBR1; TGFBR2; TLR1; TLR2; TLR3; TLR4; 
TNFRSF1A; TNFRSF21; TNFRSF9; TOMM70A; TRAM1; TRIP13; TRPV2; TYROBP; WASF2; XCR1; XPO7; ZYX 
GO 
Molecul
protein 
kinase 
124 1716 ABL1; ACVR1; ACVRL1; ATM; AXL; BTK; BUB1; CAMK1; CASK; CDK4; CDK5; CDK7; CDK8; CDKN1A; CERK; CHEK1; CHUK; CKS1B; 
CKS2; CLK1; CPNE3; CRIM1; CSF1R; CSK; CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; CSNK2B; DAPK1; DAPK3; DDR1; DYRK1A; 
EIF2AK3; EIF2AK4; FES; FLT1; FLT3; GTF2H1; HCK; IGF2R; ILK; IRAK1; IRAK4; JAK1; JAK2; JAK3; KIT; LATS2; LIMK1; LYN; MAP2K1; 
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 XLIX 
ar 
Functio
n 
activity MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K3; MAP3K4; MAP3K7; MAP3K8; MAP4K1; MAP4K3; MAP4K4; MAP4K5; MAPK1; MAPK13; 
MAPK14; MAPK6; MAPK8; MAPK9; MAPKAPK2; MATK; MELK; MERTK; MKNK1; NEK6; NEK7; NEK9; NRP1; PACSIN1; PAK1; PAK2; PCM1; 
PDK1; PDK3; PDPK1; PFTK1; PHKA1; PHKB; PIM2; PRKAG2; PRKCB1; PRKCD; PRKCH; PRKCI; PRKX; PRPF4B; ROCK1; ROCK2; 
RPS6KA2; RPS6KB1; RPS6KB2; RPS6KC1; SAP30; SRPK2; STK17B; STK3; STK39; SYK; TBK1; TEC; TGFBR1; TGFBR2; TLE3; TLK2; TPR; 
TRIO; TRPM7; TTK; TXK; TYK2; ULK1; VRK2; ZAP70 
GO 
Molecul
ar 
Functio
n 
transcripti
on factor 
activity 
101 1716 ADNP; AHR; ATF1; ATF3; ATF6; ATRX; BACH1; BAZ1B; BCL6; BTG2; CAMTA2; CBFA2T3; CBFB; CBL; CEBPG; CITED2; CNOT7; CNOT8; 
CREB3; CREM; CTCF; DMTF1; E2F1; EGR1; ELF1; ELK3; ETS2; ETV3; ETV6; FLI1; GABPA; GABPB1; GTF2I; HCLS1; HDAC2; HHEX; 
HIF1A; IRF3; IRF4; IRF5; IRF6; IRF7; KLF3; LMO2; MEF2A; MEF2C; MRPS25; MYCL1; MYNN; NFAT5; NFATC1; NFIX; NFKB1; NFKB2; 
NFYA; NFYB; NR2C2; NR3C1; PKNOX1; PLAGL2; PML; POLR3K; PPARG; PURA; RB1; RELB; RERE; RFX5; RFXAP; RUNX1; RXRA; 
SALL2; SCMH1; SIN3B; SOLH; SPIB; SRF; STAT1; STAT3; STAT5A; STAT6; SUPT4H1; TAF13; TAF1B; TARDBP; TCEA1; TCF19; TFDP1; 
UBP1; UBXD2; UGP2; VAV1; XBP1; YY1; ZDHHC14; ZDHHC2; ZDHHC3; ZDHHC6; ZDHHC9; ZFP36L1; ZNRD1 
GO 
Molecul
ar 
Functio
n 
protein 
serine/thre
onine 
kinase 
activity 
92 1716 ACVR1; ACVRL1; ATM; AXL; BUB1; CAMK1; CASK; CDK4; CDK5; CDK7; CDK8; CERK; CHEK1; CHUK; CKS1B; CKS2; CLK1; CPNE3; 
CSNK1D; CSNK1G1; CSNK2A1; CSNK2A2; CSNK2B; DAPK1; DAPK3; DYRK1A; EIF2AK3; EIF2AK4; GTF2H1; HCK; ILK; IRAK1; LATS2; 
LIMK1; MAP2K1; MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K3; MAP3K4; MAP3K7; MAP3K8; MAP4K1; MAP4K3; MAP4K4; MAP4K5; 
MAPK1; MAPK13; MAPK14; MAPK6; MAPK8; MAPK9; MAPKAPK2; MELK; MKNK1; NEK6; NEK7; NEK9; PAK1; PAK2; PDPK1; PFTK1; 
PHKA1; PHKB; PIM2; PRKAG2; PRKCB1; PRKCD; PRKCH; PRKCI; PRKX; PRPF4B; ROCK1; ROCK2; RPS6KA2; RPS6KB1; RPS6KB2; 
SAP30; SRPK2; STK17B; STK3; STK39; TBK1; TGFBR1; TGFBR2; TLK2; TRIO; TRPM7; TTK; ULK1; VRK2 
GO 
Molecul
ar 
Functio
n 
transmem
brane 
receptor 
activity 
92 1716 ACVR1; ACVRL1; AXL; CALCRL; CCR5; CCR9; CD14; CD163; CD44; CD5; CD5L; CD74; CD97; CHRNB1; CNR2; CRIM1; CRLF2; CRTAP; 
CSF1R; CSF2RA; CSF2RB; CXCL16; CXCR3; CYSLTR1; DDR1; EBI3; EBP; EEF1E1; EMR1; EVI2A; FLT1; FLT3; FPR1; FZD7; GABBR1; 
GPR124; GPR34; GPR35; GPR65; GPRC5B; HABP4; HFE; HRH2; ICAM1; IFNAR1; IFNAR2; IFNGR2; IGF2R; IL10RA; IL13RA1; IL15RA; 
IL1RAP; IL2RG; IL6ST; ITGA4; ITGA8; ITGA9; ITGAE; ITGAV; ITGAX; ITGB1; ITGB2; KIT; KLRC1; LANCL2; LGALS3BP; LIFR; M6PR; 
MERTK; MYD88; NOTCH1; NRP1; OLFM1; P2RY6; PEX7; PTGER1; PTGER2; PTGER4; PTPRE; PTPRJ; PTPRS; RRBP1; TGFBR1; 
TGFBR2; TLR1; TLR2; TLR3; TLR4; TNFRSF1A; WASF2; XCR1; XPO7 
GO 
Molecul
ar 
Functio
n 
structural 
molecule 
activity 
76 1716 ACTB; ACTR10; ACTR8; ADD1; ADD3; ARPC4; ARPC5; BFAR; CD2AP; CLDN1; CLTC; COL14A1; COL9A3; CRELD1; CRYAB; CTNNA1; 
ERBB2IP; GADD45B; GADD45G; HIP1; KRT17; LACTB; MBP; MFAP3; MRPL1; MRPL11; MRPL15; MRPL16; MRPL17; MRPL22; MRPL27; 
MRPL3; MRPL46; MRPL48; MRPL49; MRPL50; MRPS14; MRPS15; MRPS2; MRPS21; MRPS25; MRPS28; MRPS9; MYL6; MYO6; MYOM1; 
NOLA2; OLFM1; PLEC1; PNN; RDX; ROCK2; RPL11; RPL13; RPL14; RPL15; RPL23; RPL30; RPL31; RPL5; RPS10; RPS13; RPS24; RPS6; 
RPS6KA2; RPS9; SDCCAG8; SGCB; TNNI2; TPM1; TPM2; TPM3; TPM4; VAPB; VCL; WASF2 
GO calcium 67 1716 AIF1; ANXA1; ANXA4; ANXA5; ANXA6; ANXA7; AP1GBP1; ATP2A2; CABP4; CACNA1S; CALM1; CALM2; CALM3; CANX; CBL; CD97; 
CETN2; CLTA; CLTB; CRELD1; DNASE1L3; EHD1; EHD2; EHD4; EMR1; EPS15; ERO1L; FKBP9; GCA; GPD2; GRN; GSN; ITSN1; ITSN2; 
Appendix 2 
 L 
Molecul
ar 
Functio
n 
ion binding JAG2; LCP1; LRP4; LTBP2; MAN1A2; MATN2; MRC1; MST1; MYL6; NOTCH1; NOTCH2; NOTCH4; NUCB2; PLCG2; PLEK; PLS3; PLSCR1; 
PLSCR3; PML; PPEF2; PPP3CA; PPP3CB; PRKCB1; PRNP; PRRG2; RCN2; RYR1; SLC25A13; SRI; SSR4; TGM1; TGM2; TKTL1 
GO 
Molecul
ar 
Functio
n 
transcripti
on factor 
binding 
66 1716 ATF2; ATF3; ATF6; ATF7IP; BCL11A; BCL3; BRD8; CBFB; CREB3; CTCF; DR1; DRG1; E2F1; ELK3; FUS; GABPA; GTF2A1; HDAC11; 
HDAC2; HDAC5; HMGN3; HSBP1; ID3; IER5; IRF3; IRF4; MEF2A; MEF2C; MXI1; MYCBP; NAB2; NCOA1; NCOA3; NFKB2; NMI; NR2C2; 
PCAF; PIAS1; PLRG1; PML; POU2AF1; RELB; RFX5; RFXAP; RNF12; RNF14; RXRA; SAP30; SF1; SIAH2; SMARCC1; SMARCE1; SQSTM1; 
TAF7; TAF9; TBPL1; TCERG1; TFDP1; TRIM32; TRIM33; TRIP13; TSG101; UBP1; YAF2; YY1; ZFX 
GO 
Molecul
ar 
Functio
n 
protein-
tyrosine 
kinase 
activity 
63 1716 ABL1; AXL; BTK; CASK; CDK5; CHEK1; CHUK; CLK1; CRIM1; CSF1R; CSK; CSNK1D; DDR1; DYRK1A; FES; FLT1; FLT3; HCK; IGF2R; ILK; 
IRAK4; JAK1; JAK2; JAK3; KIT; LIMK1; LYN; MAP2K1; MAP2K4; MAP2K5; MAP2K6; MAP2K7; MAP3K7; MAPK1; MAPK13; MAPK14; MAPK9; 
MATK; MERTK; NEK6; NEK7; NRP1; PAK2; PDPK1; PRKCD; PRKCH; PRKX; PRPF4B; ROCK2; RPS6KA2; SRPK2; STK3; STK39; SYK; 
TBK1; TEC; TGFBR1; TLK2; TPR; TTK; TXK; TYK2; ZAP70 
GO 
Molecul
ar 
Functio
n 
transcripti
on 
cofactor 
activity 
62 1716 ATF2; ATF3; ATF6; ATF7IP; BCL11A; BCL3; BRD8; CBFB; CREB3; CTCF; DR1; E2F1; ELK3; FUS; GABPA; GTF2A1; HDAC5; HMGN3; 
HSBP1; ID3; IER5; IRF3; MEF2A; MEF2C; MXI1; MYCBP; NAB2; NCOA1; NCOA3; NFKB2; NMI; NR2C2; PCAF; PIAS1; PLRG1; PML; 
POU2AF1; RELB; RFX5; RFXAP; RNF12; RNF14; RXRA; SAP30; SF1; SIAH2; SMARCC1; SMARCE1; SQSTM1; TAF7; TAF9; TBPL1; 
TCERG1; TFDP1; TRIM32; TRIM33; TRIP13; TSG101; UBP1; YAF2; YY1; ZFX 
GO 
Molecul
ar 
Functio
n 
molecular
_function 
unknown 
59 1716 ABHD3; ABL1; AIF1; AIM1; APOA1BP; ATP6V0D1; CBFB; CD44; CDK5RAP1; CENTA2; CLTA; CLTB; COPZ2; CSRP2; CUL4B; DSCR3; 
EHD1; ETV3; FUS; HERPUD1; HRASLS3; IFIT1; IFIT2; ITSN1; LPP; LRBA; MATN2; MKRN1; MLH3; MRPL49; MRPS28; MST1; NUBP1; 
PCCA; PIGF; PPFIA4; PPIL2; PRKAG2; PTPN6; PTTG1IP; RNF6; RTN1; RTN3; RTN4; SEC24C; SEC24D; SHOC2; SPIB; STRN3; SURF4; 
TGM2; TM6SF1; TMEM8; TNFAIP1; TPM1; TPM3; TRIM17; UBE2V1; UXT 
GO cytoskelet 58 1716 ADD1; ANLN; BAIAP2; CAPZA1; CAPZA2; CAPZB; CFL2; CLASP1; CNN3; CORO1B; CORO2A; DBN1; DLG1; DSTN; EVL; FLII; FLNB; 
FSCN1; GABARAPL1; GABARAPL2; GMFB; GSN; HIP1; HOMER2; KIF1B; KLHL2; KLHL5; LCP1; LSP1; MAPRE1; MAPRE2; MARCKS; 
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 LI 
Molecul
ar 
Functio
n 
al protein 
binding 
MYO1C; MYO5A; MYO6; NEDD9; PDLIM2; PFN2; PLEC1; PLS3; RDX; SDC3; SDCBP; SEC24C; STMN3; TARDBP; TMOD3; TNNI2; TPM1; 
TPM2; TPM3; TPM4; TUBGCP5; VASP; VCL; WASF2; WASL; WDR1 
GO 
Molecul
ar 
Functio
n 
phosphori
c ester 
hydrolase 
activity 
56 1716 ACP1; ACP2; CCR5; CDC25A; CDC25C; CNP; CTDP1; DUSP1; DUSP11; DUSP16; DUSP19; DUSP22; DUSP6; DUSP7; ILKAP; IMPA1; 
INPP1; INPP4A; INPP5B; INPP5D; INPPL1; MTM1; MTMR1; MTMR4; MTMR6; NT5C2; PDE1B; PDE4B; PDE8A; PFKFB3; PLCE1; PLCG2; 
PPAP2A; PPAP2B; PPAP2C; PPEF2; PPM1A; PPM1B; PPP1CC; PPP2R1B; PPP2R2A; PPP3CA; PPP3CB; PPP6C; PTEN; PTP4A1; PTPLA; 
PTPN11; PTPN2; PTPN6; PTPN9; PTPRE; PTPRJ; PTPRS; SACM1L; UNC119 
GO 
Molecul
ar 
Functio
n 
ligase 
activity 
56 1716 ARIH1; BIRC6; CBL; CD48; CD68; CDCA7; CORO2A; CTPS; CUL1; CUL3; CUL4A; CUL4B; EPRS; FBXO11; FBXO25; FBXO3; FBXO4; 
FBXO6; HARS; HLCS; IARS; KARS; LAMP2; LAMP3; LIG1; LYPLA1; MDM2; MTHFS; NARS; NEDD4; NEDD4L; PAICS; PCCA; PJA1; QARS; 
QRSL1; RNF12; RNF14; RTCD1; SUCLG1; TRIP12; UBE2A; UBE2B; UBE2C; UBE2D1; UBE2D3; UBE2E1; UBE2E3; UBE2G1; UBE2J1; 
UBE2L3; UBE2L6; UBE2M; UBE2V1; UBE2V2; UBE3A 
GO 
Molecul
ar 
Functio
n 
ion 
transporter 
activity 
55 1716 ASNA1; ATOX1; ATP11A; ATP11B; ATP1B1; ATP2A2; ATP2C1; ATP5A1; ATP5C1; ATP5E; ATP6V0A2; ATP6V0B; ATP6V0D1; ATP6V1A; 
ATP6V1B2; ATP6V1C1; ATP6V1D; ATP6V1H; ATP7A; ATP8A1; COX15; COX5B; COX7C; GJA1; ITPR2; NDUFA5; NDUFA9; NDUFAB1; 
NDUFB4; NDUFB7; NDUFC2; NDUFS4; NDUFS5; NDUFV1; NNT; PLP2; SFXN2; SLC1A5; SLC22A5; SLC25A11; SLC30A4; SLC30A5; 
SLC30A7; SLC31A1; SLC31A2; SLC41A1; SLC4A1; SLC4A7; SLC6A6; SLC8A1; TCIRG1; TMEM1; TRPV2; UQCRB; UQCRFS1 
GO 
Molecul
ar 
Functio
n 
GTPase 
regulator 
activity 
52 1716 ABL1; ABR; ALCAM; ALS2; ARFGAP3; ARHGAP12; ARHGAP5; ARHGAP6; ARHGAP8; ARHGAP9; ARHGEF10; ARHGEF7; BNIP2; CENTA2; 
CENTD2; CHN2; CYFIP1; CYFIP2; DDEF1; ECT2; EIF2B2; FGD2; GDI1; GDI2; GIT2; GNG12; GPS1; IPO7; IQGAP1; ITSN1; MAP4K1; 
MAP4K3; MAP4K4; MAP4K5; MAPKAP1; PLCE1; PSCD2; RABIF; RAP1GDS1; RASA1; RASGRP4; RGS19; RGS2; RGS3; SHOC2; STARD8; 
TBC1D8; TIAM1; TRIO; VAV1; VAV3; WASL 
GO receptor 48 1716 ADAM23; ADAM9; AKAP9; ALCAM; ANXA1; APOE; BID; CCL22; CD80; CD8A; CKLF; CXCL10; CXCL16; CXCL9; DBI; DKK3; ENSA; 
ERBB2IP; FEM1B; FGL2; GLG1; GMFB; GPRC5B; GRN; HMGN3; IGF1; IK; IL15; IL16; IL18; INSL3; JAG2; MADD; MAP2K7; MYD88; NCOA3; 
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 LII 
Molecul
ar 
Functio
n 
binding PDGFA; PDGFC; PLXNC1; SDCBP; SRI; TAP2; TAPBP; TGFB3; TGFBI; TRIP12; TRIP6; WBP1 
GO 
Molecul
ar 
Functio
n 
GTPase 
activity 
48 1716 ARF1; ARF3; ARF4; ARFRP1; ARHGAP5; ARL1; ARL3; ARL6; CDC42; GBP1; GBP2; GBP3; GNA13; GNAI3; GNB2; GNB4; GNG10; GNG12; 
GNG2; GSPT1; GTPBP2; MFHAS1; MRAS; MX1; NCF1; NUDT1; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; RAB32; 
RAB33B; RAB5A; RAB6B; RAB7; RAC1; RALA; RALB; RAP1A; RAP1B; RAP2A; RRAS2; SAMHD1; TGM2; TUFM 
GO 
Molecul
ar 
Functio
n 
guanyl 
nucleotide 
binding 
47 1716 AK3; ARF1; ARF3; ARF4; ARFRP1; ARL1; ARL3; ARL6; CDC42; DEK; DRG1; EIF2B2; EIF2B4; GBP1; GBP2; GBP3; GNA13; GNAI3; GSPT1; 
GTPBP2; MFHAS1; MRAS; MX1; NCF1; NOLC1; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; RAB32; RAB33B; RAB5A; 
RAB6B; RAB7; RAC1; RALA; RALB; RAP1A; RAP1B; RAP2A; RRAS2; SUCLG1; TGM2; TUFM 
GO 
Molecul
ar 
Functio
n 
GTP 
binding 
47 1716 AK3; ARF1; ARF3; ARF4; ARFRP1; ARL1; ARL3; ARL6; CDC42; DEK; DRG1; EIF2B2; EIF2B4; GBP1; GBP2; GBP3; GNA13; GNAI3; GSPT1; 
GTPBP2; MFHAS1; MRAS; MX1; NCF1; NOLC1; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; RAB32; RAB33B; RAB5A; 
RAB6B; RAB7; RAC1; RALA; RALB; RAP1A; RAP1B; RAP2A; RRAS2; SUCLG1; TGM2; TUFM 
GO 
Molecul
ar 
Functio
n 
cation 
transporter 
activity 
47 1716 ATOX1; ATP11A; ATP11B; ATP1B1; ATP2A2; ATP2C1; ATP5A1; ATP5C1; ATP5E; ATP6V0A2; ATP6V0B; ATP6V0D1; ATP6V1A; ATP6V1B2; 
ATP6V1C1; ATP6V1D; ATP6V1H; ATP7A; ATP8A1; COX15; COX5B; COX7C; ITPR2; NDUFA5; NDUFA9; NDUFAB1; NDUFB4; NDUFB7; 
NDUFC2; NDUFS4; NDUFS5; NDUFV1; NNT; SFXN2; SLC1A5; SLC25A11; SLC30A4; SLC30A5; SLC30A7; SLC31A1; SLC31A2; SLC41A1; 
SLC8A1; TCIRG1; TMEM1; UQCRB; UQCRFS1 
GO actin 46 1716 ADD1; ANLN; CAPZA1; CAPZA2; CAPZB; CFL2; CNN3; CORO1B; CORO2A; DBN1; DSTN; EVL; FLII; FLNB; FSCN1; GABARAPL2; GMFB; 
GSN; HIP1; HOMER2; KLHL2; KLHL5; LCP1; LSP1; MARCKS; MYO1C; MYO5A; MYO6; NEDD9; PFN2; PLEC1; PLS3; RDX; SDCBP; 
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 LIII 
Molecul
ar 
Functio
n 
binding SEC24C; TMOD3; TNNI2; TPM1; TPM2; TPM3; TPM4; VASP; VCL; WASF2; WASL; WDR1 
GO 
Molecul
ar 
Functio
n 
receptor 
signaling 
protein 
activity 
46 1716 ACVR1; ACVRL1; ARF1; ARHGAP6; CARD10; CHN2; CHUK; CRK; EPS8; GNA13; HOMER2; IFITM3; IRAK1; ITSN2; JAK1; JAK2; JAK3; KIT; 
LASP1; LYN; MAP3K3; MAP3K4; MAP3K7; MAPK1; MAPK13; MAPK14; MAPK6; MAPK8; MAPK9; MS4A1; NSMAF; PDCL; PLCE1; 
SH3BGRL; SLA; STAM2; STAT1; STAT3; STK39; TGFBR1; TGFBR2; TIAM1; TOB2; TYK2; TYROBP; VAV3 
GO 
Molecul
ar 
Functio
n 
small 
GTPase 
regulatory/
interacting 
protein 
activity 
38 1716 ABL1; ABR; ALCAM; ALS2; ARFGAP3; ARHGAP12; ARHGAP5; ARHGAP6; ARHGAP9; ARHGEF10; ARHGEF7; CYFIP1; CYFIP2; ECT2; 
EIF2B2; FGD2; GDI1; GDI2; GNG12; IPO7; IQGAP1; ITSN1; MAP4K1; MAP4K3; MAP4K4; MAP4K5; MAPKAP1; PLCE1; PSCD2; RABIF; 
RASA1; RASGRP4; SHOC2; TIAM1; TRIO; VAV1; VAV3; WASL 
GO 
Molecul
ar 
Functio
n 
chaperone 
activity 
36 1716 ATOX1; BAG5; CANX; CCT3; CCT7; CD74; CDC37; CLN3; CRYAB; DNAJA1; DNAJB11; DNAJB4; DNAJB6; DNAJB9; DNAJC5; FKBP4; 
FUSIP1; GRPEL1; HSPA1A; HSPA1B; HSPA4; HSPA5; HSPA8; HSPH1; LMAN1; PFDN2; PPIH; PTPLA; RBBP4; SEC63; SSFA2; TAPBP; 
TBCD; TXNDC4; UXT; YWHAQ 
GO 
Molecul
ar 
Functio
n 
apoptosis 
regulator 
activity 
31 1716 APAF1; API5; BAD; BAG5; BCL10; BCL2L11; BFAR; BID; BIRC3; BIRC5; BIRC6; BNIP2; BNIP3L; CARD10; CASP2; CASP9; CFLAR; DAPK1; 
DAPK3; DFFA; DFFB; FAIM; IL18; MCL1; PRDX2; RNF7; RTN4; SH3GLB1; SON; STK17B; TAX1BP1 
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 LIV 
GO 
Molecul
ar 
Functio
n 
small 
monomeri
c GTPase 
activity 
29 1716 ARF1; ARF3; ARF4; ARFRP1; ARL1; ARL3; ARL6; CDC42; MFHAS1; MRAS; RAB10; RAB11A; RAB14; RAB24; RAB2B; RAB30; RAB31; 
RAB32; RAB33B; RAB5A; RAB6B; RAB7; RAC1; RALA; RALB; RAP1A; RAP1B; RAP2A; RRAS2 
GO 
Molecul
ar 
Functio
n 
defense/i
mmunity 
protein 
activity 
29 1716 APAF1; C1QA; C1QB; C6; CCL22; CD14; CD96; FTH1; HSPA1B; ICOS; IFI35; IFI44; IFNAR2; IFNGR2; LST1; LY75; MLF2; MST1; MX1; 
NOTCH1; PPP2R1B; PRKRA; SAMHD1; TAP2; TAPBP; TIAL1; TLR1; TLR3; TLR4 
GO 
Molecul
ar 
Functio
n 
receptor 
signaling 
protein 
serine/thre
onine 
kinase 
activity 
16 1716 ACVR1; ACVRL1; CHUK; IRAK1; MAP3K3; MAP3K4; MAP3K7; MAPK1; MAPK13; MAPK14; MAPK6; MAPK8; MAPK9; STK39; TGFBR1; 
TGFBR2 
GO 
Molecul
ar 
Functio
n 
hematopoi
etin/interfe
ron-class 
(D200-
domain) 
cytokine 
receptor 
activity 
14 1716 CRLF2; CSF2RA; CSF2RB; EBI3; IFNAR1; IFNAR2; IFNGR2; IL10RA; IL13RA1; IL15RA; IL1RAP; IL2RG; IL6ST; LIFR 
GO cytokine 14 1716 CCL22; CKLF; CXCL10; CXCL16; CXCL9; ERBB2IP; GRN; IK; IL15; IL16; IL18; PDGFA; SDCBP; TGFB3 
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 LV 
Molecul
ar 
Functio
n 
activity 
GO 
Molecul
ar 
Functio
n 
kinase 
regulator 
activity 
14 1716 CCNDBP1; CDKN1A; CSNK2B; CXCL10; GMFB; HMOX1; MADD; PHKA1; PHKB; PKIB; PKIG; PTGIS; SOCS5; YWHAQ 
GO 
Molecul
ar 
Functio
n 
apoptosis 
inhibitor 
activity 
14 1716 API5; BFAR; BIRC3; BIRC5; BIRC6; BNIP2; BNIP3L; CASP2; CFLAR; FAIM; PRDX2; RNF7; SON; TAX1BP1 
GO 
Molecul
ar 
Functio
n 
transmem
brane 
receptor 
protein 
kinase 
activity 
14 1716 ACVR1; ACVRL1; AXL; CRIM1; CSF1R; DDR1; FLT1; FLT3; IGF2R; KIT; MERTK; NRP1; TGFBR1; TGFBR2 
GO 
Molecul
ar 
Functio
n 
growth 
factor 
activity 
11 1716 DKK3; GMFB; GRN; IGF1; IL18; JAG2; MAP2K7; PDGFA; PDGFC; SDCBP; TGFB3 
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 LVI 
GO 
Molecul
ar 
Functio
n 
interleukin 
binding 
6 1716 CSF2RB; IL10RA; IL15RA; IL1RAP; IL2RG; IL6ST 
GO 
Molecul
ar 
Functio
n 
interleukin 
receptor 
activity 
6 1716 CSF2RB; IL10RA; IL15RA; IL1RAP; IL2RG; IL6ST 
GO 
Molecul
ar 
Functio
n 
growth 
factor 
binding 
6 1716 CRIM1; CSF2RB; IL10RA; IL1RAP; IL2RG; IL6ST 
GO 
Molecul
ar 
Functio
n 
apoptosis 
activator 
activity 
6 1716 APAF1; DAPK1; DAPK3; IL18; SH3GLB1; STK17B 
GO 
Molecul
ar 
Functio
n 
caspase 
activity 
6 1716 CASP2; CASP3; CASP6; CASP7; CASP9; CFLAR 
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 LVII 
GO 
Molecul
ar 
Functio
n 
transformi
ng growth 
factor-beta 
receptor 
activity 
4 1716 ACVR1; ACVRL1; TGFBR1; TGFBR2 
GO 
Molecul
ar 
Functio
n 
death 
receptor 
binding 
4 1716 BID; FEM1B; MADD; MYD88 
GO 
Molecul
ar 
Functio
n 
chemokine 
receptor 
activity 
4 1716 CCR5; CCR9; CXCR3; XCR1 
GO 
Molecul
ar 
Functio
n 
chemokine 
receptor 
binding 
4 1716 CCL22; CXCL10; CXCL16; CXCL9 
GO 
Molecul
ar 
Functio
n 
MAP 
kinase 
phosphata
se activity 
4 1716 DUSP1; DUSP16; DUSP6; DUSP7 
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 LVIII 
GO 
Molecul
ar 
Functio
n 
Ras 
interactor 
activity 
3 1716 MAPKAP1; PLCE1; SHOC2 
 
The above list was generated by use of the EASE version 2.0 software (Hosack et al. 2003). The "population" of genes is all genes assayed (i.e. all 
differentially expressed genes) and annotated within a given system of classifying genes (e.g. the 'Molecular Function' branch of the Gene 
Ontology).  Therefore the population can change from one system to the next.  "Hits" refers to genes falling within the gene category in question.  
Therefore "Population hits" for the Biological Process "apoptosis" refers to the number of genes falling within the category "apoptosis" out of all 
genes in the population annotated with a Biological Process.  EASE first maps all gene identifiers in the population to "primary gene identifiers".  
The default "primary gene identifier" in EASE is the LocusLink number.  This step controls for the possibility of multiple identifiers on the list 
referring to the same gene (typical of Genbank accessions), and that gene therefore receiving multiple spurious "votes" for its categories in the over-
representation analysis.  The primary gene identifiers are then mapped to gene categories within various categorical systems, the "Population Total" 
is determined for each system of gene categorization, and the "Population Hits" is determined for every category within those systems.   
Definitions of default fields in the results: 
System = the system of categorizing genes 
Gene Category = the specific category of genes within the System 
Population Hits = number of genes in the total group of genes assayed that belong to the specific Gene Category 
Population Total = number of genes in the total group of genes assayed that belong to any Gene Category within the System 
Genbank accessions = List of identifiers (in this case: Genbank accessions) from the gene list that fall into the Gene Category. 
Appendix 2 
 LIX 
Abarzua, F., M. Sakaguchi, M. Takaishi, Y. Nasu, K. Kurose, S. Ebara, M. Miyazaki, M. Namba, H. Kumon and N. H. Huh (2005). "Adenovirus-
mediated overexpression of REIC/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-
kinase." Cancer Res 65(21): 9617-22. 
Abarzua, F., M. Sakaguchi, R. Tanimoto, H. Sonegawa, D. W. Li, K. Edamura, T. Kobayashi, M. Watanabe, Y. Kashiwakura, H. Kaku, T. Saika, K. 
Nakamura, Y. Nasu, H. Kumon and N. H. Huh (2007). "Heat shock proteins play a crucial role in tumor-specific apoptosis by REIC/Dkk-3." 
Int J Mol Med 20(1): 37-43. 
Abi-Hanna, D., D. Wakefield and S. Watkins (1988). "HLA antigens in ocular tissues. I. In vivo expression in human eyes." Transplantation 45(3): 
610-3. 
Aktas, O., T. Prozorovski and F. Zipp (2006). "Death ligands and autoimmune demyelination." Neuroscientist 12(4): 305-16. 
Albert, M. L., B. Sauter and N. Bhardwaj (1998). "Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs." Nature 
392(6671): 86-9. 
Alderson, M. R., T. W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K. A. Schooley, R. G. Goodwin, C. A. Smith, F. Ramsdell and D. H. Lynch 
(1995). "Fas ligand mediates activation-induced cell death in human T lymphocytes." J Exp Med 181(1): 71-7. 
Alferink, J., B. Schittek, G. Schonrich, G. J. Hammerling and B. Arnold (1995). "Long life span of tolerant T cells and the role of antigen in 
maintenance of peripheral tolerance." Int Immunol 7(2): 331-6. 
Alferink, J., A. Tafuri, D. Vestweber, R. Hallmann, G. J. Hammerling and B. Arnold (1998). "Control of neonatal tolerance to tissue antigens by 
peripheral T cell trafficking." Science 282(5392): 1338-41. 
Algood, H. M. and J. L. Flynn (2004). "CCR5-deficient mice control Mycobacterium tuberculosis infection despite increased pulmonary 
lymphocytic infiltration." J Immunol 173(5): 3287-96. 
Anderson, G., J. J. Owen, N. C. Moore and E. J. Jenkinson (1994). "Thymic epithelial cells provide unique signals for positive selection of 
CD4+CD8+ thymocytes in vitro." J Exp Med 179(6): 2027-31. 
Andrade, F., L. A. Casciola-Rosen and A. Rosen (2004). "Granzyme B-induced cell death." Acta Haematol 111(1-2): 28-41. 
Apostolou, I., A. Sarukhan, L. Klein and H. von Boehmer (2002). "Origin of regulatory T cells with known specificity for antigen." Nat Immunol 
3(8): 756-63. 
Apostolou, I. and H. von Boehmer (2004). "In vivo instruction of suppressor commitment in naive T cells." J Exp Med 199(10): 1401-8. 
Aranami, T. and T. Yamamura (2008). "Th17 Cells and Autoimmune Encephalomyelitis (EAE/MS)." Allergol Int 57(2): 115-20. 
Askenasy, N., E. S. Yolcu, I. Yaniv and H. Shirwan (2005). "Induction of tolerance using Fas ligand: a double-edged immunomodulator." Blood 
105(4): 1396-404. 
Azuma, M., M. Cayabyab, D. Buck, J. H. Phillips and L. L. Lanier (1992). "CD28 interaction with B7 costimulates primary allogeneic proliferative 
responses and cytotoxicity mediated by small, resting T lymphocytes." J Exp Med 175(2): 353-60. 
Banchereau, J. and R. M. Steinman (1998). "Dendritic cells and the control of immunity." Nature 392(6673): 245-52. 
Appendix 2 
 LX 
Barrantes Idel, B., A. Montero-Pedrazuela, A. Guadano-Ferraz, M. J. Obregon, R. Martinez de Mena, V. Gailus-Durner, H. Fuchs, T. J. Franz, S. 
Kalaydjiev, M. Klempt, S. Holter, B. Rathkolb, C. Reinhard, G. Morreale de Escobar, J. Bernal, D. H. Busch, W. Wurst, E. Wolf, H. Schulz, 
S. Shtrom, E. Greiner, M. Hrabe de Angelis, H. Westphal and C. Niehrs (2006). "Generation and characterization of dickkopf3 mutant 
mice." Mol Cell Biol 26(6): 2317-26. 
Belkaid, Y., C. A. Piccirillo, S. Mendez, E. M. Shevach and D. L. Sacks (2002). "CD4+CD25+ regulatory T cells control Leishmania major 
persistence and immunity." Nature 420(6915): 502-7. 
Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance and H. D. Ochs 
(2001). "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3." Nat 
Genet 27(1): 20-1. 
Bettelli, E., M. Pagany, H. L. Weiner, C. Linington, R. A. Sobel and V. K. Kuchroo (2003). "Myelin oligodendrocyte glycoprotein-specific T cell 
receptor transgenic mice develop spontaneous autoimmune optic neuritis." J Exp Med 197(9): 1073-81. 
Bluestone, J. A. and A. K. Abbas (2003). "Natural versus adaptive regulatory T cells." Nat Rev Immunol 3(3): 253-7. 
Bopp, T., C. Becker, M. Klein, S. Klein-Hessling, A. Palmetshofer, E. Serfling, V. Heib, M. Becker, J. Kubach, S. Schmitt, S. Stoll, H. Schild, M. 
S. Staege, M. Stassen, H. Jonuleit and E. Schmitt (2007). "Cyclic adenosine monophosphate is a key component of regulatory T cell-
mediated suppression." J Exp Med 204(6): 1303-10. 
Bouneaud, C., P. Kourilsky and P. Bousso (2000). "Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of 
T cell clones escapes clonal deletion." Immunity 13(6): 829-40. 
Brocker, T., M. Riedinger and K. Karjalainen (1997). "Targeted expression of major histocompatibility complex (MHC) class II molecules 
demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo." J Exp Med 185(3): 541-50. 
Bruder, D., M. Probst-Kepper, A. M. Westendorf, R. Geffers, S. Beissert, K. Loser, H. von Boehmer, J. Buer and W. Hansen (2004). "Neuropilin-1: 
a surface marker of regulatory T cells." Eur J Immunol 34(3): 623-30. 
Burkly, L. C., S. Degermann, J. Longley, J. Hagman, R. L. Brinster, D. Lo and R. A. Flavell (1993). "Clonal deletion of V beta 5+ T cells by 
transgenic I-E restricted to thymic medullary epithelium." J Immunol 151(8): 3954-60. 
Cadigan, K. M. and Y. I. Liu (2006). "Wnt signaling: complexity at the surface." J Cell Sci 119(Pt 3): 395-402. 
Calne, R. Y., H. J. White, R. M. Binns, B. M. Herbertson, P. R. Millard, J. Pena, J. R. Salaman, J. R. Samuel and D. R. Davis (1969). 
"Immunosuppressive effects of the orthotopically transplanted porcine liver." Transplant Proc 1(1): 321-4. 
Cantrell, D. (1996). "T cell antigen receptor signal transduction pathways." Annu Rev Immunol 14: 259-74. 
Cao, X., S. F. Cai, T. A. Fehniger, J. Song, L. I. Collins, D. R. Piwnica-Worms and T. J. Ley (2007). "Granzyme B and perforin are important for 
regulatory T cell-mediated suppression of tumor clearance." Immunity 27(4): 635-46. 
Cardell, S., B. Sander and G. Moller (1992). "Primary stimulation of CD4+ cells in the presence of IL-4 or IFN-gamma alters the frequencies of 
cytokine-producing cells at restimulation." Scand J Immunol 36(6): 769-77. 
Appendix 2 
 LXI 
Chatila, T. A., F. Blaeser, N. Ho, H. M. Lederman, C. Voulgaropoulos, C. Helms and A. M. Bowcock (2000). "JM2, encoding a fork head-related 
protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome." J Clin Invest 106(12): R75-81. 
Chen, W., M. S. Ford, K. J. Young and L. Zhang (2004). "The role and mechanisms of double negative regulatory T cells in the suppression of 
immune responses." Cell Mol Immunol 1(5): 328-35. 
Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady and S. M. Wahl (2003). "Conversion of peripheral CD4+CD25- naive T 
cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3." J Exp Med 198(12): 1875-86. 
Chen, Y., V. K. Kuchroo, J. Inobe, D. A. Hafler and H. L. Weiner (1994). "Regulatory T cell clones induced by oral tolerance: suppression of 
autoimmune encephalomyelitis." Science 265(5176): 1237-40. 
Collison, L. W., C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg and D. A. Vignali (2007). "The 
inhibitory cytokine IL-35 contributes to regulatory T-cell function." Nature 450(7169): 566-9. 
Crabtree, G. R. (1989). "Contingent genetic regulatory events in T lymphocyte activation." Science 243(4889): 355-61. 
Crispe, I. N., M. Giannandrea, I. Klein, B. John, B. Sampson and S. Wuensch (2006). "Cellular and molecular mechanisms of liver tolerance." 
Immunol Rev 213: 101-18. 
Deaglio, S., K. M. Dwyer, W. Gao, D. Friedman, A. Usheva, A. Erat, J. F. Chen, K. Enjyoji, J. Linden, M. Oukka, V. K. Kuchroo, T. B. Strom and 
S. C. Robson (2007). "Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression." J 
Exp Med 204(6): 1257-65. 
Derbinski, J., A. Schulte, B. Kyewski and L. Klein (2001). "Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral 
self." Nat Immunol 2(11): 1032-9. 
Derynck, R. and Y. E. Zhang (2003). "Smad-dependent and Smad-independent pathways in TGF-beta family signalling." Nature 425(6958): 577-
84. 
Devergne, O., M. Birkenbach and E. Kieff (1997). "Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel 
heterodimeric hematopoietin." Proc Natl Acad Sci U S A 94(22): 12041-6. 
Dorr, J., I. Bechmann, S. Waiczies, O. Aktas, H. Walczak, P. H. Krammer, R. Nitsch and F. Zipp (2002). "Lack of tumor necrosis factor-related 
apoptosis-inducing ligand but presence of its receptors in the human brain." J Neurosci 22(4): RC209. 
Dubois, P. M., M. Pihlgren, M. Tomkowiak, M. Van Mechelen and J. Marvel (1998). "Tolerant CD8 T cells induced by multiple injections of 
peptide antigen show impaired TCR signaling and altered proliferative responses in vitro and in vivo." J Immunol 161(10): 5260-7. 
Edamura, K., Y. Nasu, M. Takaishi, T. Kobayashi, F. Abarzua, M. Sakaguchi, Y. Kashiwakura, S. Ebara, T. Saika, M. Watanabe, N. H. Huh and H. 
Kumon (2007). "Adenovirus-mediated REIC/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer 
model." Cancer Gene Ther 14(9): 765-72. 
Endharti, A. T., I. M. s. Rifa, Z. Shi, Y. Fukuoka, Y. Nakahara, Y. Kawamoto, K. Takeda, K. Isobe and H. Suzuki (2005). "Cutting edge: 
CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells." J Immunol 175(11): 
7093-7. 
Appendix 2 
 LXII 
Etheridge, S. L., G. J. Spencer, D. J. Heath and P. G. Genever (2004). "Expression profiling and functional analysis of wnt signaling mechanisms in 
mesenchymal stem cells." Stem Cells 22(5): 849-60. 
Fathman, C. G. and N. B. Lineberry (2007). "Molecular mechanisms of CD4+ T-cell anergy." Nat Rev Immunol 7(8): 599-609. 
Fedders, H., R. Augustin and T. C. Bosch (2004). "A Dickkopf- 3-related gene is expressed in differentiating nematocytes in the basal metazoan 
Hydra." Dev Genes Evol 214(2): 72-80. 
Ferber, I., G. Schonrich, J. Schenkel, A. L. Mellor, G. J. Hammerling and B. Arnold (1994). "Levels of peripheral T cell tolerance induced by 
different doses of tolerogen." Science 263(5147): 674-6. 
Fields, P. E., T. F. Gajewski and F. W. Fitch (1996). "Blocked Ras activation in anergic CD4+ T cells." Science 271(5253): 1276-8. 
Filaci, G., M. Fravega, D. Fenoglio, M. Rizzi, S. Negrini, R. Viggiani and F. Indiveri (2004). "Non-antigen specific CD8+ T suppressor 
lymphocytes." Clin Exp Med 4(2): 86-92. 
Floess, S., J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H. D. Chang, T. Bopp, E. Schmitt, S. Klein-Hessling, E. Serfling, A. 
Hamann and J. Huehn (2007). "Epigenetic control of the foxp3 locus in regulatory T cells." PLoS Biol 5(2): e38. 
Fontenot, J. D., M. A. Gavin and A. Y. Rudensky (2003). "Foxp3 programs the development and function of CD4+CD25+ regulatory T cells." Nat 
Immunol 4(4): 330-6. 
Friese, M. A. and L. Fugger (2005). "Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?" Brain 128(Pt 8): 1747-63. 
Gallegos, A. M. and M. J. Bevan (2004). "Central tolerance to tissue-specific antigens mediated by direct and indirect antigen presentation." J Exp 
Med 200(8): 1039-49. 
Glass, W. G., M. T. Liu, W. A. Kuziel and T. E. Lane (2001). "Reduced macrophage infiltration and demyelination in mice lacking the chemokine 
receptor CCR5 following infection with a neurotropic coronavirus." Virology 288(1): 8-17. 
Glinka, A., W. Wu, H. Delius, A. P. Monaghan, C. Blumenstock and C. Niehrs (1998). "Dickkopf-1 is a member of a new family of secreted 
proteins and functions in head induction." Nature 391(6665): 357-62. 
Glinka, Y. and G. J. Prud'homme (2008). "Neuropilin-1 is a receptor for transforming growth factor beta-1, activates its latent form, and promotes 
regulatory T cell activity." J Leukoc Biol 84(1): 302-10. 
Gondek, D. C., L. F. Lu, S. A. Quezada, S. Sakaguchi and R. J. Noelle (2005). "Cutting edge: contact-mediated suppression by CD4+CD25+ 
regulatory cells involves a granzyme B-dependent, perforin-independent mechanism." J Immunol 174(4): 1783-6. 
Gordon, L. B., P. M. Knopf and H. F. Cserr (1992). "Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into 
extracerebral sites." J Neuroimmunol 40(1): 81-7. 
Greenwald, R. J., G. J. Freeman and A. H. Sharpe (2005). "The B7 family revisited." Annu Rev Immunol 23: 515-48. 
Griffiths, G. M. (1995). "The cell biology of CTL killing." Curr Opin Immunol 7(3): 343-8. 
Grossman, W. J., J. W. Verbsky, W. Barchet, M. Colonna, J. P. Atkinson and T. J. Ley (2004). "Human T regulatory cells can use the perforin 
pathway to cause autologous target cell death." Immunity 21(4): 589-601. 
Groux, H. (2001). "An overview of regulatory T cells." Microbes Infect 3(11): 883-9. 
Appendix 2 
 LXIII 
Groux, H., A. O'Garra, M. Bigler, M. Rouleau, S. Antonenko, J. E. de Vries and M. G. Roncarolo (1997). "A CD4+ T-cell subset inhibits antigen-
specific T-cell responses and prevents colitis." Nature 389(6652): 737-42. 
Guder, C., S. Pinho, T. G. Nacak, H. A. Schmidt, B. Hobmayer, C. Niehrs and T. W. Holstein (2006). "An ancient Wnt-Dickkopf antagonism in 
Hydra." Development 133(5): 901-11. 
Harling-Berg, C., P. M. Knopf, J. Merriam and H. F. Cserr (1989). "Role of cervical lymph nodes in the systemic humoral immune response to 
human serum albumin microinfused into rat cerebrospinal fluid." J Neuroimmunol 25(2-3): 185-93. 
Harling-Berg, C. J., P. M. Knopf and H. F. Cserr (1991). "Myelin basic protein infused into cerebrospinal fluid suppresses experimental 
autoimmune encephalomyelitis." J Neuroimmunol 35(1-3): 45-51. 
Harrington, L. E., P. R. Mangan and C. T. Weaver (2006). "Expanding the effector CD4 T-cell repertoire: the Th17 lineage." Curr Opin Immunol 
18(3): 349-56. 
Harris, J. E., K. D. Bishop, N. E. Phillips, J. P. Mordes, D. L. Greiner, A. A. Rossini and M. P. Czech (2004). "Early growth response gene-2, a 
zinc-finger transcription factor, is required for full induction of clonal anergy in CD4+ T cells." J Immunol 173(12): 7331-8. 
Hayday, A. and R. Tigelaar (2003). "Immunoregulation in the tissues by gammadelta T cells." Nat Rev Immunol 3(3): 233-42. 
Heath, W. R., C. Kurts, J. F. Miller and F. R. Carbone (1998). "Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens." J 
Exp Med 187(10): 1549-53. 
Heissmeyer, V. and A. Rao (2004). "E3 ligases in T cell anergy--turning immune responses into tolerance." Sci STKE 2004(241): pe29. 
Hermann, M., D. Pirkebner, A. Draxl, P. Berger, G. Untergasser, R. Margreiter and P. Hengster (2007). "Dickkopf-3 is expressed in a subset of 
adult human pancreatic beta cells." Histochem Cell Biol 127(5): 513-21. 
Holscher, C. (2004). "The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases." Med Microbiol 
Immunol 193(1): 1-17. 
Hori, S., T. Nomura and S. Sakaguchi (2003). "Control of regulatory T cell development by the transcription factor Foxp3." Science 299(5609): 
1057-61. 
Horwitz, D. A., S. G. Zheng and J. D. Gray (2003). "The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of 
CD4+ CD25+ and CD8+ regulatory T cell subsets." J Leukoc Biol 74(4): 471-8. 
Hosack, D. A., G. Dennis, Jr., B. T. Sherman, H. C. Lane and R. A. Lempicki (2003). "Identifying biological themes within lists of genes with 
EASE." Genome Biol 4(10): R70. 
Hsieh, C. S., Y. Zheng, Y. Liang, J. D. Fontenot and A. Y. Rudensky (2006). "An intersection between the self-reactive regulatory and 
nonregulatory T cell receptor repertoires." Nat Immunol 7(4): 401-10. 
Hsieh, S. Y., P. S. Hsieh, C. T. Chiu and W. Y. Chen (2004). "Dickkopf-3/REIC functions as a suppressor gene of tumor growth." Oncogene 
23(57): 9183-9. 
Hu, D., K. Ikizawa, L. Lu, M. E. Sanchirico, M. L. Shinohara and H. Cantor (2004). "Analysis of regulatory CD8 T cells in Qa-1-deficient mice." 
Nat Immunol 5(5): 516-23. 
Appendix 2 
 LXIV 
Hua, C., C. Boyer, M. Buferne and A. M. Schmitt-Verhulst (1986). "Monoclonal antibodies against an H-2Kb-specific cytotoxic T cell clone detect 
several clone-specific molecules." J Immunol 136(6): 1937-44. 
Huesmann, M., B. Scott, P. Kisielow and H. von Boehmer (1991). "Kinetics and efficacy of positive selection in the thymus of normal and T cell 
receptor transgenic mice." Cell 66(3): 533-40. 
Huffnagle, G. B., L. K. McNeil, R. A. McDonald, J. W. Murphy, G. B. Toews, N. Maeda and W. A. Kuziel (1999). "Cutting edge: Role of C-C 
chemokine receptor 5 in organ-specific and innate immunity to Cryptococcus neoformans." J Immunol 163(9): 4642-6. 
Huseby, E. S., D. Liggitt, T. Brabb, B. Schnabel, C. Ohlen and J. Goverman (2001). "A pathogenic role for myelin-specific CD8(+) T cells in a 
model for multiple sclerosis." J Exp Med 194(5): 669-76. 
Huseby, E. S., C. Ohlen and J. Goverman (1999). "Cutting edge: myelin basic protein-specific cytotoxic T cell tolerance is maintained in vivo by a 
single dominant epitope in H-2k mice." J Immunol 163(3): 1115-8. 
Itoh, M., T. Takahashi, N. Sakaguchi, Y. Kuniyasu, J. Shimizu, F. Otsuka and S. Sakaguchi (1999). "Thymus and autoimmunity: production of 
CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance." J 
Immunol 162(9): 5317-26. 
Jenkins, M. K., D. M. Pardoll, J. Mizuguchi, H. Quill and R. H. Schwartz (1987). "T-cell unresponsiveness in vivo and in vitro: fine specificity of 
induction and molecular characterization of the unresponsive state." Immunol Rev 95: 113-35. 
Jeremias, I., I. Herr, T. Boehler and K. M. Debatin (1998). "TRAIL/Apo-2-ligand-induced apoptosis in human T cells." Eur J Immunol 28(1): 143-
52. 
Ji, Q. and J. Goverman (2007). "Experimental autoimmune encephalomyelitis mediated by CD8+ T cells." Ann N Y Acad Sci 1103: 157-66. 
Jiang, H., S. Curran, E. Ruiz-Vazquez, B. Liang, R. Winchester and L. Chess (2003). "Regulatory CD8+ T cells fine-tune the myelin basic protein-
reactive T cell receptor V beta repertoire during experimental autoimmune encephalomyelitis." Proc Natl Acad Sci U S A 100(14): 8378-83. 
Jiang, L., P. Yang, H. He, B. Li, X. Lin, S. Hou, H. Zhou, X. Huang and K. Aize (2007). "Increased expression of Foxp3 in splenic CD8+ T cells 
from mice with anterior chamber-associated immune deviation." Mol Vis 13: 968-74. 
Jordan, M. S., A. Boesteanu, A. J. Reed, A. L. Petrone, A. E. Holenbeck, M. A. Lerman, A. Naji and A. J. Caton (2001). "Thymic selection of 
CD4+CD25+ regulatory T cells induced by an agonist self-peptide." Nat Immunol 2(4): 301-6. 
Jorgensen, S. H., P. E. Jensen, H. Laursen and P. S. Sorensen (2005). "Intravenous immunoglobulin ameliorates experimental autoimmune 
encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically." Neurol Res 27(6): 591-7. 
Jorgensen, S. H., N. Storm, P. E. Jensen, H. Laursen and P. S. Sorensen (2007). "IVIG enters the central nervous system during treatment of 
experimental autoimmune encephalomyelitis and is localised to inflammatory lesions." Exp Brain Res 178(4): 462-9. 
June, C. H., J. A. Bluestone, L. M. Nadler and C. B. Thompson (1994). "The B7 and CD28 receptor families." Immunol Today 15(7): 321-31. 
Kaech, S. M., S. Hemby, E. Kersh and R. Ahmed (2002). "Molecular and functional profiling of memory CD8 T cell differentiation." Cell 111(6): 
837-51. 
Appendix 2 
 LXV 
Kang, S. M., B. Beverly, A. C. Tran, K. Brorson, R. H. Schwartz and M. J. Lenardo (1992). "Transactivation by AP-1 is a molecular target of T cell 
clonal anergy." Science 257(5073): 1134-8. 
Kaplan, H. J. and J. W. Streilein (1977). "Immune response to immunization via the anterior chamber of the eye. I. F. lymphocyte-induced immune 
deviation." J Immunol 118(3): 809-14. 
Kapp, J. A., K. Honjo, L. M. Kapp, X. Xu, A. Cozier and R. P. Bucy (2006). "TCR transgenic CD8+ T cells activated in the presence of TGFbeta 
express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection." Int Immunol 18(11): 1549-62. 
Kappler, J. W., N. Roehm and P. Marrack (1987). "T cell tolerance by clonal elimination in the thymus." Cell 49(2): 273-80. 
Kawabe, Y. and A. Ochi (1990). "Selective anergy of V beta 8+,CD4+ T cells in Staphylococcus enterotoxin B-primed mice." J Exp Med 172(4): 
1065-70. 
Kawahata, K., Y. Misaki, M. Yamauchi, S. Tsunekawa, K. Setoguchi, J. Miyazaki and K. Yamamoto (2002). "Generation of CD4(+)CD25(+) 
regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by 
endogenous TCR expression." J Immunol 168(9): 4399-405. 
Kawano, Y., M. Kitaoka, Y. Hamada, M. M. Walker, J. Waxman and R. M. Kypta (2006). "Regulation of prostate cell growth and morphogenesis 
by Dickkopf-3." Oncogene 25(49): 6528-37. 
Kawano, Y. and R. Kypta (2003). "Secreted antagonists of the Wnt signalling pathway." J Cell Sci 116(Pt 13): 2627-34. 
Kearney, E. R., K. A. Pape, D. Y. Loh and M. K. Jenkins (1994). "Visualization of peptide-specific T cell immunity and peripheral tolerance 
induction in vivo." Immunity 1(4): 327-39. 
Kim, J. M., J. P. Rasmussen and A. Y. Rudensky (2007). "Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice." 
Nat Immunol 8(2): 191-7. 
Kimpton, W. G., E. A. Washington and R. N. Cahill (1995). "Virgin alpha beta and gamma delta T cells recirculate extensively through peripheral 
tissues and skin during normal development of the fetal immune system." Int Immunol 7(10): 1567-77. 
Kingsley, C. I., M. Karim, A. R. Bushell and K. J. Wood (2002). "CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-
dependent immunoregulation of alloresponses." J Immunol 168(3): 1080-6. 
Kisielow, P. (1988). "The true function of the thymus." Immunol Today 9(12): 367. 
Knolle, P. A., E. Schmitt, S. Jin, T. Germann, R. Duchmann, S. Hegenbarth, G. Gerken and A. W. Lohse (1999). "Induction of cytokine production 
in naive CD4(+) T cells by antigen-presenting murine liver sinusoidal endothelial cells but failure to induce differentiation toward Th1 
cells." Gastroenterology 116(6): 1428-40. 
Kobayashi, K., M. Ouchida, T. Tsuji, H. Hanafusa, M. Miyazaki, M. Namba, N. Shimizu and K. Shimizu (2002). "Reduced expression of the 
REIC/Dkk-3 gene by promoter-hypermethylation in human tumor cells." Gene 282(1-2): 151-8. 
Kohn, A. D. and R. T. Moon (2005). "Wnt and calcium signaling: beta-catenin-independent pathways." Cell Calcium 38(3-4): 439-46. 
Korn, T., M. Oukka, V. Kuchroo and E. Bettelli (2007). "Th17 cells: effector T cells with inflammatory properties." Semin Immunol 19(6): 362-71. 
Appendix 2 
 LXVI 
Krakowski, M. and T. Owens (1996). "Interferon-gamma confers resistance to experimental allergic encephalomyelitis." Eur J Immunol 26(7): 
1641-6. 
Kretschmer, K., I. Apostolou, D. Hawiger, K. Khazaie, M. C. Nussenzweig and H. von Boehmer (2005). "Inducing and expanding regulatory T cell 
populations by foreign antigen." Nat Immunol 6(12): 1219-27. 
Krupnik, V. E., J. D. Sharp, C. Jiang, K. Robison, T. W. Chickering, L. Amaravadi, D. E. Brown, D. Guyot, G. Mays, K. Leiby, B. Chang, T. 
Duong, A. D. Goodearl, D. P. Gearing, S. Y. Sokol and S. A. McCarthy (1999). "Functional and structural diversity of the human Dickkopf 
gene family." Gene 238(2): 301-13. 
Kumar, V. (2004). "Homeostatic control of immunity by TCR peptide-specific Tregs." J Clin Invest 114(9): 1222-6. 
Kuphal, S., S. Lodermeyer, F. Bataille, M. Schuierer, B. H. Hoang and A. K. Bosserhoff (2006). "Expression of Dickkopf genes is strongly reduced 
in malignant melanoma." Oncogene 25(36): 5027-36. 
Kurts, C., W. R. Heath, H. Kosaka, J. F. Miller and F. R. Carbone (1998). "The peripheral deletion of autoreactive CD8+ T cells induced by cross-
presentation of self-antigens involves signaling through CD95 (Fas, Apo-1)." J Exp Med 188(2): 415-20. 
Kwidzinski, E. and I. Bechmann (2007). "IDO expression in the brain: a double-edged sword." J Mol Med 85(12): 1351-9. 
Lampson, L. A. and C. A. Fisher (1984). "Weak HLA and beta 2-microglobulin expression of neuronal cell lines can be modulated by interferon." 
Proc Natl Acad Sci U S A 81(20): 6476-80. 
Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein and D. J. Cua (2005). "IL-
23 drives a pathogenic T cell population that induces autoimmune inflammation." J Exp Med 201(2): 233-40. 
Leifeld, L., C. Trautwein, F. L. Dumoulin, M. P. Manns, T. Sauerbruch and U. Spengler (1999). "Enhanced expression of CD80 (B7-1), CD86 (B7-
2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure." Am J Pathol 154(6): 1711-20. 
Lenardo, M., K. M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang and L. Zheng (1999). "Mature T lymphocyte apoptosis--immune 
regulation in a dynamic and unpredictable antigenic environment." Annu Rev Immunol 17: 221-53. 
Li, M. O., Y. Y. Wan and R. A. Flavell (2007). "T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and 
Th17-cell differentiation." Immunity 26(5): 579-91. 
Li, W., C. D. Whaley, A. Mondino and D. L. Mueller (1996). "Blocked signal transduction to the ERK and JNK protein kinases in anergic CD4+ T 
cells." Science 271(5253): 1272-6. 
Limmer, A., J. Ohl, C. Kurts, H. G. Ljunggren, Y. Reiss, M. Groettrup, F. Momburg, B. Arnold and P. A. Knolle (2000). "Efficient presentation of 
exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance." Nat Med 6(12): 1348-54. 
Liu, Y. J., V. Soumelis, N. Watanabe, T. Ito, Y. H. Wang, W. Malefyt Rde, M. Omori, B. Zhou and S. F. Ziegler (2007). "TSLP: an epithelial cell 
cytokine that regulates T cell differentiation by conditioning dendritic cell maturation." Annu Rev Immunol 25: 193-219. 
Lodygin, D., A. Epanchintsev, A. Menssen, J. Diebold and H. Hermeking (2005). "Functional epigenomics identifies genes frequently silenced in 
prostate cancer." Cancer Res 65(10): 4218-27. 
Loeser, S. and J. M. Penninger (2007). "Regulation of peripheral T cell tolerance by the E3 ubiquitin ligase Cbl-b." Semin Immunol 19(3): 206-14. 
Appendix 2 
 LXVII 
Lohse, A. W., P. A. Knolle, K. Bilo, A. Uhrig, C. Waldmann, M. Ibe, E. Schmitt, G. Gerken and K. H. Meyer Zum Buschenfelde (1996). "Antigen-
presenting function and B7 expression of murine sinusoidal endothelial cells and Kupffer cells." Gastroenterology 110(4): 1175-81. 
Lord, S. J., R. V. Rajotte, G. S. Korbutt and R. C. Bleackley (2003). "Granzyme B: a natural born killer." Immunol Rev 193: 31-8. 
Lutz, M. B. and G. Schuler (2002). "Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?" Trends 
Immunol 23(9): 445-9. 
Lyakh, L., P. Ghosh and N. R. Rice (1997). "Expression of NFAT-family proteins in normal human T cells." Mol Cell Biol 17(5): 2475-84. 
Macian, F., F. Garcia-Cozar, S. H. Im, H. F. Horton, M. C. Byrne and A. Rao (2002). "Transcriptional mechanisms underlying lymphocyte 
tolerance." Cell 109(6): 719-31. 
Madakamutil, L. T., I. Maricic, E. Sercarz and V. Kumar (2003). "Regulatory T cells control autoimmunity in vivo by inducing apoptotic depletion 
of activated pathogenic lymphocytes." J Immunol 170(6): 2985-92. 
Mahic, M., K. Henjum, S. Yaqub, B. A. Bjornbeth, K. M. Torgersen, K. Tasken and E. M. Aandahl (2008). "Generation of highly suppressive 
adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation." Eur J Immunol 38(3): 640-6. 
Maloy, K. J. and F. Powrie (2001). "Regulatory T cells in the control of immune pathology." Nat Immunol 2(9): 816-22. 
Maloy, K. J., L. Salaun, R. Cahill, G. Dougan, N. J. Saunders and F. Powrie (2003). "CD4+CD25+ T(R) cells suppress innate immune pathology 
through cytokine-dependent mechanisms." J Exp Med 197(1): 111-9. 
Mao, B., W. Wu, G. Davidson, J. Marhold, M. Li, B. M. Mechler, H. Delius, D. Hoppe, P. Stannek, C. Walter, A. Glinka and C. Niehrs (2002). 
"Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling." Nature 417(6889): 664-7. 
Mao, B., W. Wu, Y. Li, D. Hoppe, P. Stannek, A. Glinka and C. Niehrs (2001). "LDL-receptor-related protein 6 is a receptor for Dickkopf 
proteins." Nature 411(6835): 321-5. 
Mariani, S. M. and P. H. Krammer (1998). "Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells." Eur J Immunol 28(5): 
1492-8. 
McLean, J. M. and R. J. Scothorne (1970). "The lymphatics of the endometrium in the rabbit." J Anat 107(Pt 1): 39-48. 
Medawar (1948). "Immunity to homologous skin grafting III. The fate of skin homografts transplanted to the brain and to the anterior chamber of 
the eye." Br J Exp Path 29: 58-69. 
Micklem, H. S., C. E. Ford, E. P. Evans and J. Gray (1966). "Interrelationships of myeloid and lymphoid cells: studies with chromosome-marked 
cells transfused into lethally irradiated mice." Proc R Soc Lond B Biol Sci 165(998): 78-102. 
Micsenyi, A., X. Tan, T. Sneddon, J. H. Luo, G. K. Michalopoulos and S. P. Monga (2004). "Beta-catenin is temporally regulated during normal 
liver development." Gastroenterology 126(4): 1134-46. 
Modigliani, Y., A. Coutinho, P. Pereira, N. Le Douarin, V. Thomas-Vaslin, O. Burlen-Defranoux, J. Salaun and A. Bandeira (1996). "Establishment 
of tissue-specific tolerance is driven by regulatory T cells selected by thymic epithelium." Eur J Immunol 26(8): 1807-15. 
Mogil, R. J., L. Radvanyi, R. Gonzalez-Quintial, R. Miller, G. Mills, A. N. Theofilopoulos and D. R. Green (1995). "Fas (CD95) participates in 
peripheral T cell deletion and associated apoptosis in vivo." Int Immunol 7(9): 1451-8. 
Appendix 2 
 LXVIII 
Monaghan, A. P., P. Kioschis, W. Wu, A. Zuniga, D. Bock, A. Poustka, H. Delius and C. Niehrs (1999). "Dickkopf genes are co-ordinately 
expressed in mesodermal lineages." Mech Dev 87(1-2): 45-56. 
Moore, M. A. and J. J. Owen (1965). "Chromosome marker studies on the development of the haemopoietic system in the chick embryo." Nature 
208(5014): 956 passim. 
Moore, M. A. and J. J. Owen (1967). "Experimental studies on the development of the thymus." J Exp Med 126(4): 715-26. 
Morelli, A. E. and A. W. Thomson (2003). "Dendritic cells: regulators of alloimmunity and opportunities for tolerance induction." Immunol Rev 
196: 125-46. 
Mukhopadhyay, M., S. Shtrom, C. Rodriguez-Esteban, L. Chen, T. Tsukui, L. Gomer, D. W. Dorward, A. Glinka, A. Grinberg, S. P. Huang, C. 
Niehrs, J. C. Belmonte and H. Westphal (2001). "Dickkopf1 is required for embryonic head induction and limb morphogenesis in the 
mouse." Dev Cell 1(3): 423-34. 
Murai, M., H. Yoneyama, T. Ezaki, M. Suematsu, Y. Terashima, A. Harada, H. Hamada, H. Asakura, H. Ishikawa and K. Matsushima (2003). 
"Peyer's patch is the essential site in initiating murine acute and lethal graft-versus-host reaction." Nat Immunol 4(2): 154-60. 
Murphy, P. M., M. Baggiolini, I. F. Charo, C. A. Hebert, R. Horuk, K. Matsushima, L. H. Miller, J. J. Oppenheim and C. A. Power (2000). 
"International union of pharmacology. XXII. Nomenclature for chemokine receptors." Pharmacol Rev 52(1): 145-76. 
Nagata, S. (1997). "Apoptosis by death factor." Cell 88(3): 355-65. 
Najafian, N., T. Chitnis, A. D. Salama, B. Zhu, C. Benou, X. Yuan, M. R. Clarkson, M. H. Sayegh and S. J. Khoury (2003). "Regulatory functions 
of CD8+CD28- T cells in an autoimmune disease model." J Clin Invest 112(7): 1037-48. 
Nakao, A., T. Imamura, S. Souchelnytskyi, M. Kawabata, A. Ishisaki, E. Oeda, K. Tamaki, J. Hanai, C. H. Heldin, K. Miyazono and P. ten Dijke 
(1997). "TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4." Embo J 16(17): 5353-62. 
Nelson, W. J. and R. Nusse (2004). "Convergence of Wnt, beta-catenin, and cadherin pathways." Science 303(5663): 1483-7. 
Neumann, H., I. M. Medana, J. Bauer and H. Lassmann (2002). "Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases." Trends 
Neurosci 25(6): 313-9. 
Ng-Cashin, J., J. J. Kuhns, S. E. Burkett, J. D. Powderly, R. R. Craven, H. W. van Deventer, S. L. Kirby and J. S. Serody (2003). "Host absence of 
CCR5 potentiates dendritic cell vaccination." J Immunol 170(8): 4201-8. 
Niederkorn, J. Y. (2006). "See no evil, hear no evil, do no evil: the lessons of immune privilege." Nat Immunol 7(4): 354-9. 
Niehrs, C. (2006). "Function and biological roles of the Dickkopf family of Wnt modulators." Oncogene 25(57): 7469-81. 
Nikcevich, K. M., K. B. Gordon, L. Tan, S. D. Hurst, J. F. Kroepfl, M. Gardinier, T. A. Barrett and S. D. Miller (1997). "IFN-gamma-activated 
primary murine astrocytes express B7 costimulatory molecules and prime naive antigen-specific T cells." J Immunol 158(2): 614-21. 
Noh, D. Y., S. H. Shin and S. G. Rhee (1995). "Phosphoinositide-specific phospholipase C and mitogenic signaling." Biochim Biophys Acta 
1242(2): 99-113. 
Ono, M., H. Yaguchi, N. Ohkura, I. Kitabayashi, Y. Nagamura, T. Nomura, Y. Miyachi, T. Tsukada and S. Sakaguchi (2007). "Foxp3 controls 
regulatory T-cell function by interacting with AML1/Runx1." Nature 446(7136): 685-9. 
Appendix 2 
 LXIX 
Oshima, T., F. S. Laroux, L. L. Coe, Z. Morise, S. Kawachi, P. Bauer, M. B. Grisham, R. D. Specian, P. Carter, S. Jennings, D. N. Granger, T. Joh 
and J. S. Alexander (2001). "Interferon-gamma and interleukin-10 reciprocally regulate endothelial junction integrity and barrier function." 
Microvasc Res 61(1): 130-43. 
Ouyang, W., J. K. Kolls and Y. Zheng (2008). "The biological functions of T helper 17 cell effector cytokines in inflammation." Immunity 28(4): 
454-67. 
Pacholczyk, R., J. Kern, N. Singh, M. Iwashima, P. Kraj and L. Ignatowicz (2007). "Nonself-antigens are the cognate specificities of Foxp3+ 
regulatory T cells." Immunity 27(3): 493-504. 
Pandiyan, P., L. Zheng, S. Ishihara, J. Reed and M. J. Lenardo (2007). "CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-
mediated apoptosis of effector CD4+ T cells." Nat Immunol 8(12): 1353-62. 
Phillips, T. A., J. Ni, G. Pan, S. M. Ruben, Y. F. Wei, J. L. Pace and J. S. Hunt (1999). "TRAIL (Apo-2L) and TRAIL receptors in human placentas: 
implications for immune privilege." J Immunol 162(10): 6053-9. 
Pickart, C. M. and D. Fushman (2004). "Polyubiquitin chains: polymeric protein signals." Curr Opin Chem Biol 8(6): 610-6. 
Pinho, S. and C. Niehrs (2007). "Dkk3 is required for TGF-beta signaling during Xenopus mesoderm induction." Differentiation 75(10): 957-67. 
Pitkanen, J. and P. Peterson (2003). "Autoimmune regulator: from loss of function to autoimmunity." Genes Immun 4(1): 12-21. 
Pollard, S. L. and P. W. Holland (2000). "Evidence for 14 homeobox gene clusters in human genome ancestry." Curr Biol 10(17): 1059-62. 
Popko, B. and K. D. Baerwald (1999). "Oligodendroglial response to the immune cytokine interferon gamma." Neurochem Res 24(2): 331-8. 
Praseedom, R. K., K. D. McNeil, C. J. Watson, G. J. Alexander, R. Y. Calne, J. Wallwork and P. J. Friend (2001). "Combined transplantation of the 
heart, lung, and liver." Lancet 358(9284): 812-3. 
Puccetti, P. and U. Grohmann (2007). "IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-kappaB activation." Nat Rev 
Immunol 7(10): 817-23. 
Qin, H. Y., R. Mukherjee, E. Lee-Chan, C. Ewen, R. C. Bleackley and B. Singh (2006). "A novel mechanism of regulatory T cell-mediated down-
regulation of autoimmunity." Int Immunol 18(7): 1001-15. 
Quill, H. and R. H. Schwartz (1987). "Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid 
membranes: specific induction of a long-lived state of proliferative nonresponsiveness." J Immunol 138(11): 3704-12. 
Read, S., R. Greenwald, A. Izcue, N. Robinson, D. Mandelbrot, L. Francisco, A. H. Sharpe and F. Powrie (2006). "Blockade of CTLA-4 on 
CD4+CD25+ regulatory T cells abrogates their function in vivo." J Immunol 177(7): 4376-83. 
Refaeli, Y., L. Van Parijs, C. A. London, J. Tschopp and A. K. Abbas (1998). "Biochemical mechanisms of IL-2-regulated Fas-mediated T cell 
apoptosis." Immunity 8(5): 615-23. 
Reibke, R., N. Garbi, R. Ganss, G. J. Hammerling, B. Arnold and T. Oelert (2006). "CD8+ regulatory T cells generated by neonatal recognition of 
peripheral self-antigen." Proc Natl Acad Sci U S A 103(41): 15142-7. 
Reinke, E. and Z. Fabry (2006). "Breaking or making immunological privilege in the central nervous system: the regulation of immunity by 
neuropeptides." Immunol Lett 104(1-2): 102-9. 
Appendix 2 
 LXX 
Roman-Gomez, J., A. Jimenez-Velasco, X. Agirre, J. A. Castillejo, G. Navarro, M. Barrios, E. J. Andreu, F. Prosper, A. Heiniger and A. Torres 
(2004). "Transcriptional silencing of the Dickkopfs-3 (Dkk-3) gene by CpG hypermethylation in acute lymphoblastic leukaemia." Br J 
Cancer 91(4): 707-13. 
Romeo, P. H., V. Lemarchandel and R. Tordjman (2002). "Neuropilin-1 in the immune system." Adv Exp Med Biol 515: 49-54. 
Safford, M., S. Collins, M. A. Lutz, A. Allen, C. T. Huang, J. Kowalski, A. Blackford, M. R. Horton, C. Drake, R. H. Schwartz and J. D. Powell 
(2005). "Egr-2 and Egr-3 are negative regulators of T cell activation." Nat Immunol 6(5): 472-80. 
Saha, D., P. K. Datta and R. D. Beauchamp (2001). "Oncogenic ras represses transforming growth factor-beta /Smad signaling by degrading tumor 
suppressor Smad4." J Biol Chem 276(31): 29531-7. 
Sakaguchi, S., T. Yamaguchi, T. Nomura and M. Ono (2008). "Regulatory T cells and immune tolerance." Cell 133(5): 775-87. 
Sarris, M., K. G. Andersen, F. Randow, L. Mayr and A. G. Betz (2008). "Neuropilin-1 expression on regulatory T cells enhances their interactions 
with dendritic cells during antigen recognition." Immunity 28(3): 402-13. 
Sato, N., W. A. Kuziel, P. C. Melby, R. L. Reddick, V. Kostecki, W. Zhao, N. Maeda, S. K. Ahuja and S. S. Ahuja (1999). "Defects in the 
generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage 
inflammatory protein-1 alpha-, or CCR2-deficient mice." J Immunol 163(10): 5519-25. 
Schartner, J. M., C. G. Fathman and C. M. Seroogy (2007). "Preservation of self: an overview of E3 ubiquitin ligases and T cell tolerance." Semin 
Immunol 19(3): 188-96. 
Schmitt, E., P. Hoehn, C. Huels, S. Goedert, N. Palm, E. Rude and T. Germann (1994). "T helper type 1 development of naive CD4+ T cells 
requires the coordinate action of interleukin-12 and interferon-gamma and is inhibited by transforming growth factor-beta." Eur J Immunol 
24(4): 793-8. 
Schroeder, A., O. Mueller, S. Stocker, R. Salowsky, M. Leiber, M. Gassmann, S. Lightfoot, W. Menzel, M. Granzow and T. Ragg (2006). "The 
RIN: an RNA integrity number for assigning integrity values to RNA measurements." BMC Mol Biol 7: 3. 
Schwartz, R. H. (2003). "T cell anergy." Annu Rev Immunol 21: 305-34. 
Seddon, B. and D. Mason (2000). "The third function of the thymus." Immunol Today 21(2): 95-9. 
Sharabi, A. and E. Mozes (2008). "The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required 
for the optimal induction and function of foxp3-expressing CD4 cells." J Immunol 181(5): 3243-51. 
Shevach, E. M., R. S. McHugh, C. A. Piccirillo and A. M. Thornton (2001). "Control of T-cell activation by CD4+ CD25+ suppressor T cells." 
Immunol Rev 182: 58-67. 
Sloan-Lancaster, J., B. D. Evavold and P. M. Allen (1993). "Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting 
cells." Nature 363(6425): 156-9. 
Sonobe, Y., S. Jin, J. Wang, J. Kawanokuchi, H. Takeuchi, T. Mizuno and A. Suzumura (2007). "Chronological changes of CD4(+) and CD8(+) T 
cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis." Tohoku J Exp Med 213(4): 329-39. 
Appendix 2 
 LXXI 
Steinman, L. (2001). "Myelin-specific CD8 T cells in the pathogenesis of experimental allergic encephalitis and multiple sclerosis." J Exp Med 
194(5): F27-30. 
Steinman, R. M., D. Hawiger and M. C. Nussenzweig (2003). "Tolerogenic dendritic cells." Annu Rev Immunol 21: 685-711. 
Steinman, R. M. and M. C. Nussenzweig (2002). "Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance." 
Proc Natl Acad Sci U S A 99(1): 351-8. 
Steinman, R. M. and M. D. Witmer (1978). "Lymphoid dendritic cells are potent stimulators of the primary mixed leukocyte reaction in mice." Proc 
Natl Acad Sci U S A 75(10): 5132-6. 
Stephens, G. L. and E. M. Shevach (2007). "Foxp3+ regulatory T cells: selfishness under scrutiny." Immunity 27(3): 417-9. 
Stockinger, B. and M. Veldhoen (2007). "Differentiation and function of Th17 T cells." Curr Opin Immunol 19(3): 281-6. 
Stone, J. C. (2006). "Regulation of Ras in lymphocytes: get a GRP." Biochem Soc Trans 34(Pt 5): 858-61. 
Street, N. E. and T. R. Mosmann (1991). "Functional diversity of T lymphocytes due to secretion of different cytokine patterns." Faseb J 5(2): 171-
7. 
Streilein, J. W. (2003). "Ocular immune privilege: therapeutic opportunities from an experiment of nature." Nat Rev Immunol 3(11): 879-89. 
Sun, C. M., J. A. Hall, R. B. Blank, N. Bouladoux, M. Oukka, J. R. Mora and Y. Belkaid (2007). "Small intestine lamina propria dendritic cells 
promote de novo generation of Foxp3 T reg cells via retinoic acid." J Exp Med 204(8): 1775-85. 
Sun, D., J. N. Whitaker, Z. Huang, D. Liu, C. Coleclough, H. Wekerle and C. S. Raine (2001). "Myelin antigen-specific CD8+ T cells are 
encephalitogenic and produce severe disease in C57BL/6 mice." J Immunol 166(12): 7579-87. 
Suwa, T., M. Chen, C. L. Hawks and P. J. Hornsby (2003). "Zonal expression of dickkopf-3 and components of the Wnt signalling pathways in the 
human adrenal cortex." J Endocrinol 178(1): 149-58. 
Takeuchi, H., J. Wang, J. Kawanokuchi, N. Mitsuma, T. Mizuno and A. Suzumura (2006). "Interferon-gamma induces microglial-activation-
induced cell death: a hypothetical mechanism of relapse and remission in multiple sclerosis." Neurobiol Dis 22(1): 33-9. 
Tang, Q. and J. A. Bluestone (2008). "The Foxp3+ regulatory T cell: a jack of all trades, master of regulation." Nat Immunol 9(3): 239-44. 
Thakker, P., M. W. Leach, W. Kuang, S. E. Benoit, J. P. Leonard and S. Marusic (2007). "IL-23 is critical in the induction but not in the effector 
phase of experimental autoimmune encephalomyelitis." J Immunol 178(4): 2589-98. 
van Leeuwen, J. E. and L. E. Samelson (1999). "T cell antigen-receptor signal transduction." Curr Opin Immunol 11(3): 242-8. 
van Meerwijk, J. P., S. Marguerat, R. K. Lees, R. N. Germain, B. J. Fowlkes and H. R. MacDonald (1997). "Quantitative impact of thymic clonal 
deletion on the T cell repertoire." J Exp Med 185(3): 377-83. 
Volkmann, A., T. Zal and B. Stockinger (1997). "Antigen-presenting cells in the thymus that can negatively select MHC class II-restricted T cells 
recognizing a circulating self antigen." J Immunol 158(2): 693-706. 
Wagner, D. H., Jr. (2007). "Re-shaping the T cell repertoire: TCR editing and TCR revision for good and for bad." Clin Immunol 123(1): 1-6. 
Wan, Y. Y. and R. A. Flavell (2007). "Regulatory T cells, transforming growth factor-beta, and immune suppression." Proc Am Thorac Soc 4(3): 
271-6. 
Appendix 2 
 LXXII 
Wang, S., Z. F. Boonman, H. C. Li, Y. He, M. J. Jager, R. E. Toes and J. Y. Niederkorn (2003). "Role of TRAIL and IFN-gamma in CD4+ T cell-
dependent tumor rejection in the anterior chamber of the eye." J Immunol 171(6): 2789-96. 
Wenkel, H., J. W. Streilein and M. J. Young (2000). "Systemic immune deviation in the brain that does not depend on the integrity of the blood-
brain barrier." J Immunol 164(10): 5125-31. 
Willenborg, D. O., S. Fordham, C. C. Bernard, W. B. Cowden and I. A. Ramshaw (1996). "IFN-gamma plays a critical down-regulatory role in the 
induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis." J Immunol 157(8): 3223-7. 
Wu, Y., M. Borde, V. Heissmeyer, M. Feuerer, A. D. Lapan, J. C. Stroud, D. L. Bates, L. Guo, A. Han, S. F. Ziegler, D. Mathis, C. Benoist, L. Chen 
and A. Rao (2006). "FOXP3 controls regulatory T cell function through cooperation with NFAT." Cell 126(2): 375-87. 
Wysocki, C. A., Q. Jiang, A. Panoskaltsis-Mortari, P. A. Taylor, K. P. McKinnon, L. Su, B. R. Blazar and J. S. Serody (2005). "Critical role for 
CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease." Blood 106(9): 3300-7. 
Yue, W., Q. Sun, S. Dacic, R. J. Landreneau, J. M. Siegfried, J. Yu and L. Zhang (2008). "Downregulation of Dkk3 activates beta-catenin/TCF-4 
signaling in lung cancer." Carcinogenesis 29(1): 84-92. 
Yurchenko, E., M. Tritt, V. Hay, E. M. Shevach, Y. Belkaid and C. A. Piccirillo (2006). "CCR5-dependent homing of naturally occurring CD4+ 
regulatory T cells to sites of Leishmania major infection favors pathogen persistence." J Exp Med 203(11): 2451-60. 
Zehntner, S. P., L. Bourbonniere, M. Hassan-Zahraee, E. Tran and T. Owens (2004). "Bone marrow-derived versus parenchymal sources of 
inducible nitric oxide synthase in experimental autoimmune encephalomyelitis." J Neuroimmunol 150(1-2): 70-9. 
Zinkernagel, R. M., M. F. Bachmann, T. M. Kundig, S. Oehen, H. Pirchet and H. Hengartner (1996). "On immunological memory." Annu Rev 
Immunol 14: 333-67. 
Zinkernagel, R. M. and P. C. Doherty (1974). "Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a 
syngeneic or semiallogeneic system." Nature 248(450): 701-2. 
Zinkernagel, R. M. and P. C. Doherty (1979). "MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation 
antigens determining T-cell restriction-specificity, function, and responsiveness." Adv Immunol 27: 51-177. 
 
 
 
